Retsudvalget 2017-18
REU Alm.del
Offentligt
1945491_0001.png
Monitoring
Health Concerns
Related to Marijuana
in Colorado: 2016
Changes in Marijuana Use Patterns,
Systematic Literature Review,
and Possible Marijuana-Related
Health Effects
colorado.gov/cdphe/marijuana-health-report
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0002.png
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0003.png
Presented to the Colorado State Board of Health, the Colorado
Department of Revenue, and the Colorado General Assembly on Monday,
January 30, 2017 by the Retail Marijuana Public Health Advisory
Committee pursuant to 25-1.5-110, C.R.S.
This report has been reviewed by Larry Wolk, MD, MSPH, Executive
Director and Chief Medical Officer, Colorado Department of Public Health
and Environment
Retail Marijuana Public Health Advisory Committee
The Retail Marijuana Public Health Advisory Committee was established per Senate Bill 13-283 and 25-
1.5-110, C.R.S. Duties of the Committee are to review the currently available scientific literature and
data on health effects of marijuana use and data on patterns of marijuana use, on an ongoing basis.
This document summarizes health topics and data reviewed beginning in 2014 with updates conducted
through 2016. As a committee, we agree that reported findings reflect current science. Public health
messages were developed by the committee to accurately communicate scientific findings.
Recommendations reported were developed by the committee with the goal of protecting consumers of
marijuana and the general public.
25-1.5-110, C.R.S. Monitor health effects of marijuana
“The
department shall monitor changes in drug use patterns, broken down by county and race and
ethnicity, and the emerging science and medical information relevant to the health effects associated
with marijuana use. The department shall appoint a panel of health care professionals with expertise
in cannabinoid physiology to monitor the relevant information. The panel shall provide a report by
January 31, 2015, and every two years thereafter to the state Board of Health, the Department of
Revenue, and the General Assembly. The department shall make the report available on its web site.
The panel shall establish criteria for studies to be reviewed, reviewing studies and other data, and
making recommendations, as appropriate, for policies intended to protect consumers of marijuana or
marijuana products and the general public. The department may collect Colorado-specific data that
reports adverse health events involving marijuana use from the all-payer claims database, hospital
discharge data, and behavioral risk factors.”
HISTORY:
Source: L. 2013: Entire section added,
(SB 13-283), ch. 332, p. 1894, § 10,
effective
May 28.L. 2016: Entire section amended,
(SB 16-090), ch. 45, p. 107, § 1,
effective August 10.
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0004.png
Retail Marijuana Public Health Advisory Committee members
Chairman: Mike Van Dyke, PhD, CIH, Chief, Environmental Epidemiology, Occupational Health and
Toxicology Branch
Shireen Banerji, PharmD, DABAT, Clinical Manager, Rocky Mountain Poison Center
Laura Borgelt, PharmD, Associate Dean and Professor, Departments of Clinical Pharmacy and Family
Medicine, University of Colorado Anschutz Medical Campus
Russell Bowler, MD, PhD, Professor of Medicine, National Jewish Health and University of Colorado
Ashley Brooks-Russell, PhD, MPH, Assistant Professor, Colorado School of Public Health; Member, Injury
Prevention, Education and Research Program
Ken Gershman, MD, MPH, Manager, Medical Marijuana Research Grants Program Colorado Department
of Public Health and Environment
Heath Harmon, MPH, Director of Health Divisions, Boulder County Public Health
Rebecca Helfand, PhD, Director of Data and Evaluation, Office of Behavioral Health, Colorado
Department of Human Services
Sharon Langendoerfer, MD, Retired Pediatrician and Neonatologist, Denver Health Medical Center
Andrew Monte, MD, Emergency Medicine Physician, Medical Toxicologist, University of Colorado and
Rocky Mountain Poison and Drug Center
Kristina T. Phillips, PhD, Clinical Psychologist, Professor, School of Psychological Sciences, University of
Northern Colorado
Judith Shlay, MD, MSPH, Interim Director, Denver Public Health; Professor of Family Medicine,
University of Colorado School of Medicine
Christian Thurstone, MD, Psychiatrist and Medical Director of Addiction Services, Denver Health;
Associate Professor of Psychiatry, University of Colorado
George Sam Wang, MD, Assistant Professor of Pediatrics, Department of Pediatrics, Section of
Emergency Medicine and Medical Toxicology, University of Colorado Anschutz Medical Campus and
Children’s Hospital Colorado; Volunteer Faculty, Rocky Mountain Poison and Drug Center
Tista Ghosh, MD, MPH, Deputy Chief Medical Officer and Director of Health Programs, Colorado
Department of Public Health and Environment (Alternate Member)
Colorado Department of Public Health and Environment technical staff
Mike Van Dyke, PhD, CIH, Chief, Environmental Epidemiology, Occupational Health and Toxicology
Branch
Daniel I. Vigil, MD, MPH, Manager, Marijuana Health Monitoring and Research Program
Katelyn E. Hall, MPH, Statistical Analyst, Marijuana Health Monitoring and Research Program
Elyse Contreras, MPH, Coordinator, Marijuana Health Monitoring and Research Program
Rowena Crow, MD, Statistical Analyst, Marijuana Health Monitoring and Research Program
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0005.png
Additional authors
Amy Anderson Mellies, MPH, Health Data Analyst, Health Surveys and Evaluation Branch, Colorado
Department of Public Health and Environment
Lisa Barker, MPH, Retail Marijuana Health Monitoring, Colorado Department of Public Health and
Environment
Kevin Berg, MA, GIS Epidemiologist, Environmental Epidemiology, Colorado Department of Public
Health and Environment
Kirk Bol, MSPH, Manager, Vital Statistics and Disease Registry Branch, Colorado Department of Public
Health and Environment
Alvin C. Bronstein, MD, Rocky Mountain Poison Center; University of Colorado
Todd Carlson, MD, Internal Medicine Resident, University of Colorado
Teresa Foo, MD, MPH, Marijuana Clinical Guidelines Coordinator, Colorado Department of Public Health
and Environment; Clinical Instructor, University of Colorado
David Goff Jr., MD, PhD, FACP, FAHA, Dean and Professor, Colorado School of Public Health
Alison Grace Bui, MPH, Epidemiologist, Health Surveys and Evaluation Branch, Colorado Department of
Public Health and Environment
Christopher H. Domen, PhD, ABPP-CN, Assistant Professor, Department of Neurosurgery, University of
Colorado School of Medicine
Renee M. Johnson, PhD, MPH, Associate Professor, Department of Mental Health, Johns Hopkins
Bloomberg School of Public Health
Ashley Juhl, MSPH, Maternal and Child Health Epidemiologist, Health Surveys and Evaluation Branch,
Colorado Department of Public Health and Environment
Leonardo Kattari, MSW, Healthy Kids Colorado Survey Coordinator, Prevention Services Division,
Colorado Department of Public Health and Environment
Mike Kosnett, MD, MPH, Associate Clinical Professor, Division of Clinical Pharmacology and Toxicology,
Department of Medicine, University of Colorado School of Medicine, Department of Environmental and
Occupational Health, Colorado School of Public Health
Bruce Mendelson, MPA, Denver Office of Drug Strategy, University of Colorado
Madeline Morris, BS, Graduate Student, Colorado School of Public Health
Allison Rosenthal, MPH, Applied Epidemiology Fellow, Substance Abuse Mental Health Services
Administration and Council of State and Territorial Epidemiologists
Anne Schiffmacher, MPH, Maternal and Child Health Data Analyst, Health Surveys and Evaluation
Branch, Colorado Department of Public Health and Environment
Kim Siegel, MD, MPH, Occupational Medicine Resident, University of Colorado
Rickey Tolliver, MPH, Chief, Health Surveys and Evaluation Branch, Colorado Department of Public
Health and Environment
Michael F. Wempe, PhD, Associate Research Professor, Department of Pharmaceutical Sciences,
University of Colorado Anschutz Medical Campus
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0006.png
Other contributors
Alejandro Azofeifa, DDS, MSc, MPH
Shannon Barbare
Rio Chowdhury
Erin Flynn, MPH
Rachel K. Herlihy, MD, MPH
Diana Herrero, MS
Ali Maffey, MSW
Mark Salley
Megan Snow, MS, CHES
Jan Stapleman
Community Epidemiology and Program Evaluation Group, Colorado School of Public Health
Substance Abuse and Mental Health Services Administration (SAMHSA), National Survey on Drug Use and
Health (NSDUH) analysis team
Public meeting attendees
Contact
[email protected]
Press contact
Mark Salley
Director, Office of Communicatoins
Colorado Department of Public Health and Environment
[email protected]
303-692-2013
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0007.png
Monitoring Health Concerns
Related to Marijuana in
Colorado: 2016
Table of Contents
Executive Summary
Section1: Monitoring Changes in Marijuana Use Patterns
Background and Summary of Key Findings
Behavioral Risk Factor Surveillance Survey (BRFSS)
Child Health Survey (CHS)
Healthy Kids Colorado Survey (HKCS)
Pregnancy Risk Assessment Monitoring System (PRAMS)
i - x
1
2
7
27
37
61
-
-
-
-
-
6
26
36
60
70
71
72
81
93
109
119
127
145
157
165
179
193
209
221
-
-
-
-
-
-
-
-
-
-
-
-
-
80
92
108
118
126
144
156
164
178
192
208
220
228
229
230 - 234
235 - 246
247 - 270
271 - 278
279 - 286
Section 2: Scientific Literature Review on Potential Health Effects of
Marijuana Use
Background and Summary of Key Findings
Systematic Literature Review Process
Marijuana Use Among Adolescents and Young Adults
Marijuana Use and Cancer
Marijuana Use and Cardiovascular Effects
Marijuana Dose and Drug Interactions
Marijuana Use and Driving
Marijuana Use and Gastrointestinal and Reproductive Effects
Marijuana Use and Injury
Marijuana Use and Neurological, Cognitive and Mental Health Effects
Marijuana Use During Pregnancy and Breastfeeding
Marijuana Use and Respiratory Effects
Unintentional Marijuana Exposures in Children
Section 3: Monitoring Possible Marijuana-Related Health Effects in Colorado
Background and Summary of Key Findings
Rocky Mountain Poison and Drug Center (RMPDC) Data
Colorado Hospital Association (CHA) Data
Retail Marijuana Public Health Advisory Committee 2015-2016 Membership
Roster
Glossary
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0008.png
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0009.png
Monitoring Health
Concerns Related to
Marijuana in
Colorado: 2016
Executive Summary
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0010.png
Executive Summary
Retail Marijuana Public Health Advisory Committee Members
2015-2016
Chairman: Mike Van Dyke, PhD, CIH, Chief, Environmental Epidemiology, Occupational Health and
Toxicology Branch
Laura Borgelt, PharmD, Associate Dean and Professor, Departments of Clinical Pharmacy and Family
Medicine, University of Colorado Anschutz Medical Campus
Russell Bowler, MD, PhD, Professor of Medicine, National Jewish Health and University of Colorado
Shireen Banerji, PharmD, DABAT, Clinical Manager, Rocky Mountain Poison Center
Ashley Brooks-Russell, PhD, MPH, Assistant Professor, Colorado School of Public Health; Member, Injury
Prevention, Education and Research Program
Ken Gershman, MD, MPH, Manager, Medical Marijuana Research Grants Program Colorado Department
of Public Health and Environment
Heath Harmon, MPH, Director of Health Divisions, Boulder County Public Health
Sharon Langendoerfer MD, Retired Pediatrician and Neonatologist, Denver Health Medical Center
Andrew Monte, MD, Emergency Medicine Physician, Medical Toxicologist, University of Colorado and
Rocky Mountain Poison and Drug Center
Judith Shlay, MD, MSPH, Interim Director, Denver Public Health; Professor of Family Medicine,
University of Colorado School of Medicine
George Sam Wang, MD, Assistant Professor of Pediatrics, Department of Pediatrics, Section of
Emergency Medicine and Medical Toxicology, University of Colorado Anschutz Medical Campus and
Children’s Hospital Colorado; Volunteer Faculty, Rocky Mountain Poison and Drug Center
Rebecca Helfand, PhD, Director of Data and Evaluation, Office of Behavioral Health, Colorado
Department of Human Services
Kristina Phillips, PhD, Clinical Psychologist, Professor, School of Psychological Sciences, University of
Northern Colorado
Christian Thurstone, MD, Psychiatrist and Medical Director of Addiction Services, Denver Health;
Associate Professor of Psychiatry, University of Colorado
Tista Ghosh, MD, MPH, Deputy Chief Medical Officer and Director of Health Programs, Colorado
Department of Public Health and Environment (Alternate Member)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
ii
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0011.png
Executive Summary
Introduction
When Colorado became one of the first two states in the nation to legalize retail marijuana, the
Colorado Legislature mandated that the Colorado Department of Public Health and Environment
(CDPHE) study the potential public health effects of marijuana. Though medical marijuana has been
legal in Colorado since 2000, it was largely viewed as an individual doctor/patient decision outside the
scope of public health policy. However, the legalization of retail (non-medical) marijuana and the
potential for greater availability of marijuana in the community prompted a closer look at potential
health effects on the population at large.
Legalized retail marijuana presents a paradigm shift, grouping marijuana with other legal substances
like alcohol, tobacco and prescription drugs, as opposed to illicit drugs like cocaine and heroin. As with
alcohol, tobacco and prescription drugs, misuse of marijuana can have serious health consequences.
The standard public health approaches to alcohol, tobacco and prescription drugs are to monitor use
patterns and behaviors, health care use, potential health effects, and emerging scientific literature to
guide the development of policies or consumer education strategies to prevent serious health
consequences. This report presents information on marijuana use patterns, potential health effects and
the most recent scientific findings associated with marijuana use, with a key objective of helping
facilitate evidence-based policy decisions and science-based public education campaigns.
In 25-1.5-110, C.R.S., the Colorado Department of Public Health and Environment (CDPHE) was given
statutory responsibility to:
“…
monitor changes in drug use patterns, broken down by county and race and ethnicity, and the
emerging science and medical information relevant to the health effects associated with marijuana
use.”
“…
appoint a panel of health care professionals with expertise in cannabinoid physiology to monitor
the relevant information.”
“…
collect Colorado-specific data that reports adverse health events involving marijuana use from
the all-payer
claims database, hospital discharge data, and behavioral risk factors.”
Based on this charge, CDPHE has appointed a 14-member committee, the Retail Marijuana Public
Health Advisory Committee (RMPHAC), to review scientific literature on the health effects of marijuana
and Colorado-specific health outcome and use pattern data. Members of this committee (see Retail
Marijuana Public Health Advisory Committee membership roster) consist of individuals in the fields of
public health, medicine, epidemiology and medical toxicology who demonstrate expertise related to
marijuana through their work, training or research. This committee was charged with the duties as
outlined in C.R.S. 25-1.5-110
to “…
establish criteria for studies to be reviewed, reviewing studies and
other data, and making recommendations, as appropriate, for policies intended to protect consumers
of
marijuana or marijuana products and the general public.”
The committee began meeting in May
2014 and in January 2015 published the first edition of this report. The overall goal of the committee
was to implement an unbiased and transparent process for evaluating scientific literature as well as
marijuana use and health outcome data. The committee was particularly interested in ensuring quality
information is shared about the known physical and mental health effects associated with marijuana
use
and also about what is unknown at present. The official committee bylaws are included in the
Appendix, Retail Marijuana Public Health Advisory Committee Bylaws.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
iii
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0012.png
Executive Summary
Monitoring changes in marijuana use patterns
This report includes detailed information about marijuana use patterns in Colorado that has been
gathered using several prominent population-based surveys. These surveys are:
1. The Behavioral Risk Factor Surveillance System survey, a survey of adults sponsored by the U.S.
Centers for Disease Control and Prevention (CDC).
2. The Child Health Survey, a survey of adults with children ages 1-14 years old in their home about
the children’s health and environment.
3. The Healthy Kids Colorado Survey of middle and high school students, a collaboration of CDPHE,
Colorado Department of Education, and Colorado Department of Human Services.
4. The Pregnancy Risk Assessment Monitoring System survey, a survey of women who recently gave
birth.
The data available at this time cannot answer all of the important questions about whether or how
marijuana use patterns may be changing as a result of legalization. However, they do provide
important insights into marijuana use in adults and vulnerable populations such as pregnant women,
youth, and those with racial, ethnic, and sexual orientation disparities. A summary of key trends:
Encouraging trends
For adults and adolescents, past-month marijuana use has not changed since legalization either in
terms of the number of people using or the frequency of use among users.
Based on the most comprehensive data available, past month marijuana use among Colorado
adolescents is nearly identical to the national average.
We have not identified any
new
disparities in marijuana use by age, gender, race, ethnicity or
sexual orientation since legalization.
Daily or near-daily marijuana use among adults is much lower than daily or near-daily alcohol or
tobacco use. Among adolescents, past month marijuana use is lower than past month alcohol use.
Trends to continue monitoring
About 6 percent of pregnant women use marijuana while pregnant. This percentage is higher
among those with unintended pregnancies as well as younger mothers or those with less education.
At least 14,000 children in Colorado are at risk of accidentally eating marijuana products that are
not safely stored and at least 16,000 are at risk of being exposed to secondhand marijuana smoke
in the home.
More than 5 percent of high school students use marijuana daily or near daily. This rate has
remained stable since at least 2005.
Past month marijuana use among adults in Colorado is higher than the national average. In
Colorado, one in four adults age 18-25 reported past month marijuana use and one in eight use
daily or near-daily. These numbers have been consistent since legalization.
There continue to be disparities in marijuana use based on race/ethnicity for adolescents and
sexual orientation for both adults and adolescents.
While past month marijuana use among adults and adolescents was stable for most regions in
Colorado, adult use in the Northwest Colorado region increased from 2014 to 2015.
More than 1-in-3 adolescents who use marijuana first use it by age 14, supporting prevention
efforts aimed at children before they enter ninth grade.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
iv
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0013.png
Executive Summary
Scientific literature review on potential health effects
of marijuana use
The committee used a standardized systematic literature review process to search and grade the
existing scientific literature on health effects of marijuana. Findings were synthesized into evidence
statements that summarize the quantity and quality of supporting scientific evidence. These evidence
statements were classified as follows:
Substantial evidence - indicates robust scientific findings that support an association between
marijuana use and the outcome.
Moderate evidence - indicates that scientific findings support an association between marijuana
use and the outcome, but these findings have some limitations.
Limited evidence - indicates modest scientific findings that support an association between
marijuana use and the outcome, but these findings have significant limitations.
Mixed evidence - indicates both supporting and non-supporting scientific findings for an association
between marijuana use and the outcome with neither direction dominating.
Body of research failing to show an association - indicates that the topic has been researched
without evidence of an association; is further classified as a limited, moderate or substantial body
of research.
Insufficient evidence - indicates that the outcome has not been sufficiently studied to conclude
whether or not there is an association between marijuana use and the outcome.
The committee also translated these evidence statements into plain language so the public can
understand them when used in public health messages. In addition, the committee was asked to
develop public health recommendations based on potential concerns identified through the review
process and to articulate research gaps based on common limitations of existing research. All of these
were presented to the full committee during open public meetings that offered opportunities for
stakeholder input. Final statements, recommendations, and research gaps were formally approved by a
majority vote of the committee.
An important note for all key findings is that the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove the marijuana
use alone
caused
the effect. Despite the best efforts of researchers to account for confounding
factors, there may be other important factors related to
causality
that were not identified. In
addition, marijuana use was illegal everywhere in the United States prior to 1996. Research funding,
when appropriated, was commonly sought to identify adverse effects from marijuana use. This legal
fact introduces both funding bias and publication bias into the body of literature related to marijuana
use. Another limitation of the available research data is that most studies did not or could not measure
the THC level (potency) of marijuana used by subjects, nor which other cannabinoids were present.
There are diverse products now available in Colorado, many of which are likely higher in potency than
the marijuana used by study subjects for much of the literature reviewed.
The Retail Marijuana Public Health Advisory Committee recognizes the limitations and biases inherent
in the published literature and made efforts to ensure the information reviewed and synthesized is
reflective of the current state of medical knowledge. Where information was lacking
for whatever
reason
the committee identified this knowledge gap and recommended further research. This
information will be updated as new research becomes available.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
v
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0014.png
Executive Summary
Marijuana use among adolescents and young adults
The committee reviewed
the relationships between adolescent and young adult marijuana use and
cognitive abilities, academic performance, mental health and future substance use. Weekly marijuana
use by adolescents is associated with impaired learning, memory, math and reading, even 28 days after
last use. Weekly use is also associated with failure to graduate from high school. Adolescents and young
adults who use marijuana are more likely to experience psychotic symptoms as adults, such as
hallucinations, paranoia, delusional beliefs and feeling emotionally unresponsive. Evidence shows that
marijuana users can become addicted to marijuana and that treatment for marijuana addiction can
decrease use and dependence. Additionally, marijuana users who quit have lower risks of cognitive and
mental health outcomes than those who continue to use.
Marijuana use and cancer
The committee reviewed
different forms of cancer relative to marijuana use, as well as the chemicals
released in marijuana smoke and vapor. Strong evidence shows that marijuana smoke contains many of
the same cancer-causing chemicals found in tobacco smoke. However, there is conflicting research for
whether or not a higher cumulative level of marijuana smoking is associated with lung cancer. Limited
evidence suggests an association between marijuana use and both testicular and prostate cancers. On
the other hand, the limited evidence available concerning cancers of the bladder, head and neck
suggests that they might not have any association with marijuana use.
Marijuana use and cardiovascular effects
The committee reviewed
myocardial infarction, stroke and death from cardiovascular causes, relative
to marijuana use. There is a moderate level of scientific evidence that marijuana use increases risk for
some forms of stroke in individuals younger than 55 years of age, and more limited evidence that
marijuana use may increase risk for heart attack. Research is lacking concerning other cardiovascular
events and conditions, including death.
Marijuana dose and drug interactions
The committee reviewed
THC (tetrahydrocannabinol, the main psychoactive component of marijuana)
levels relative to marijuana dose and method of use, the effects of secondhand marijuana smoke, drug-
drug interactions involving marijuana, and relationships between marijuana and opioid use. One very
important finding is that it can take up to four hours after consuming an edible marijuana product to
reach the peak THC blood concentration and feel the full effects. There is credible evidence of
clinically important drug-drug interactions between marijuana and multiple medications, including
some anti-seizure medications and a common blood-thinner. Data about potential interactions are
lacking for many drugs at this time and likely to evolve substantially over coming years. Finally, there
is some evidence that opioid pain medication overdose deaths are lower in states with legal medical
marijuana than would be expected based on trends in states without legal medical marijuana. There is
conflicting evidence for whether or not marijuana use is associated with a decrease in opioid use
among chronic pain patients or individuals with a history of problem drug use.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
vi
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0015.png
Executive Summary
Marijuana use and driving
The committee reviewed
driving impairment and motor vehicle crash risk relative to marijuana use, as
well as evidence indicating how long it takes for impairment to resolve after marijuana use. They
found that the risk of a motor vehicle crash increases among drivers with recent marijuana use.
Furthermore, the higher the blood THC level, the higher the motor vehicle crash risk. In addition, using
alcohol and marijuana together increases impairment and the risk of a motor vehicle crash more than
using either substance alone. For less than weekly marijuana users, using marijuana containing 10
milligrams or more of THC is likely to impair the ability to safely drive, bike, or perform other safety-
sensitive activities. Less than weekly users should wait at least six hours after smoking or eight hours
after eating or drinking marijuana to allow time for impairment to resolve.
Marijuana use and gastrointestinal or reproductive effects
The committee reviewed
gastrointestinal diseases, particularly cyclic vomiting, and infertility or
abnormal reproductive function. Evidence shows that long-time, daily or near daily marijuana use is
associated with cyclic vomiting, which has been called cannabinoid hyperemesis syndrome. In such
cases, stopping marijuana use may relieve the vomiting. There is conflicting research for whether or
not marijuana use is associated with male infertility or abnormal reproductive function, and research is
lacking on female reproductive function related to marijuana use.
Marijuana use and injury
The committee reviewed
workplace, recreational and other non-driving injuries, burns from hash-oil
extraction or failed electronic smoking devices, and physical dating violence. Evidence shows that
marijuana use may increase the risk of workplace injury while impaired, but is unclear for other types
of non-driving related injury. There have been many reports of severe burns resulting from home-
extraction of butane hash-oil leading to explosions, and cases of electronic smoking devices exploding,
leading to trauma and burns. Concerning dating violence, adolescent girls who use marijuana may be
more likely to commit physical violence against their dating partners, and adolescent boys who use
marijuana may be more likely to be victims of physical dating violence.
Marijuana use and neurological, cognitive and mental health effects
The committee reviewed
the potential relationships between marijuana use and cognitive impairment,
mental health disorders and substance abuse. Strong evidence shows that daily or near daily marijuana
users are more likely to have impaired memory lasting a week or more after quitting. An important
acute effect of THC is psychotic symptoms, such as hallucinations, paranoia and delusional beliefs
during intoxication. These symptoms are worse with higher doses. Daily or near daily marijuana use is
associated with developing a psychotic disorder such as schizophrenia. Finally, evidence shows that
marijuana users can become addicted to marijuana and that treatment for marijuana addiction can
decrease use and dependence.
Marijuana use during pregnancy and breastfeeding
The committee
reviewed adverse birth outcomes, effects of prenatal marijuana use on exposed
offspring later in childhood or adolescence and effects of marijuana use by a breastfeeding mother.
Biological evidence shows that THC passes through the placenta to the fetus, so that the unborn child
is exposed to THC if the mother uses marijuana, and that THC passes through breast milk to a
breastfeeding child. Marijuana use during pregnancy may be associated with an increased risk of heart
defects or stillbirth. Stronger evidence was found for effects that are seen months or years after birth
if a child’s mother used marijuana while pregnant with the child. These include decreased growth and
impaired cognitive function and attention. Decreased academic ability or increased depression
symptoms may also occur.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
vii
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0016.png
Executive Summary
Marijuana use and respiratory effects
The committee
reviewed respiratory diseases like chronic obstructive pulmonary disorder (COPD),
chronic bronchitis and asthma, respiratory infections and lung function relative to smoked marijuana.
They also reviewed potential health effects of vaporized marijuana. Strong evidence shows an
association between daily or near-daily marijuana use and chronic bronchitis. Additionally, daily or
near daily marijuana use may be associated with bullous lung disease and pneumothorax in individuals
younger than 40 years of age. Research is lacking concerning any possible association between
marijuana use and COPD, emphysema or respiratory infections. Smokers who switch from marijuana
smoking to marijuana vaporizing may have fewer respiratory symptoms and improved pulmonary
function. Finally, a notable effect of acute use is a short-term improvement in lung airflow.
Unintentional marijuana exposures in children
The committee
reviewed unintentional marijuana exposure relative to marijuana legalization and
child-resistant packaging. They found strong evidence that more unintentional marijuana exposures of
children occur in states with increased legal access to marijuana, and that the exposures can lead to
significant clinical effects requiring hospitalization. Additionally, evidence shows that child resistant
packaging prevents exposure to children from potentially harmful substances, such as THC.
Monitoring possible marijuana-related health effects
This report includes detailed information about population-based health effects of legalized marijuana
in Colorado, using two primary public health datasets:
1. Exposure calls to the Rocky Mountain Poison and Drug Center, typically used as a surrogate data
source to determine the potential for adverse health effects from exposure to chemicals and drugs.
2. Hospital and emergency department data provided by the Colorado Hospital Association, which
collects data from participating hospitals in the state of Colorado.
The data presented here provide important insights into the yearly volume, trends over time and
nature of marijuana exposure calls to the poison center among different age groups and the rates of
hospitalizations and emergency department visits for which a marijuana-related billing code was used.
A summary of key trends:
Encouraging trends
Marijuana exposure calls to the poison center appear to be decreasing since 2015, including
unintentional exposures in children ages 0-8 years.
The overall rate of emergency department visits with marijuana-related billing codes dropped 27
percent from 2014 to 2015 (2016 data is not available yet).
Trends to continue monitoring
Marijuana exposure calls to the poison center continue to be higher in years after medical
marijuana commercialization (2010-2016) than in previous years (2000-2009), including calls about
children 0-8 years old with unintentional marijuana exposure.
Edible marijuana products were involved in about 40 percent of marijuana exposure calls to the
poison center. For children 0-8 years old, calls about edible marijuana were twice as common as
calls about smokeable marijuana.
The overall rate of hospitalizations with marijuana-related billing codes has increased each year
since 2008.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
viii
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0017.png
Executive Summary
Among young adults (ages 18-25 years) in 2014 and 2015, about 8 percent of all hospitalizations and
2 percent of all emergency department visits had a marijuana-related billing code. This was higher
than the rate among other age groups, and likely reflects the higher rate of marijuana use in this
age group.
Disparities in hospitalizations and emergency department visits also existed by sex and race, with
higher rates among males and blacks across all time periods.
Hospitalizations with marijuana-related billing codes are nine times more likely to have a primary
mental health diagnosis compared to those without marijuana-related billing codes.
These data should be interpreted carefully, keeping in mind that observed increases have many
potential explanations including:
changes in the amount or type of marijuana use in Colorado,
changes in physician screening or reporting related to marijuana, increased honesty in reporting
marijuana use to health care providers after legalization, and changes in coding practices by hospitals
and emergency departments. In addition, possible marijuana-related cases accounted for 3 percent of
hospitalizations and less than 1 percent of emergency department visits in Colorado in 2015. More data
and time are needed to determine if the observed increases are a direct and sustained result of
changes in Colorado marijuana use.
Public health recommendations
The committee made a number of public health recommendations interspersed throughout this report.
It recommends Colorado support research to fill important gaps in public health knowledge and
continue improving and standardizing data about marijuana use history and health effects in public
health surveillance, medical care settings and research.
Collection and in-depth analysis of data regarding marijuana use should be continued using population-
based surveys such as the Behavioral Risk Factors Surveillance System, the Healthy Kids Colorado
Survey and Pregnancy Risk Assessment Monitoring System. Colorado also should continue to develop,
improve and expand tools to monitor marijuana use patterns, such as CDPHE’s Cannabis Users’ Survey
on Health.
CDPHE should continue using poison center and hospital data to monitor trends in potential marijuana
health effects and assess the impact over time, especially among groups with higher rates of marijuana
use. For the poison center, this includes implementing a surveillance protocol currently being
developed and conducting more detailed data collection and analysis of unintentional marijuana
exposures, especially in children under 9 years old. In order to better assess potential health impacts,
data on hospitalizations and emergency department visits related to marijuana should be further
explored. This includes continuing analysis of primary diagnoses in relation to marijuana-related billing
codes and targeted projects like CDPHE’s
collaboration to evaluate ski-related
injuries and marijuana.
In addition, improved testing methods and documentation are needed in relation to motor vehicle
crashes and driving under the influence of drugs (DUID). Evaluation of death certificate
and coroner’s
report data should continue, to determine how it can best be used in monitoring for potential
marijuana-related deaths.
Public education on potential health effects of marijuana is important, particularly related to the
effects of use during pregnancy, adolescent use, driving after using and unsafe storage around
children. Dispensaries and industry should continue to partner with public health to disseminate
education about these topics of highest concern. Education for health care providers on the known
health effects of marijuana use may encourage more open dialogue between providers and patients.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
ix
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0018.png
Executive Summary
Research gaps
Important research gaps related to the population-based health effects of marijuana use were
identified during the literature and data review process. These research gaps were based on common
limitations of existing research, exposures or outcomes not sufficiently studied, or issues important to
public education or policymaking. These research gaps provide an important framework for continuing
to prioritize research related to marijuana use and public health.
The committee strongly recommends
that Colorado support research to fill these important gaps in public health knowledge. While outside
the scope of this committee’s duties, the committee also recognizes that more research is needed on
the potential therapeutic benefits of marijuana.
A common theme among the research gaps was the need for studies with better defined marijuana-use
histories and practices. This should include frequency, amount, potency, and method of marijuana use,
length of abstinence, and a standardized method for documenting cumulative lifetime marijuana
exposure. A key need is to separately evaluate effects for less frequent users versus daily or near-daily
users. Researchers should consider evaluating separately by age group, sex or other characteristics
when the health effect being studied could differ among groups - for example, by age for
cardiovascular effects or by sex for mental health effects.
Research gaps particularly important to public health and safety include: 1) Additional research using
marijuana with THC levels consistent with currently available products; 2) Research on impairment in
marijuana users who use more than weekly and may have developed tolerance; 3) Research to identify
improved testing methods for impairment either through alternate biological testing methods or
physical tests of impairment; and 4) Research to better characterize the
pharmacokinetics/pharmacodynamics, potential drug interactions, health effects, and impairment
related to newer methods of marijuana use such as edibles and vaporizing as well as other
cannabinoids such as cannabidiol (CBD).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
x
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0019.png
Section 1
Monitoring Changes in
Marijuana Use
Patterns
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0020.png
Section 1: Monitoring Changes in Marijuana Use Patterns in Colorado
Background
The Colorado Department of Public Health and Environment (CDPHE) was given statutory (In 25-1.5-
110, C.R.S.) responsibility to:
“… monitor changes in drug use patterns, broken
down by county and race and ethnicity, and the
emerging science and medical information relevant to the health effects associated with marijuana
use.”
Patterns of drug use are typically determined by using population-based surveys that ask specific
questions about substance use. Colorado has created and manages several population-based surveys to
assess the prevalence of a variety of health conditions and behaviors of specific populations. In
addition, there are a few national surveys that collect state level data on marijuana use. The data
from these surveys are compiled here to meet the reporting requirements set forth in 25-1.5-110,
C.R.S. These data also have been presented to the Retail Marijuana Public Health Advisory Committee,
which was charged with the duties outlined in 25-1.5-110,
C.R.S. to “…establish criteria for studies to
be reviewed, reviewing studies and other data, and making recommendations, as appropriate, for
policies intended to protect consumers of marijuana or marijuana products and the
general public.”
Reviewing marijuana use patterns in Colorado provides important insight to the committee members as
they consider public health recommendations.
Data sources
Adult use: Behavioral Risk Factor Surveillance System (BRFSS)
The Behavioral Risk Factor Surveillance System (BRFSS) is a telephone survey of adults ages 18 years
and older, sponsored by the U.S. Centers for Disease Control
and Prevention (CDC). It is the nation’s
premier system of health-related telephone surveys that collect data from U.S. residents regarding
their health-related risk behaviors, chronic health conditions and safety practices. CDPHE, in a
cooperative agreement with CDC, manages and administers BRFSS in Colorado. In 2014 and 2015,
Colorado added questions on marijuana use to the state-level BRFSS.
Marijuana in homes with children: Child Health Survey (CHS)
The Child Health Survey (CHS) is a telephone survey conducted among respondents to the BRFSS Survey
who have children ages 1-14 in their home. Adult respondents answer questions about their children
and the home environment. This annual survey provides data on a wide range of health issues and risk
factors affecting children and youth in Colorado. Since 2014, questions about marijuana use and
storage in the home have been included in the survey.
Adolescent and young adult use: Healthy Kids Colorado Survey (HKCS)
The Healthy Kids Colorado Survey (HKCS) collects health information from public high school and
middle school students. It is a voluntary, anonymous survey, completed by students individually in their
classrooms and parents are notified ahead of time. HKCS is a collaboration of CDPHE, Colorado
Department of Education and Colorado Department of Human Services. This survey includes the
questions on the national Youth Risk Behavioral Surveillance Survey (YRBSS). HKCS has included
questions on marijuana since 1999.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
2
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0021.png
Section 1: Monitoring Changes in Marijuana Use Patterns in Colorado
Adolescent and adult use: National Survey on Drug Use and Health (NSDUH)
The Substance Abuse and Mental Health Services Administration (SAMHSA) tracks national and state
level data on tobacco, alcohol, marijuana, and illicit drug use through the National Survey on Drug Use
and Health (NSDUH). This survey is completed by in-person
interview at the respondent’s home, and
includes one or two residents who are at least 12 years old. Although the survey design differs from
BRFSS and HKCS, it can be used for comparisons of state and national marijuana use estimates. This
report does not have a NSDUH-specific chapter, but NSDUH data are included for comparison in the
BRFSS and HKCS chapters.
Use during pregnancy: Pregnancy Risk Assessment Monitoring System (PRAMS)
The Pregnancy Risk Assessment Monitoring System (PRAMS) is a mailed survey of women who recently
gave birth. It is sponsored by the Centers for Disease Control and Prevention (CDC). It provides data not
available from other sources about pregnancy and the first few months after delivery, and allows CDC
and states to monitor changes in maternal and child health indicators, such as unintended pregnancy,
prenatal care, breastfeeding, infant health, smoking and alcohol use. In 2014, Colorado added
questions about marijuana use before, during and after pregnancy to the state-level PRAMS.
Each of these surveys only collects self-reported information, so there is no way to confirm whether
each respondent has answered truthfully. These types of surveys have been validated in various
studies, which indicate most people do answer truthfully. Consistency in methodology from year to
year for each of the surveys provides confidence that trends over time can be effectively monitored.
Key details about all five surveys
Survey
BRFSS
CHS
HKCS
NSDUH
PRAMS
Population and ages studied
Adults age 18 and up
Parents of children age 1-14
Adolescents and young adults age 11-18
Adolescents and adults age 12 and up
Pregnant and recently pregnant women
Years
2014-2015
2014-2015
1999-2015
1971-2015
2014
Data collection method
Telephone survey
Telephone survey
In-school paper survey
In-person, at home survey
Mailed paper survey
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
3
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0022.png
Section 1: Monitoring Changes in Marijuana Use Patterns in Colorado
Summary of key findings
The most prominent findings from all surveys are described below. For additional results and details,
see the individual chapters for BRFSS (page 9), CHS(page 29), HKCS (page 39) and PRAMS (page 63).
Trends in adult marijuana use in Colorado
In 2015, BRFSS data showed an estimated 13% of Colorado adults ages 18 and up had used marijuana in
the past-month. The NSDUH estimate for past-month use differs, at 17%. However, neither survey
showed a statistical change from 2014 to 2015. According to NSDUH data, adult use in Colorado
continued to be higher than the national average, which was 8%. BRFSS in 2015 showed past-month
adult marijuana use in Colorado was highest among those 18-25 years old (26%); males (17%); and those
who reported gay, lesbian, bisexual or other sexual orientation (37%). None of these groups saw a
statistical change in use between 2014 and 2015. Northwest Colorado saw an increase in past-month
use from 2014 (10%) to 2015 (16%), while other regions had no statistical change.
In 2015, 6% of adults reported using marijuana daily or near-daily. This was lower than daily or near-
daily alcohol (22%) or tobacco use (16%). Of 18- to 25-year old marijuana users, 50% report using daily
or near-daily (13% of all 18- to 25-year olds). Among adult past-month marijuana users, 79% smoke, 30%
“vape” and 33% use edibles. Respondents could report using more than one method, which 50% of users
did. Finally, approximately 2% of adults drove a vehicle in the past 30 days after using marijuana.
Trends in adolescent marijuana use in Colorado
HKCS results from 2015 indicate approximately 21% of Colorado high school students had used
marijuana in the past-month. This is not statistically different from 2013 (20%) and is nearly identical
to national estimates from YRBSS (22%). From 2005-2015, past-month use fluctuated between
approximately 20% and 25%, with no clear trend. The most recent NSDUH data for high school age
adolescents (14- to 17-year olds) is from 2012-2014 and shows 17% past-month use. This compares with
the 2013 HKCS estimate of 19%. According to HKCS in 2015, past-month adolescent marijuana use was
nearly identical among males and females (21%). Comparing grade levels, use was highest among
juniors (26%) and seniors (28%). As with adults, students identifying as gay, lesbian, or bisexual were
more likely to report past-month use (35%) than those identifying as heterosexual (20%). Use is higher
among Hispanics (24%) and multiple or other races (28%) than among whites (20%).
In 2015, past-month marijuana use among high school students in Colorado (21%) was lower than past-
month alcohol use (30%) and higher than past-month tobacco use (9%). Smoking marijuana is the most
popular method of use among high school students, with 87% reporting it as their usual method of use.
Edibles dropped from 5% in 2013 to 2% in 2015. In 2015, 27% of past-month high school users (more than
5% of all high school students) used daily or near-daily. Concerning age of first use, 41% of high school
seniors who had ever used marijuana said they first used it by age 14 or before and another 43% had
first used by age 16. 2015 data also showed that 8% of Colorado middle school students had ever used
marijuana and 4% used within the past-month.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
4
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0023.png
Section 1: Monitoring Changes in Marijuana Use Patterns in Colorado
Marijuana in Colorado homes with children
In 2015, CHS data showed 8% of adults with children 1-14 years old in the home had marijuana or
marijuana products in or around the home. In 82% of these homes, marijuana was stored safely, while
in 18% it was potentially stored unsafely. It is estimated that approximately 14,000 homes in Colorado
with children 1-14 years old had marijuana in the home with potentially unsafe storage.
For 2014 and 2015 together, 3% of adults with children 1-14 years old in the home reported marijuana
being used inside the home. Of these, 83% reported the marijuana was smoked, vaporized, or dabbed.
It is estimated that approximately 16,000 homes in Colorado had children 1-14 years old with possible
exposure to secondhand marijuana smoke or vapor in the home.
Trends in marijuana use during pregnancy and breastfeeding in Colorado
PRAMS results from 2014 show 11% of new mothers had used marijuana shortly before their pregnancy
and 6% of new mothers used it during their pregnancy. By comparison, 13% used alcohol and 6% used
tobacco during pregnancy. A 2016 article reported use during pregnancy was approximately 4%
nationally (see PRAMS chapter for details), an estimate that is not statistically different from PRAMS
results for Colorado. According to PRAMS, use during pregnancy in Colorado was statistically higher
among women 20-24 years old (13%) than among women 25-34 years old (4%) or women 35 years old or
older (3%). It also was higher among women with less than a 12
th
-grade education (16%) than among
women with some college (4%). Use during pregnancy was lower among women who intended to
become pregnant (4%) than women with unintended pregnancies (9%). Finally, approximately 5% of new
mothers used marijuana after pregnancy when they were also breastfeeding.
Discussion
The citizens of Colorado exhibit behaviors much more complex than any survey can capture. Currently
available data cannot answer all the important questions we have about whether or not marijuana use
patterns are changing as a result of legalization. The data presented here provide important insights
into marijuana use in adults as well as vulnerable populations such as pregnant women; youth; and
those with racial, ethnic and sexual orientation disparities.
Encouraging trends
For adults and adolescents, past-month marijuana use has not changed since legalization either in
terms of the number of people using or the frequency of use among users.
Based on the most comprehensive data available, past-month marijuana use among Colorado
adolescents is nearly identical to the national average.
We have not identified any
new
disparities in marijuana use by age, gender, race, ethnicity or
sexual orientation since legalization.
Daily or near-daily marijuana use among adults is much lower than daily or near-daily alcohol or
tobacco use. Among adolescents, past month marijuana use is lower than past month alcohol use.
Trends to continue monitoring
About 6 percent of pregnant women choose to use marijuana while pregnant. This percentage is
higher among those with unintended pregnancies as well as younger mothers or those with less
education.
At least 14,000 children in Colorado are at risk of accidentally eating marijuana products that are
not safely stored, and at least 16,000 are at risk of being exposed to secondhand marijuana smoke
in the home.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
5
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0024.png
Section 1: Monitoring Changes in Marijuana Use Patterns in Colorado
More than 5 percent of high school students use marijuana daily or near daily. This rate has
remained stable since at least 2005.
Past-month marijuana use among adults in Colorado is higher than the national average. In
Colorado, one in four adults ages 18-25 reported past-month marijuana use and one in eight use
daily or near-daily. These numbers have been consistent since legalization.
There continued to be disparities in marijuana use based on race/ethnicity for adolescents and
sexual orientation for both adults and adolescents.
While past-month marijuana use among adults and adolescents was stable for most regions in
Colorado, adult use in the Northwest Colorado region increased from 2014 to 2015.
More than 1-in-3 adolescents who use marijuana first use it by age 14, supporting prevention
efforts aimed at children before they enter ninth grade.
Recommendations and future directions
1. Continue assessing prevalence of marijuana use via large Colorado-based surveys including the
Pregnancy Risk Assessment Monitoring System, Healthy Kids Colorado Survey, and the Behavioral
Risk Factor Surveillance System. Data from surveys identify trends in use patterns that can be used
to inform and target education and prevention strategies. National surveys do not have a sufficient
Colorado sample size to fully address patterns of use by age, race/ethnicity, and any county or
regional catchment. Continued surveys using the same methodology can act as a feedback loop to
ensure marijuana policies and education campaigns are effective.
2. Continue to develop, improve and expand tools to monitor marijuana use patterns. Results from
the Cannabis Users Survey on Health (CUSH) will be reported in spring 2017. CUSH is a survey
created by CDPHE to gather more detailed information about adult marijuana use, including
methods, amounts and frequency of use; reasons for using; how it is purchased or obtained;
concurrent use with other substances; and any adverse effects experienced. CDPHE is collaborating
with other states and national organizations to expand use of this survey to other states.
3. Continue in-depth analyses of existing survey data to assess risk and protective factors for
marijuana use, including changes in the perception of harm from marijuana use.
4. Continue collaboration with other state and national agencies to identify data that might add
additional detail on use patterns in specific populations or geographic areas in the state.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
6
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0025.png
Section 1
Monitoring Changes in
Marijuana Use
Patterns
Chapter 1
Behavioral Risk Factor
Surveillance System (BRFSS)
2014-2015 Survey Results
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0026.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Authors
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Katelyn E. Hall, MPH
Statistical Analyst
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Elyse Contreras, MPH
Coordinator
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Amy Anderson Mellies, MPH
Health Data Analyst
Health Surveys and Evaluation Branch, Colorado Department of Public Health and Environment
Alison Grace Bui, MPH
Epidemiologist
Health Surveys and Evaluation Branch, Colorado Department of Public Health and Environment
Rickey Tolliver, MPH
Chief
Health Surveys and Evaluation Branch, Colorado Department of Public Health and Environment
Mike Van Dyke, PhD, CIH
Chief
Environmental Epidemiology, Occupational Health, and Toxicology Branch, Colorado Department of
Public Health and Environment
Reviewer
Shireen Banerji, PharmD, DABAT
Clinical Manager, Rocky Mountain Poison Center
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
8
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0027.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
The BRFSS survey and marijuana use in Colorado
The Behavioral Risk Factor Surveillance System (BRFSS) collects data on adult, individual-level
behavioral health risk factors associated with leading causes of premature mortality and morbidity. It is
the nation’s premier system of health-related
telephone surveys that collect state data about U.S.
residents regarding their health-related risk behaviors, chronic health conditions, and safety practices.
By collecting behavioral health risk data at the state and local level, BRFSS has become a powerful tool
for targeting and building health promotion activities.
1
Colorado participates in BRFSS using core and optional
modules, and it is able to add ‘state-added’
questions to customize data collection to topics most relevant to Coloradans. In 2014 and 2015
Colorado added questions on marijuana use to the BRFSS (Table 1).
2
These questions have begun to
give insight into marijuana use patterns among Colorado’s adult population.
For additional survey details and information about analysis methods, see Appendix B.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
9
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0028.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Survey questions
Table 1. Behavioral Risk Factor Surveillance System questions asked of Colorado
adults about marijuana use and methods of marijuana use, 2014-2015.
1. Have you ever used marijuana or hashish? (all respondents were asked)
a. Yes
b. No
c. Don't Know/Not Sure
2014/2015
2. How old were you the first time you used marijuana or hashish? (only ever users 2014/2015
were asked)
a. Age: _______
b. Don't Know/Not Sure
3. During the past 30 days on how many days did you use marijuana or hashish?
(only ever users were asked)
a. Number of Days: ________
b. None
c. Don't Know/Not Sure
2014/2015
4. During the past 30 days, how many times did you drive a car or other vehicle
2014/2015
when you had been using marijuana or hashish? (only current users were asked)
a. Number of days ________
b. Don't Know/Not Sure
5. On the days that you did use marijuana, how many times per day did you use it 2015
on average? (only current users were asked)
a. Number of times: ________
b. None
c. Don't know/Not sure
6. During the past 30 days, how did you use marijuana? For each of the following
methods please say YES if it does apply or NO if it does not apply or Don't
know/Not sure. (only current users were asked)
a. Was it vaporized? (e-cigarette-like vaporizer)
b. Was it smoked? (in a joint, bong, pipe, blunt)
c. Was it eaten in food? (in brownies, cakes, cookies, candy)
d. Was it consumed in a beverage? (tea, cola, alcohol)
e. Was it dabbed?
f. Was it used in some other way? _______________ (specify)
2015
The National Survey on Drug Use and Health
The Substance Abuse and Mental Health Services Administration (SAMHSA) tracks national and state
level data on tobacco, alcohol, marijuana, and illicit drugs including non-medical use of prescription
drugs through the National Survey on Drug Use and Health (NSDUH).
3
National and Colorado past 30 day
marijuana use estimates from the NSDUH survey were compared with the Colorado BRFSS past 30 day
marijuana use estimate (Figure 2).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
10
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0029.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Definitions
Current use
having used marijuana or hashish on at least one day in the past 30 days (answered at
least ‘1 day in the past 30 days’ on question 3) (Table 1)
Dabbing
a method of marijuana use where a "dab" (small amount) of marijuana concentrate is placed
on a pre-heated surface, creating concentrated marijuana vapor to be inhaled.
Daily or near daily use
- having used marijuana or hashish on twenty to thirty days in the past 30 days
(answered ‘20-30 days in the past 30 days’ on question 3) (Table 1)
Ever use
having used marijuana or hashish at least
once in their lifetime (answered ‘Yes’ on question
1) (Table 1)
Monthly use
- having
used marijuana or hashish on one to three days in the past 30 days (answered ‘1-3
days in the past 30 days’ on question 3) (Table 1)
Vaping (vaporization of marijuana)
- a method of marijuana use where marijuana vapor, rather than
smoke, is inhaled. Marijuana flower or concentrate is heated in a vaporizing device (vaporizer) to a
temperature below the point of combustion, to produce vapor.
Weekly use
- having used marijuana or hashish on four to nineteen days in the past 30 days (answered
‘4-19 days in the past 30 days’ on question 3) (Table 1)
How to interpret survey results
Respondents to the BRFSS survey are a sample of Colorado adults. The percent of survey respondents
selecting a specific answer might not be exactly the same as if all adults in Colorado were surveyed.
Therefore, the survey results are estimates, and each has a range of possible values (also called margin
of error, confidence interval, or 95% CI). These ranges are very important when comparing two
estimates, and the following terms are used throughout this report:
‘Not statistically different’-
Typically, if the ranges of possible values
overlap
for two different survey
results (like two different years, or male vs. female), we cannot be confident that there is a true
difference between the two (also called ‘not statistically significant.’) In some cases, an additional
statistical test is done to confirm.
‘Statistically higher’ or ‘statistically lower’-
If the ranges of possible values
do not overlap
for two
different results, we CAN be confident that there is a true difference between the two (also called
‘statistically significant.’)
On the figures in this report, these ranges of possible values are indicated by black bars. In footnotes,
they are referred to by the statistical term ‘95% CI.’
Results
Results are displayed in Figures 1-13 below.
Trends in marijuana use in Colorado
Ever marijuana use among Colorado adults was estimated at 49.3% in 2015. Survey results indicated
that there were no statistical differences in ever marijuana use from 2014 (48.8%) to 2015 (49.3%).
Current marijuana use among adults was estimated at 13.4% from 2015 BRFSS (Figure 1). The 2015
NSDUH estimate for current use was statistically higher, at 17.1% (Figure 2). Neither survey showed a
statistical difference in current use from 2014 to 2015 (Figure 2). NSDUH estimates of current
marijuana use among Colorado adults from 2006-2015 were statistically higher than the national
estimates for adult current marijuana use for each year (Figure 2). Monthly, weekly, and daily or near
daily marijuana use among adults in 2015 was 3.5%, 3.6%, and 6.3% respectively. In both 2014 and
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
11
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0030.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
2015, daily or near daily marijuana use was statistically higher than monthly or weekly marijuana use
(Figure 3). Comparing across years within each level of use, there were no statistical differences
between 2014 and 2015 (Figure 3). In 2015, 2.1% of adults drove a vehicle in the past 30 days when
using marijuana (Figure 4). This was not statistically higher than in 2014 (2.5%).
Current marijuana use in Colorado by age, gender, race & ethnicity, and sexual
orientation
In both 2014 and 2015, current marijuana use was lower among adults 35 years and older (9.3%, 10.3%)
than among those 18-25 (27.5%, 26.1%) or 26-34 years of age (19.8%, 18.3) (Figure 5). Comparing across
years within each age category, there were no statistical differences between 2014 and 2015 (Figure
5). In both 2014 and 2015, current marijuana use was higher among males (17.2%, 16.9%) than females
(10.0%, 10.0%) (Figure 6). Comparing across years within each gender, there were no statistical
differences in current marijuana use from 2014 to 2015 (Figure 6). There also were no statistical
differences in current marijuana use estimates from 2014 to 2015 within any of the race/ethnicity
groups: Hispanic, White, Black, Multiracial, or Other Race (Figure 7). In both 2014 and 2015, current
marijuana use was higher among those who reported Gay, Lesbian, Bisexual, or Other sexual
orientation (30.1%,36.9%) compared to those who reported Heterosexual orientation (12.9%, 12.4%)
(Figure 8). Comparing across years within each sexual orientation category, there were no statistical
differences in current marijuana use from 2014 to 2015 (Figure 8).
Current marijuana use in Colorado by region
In 2015, the range of current marijuana use was 11.2% to 17.0% across regions compared to 10.3% to
15.1% in 2014. The Northwest region of Colorado had a statistical increase in current marijuana use
from 10.3% in 2014 to 16.0% in 2015 (Figure 9). There were no statistical differences in current
marijuana use from 2014 to 2015 in all other regions (Figure 9).
Daily or near daily marijuana use in Colorado
In both 2014 and 2015, daily or near daily marijuana use (6.0%, 6.3%) among adults was lower than
daily or near daily alcohol (22.8%, 21.8%) or tobacco use (15.9%, 15.6%) (Figure 10). Comparing across
years within each substance, there were no statistical differences between 2014 and 2015 (Figure 10).
In both 2014 and 2015, daily or near daily marijuana use was lower among adults 35 years and older
(3.6%, 4.8%) than among those 18-25 (13.3%, 13.1%) or 26-34 years of age (9.9%, 8.4%) (Figure 11).
Comparing across years within each age group, there were no statistical differences in daily or near
daily marijuana use between 2014 and 2015 (Figure 11).
Methods of marijuana use
Data on methods of use were only available for 2015. Dabbing was reported less among current users
aged 35 years and older (7.0%) than among those 18-25 (36.0%) or 26-34 (25.2%) years of age (Figure
12). There were no statistical differences between age groups in the number of adults who smoked,
vaporized, or ate/drank marijuana (Figure 12). Approximately half of adults who currently use
marijuana reported using it through multiple methods (49.9%), which was statistically higher than all
other reported methods of marijuana use (Figure 13). Only smoked (40.4%) was the next most
commonly reported method of use after multiple methods followed by only vaporized (5.8%), only
ate/drank (3.6%) and only dabbed (0.3%) in the past 30 days (Figure 13).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
12
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0031.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 1. Ever and current marijuana use among Colorado adults (18+ years),
2014-2015.
Produced by: EEOHT, CDPHE 2016.
*Black bars indicate margins of error (95% Confidence Intervals).
†Ever Use was marijuana use at least once in a lifetime. Current Use is defined as marijuana use at least once in the past 30
days.
‡Data Source: Colorado Behavioral Risk Factor Surveillance System 2015.
Major findings
Ever marijuana use among Colorado adults (18+ years) was not statistically different from 2014
to 2015.
a
Current marijuana use (marijuana use at least once in the past 30 days) among adults was not
statistically different from 2014 to 2015.
b
a
b
Ever marijuana use 2014 vs. 2015:
Χ
2
= 0.15, p=0.7017
Current marijuana use 2014 vs. 2015:
Χ
2
= 0.07, p=0.7922
For an
explanation of terms, see “How to interpret survey results”
above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.1.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
13
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0032.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 2. Current marijuana use among adults (18+ years): NSDUH 2006-2015 and
BRFSS 2014-2015.
Produced by: EEOHT, CDPHE 2016.
*Black bars indicate margins of error (95% Confidence Intervals).
†Daily or Near Daily Use is defined as using 20-30
days in the past 30 days (marijuana or alcohol) or reporting everyday or
someday use (smoking tobacco).
‡Data Source: Substance Abuse and Mental Health Services Administration, National Survey on Drug Use and Health (NSDUH)
2006-2014. Colorado Behavioural Risk Factors Surveillance System (BRFSS) 2014-2015
Major findings
BRFSS estimated current marijuana use among Colorado adults was not statistically different from
2014 to 2015.
c
NSDUH estimated current marijuana use among Colorado adults was not statistically different from
2014 to 2015.
d
In 2015, the NSDUH estimate for current marijuana use among Colorado adults was statistically
higher than the BRFSS estimate.
e
NSDUH estimates of current marijuana use among Colorado adults from 2006-2015 were statistically
higher than the national estimates for adult current marijuana use for each year.
f
c
d
e
Current marijuana use (BRFSS): 2014 13.6% (95% CI 12.4-14.8%), 2015 13.4% (95% CI 12.3-14.5%)
Current marijuana use (NSDUH): 2014 15.2% (95% CI 13.1-17.5%), 2015 17.1% (95% CI 15.0-19.5%)
Current marijuana use: 2014 BRFSS 13.6% (95% CI 12.4-14.8%), 2014 NSDUH 15.2% (95% CI 13.1-17.5%), 2015 BRFSS 13.4% (95% CI
12.3-14.5%), 2015 NSDUH 17.1% (95% CI 15.0-19.5%)
f
See Appendix B, Table B.2 for Colorado & National NSDUH estimates from 2006-2015
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.2.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
14
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0033.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 3. Monthy, weekly, and daily or near daily marijuana use among Colorado
adults (18+ years), 2014-2015.
Produced by: EEOHT, CDPHE 2016.
*Black bars indicate margins of error (95% Confidence Intervals).
†Monthy use was using marijuana 1-3
days in the past 30 days, weekly use was using marijuana 4-19 days in the past 30 days, and
daily or near daily use was using marijuana 20 or more days in the past 30 days.
‡Data Source: Colorado Behavioral Risk Factor Surveillance System 2015.
Major findings
In both 2014 and 2015, daily or near daily marijuana use among adults was statistically higher than
monthly or weekly marijuana use.
g
Comparing across years within each level of use, there were no statistical differences between
2014 and 2015.
h
g
In 2014: daily/near daily 6.0% (95% CI 5.2-6.9%), monthly 4.2% (95% CI 3.5-4.8%), weekly 3.4% (95% CI: 2.8-4.0%). In 2015:
daily/near daily 6.3% (95% CI 5.5-7.2%), monthly 3.5% (95% CI 2.9-4.0%), weekly 3.6 (95% CI 3.0-4.2%).
h
Monthly, weekly and daily/near daily use 2014 vs. 2015:
Χ
2
= 2.56, p=0.4636
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.3.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
15
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0034.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 4. Colorado adults (18+ years) who drove a vehicle when using marijuana in
the past 30 days, 2014-2015.
Produced by: EEOHT, CDPHE 2016.
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use was marijuana use at least once in the past 30 days.
‡Data Source: Colorado Behavioral Risk Factor Surveillance System 2015.
Major findings
The prevalence of Colorado adults who drove a vehicle when using marijuana in the past 30 days
was not statistically different from 2014 to 2015.
i
i
Drove a vehicle when using marijuana, 2014 vs. 2015:
Χ
2
= 1.26, p=0.2609
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.4.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
16
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0035.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 5. Current marijuana use among Colorado adults (18+ years) by age
categories, 2014-2015.
Produced by: EEOHT, CDPHE 2016.
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use was marijuana use at least once in the past 30 days.
‡Data Source: Colorado Behavioral Risk Factor Surveillance System 2015.
Major findings
Current marijuana use was statistically lower among adults 35 years and older than among adults
18-25 years or 26-34 years of age in both 2014 and 2015.
j
Comparing across years within each age category, there were no statistical differences between
2014 and 2015.
k
j
In 2014: 35+ years 9.3% (95% CI 8.3-10.3%), 26-34 years 19.8% (95% CI 16.3-23.4%), 18-25 years 27.5% (95% CI 22.6-32.3%). In
2015: 35+ years 10.3% (95% CI 9.3-11.2%), 18-25 years 26.1% (95% CI 21.2-31.0%), 26-34 years 18.3% (95% CI 14.7-21.9%).
Current use 2014 vs. 2015: 18-25 years
Χ
2
= 0.15, p=0.6974; 26-34 years
Χ
2
= 0.36, p=0.5470; 35 years and older
Χ
2
= 1.97,
p=0.1607.
k
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.5.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
17
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0036.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 6. Current marijuana use among Colorado adults (18+ years) by gender,
2014-2015.
Produced by: EEOHT, CDPHE 2016.
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use was marijuana use at least once in the past 30 days.
‡Data Source:
Colorado Behavioral Risk Factor Surveillance System 2015.
Major findings
Current marijuana use was statistically higher among male adults compared to female adults in
both 2014 and 2015.
l
Comparing across years within each gender, there were no statistical differences in current
marijuana use from 2014 to 2015.
m
l
In 2014: males 17.2% (95% CI 15.4-19.1%), females 10.0% (95% CI 8.6-11.4%). In 2015: males 16.9% (95% CI 15.1-18.6%), females
10.0% (95% CI 8.7-11.4%).
m
Current use 2014 vs. 2015: adult males
Χ
2
= 0.07, p=0.7846; adult females
Χ
2
= 0.003, p=0.9509.
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.6.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
18
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0037.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 7. Current marijuana use among Colorado adults (18+ years) by race and
ethnicity, 2014-2015.
Produced by: EEOHT, CDPHE 2016.
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use was marijuana use at least once in the past 30 days.
‡Data Source: Colorado Behavioral Risk Factor Surveillance System 2015.
Major findings
There were no statistical differences in estimates of current marijuana use from 2014 to 2015
within any of the race/ethnicity groups: Hispanic, White, Black, Multiracial, or Other Race.
n
Current use 2014 vs. 2015: Hispanic
Χ
2
= 0.14, p=0.7087; multiracial
Χ
2
= 0.57, p=0.4516; other
Χ
2
= 2.30, p=0.1298; white non-
Hispanic
Χ
2
= 0.02, p=0.8845; black
Χ
2
= 3.45, p=0.0633.
n
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.7.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
19
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0038.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 8. Current marijuana use among Colorado adults (18+ years) by sexual
orientation, 2014-2015.
Produced by: EEOHT, CDPHE 2016.
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use was marijuana use at least once in the past 30 days.
‡Data Source: Colorado Behavioral Risk Factor Surveillance System 2015.
Major findings
Current marijuana use was higher among those who reported Gay, Lesbian, Bisexual, or Other
sexual orientation compared to those who reported Heterosexual orientation in both 2014 and
2015.
o
Comparing across years within each sexual orientation category, there were no statistical
differences in current marijuana use from 2014 to 2015.
p
In 2014: Gay, Lesbian, Bisexual, or Other 30.1% (95% CI 21.7-38.4%), Heterosexual 12.9% (95% CI 11.8-14.1%). In 2015: Gay,
Lesbian, Bisexual, or Other 36.9% (95% CI 28.1-45.8%), Heterosexual 12.4% (95% CI 11.4-13.5%).
Current use 2014 vs. 2015: heterosexual adults
Χ
2
= 0.41, p=0.5226;
gay, lesbian, bisexual, or other sexual orientation adults Χ
2
=
1.23, p=0.2669.
p
o
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.8.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
20
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0039.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 9. Current marijuana use among Colorado adults (18+ years) by regions,
2014-2015.
Produced by: EEOHT, CDPHE 2016.
†Black bars indicate margins of error (95%
Confidence Intervals).
‡Current Use was marijuana use at least once in the past 30 days.
§Data Source: Colorado Behavioral Risk Factor Surveillance System 2015.
Major findings
Current marijuana use among adults in Colorado’s Northwest region was
statistically higher in 2015
than in 2014.
q
There were no statistical differences in estimates of current marijuana use from 2014 to 2015
within the other regions of Colorado: Southwest, Denver-Boulder, South Central, Southeast, or
Northeast.
r
q
r
Current use among adults in the Northwest Region in 2014 vs. 2015:
Χ
2
= 4.91, p=0.027
Current use 2014 vs. 2015:
Southwest Region Χ
2
= 0.89, p=0.3457; Denver-Boulder
Region Χ
2
= 1.91 p=0.1664; South Central
Region Χ
2
= 0.48, p=0.487;
Southeast Region Χ
2
= 0.11, p=0.742;
Northeast Region Χ
2=
0.09, p=0.765.
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.9.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
21
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0040.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 10. Daily or near daily use of alcohol, tobacco, and marijuana among
Colorado adults (18+ years) 2014-2015.
Produced by: EEOHT, CDPHE 2016.
*Black bars indicate margins of error (95% Confidence Intervals).
†Daily or Near Daily Use is defined as
using 20-30 days in the past 30 days (marijuana or alcohol) or reporting everyday or
someday use (smoking tobacco).
‡Data Source: Colorado Behavioral Risk Factor Surveillance System 2015.
Major findings
The prevalence of daily or near daily marijuana use among Colorado adults was statistically lower
than daily or near daily alcohol or tobacco use in both 2014 and 2015.
Comparing across years within each substance, there were no statistical differences between 2014
and 2015.
s
s
In 2014: Marijuana 6.0% (95% CI 5.2-6.9%), Alcohol 22.8% (95% CI 21.2-24.5%), Tobacco 15.9% (95% CI 14.7-17.1%). In 2015:
Marijuana 6.3% (95% CI 5.5-7.2%), Alcohol 21.8% (95% CI 20.4-23.3%), Tobacco 15.6% (95% CI 14.6-16.7%).
For an explanation of terms,
see “How
to interpret survey results” above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.10.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
22
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0041.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 11. Daily or near daily marijuana use among Colorado adults (18+ years) by
age categories, 2014-2015.
Produced by: EEOHT, CDPHE 2016.
*Black bars indicate margins of error (95% Confidence Intervals).
†Daily or near daily was using marijuana 20 or more days in the
past 30 days.
‡Data Source: Colorado Behavioral Risk Factor Surveillance System 2015.
Major findings
Daily or near daily marijuana use was statistically lower among adults 35 years and older than
among those 18-25 or 26-34 years of age in both 2014 and 2015.
t
Comparing across years within each age group, there were no statistical differences in daily or near
daily marijuana use between 2014 and 2015.
u
t
In 2014: 35+ years 3.6% (95% CI 3.0-4.3%), 18-25 years 13.3% (95% CI 9.4-17.2%), 26-34 years 9.9% (95% CI 7.1-12.6%). In 2015:
35+ years 4.8% (95% CI 4.1-5.5%), 18-25 years 13.1% (95% CI 9.3-17.0%), 26-34 years 8.4% (95% CI 5.7-11.1%).
u
Current use 2014 vs. 2015: 18-25 years
Χ
2
= 0.22, p=0.8991; 26-34 years
Χ
2
= 0.63, p=0.729; 35 years and older
Χ
2
= 5.86,
p=0.0534.
For an
explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.11.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
23
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0042.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 12. Methods of marijuana use among Colorado adults (18+ years) who
reported current use, by age categories, 2015.
Produced by: EEOHT, CDPHE 2016.
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use was marijuana use at least once in the past 30 days. Use of more than one method may have been
reported in the
past 30 days.
‡Data Source: Colorado Behavioral Risk Factor Surveillance System 2015.
Major findings
Reported dabbing marijuana in the past 30 days was statistically lower among Colorado adults aged
35 years and older than among those 18-25 or 26-34 years of age.
v
There were not statistical differences between age groups within those that smoked, vaporized, or
ate/drank marijuana.
w
v
w
Dabbed: 18-25 years 36.0% (95% CI 25.3-46.7%), 26-34 years 25.2% (95% CI 14.5-35.9%), 35+ years 7.0% (95% CI 4.2-9.8%).
Smoked: 18-25 years 89.5% (95% CI 83.1-95.9%), 26-34 years 86.9% (95% CI 78.6-95.2%), 35+ years 78.9% (95% CI 75.1-82.8%).
Vaporized: 18-25 years 34.8% (95% CI 24.1-45.5%), 26-34 years 36.4% (95% CI 25.4-47.5%), 35+ years 29.7% (95% CI 25.0-34.5%).
Ate/drank: 18-25 years 37.9% (95% CI 27.2-48.6%), 26-34 years 39.1% (95% CI 28.1-50.1%), 35+ years 33.5% (95% CI 28.7-38.2%).
For an explanation
of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.12.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
24
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0043.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
Figure 13. Methods of marijuana use among Colorado adults (18+ years) who
reported current use, 2015.
Produced by: EEOHT, CDPHE 2016.
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use was marijuana use at least once in the past 30
days.
‡Data Source: Colorado Behavioral Risk Factor Surveillance System 2015.
Major findings
Approximately half of adults who currently use marijuana use it through multiple methods.
The prevalence of Colorado adults who used marijuana multiple methods in the past 30 days was
statistically higher than those who only smoked, only vaporized, only ate/drank, and only dabbed
in the past 30 days.
x
x
Multiple methods 49.9% (95% CI 45.4-54.5%), Only Smoked 40.4% (95% CI 36.0-44.8%), Only Vaporized 5.8% (95% CI 3.6-8.0%),
Only Ate/Drank 3.6% (95% CI 2.3-4.9%), Only Dabbed 0.3% (95% CI 0.0-0.6%).
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix B. For data, see
Appendix B, Table B.13.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
25
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0044.png
Section 1: Behavioral Risk Factor Surveillance System (BRFSS)
References
1. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System: Annual
Survey Data. http://www.cdc.gov/brfss/annual_data/annual_data.htm. Accessed October 7,
2016.
2. Colorado Department of Public Health and Environment. Colorado Health and Environmental Data:
Adult Health Data: Behavioral Risk Factor Surveillance System.
http://www.chd.dphe.state.co.us/topics.aspx?q=Adult_Health_Data. Accessed October 7, 2016.
3. Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and
Health. https://nsduhweb.rti.org/respweb/homepage.cfm.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
26
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0045.png
Section 1
Monitoring Changes in
Marijuana Use
Patterns
Chapter 2
Child Health Survey (CHS)
2014-2015 Survey Results
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0046.png
Section 1: Child Health Survey (CHS)
Authors
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Katelyn E. Hall, MPH
Statistical Analyst
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Elyse Contreras, MPH
Coordinator
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Ashley Juhl, MSPH
Maternal and Child Health Epidemiologist
Health Surveys and Evaluation Branch, Colorado Department of Public Health and Environment
Anne Schiffmacher, MPH
Maternal and Child Health Epidemiologist
Health Surveys and Evaluation Branch, Colorado Department of Public Health and Environment
Allison Grace Bui, MPH
Epidemiologist
Health Surveys and Evaluation Branch, Colorado Department of Public Health and Environment
Rickey Tolliver, MPH
Chief
Health Surveys and Evaluation Branch, Colorado Department of Public Health and Environment
Mike Van Dyke, PhD, CIH
Chief
Environmental Epidemiology, Occupational Health, and Toxicology Branch, Colorado Department of
Public Health and Environment
Reviewer
Ashley Brooks-Russell, PhD, MPH
Assistant Professor
Injury Prevention, Education and Research Program, Colorado School of Public Health
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
28
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0047.png
Section 1: Child Health Survey (CHS)
The CHS survey and marijuana-related behaviors in Colorado
Since 2004, the Colorado Department of Public Health and Environment has conducted the Child Health
Survey (CHS). This annual survey provides data on a wide range of health issues and risk factors
affecting children and youth in Colorado for children ages 1-14. The CHS is conducted as a telephone
survey among respondents to the Behavioral Risk Factor Surveillance System (BRFSS) Survey who have
children ages 1-14 years old. Data from the CHS help to identify areas where education, resources to
assist parents, policy changes or other data-informed actions can
improve the health of Colorado’s
children.
1
Since 2014, questions about marijuana use and storage in the home have been included in the survey
(Table 1). The presence of marijuana in or around the home was evaluated using question 1, and was
asked of
all survey participants. Participants who answered ‘YES’ to this question were asked how their
marijuana is stored, in question 2. Marijuana being used in the home was evaluated using question 3,
and was asked of all survey participants. Participants who answered
‘YES’ to this question were asked
how the marijuana was used inside the home in question 4. Results enable CDPHE to estimate the
number of children in Colorado who may be exposed to secondhand marijuana smoke or unintentional
ingestion due to unsafe storage of marijuana products in the home.
For additional survey details and information about analysis methods, see Appendix C.
Survey questions
Table 1. Child Health Survey questions about marijuana storage or use in or
around the home, 2014-2015.
1. Is there any marijuana or marijuana product in or around your home right now?
Yes
No
2. Where is the marijuana that is currently in or around your home being stored? For each of the
following methods please say yes if it does apply or no if it does not apply.
In a childproof container or packaging
In a locked container such as a cabinet, drawer or safe
In a location your child cannot access (such as out of reach)
Someplace else? (specify)
3. During the past 30 days, has anyone- including yourself, used marijuana or hashish inside your home?
Yes
No
4. How was the marijuana that was used inside your home consumed? For each of the following methods
please say yes if it does apply or no if it does not apply.
It was vaporized (e-cigarette-like vaporizer)
It was smoked (in a joint, bong, pipe, blunt)
It was eaten in food (in brownies, cakes, cookies, candy)
It was consumed in a beverage (tea, cola, alcohol)
It was used in some other way (specify)
It was dabbed
(response option was added in 2015)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
29
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0048.png
Section 1: Child Health Survey (CHS)
Definitions
Dabbing
a method of marijuana use where a "dab" (small amount) of marijuana concentrate is placed
on a pre-heated surface, creating concentrated marijuana vapor to be inhaled.
Possible exposure to second-hand marijuana smoke or vapor within the home
- defined by
combining three responses from question 4:
it was vaporized; it was smoked;
and
it was dabbed.
Dabbing was added as a response in 2015; therefore, this category could be underrepresented in 2014
because respondents who dabbed within the home may have indicated
it was used in some other way.
Safe storage of marijuana
- defined by combining three responses from question 2:
in a childproof
container or packaging; in a locked container such as a cabinet, drawer, or safe;
and
in a location your
child cannot access.
The response
someplace else
was considered potentially unsafe storage and a risk
for unintentional ingestion.
Vaping (vaporization of marijuana)
- a method of marijuana use where marijuana vapor, rather than
smoke, is inhaled. Marijuana flower or concentrate is heated in a vaporizing device (vaporizer) to a
temperature below the point of combustion, to produce vapor.
How to interpret survey results
Respondents to the Child Health Survey are a sample of Colorado adults with children 1-14 years old.
The percent of survey respondents selecting a specific answer might not be exactly the same as if all
adults with children 1-14 years old in Colorado were surveyed. Therefore, the survey results are
estimates, and each has a range of possible values (also called margin of error, confidence interval, or
95% CI). These ranges are very important when comparing two estimates, and the following terms are
used throughout this report:
‘Not statistically different’-
Typically, if the ranges of possible values
overlap
for two different survey
results (like two different years, or male vs. female), we cannot be confident that there is a true
difference between the two (also called ‘not statistically significant.’) In some cases, an additional
statistical test is done to confirm.
‘Statistically higher’ or ‘statistically lower’-
If the ranges of possible values
do not overlap
for two
different results, we CAN be confident that there is a true difference between the two (also called
‘statistically significant.’)
On the figures in this report, these ranges of possible values are indicated by black bars. In footnotes,
they are referred to by the statistical term ‘95% CI.’
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
30
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0049.png
Section 1: Child Health Survey (CHS)
Results
Results are displayed in Figures 1-3 below.
Marijuana in or around the home and safe storage
In 2015, 7.9% of adults with children 1-14 years old in the home reported having marijuana or
marijuana products in or around the home (Figures 1 & 2). In 82.2% of these homes, marijuana was
stored safely, while in 17.8% the marijuana was potentially stored unsafely (Figure 2). It was estimated
that approximately 14,000 homes in Colorado with children 1-14 years old had marijuana in the home
with potentially unsafe storage.
Comparing across years, there were no statistical differences from 2014 to 2015 in the prevalence of
marijuana or marijuana products in or around the home (6.9%, 7.9%; Figure 1) or safe storage in homes
with marijuana (86.0%, 82.2%; Figure 2). There were no differences in marijuana being in or around the
home by child’s age, highest household education, or household income,
or difference from 2014 to
2015 (data not shown).
Marijuana used inside the home and secondhand smoke exposure
For 2014 and 2015 together, 3.2% of adults with children 1-14 years old in the home reported
marijuana being used inside the home (Figure 3). Of these, 83.2% reported the marijuana was smoked,
vaporized, or dabbed (Figure 3). It was estimated that approximately 16,000 homes in Colorado had
children 1-14 years old with possible exposure to secondhand marijuana smoke or vapor in the home.
Comparing across years, there were no statistical differences from 2014 to 2015 in the prevalence of
marijuana being used inside the home (3.9%, 2.6%; Figure 1).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
31
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0050.png
Section 1: Child Health Survey (CHS)
Figure 1. Presence of marijuana in or around the home or used in the home where
children live, 2014-2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Data Source:
Colorado Child Health Survey 2014-2015 a call-back survey from BRFSS for adults with children 14 years old or
younger in the home.
Major findings
The prevalence of marijuana or marijuana products in or around homes where children live was not
statistically different between 2014 and 2015.
a
The prevalence of marijuana being used inside homes where children live was not statistically
different between 2014 and 2015.
b
a
b
Marijuana or marijuana products in or around the home: 2014 6.9% (95% CI 4.9-8.9%), 2015 7.9% (95% CI 4.9-10.9%)
Marijuana used inside the home: 2014 3.9% (95% CI 2.4-5.4%), 2015 2.6% (95% CI 0.8-4.4%)
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix C. For data, see
Appendix C, Table C.1.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
32
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0051.png
Section 1: Child Health Survey (CHS)
Figure 2. Percent of adults with children and marijuana in or around the home
who store their marijuana in a safe place, 2014-2015.
2014
Marijuana in or around the home
Marijuana storage in or around the home
*
2015
Marijuana in or around the home
Marijuana storage in or around the home
*
Produced by: EEOHT, CDPHE 2016
*Statistically different due to non overlapping 95% confidence intervals (95% CI).
†Black bars indicate margins of error (95% Confidence Intervals)
‡Data Source: Colorado Child Health Survey 2014-2015
a call-back survey from BRFSS for adults with children 14 years or younger
in the home.
§Safe storage included a childproof container, a locked container, or a location a child cannot access.
Major findings:
The prevalence of marijuana being stored safely in homes where children live was not statistically
different between 2014 and 2015.
c
Marijuana safe storage: 2014 86.0% (95% CI 76.4-95.6%), 2015 82.2% (95% CI 70.1-94.2%)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
33
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0052.png
Section 1: Child Health Survey (CHS)
Figure 3. Methods of marijuana use among adults with children in the home, 2014-
2015 (years combined).
2014-2015
Marijuana use in the home
Methods of marijuana use in the home
*
Produced by: EEOHT, CDPHE 2016
*Statistically different due to non overlapping 95% confidence intervals (95% CI).
†Black bars indicate margins of error (95% CI)
‡Dabbing
was added as a response in 2015.
§ Data Source: Colorado Child Health Survey 2014-2015 a call-back survey from BRFSS for adults with children 14 years or younger
in the home.
Major findings
Among adults who use marijuana in a home where children live, the prevalence of
‘smoked,
vaporized or dabbed’ was statistically
higher than ‘ate or drank’.
d
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix C. For data, see
Appendix C, Table C.2.
d
For 2014-2015 combined years: smoked, vaporized or dabbed 83.2% (95% CI 64.3-100.0%), ate or drank 24.0% (95% CI 5.2-42.7%)
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix C. For data, see
Appendix C, Table C.3.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
34
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0053.png
Section 1: Child Health Survey (CHS)
References
1. Colorado Department of Public Health and Environment. Maternal and Child Health Data, Colorado
Child Health Survey Data. 2016;
http://www.chd.dphe.state.co.us/topics.aspx?q=Maternal_Child_Health_Data. Accessed January 1,
2017.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
35
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0054.png
Section 1: Child Health Survey (CHS)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
36
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0055.png
Section 1
Monitoring Changes in
Marijuana Use
Patterns
Chapter 3
Healthy Kids Colorado Survey
(HKCS)
2005-2015 Survey Results
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0056.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Authors
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Katelyn E. Hall, MPH
Statistical Analyst
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Elyse Contreras, MPH
Coordinator
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Amy Anderson Mellies, MPH
Health Data Analyst
Health Surveys and Evaluation, Colorado Department of Public Health and Environment
Leonardo Kattari, MSW
Healthy Kids Colorado Survey Coordinator
Prevention Services, Colorado Department of Public Health and Environment
Kevin Berg, MA
GIS Epidemiologist
Environmental Epidemiology, Colorado Department of Public Health and Environment
Rickey Tolliver, MPH
Chief
Health Surveys and Evaluation, Colorado Department of Public Health and Environment
Mike Van Dyke, PhD, CIH
Chief
Environmental Epidemiology, Occupational Health, and Toxicology, Colorado Department of Public
Health and Environment
Reviewer
Ashley Brooks-Russell, PhD, MPH
Assistant Professor
Injury Prevention, Education and Research Program, Colorado School of Public Health
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
38
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0057.png
Section 1: Healthy Kids Colorado Survey (HKCS)
The HKCS survey and marijuana use in Colorado
The Healthy Kids Colorado Survey (HKCS) collects health information in the fall of odd years from
public high school and middle school students. It is a voluntary, anonymous survey, and parents are
notified ahead of time. HKCS is a collaboration of the Colorado Department of Public Health and
Environment (CDPHE), the Colorado Department of Education, and the Colorado Department of Human
Services, who recognized the need to gather critical data while minimizing the student survey requests
to Colorado schools. Both state and regional data are available to provide schools and communities
with information to support effective strategies to protect the health and promote academic
achievement of Colorado youth. This survey also fulfills Colorado’s reporting requirement
for the CDC-
sponsored Youth Risk Behavioral Surveillance Survey (YRBS)
1
and ensures Colorado data can be
compared to both national data and data from other states. HKCS provides data on a wide range of
health issues and risk factors affecting children and youth including: nutrition, physical activity, safety
behaviors, mental health, alcohol, tobacco and other substance use, and sexual behaviors (high school
only). The survey has included questions on marijuana since 1999.
2
This report includes results from
2005-2015 for high school and 2011-2015 for middle school.
For additional survey details and information about analysis methods, see Appendix D.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
39
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0058.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Survey questions
Table 1. Healthy Kids Colorado Survey questions asked of middle school and high
school students about whether they use marijuana, when they use it and how they
use it, 2005-2015.
Not all questions were included in all years and not all questions were asked of both middle school and
high school students.
1. During your life, how many times have you used marijuana?
o
o
o
o
0 times
1 or 2 times
3 to 9 times
10 to 19 times
o
o
o
20 to 39 times
40 to 99 times
100 or more times
2. How old were you when you tried marijuana for the first time?
o
o
o
o
I have never tried marijuana
8 years old or younger
9 or 10 years old
11 or 12 years old
o
o
o
13 or 14 years old
15 or 16 years old
17 years old or older
3. During the past 30 days, how many times did you use marijuana?
o
o
o
0 times
1 or 2 times
3 to 9 times
o
o
o
10 to 19 times
20 to 39 times
40 or more times
4. During the past 30 days, how did you use marijuana? (Select all that apply.)
o
o
o
o
o
o
I
I
I
I
I
I
did not use marijuana during the past 30 days
smoked it
ate it (in an edible, candy, tincture or other food)
used a vaporizer
dabbed it*
used it in some other way
5. During the past 30 days, how did you usually use marijuana? (Select only one response.)
o
o
o
o
o
I
I
I
I
I
did not use marijuana during the past 30 days
smoked it I ate it (in an edible, candy, tincture or other food)
used a vaporizer
dabbed it*
used it in some other way
*
The response option of “I dabbed it” was added in 2015
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
40
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0059.png
Section 1: Healthy Kids Colorado Survey (HKCS)
The National Survey on Drug Use and Health
The Substance Abuse and Mental Health Services Administration (SAMHSA) tracks national and state
level data on tobacco, alcohol, marijuana, and illicit drugs including non-medical use of prescription
drugs through the National Survey on Drug Use and Health (NSDUH).
3
Colorado past 30 day marijuana
use estimates from the NSDUH survey were compared with the Colorado HKCS past 30 day marijuana
use estimates (Figure 2).
Definitions
Current use
Having used marijuana at least once in the past 30 days (any answer
other than ‘0 times’
on question 3) (Table 1)
Dabbing
a method of marijuana use where a "dab" (small amount) of marijuana concentrate is placed
on a pre-heated surface, creating concentrated marijuana vapor to be inhaled.
Ever use
having used marijuana at least once in their lifetime (any answer other
than ‘0 times’ on
question 1) (Table 1)
Tried marijuana before age 13
answered
‘11 or 12 years old’, ‘9 or 10 years old’, or ‘8 years
old or
younger’ on question 2
(Table 1)
Vaping (vaporization of marijuana)
- a method of marijuana use in which marijuana vapor, rather than
smoke, is inhaled. Marijuana flower or concentrate is heated in a vaporizing device (vaporizer) to a
temperature below the point of combustion, to produce vapor.
How to interpret survey results
Respondents to the Healthy Kids Colorado Survey are a sample of Colorado high school and middle
school students. The percent of survey respondents selecting a specific answer might not be exactly
the same as if every student in Colorado were surveyed. Therefore, the survey results are estimates,
and each has a range of possible values (also called margin of error, confidence interval, or 95% CI).
These ranges are very important when comparing two estimates, and the following terms are used
throughout this report:
‘Not statistically different’-
Typically, if the ranges of possible values
overlap
for two different survey
results (like two different years, or male vs. female), we cannot be confident that there is a true
difference between the two (also called ‘not statistically significant.’) In some cases, an additional
statistical test is done to confirm.
‘Statistically higher’ or ‘statistically lower’-
If the ranges of possible values
do not overlap
for two
different results, we CAN be confident that there is a true difference between the two (also called
‘statistically significant.’)
On the figures in this report, these ranges of possible values are indicated by black bars. In footnotes,
they are referred to by the statistical term ‘95% CI.’
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
41
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0060.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Results
Results are displayed in Figures 1-13 and Maps 1-2 below.
Trends in marijuana use in Colorado
Survey results from 2015 indicate that approximately 38% of Colorado high school students report
having ever used marijuana and 21% report use in the past 30 days (Figures 1 & 3). These estimates are
similar to national estimates of ever and current marijuana use among high school students (Figure 1).
From 2005-2015, estimates of current marijuana use among Colorado high school students have
fluctuated between approximately 20% and 25% (Figures 1 & 3). From 2005 to 2013, the HKCS estimates
of current marijuana use among high school students in Colorado were higher than the NSDUH
estimates for current marijuana use among high school aged adolescents. However, the difference
became smaller in 2013, at 19.7% on HKCS and 17.4% on NSDUH (Figure 2). Among Colorado middle
school students in 2015, an estimated 7.6% had ever used marijuana and an estimated 4.4% reported
currently using marijuana (Figure 3). Current marijuana use among high school students in Colorado has
remained below current alcohol use from 2005 to 2015 and above current tobacco smoking from 2011
to 2015. Current alcohol use and tobacco smoking among high school students in Colorado has trended
downward since 2005, while current marijuana use has remained stable (Figure 4). In both 2013 and
2015, current marijuana use among Colorado 9
th
graders (13.7%, 12.4%) was statistically lower than
among 10
th
graders (19.0%, 18.8%), which was statistically lower than among 11
th
graders (22.1%, 26.3%)
(Figure 5).
Marijuana use among Colorado high school students by gender, race & ethnicity,
and sexual orientation
Current marijuana use among male high school students in 2013 (21.5%) was statistically higher than
among female students (17.7%), but current use for both genders was nearly identical in 2015 (21.4%,
21.0%) (Figure 6). Current marijuana use among middle school students was not statistically different
between males and females in 2013 (5.3%, 4.8%) or 2015 (3.8%, 5.2%) (Figure 7). Prevalence of current
marijuana use and age of first use varied among students of different races and ethnicities (Figures 8 &
11). The percent of white non-Hispanic students who tried marijuana before age 13 was statistically
lower than among black, Hispanic, or multiple or other race students (Figure 11). Prevalence of
marijuana use also varied among students with different sexual orientation. In both 2013 and 2015,
estimated current use of marijuana among students identifying as gay, lesbian, or bisexual (39.7%,
34.9%) was statistically higher than the estimated current use among students identifying as
heterosexual (17.7%, 19.5%) (Figure 9). In 2015, a large portion of high seniors reported first trying
marijuana at ages 13-14 years old (27.0%) and 15-16 years old (43.1%) compared to younger ages and 17
and older (Figure 10).
Methods and frequency of marijuana use in Colorado
In 2015, 87% of high school students who currently used marijuana reported that smoking was their
usual method of use
much higher than edibles (2%), vaping (5%), or other methods of use (6%) (Figure
12). More than one-third of high school or middle school students who reported current marijuana use
in 2015 had used once or twice in the past 30 days, while approximately 27% of high school students
and 20% of middle school students had used 20 or more times in the past 30 days (Figure 13). The
estimates of marijuana use at each frequency level fluctuated from 2005 to 2015, with no notable
trends (Figure 14).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
42
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0061.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Marijuana use also varies greatly
by Health Statistics Region (HSR). Some of Colorado’s larger counties
represent a single HSR, but for smaller or less populated areas, several counties may be represented by
a single HSR (Maps 1 & 2). In both 2013 and 2015, health statistics regions 7 (Pueblo County 32.0%,
30.1%) and 9 (Dolores, San Juan, Montezuma, La Plata, and Archuleta Counties 24.6%, 26.2%) were
statistically higher than the state prevalence (19.7%, 21.2%) for current marijuana use among high
school students. For all but one HSR, current marijuana use among high school students in 2015 was not
statistically different from 2013. Health statistics region 10 (Montrose, Delta, Gunnison, Ouray,
Hinsdale, and San Miguel Counties) did have statistically lower current marijuana use among high
school students in 2015 (17.5%) than in 2013 (26.7%) (Map 2).
Marijuana use in Colorado by region
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
43
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0062.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 1. Prevalence of ever and current marijuana use for high school students in
Colorado (HKCS) compared to the national prevalence (YRBS), 2005-2015.
36.9
19.7
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Ever Use is defined as marijuana use at least one time during a student's lifetime and Current
Use is defined as marijuana use at
least once in the past 30 days.
‡Data Source:
Colorado estimates are from the Healthy Kids Colorado Survey (HKCS) and United States estimates are from the
Youth Risk Behavioral Surveillance System survey. Note: Data for the year 2007 was not included due to low sample size.
Major findings
HKCS estimates for both ever and current marijuana use in Colorado have had no statistical
difference from the YRBS national estimates from 2005 through 2015, except for current use in
2013.
In 2013, the HKCS estimate of current marijuana use among high school students in Colorado was
statistically lower than the YRBS national estimate.
a
Comparing 2015 HKCS estimates with 2013, there was no statistical difference in current use or
ever use among Colorado high school students.
b
The 2015 HKCS estimates for both ever and current marijuana use among high school students in
Colorado were nearly identical to the 2015 YRBS national estimates.
a
In 2013: HKCS estimate for Colorado 19.7%, (95% CI 18.7-20.6%), YRBS national estimate 23.4% (95% CI 21.3-25.7%).
Current marijuana use in Colorado (HKCS): 2013 19.7% (95% CI 18.7-20.6%), 2015 21.2% (95% CI 19.7-22.7%). Ever marijuana use
in Colorado (HKCS): 2013 36.8% (95% CI 35.4-38.3%), 2015 38.0% (95% CI 36.0-40.0%)
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix D. For data, see
Appendix D, Table D.1.
b
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
44
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0063.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 2. Prevalence of current marijuana use for high school aged adolescents in
Colorado, 2005-2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use is defined as marijuana use at least once
in the past 30 days.
‡Data Source: Healthy Kids Colorado Survey (HKCS) prevalence estimates for 2005-2015
and National Survey on Drug Use and
Health (NSDUH) for 2004-2014 ages 14-17. Both are for Colorado only.
Major findings
From 2005 to 2013, the HKCS estimates of current marijuana use among high school students in
Colorado were higher than the NSDUH estimates for current marijuana use among high school aged
adolescents in Colorado. However, the difference became smaller in 2013.
c
c
NSDUH data was a 3-year aggregate 2012-2014. For data, see Appendix D, Table D.2.
For statistical methods, see Appendix D.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
45
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0064.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 3. Prevalence of ever and current marijuana use for high school and middle
school students in Colorado, 2005-2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Ever Use is defined as marijuana use at least one time
during a student's lifetime and Current Use is defined as marijuana use at
least once in the past 30 days.
‡Data Source: Healthy Kids Colorado Survey (HKCS) prevalence estimates for 2005-2015.
Data for the year 2007 was not included
due to low sample size. Data for middle school marijuana use was not collected before 2011.
Major findings
Among Colorado high school students, over the years 2005 to 2015, estimates of current marijuana
use have fluctuated between 19.7% and 24.8%. None of these estimates were statistically different
from each other.
d
Among Colorado high school students, over the years 2005 to 2015, estimates of having ever used
marijuana have fluctuated between 36.9% and 42.6%. None of these estimates were statistically
different from each other.
d
Among Colorado middle school students in 2015, an estimated 4.4% were currently using marijuana
and an estimated 7.6% had ever used marijuana. Between 2011 and 2015, none of the estimates
were statistically different.
d
For data, see Appendix D, Table D.3.
For statistical methods, see Appendix D.
d
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
46
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0065.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 4. Prevalence of current marijuana use for high school students in Colorado
compared to current alcohol use and tobacco smoking in Colorado, 2009-2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use is defined as marijuana use at least once in the past 30 days.
‡Data Source: Healthy Kids Colorado Survey (HKCS) prevalence estimates for 2005-2015.
Note: Data for the year 2007 was not
included due to low sample size.
Major findings
The prevalence of current marijuana use among high school students in Colorado has remained
statistically higher than current tobacco smoking from 2011 through 2015 and has remained
statistically lower than current alcohol use from 2009 through 2015.
Current alcohol use was statistically lower in 2015 compared to 2009.
e
Current tobacco smoking was statistically lower in 2015 compared to 2013 and in 2013 compared to
2011.
f
Current marijuana use has remained stable from 2009 through 2015 with the prevalence of current
marijuana use among high school students ranging from 19.7%-24.8%.
Current
alcohol use: 2015 30.2% (95% CI 28.3-32.2%), 2009 40.8% (95% CI 35.8-46.0%)
Current tobacco use: 2015 8.6% (95% CI 7.7-9.5%), 2013 10.7% (95% CI 10.0-11.4%), 2011 15.7% (95% CI 12.8-19.0%)
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix D. For data, see
Appendix D, Table D.4.
f
e
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
47
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0066.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 5. Prevalence of current marijuana use for high school and middle school
students in Colorado by grade, 2013-2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use is defined as marijuana use at least once in the past 30 days.
‡Data Source: Healthy Kids Colorado Survey (HKCS) prevalence estimates for 2013-2015.
Major findings
In both 2013 and 2015, estimates of current marijuana use among Colorado students in each grade
level trended upward from 6
th
through 12
th
grade, with current use higher in older grades than
younger grades.
In both 2013 and 2015, estimated current use among Colorado 9
th
graders was statistically lower
than among 10
th
graders, and current use among 10
th
graders was statistically lower than among
11
th
graders.
g
Estimated current use among Colorado 11
th
graders was statistically higher in 2015 than it was in
2013. There was not a statistical difference in current use among all other grades between 2013
and 2015.
h
g
In 2013: 9
th
graders 13.7% (95% CI 12.3-15.1%), 10
th
graders 19.0% (95% CI 17.7-20.3%), 11
th
graders 22.1% (95% CI 20.6-23.5%); In
2015: 9
th
graders 12.4% (95% CI 10.0-14.7%), 10
th
graders 18.8% (95% CI 16.3-21.3%), 11
th
graders 26.3% (95% CI 23.8-28.7%)
h
Current use among Colorado 11
th
graders: 2015 26.3% (95% CI 23.8-28.7%), 2013 (22.1%, 95% CI: 20.6%-23.5%).
For an explanation
of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix D. For data, see
Appendix D, Table D.5.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
48
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0067.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 6. Prevalence of current marijuana use for high school students in Colorado
by gender, 2013-2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use is defined as marijuana use at least once in the past 30 days.
‡Data Source: Healthy Kids Colorado Survey (HKCS) prevalence estimates for 2013-2015.
Major findings
The estimate of female high school students in Colorado who reported current marijuana use in
2015 was statistically higher than in 2013.
i
Estimates for current marijuana use among male high school students in Colorado were nearly
identical in 2013 and 2015.
Colorado female high school students current marijuana use: 2013 17.7% (95% CI 16.6-18.8%), 2015 21.0% (95% CI 19.3-22.6%)
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix D. For data, see
Appendix D, Table D.6.
i
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
49
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0068.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 7. Prevalence of current marijuana use for middle school students in
Colorado by gender, 2013-2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use is defined as marijuana use at least
once in the past 30 days.
‡Data Source: Healthy Kids Colorado Survey (HKCS) prevalence estimates for 2013-2015.
Major findings
Current marijuana use was not statistically different between 2013 and 2015 for either male or
female middle school students in Colorado.
j
Males: 2013 5.3% (95% CI 4.1-6.5%), 2015 3.8% (95% CI 1.3-6.2%); Females: 2013 4.8% (95% CI 3.8-5.9%), 2015 5.2% (95% CI 1.7-
8.6%)
For an explanation
of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix D. For data, see
Appendix D, Table D.7.
j
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
50
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0069.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 8. Prevalence of current marijuana use for high school students in Colorado
by race/ethnicity, 2013-2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use is defined as
marijuana use at least once in the past 30 days.
‡Hispanic includes respondents who selected “Hispanic” for ethnicity and “white” for race. Those who selected “Hispanic” for
ethnicity and a non-white race are included under
“multiple or other race”.
AI: American Indian, AN: Alaska Native, NH: Native Hawaiian, PI: Pacific Islander.
§Data Source: Healthy Kids Colorado Survey (HKCS) prevalence estimates for 2013-2015.
Major findings
In both 2013 and 2015, current marijuana use was statistically lower among Asian high school
students than among white, Hispanic, black, and multiple or other race students.
k
In both 2013 and 2015, current marijuana use was statistically higher among multiple or other race
high school students than among white students.
k
In 2013, current marijuana use was also statistically higher among Hispanic, black and American
Indian/Alaskan Native high school students than among white students.
k
For data, see Appendix D, Table D.8.
For an explanation of terms, see “How
to interpret survey results”
above. For statistical methods, see Appendix
D.
k
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
51
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0070.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 9. Prevalence of current marijuana use among high school students in
Colorado by sexual orientation, 2013-2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use is defined as marijuana use at least once in the past 30 days.
‡Data Source: Healthy Kids Colorado Survey (HKCS)
prevalence estimates for 2013-2015.
Major findings
In 2013 and 2015, current use of marijuana among students identifying as gay, lesbian or bisexual,
was statistically higher than estimated current use among students identifying as heterosexual.
l
l
In 2013: gay, lesbian, or bisexual students 39.7% (95% CI 36.5-42.9%), heterosexual students 17.7% (95% CI 16.7-18.7%). In 2015:
gay, lesbian, or bisexual students 34.9% (95% CI 30.4-39.4%), heterosexual students 19.5% (95% CI 17.8-21.1%).
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix D. For data, see
Appendix D, Table D.9.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
52
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0071.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 10. Age of first marijuana use among high school seniors in Colorado who
reported ever using marijuana, 2013-2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use is defined as marijuana
use at least once in the past 30 days.
‡Data Source: Healthy Kids Colorado Survey (HKCS) prevalence estimates for 2013-2015.
Major findings
In 2015, among high school seniors who had used marijuana at least once in the past, an estimated
84.4% of them first used by age 16 or before, 41.3% first used by age 14 or before, and 14.3% first
used by age 12 or before.
m
Age of first marijuana use followed a similar pattern among high school seniors surveyed in 2013
who reported ever using marijuana.
First used by age 12 includes the “Less than 9” (2.7%), “9-10” (2.4%) and “11-12” (9.2%),
totaling 14.3%; first used by age 14
includes those plus “13-14” (27.0%), totaling 41.3%; first used by age 16 includes those plus “15-16” (43.1%),
totaling 84.4%
For data, see Appendix D, Table D.10.
m
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
53
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0072.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 11. Prevalence of high school students in Colorado who tried marijuana
before age 13 by race/ethnicity, 2013-2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Hispanic includes respondents who selected “Hispanic” for ethnicity and “white” for race. Those who selected “Hispanic” for
ethnicity and a non-white race
are included under “multiple or other race”.
AI: American Indian, AN: Alaska Native, NH: Native Hawaiian, PI: Pacific Islander.
‡Data Source: Healthy Kids Colorado Survey (HKCS) prevalence estimates for 2013-2015.
Major findings
In both 2013 and 2015, the estimated percent of white students who first tried marijuana before
age 13 was statistically lower than among black, Hispanic, and multiple or other race students.
n
In 2013, the estimated percent of Asian students who first tried marijuana before age 13 was
statistically lower than among black, Hispanic, American Indian/Alaskan Native and multiple or
other race students.
n
For an explanation of terms,
see “How
to interpret survey results”
above. For statistical methods, see Appendix
D. For data,
see Appendix D, Table D.11.
n
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
54
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0073.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 12. Usual methods of marijuana use among high school students in Colorado
who reported current marijuana use, 2011-2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use is defined as marijuana use at least once in the past 30 days.
‡In 2015 the 'Other' category included 'Other' and 'Dabbing.'
§Data Source: Healthy Kids Colorado Survey (HKCS) prevalence estimates for 2011-2015.
Major findings
A large majority of high school students who currently use marijuana report that smoking is their
usual method of use, as compared to edibles, vaping or other methods of use.
The percentage of high school students who reported usually using edibles was statistically lower in
2015 compared to 2013.
o
Usually use edibles: 2013 5.2% (95% CI 4.2-6.1%), 2015 2.1% (95% CI 1.2-3.0%)
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix D. For data, see
Appendix D, Table D.12.
o
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
55
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0074.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 13. Frequency of marijuana use among high school and middle school
students in Colorado who reported current marijuana use, 2015.
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use is defined as marijuana use at least once in the past 30 days.
‡Data Source: Healthy Kids Colorado Survey (HKCS) prevalence estimates for 2013-2015.
Major findings
In 2015, among high school students currently using marijuana, an estimated 35.8% used it once or
twice in the past 30 days, while 26.8% used it 20 or more times.
p
Among middle school students currently using marijuana, an estimated 40.3 % used once or twice in
the past 30 days and 19.8% used 20 or more times.
q
p
20 or more times includes “20-39” (8.3%) and “40 or more” (18.5%), totaling 26.8%
20 or more times includes “20-39” (8.7%) and “40 or more”
(11.1%), totaling 19.8%
For statistical methods, see Appendix D. For data, see Appendix D, Table D.13.
q
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
56
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0075.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Figure 14. Frequency of marijuana use among high school students in Colorado,
2005-2015.
5.3
Produced by: EEOHT, CDPHE 2016
*Black bars indicate margins of error (95% Confidence Intervals).
†Current Use is defined as marijuana use at least once in the past 30 days.
‡Data Source: Healthy Kids Colorado Survey (HKCS) prevalence estimates for 2005-2015.
Note: Data for the year 2007 was not
included due to low sample size.
Major findings
The estimated percent of Colorado high school students using marijuana at each frequency level
fluctuated for surveys from 2005 to 2015, with no notable trends.
r
For data, see Appendix D, Table D.14.
For statistical methods, see Appendix D.
r
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
57
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0076.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Map 1. Prevalence of current marijuana use among high school students in
Colorado, 2013
Major findings
In 2013, health statistic regions 7 (Pueblo County, 32.0%), 10 (Montrose, Delta, Gunnison, Ouray,
Hinsdale, and San Miguel Counties, 26.7%), 20 (Denver County, 26.6%), 17 (Gilpin, Clear Creek,
Park, and Teller Counties, 25.1%), 9 (Dolores, San Juan, Montezuma, La Plata, and Archuleta
Counties, 24.6%), and 13 (Lake, Chaffee, Fremont, and Custer Counties, 22.9%), were statistically
higher than the 2013 Colorado state estimate of current use among high school students of 19.7%.
s
In 2013:
HSR 7 - 32.0% (95% CI 25.7-38.4%), HSR 10 - 26.7% (95% CI 22.3-31.0%), HSR 20 - 26.6% (95% CI 22.5-30.8%), HSR 17 -
25.1% (95% CI 21.9-28.3%), HSR 9 - 24.6% (95% CI 20.9-28.3%), HSR 13
22.9% (95% CI 21.2-24.7%), all of Colorado - 19.7% (95% CI
18.7-20.6%)
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix D.
s
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
58
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0077.png
Section 1: Healthy Kids Colorado Survey (HKCS)
Map 2. Prevalence of Current Marijuana Use among High School Students in
Colorado, 2015
Major findings
In 2015, health statistics regions 7 (Pueblo County, 30.1%) and 9 (Dolores, San Juan, Montezuma, La
Plata, and Archuleta Counties, 26.2%) were statistically higher than the 2015 Colorado state
estimate of current use among high school students of 21.2%.
t
Current marijuana use in health statistics region 10 (Montrose, Delta, Gunnison, Ouray, Hinsdale,
and San Miguel Counties) was statistically lower in 2015 (17.5%) than it was in 2013 (26.7%).
u
For all other health statistics regions, current use in 2015 was not statistically different from
current use in 2013.
In 2015: HSR 7 - 30.1% (95% CI 27.1-33.2%), HSR 9 - 26.2% (95% CI 24.7-37.7%), all of Colorado - 21.2% (95% CI 19.7-22.7%)
HSR 10: 2013 - 26.7% (95% CI 22.3-31.0%), 2015 - 17.5% (95% CI12.7-22.3%)
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix D.
u
t
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
59
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0078.png
Section 1: Healthy Kids Colorado Survey (HKCS)
References
1. Centers for Disease Control and Prevention. Youth Risk Behavioral Surveillance System.
Adolescent
and School Health
http://www.cdc.gov/healthyyouth/data/yrbs/.
2. Colorado Department of Public Health and Environment. Adolescent Health Data, Healthy Kids
Colorado Survey.
Colorado Health and Environmental Data
2015;
http://www.chd.dphe.state.co.us/topics.aspx?q=Adolescent_Health_Data, 2016.
3. Substance Abuse and Mental Health Services Administration. Population Data / NSDUH.
https://www.samhsa.gov/data/population-data-nsduh/2015.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
60
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0079.png
Section 1
Monitoring Changes in
Marijuana Use
Patterns
Chapter 4
Pregnancy Risk Assessment
Monitoring System (PRAMS)
2014 Survey Results
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0080.png
Section 1: Pregnancy Risk Assessment Monitoring System (PRAMS)
Authors
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Katelyn E. Hall, MPH
Statistical Analyst
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Elyse Contreras, MPH
Coordinator
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Ashley Juhl, MSPH
Maternal and Child Health Epidemiologist
Health Surveys and Evaluation Branch, Colorado Department of Public Health and Environment
Anne Schiffmacher, MPH
Maternal and Child Health Epidemiologist
Health Surveys and Evaluation Branch, Colorado Department of Public Health and Environment
Allison Grace Bui, MPH
Epidemiologist
Health Surveys and Evaluation Branch, Colorado Department of Public Health and Environment
Rickey Tolliver, MPH
Chief
Health Surveys and Evaluation Branch, Colorado Department of Public Health and Environment
Mike Van Dyke, PhD, CIH
Chief
Environmental Epidemiology, Occupational Health, and Toxicology Branch, Colorado Department of
Public Health and Environment
Reviewer
Laura Borgelt, PharmD
Associate Dean and Professor
Departments of Clinical Pharmacy and Family Medicine, University of Colorado Anschutz Medical
Campus
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
62
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0081.png
Section 1: Pregnancy Risk Assessment Monitoring System (PRAMS)
The PRAMS survey and marijuana use in Colorado
The Pregnancy Risk Assessment Monitoring System (PRAMS) is a survey sponsored by the Centers for
Disease Control and Prevention (CDC). The survey asks new mothers questions about their pregnancy
and their new baby. It provides data not available from other sources about pregnancy and the first
few months after delivery, and allows CDC and the states to monitor changes in maternal and child
health indicators, such as unintended pregnancy, prenatal care, breastfeeding, infant health, smoking
and alcohol use. These data can be used to identify groups of women and infants at high risk for health
problems, to monitor changes in health status, and to measure progress toward goals in improving the
health of mothers and infants.
1
In 2014, PRAMS in Colorado asked about marijuana use before, during
and after pregnancy (Table 1).
2
For additional survey details and information about analysis methods, see Appendix E.
Survey questions
Table 1.
Pregnancy Risk Assessment Monitoring System question about marijuana use,
2014.
1. During any of the following time periods, did you use marijuana or hashish (hash)? For each time
period, say No if you did not use then or say Yes if you did.
a.
b.
c.
d.
e.
f.
During the 3 months before I got pregnant.
During the first 3 months of my pregnancy.
During the last 3 months of my pregnancy.
At any time during my most recent pregnancy.
Since my baby was born.
Don’t know/don’t remember
Definitions
Using marijuana during pregnancy
was defined by combining three responses:
during the first 3
months of my pregnancy; during the last 3 months of my pregnancy;
and
at any time during my most
recent pregnancy.
Using marijuana and breastfeeding after delivery
was defined as answering
‘Yes’
to using marijuana
since my baby was born
AND answering
‘Yes’
to one of two breastfeeding questions:
Did you ever
breastfeed or pump breastmilk to feed your new baby;
or
Are you currently breastfeeding or feeding
pumped milk to your new baby.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
63
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0082.png
Section 1: Pregnancy Risk Assessment Monitoring System (PRAMS)
How to interpret survey results
Respondents to the PRAMS survey are a sample of Colorado women who recently gave birth. The
percent of survey respondents selecting a specific answer might not be exactly the same as if all
Colorado women who recently gave birth were surveyed. Therefore, the survey results are estimates,
and each has a range of possible values (also called margin of error, confidence interval, or 95% CI).
These ranges are very important when comparing two estimates, and the following terms are used
throughout this report:
‘Not statistically different’-
Typically, if the ranges of possible values
overlap
for two different survey
results (like two different years, or male vs. female), we cannot be confident that there is a true
difference between the two (also called ‘not statistically significant.’) In some cases, an additional
statistical test is done to confirm.
‘Statistically higher’ or ‘statistically lower’-
If the ranges of possible values
do not overlap
for two
different results, we CAN be confident that there is a true difference between the two (also called
‘statistically significant.’)
On the figures in this report, these ranges of possible values are indicated by black bars. In footnotes,
they are referred to by the statistical term ‘95% CI.’
Results
Results are displayed in Figures 1-5 below.
In 2014, among new mothers in Colorado, marijuana use before pregnancy (11.2%) was statistically
lower than use of tobacco (16.9%) or alcohol (66.7%) before pregnancy (Figure 1). During pregnancy,
alcohol use (12.8%) was statistically higher than use of tobacco (6.4%) or marijuana (5.7%) (Figure 2). A
2016 article estimated that 3.9% of pregnant women in the United States overall used marijuana during
pregnancy (data not shown).
3
This was not statistically different from the PRAMS estimate of 5.7% for
Colorado.
Marijuana use before pregnancy (11.2%) was statistically higher than use during pregnancy (5.7%) or use
by breastfeeding mothers after delivery (4.5%) (Figure 3). There was no statistical difference between
use during pregnancy and use by breastfeeding mothers after delivery. Marijuana use during pregnancy
was statistically higher among women with an unintended pregnancy (9.1%) than among women who
intended to become pregnant (4.0%) (Figure 4).
When marijuana use during pregnancy was compared among different demographics, both education
and age showed statistical differences, while race/ethnicity did not. Use during pregnancy was
statistically higher among women with less than a 12
th
grade education (15.7%) than among women
with some college (4.1%) (Figure 5). It was also statistically higher among women 20-24 years old
(12.6%) than among women 25-34 years old (4.3%) or women 35 years old or older (2.7%) (Figure 5).
There were no statistical differences in marijuana use during pregnancy by race/ethnicity (Figure 5).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
64
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0083.png
Section 1: Pregnancy Risk Assessment Monitoring System (PRAMS)
Figure 1. Colorado women who reported using substances before pregnancy,
2014.
Produced by: EEOHT, CDPHE 2016
*95% confidence intervals do not overlap.
†Black bars indicate margins of error (95% Confidence Intervals).
‡Data Source: Colorado Pregnancy Risk Assessment Monitoring System 2014.
Major findings
The prevalence of marijuana use before pregnancy among women who recently gave birth was
statistically lower than use of tobacco or alcohol before pregnancy.
a
a
2014 substance use before pregnancy: alcohol 66.7% (95% CI 63.4-69.9%), tobacco 14.4% (95% CI 14.4-19.4%), marijuana 11.2%
(95% CI 9.0-13.3%)
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix E. For data, see
Appendix E, Table E.1.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
65
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0084.png
Section 1: Pregnancy Risk Assessment Monitoring System (PRAMS)
Figure 2. Colorado women who reported using substances during pregnancy, 2014.
Produced by: EEOHT, CDPHE 2016
*95% confidence intervals do not overlap.
†Black bars indicate margins of error (95% Confidence Intervals).
‡Tobacco and alcohol use was during the last 3 months of pregnancy.
§Data Source: Colorado Pregnancy Risk Assessment Monitoring System 2014.
Major findings
The prevalence of alcohol use during pregnancy was statistically higher than use of tobacco or
marijuana during pregnancy. The use of marijuana was not statistically different from use of
tobacco.
b
b
2014 substance use during pregnancy: alcohol 12.8% (95% CI 10.5-15.0%), tobacco 6.4% (95% CI 4.8-8.1%), marijuana 5.7% (95%
CI 4.2-7.2%)
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix E. For data, see
Appendix E, Table E.2.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
66
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0085.png
Section 1: Pregnancy Risk Assessment Monitoring System (PRAMS)
Figure 3. Colorado women who reported using marijuana before, during, and after
pregnancy, 2014.
Produced by: EEOHT, CDPHE 2016
*95% confidence intervals do not overlap.
†Black bars indicate margins of error (95% Confidence Intervals).
‡Data Source: Colorado Pregnancy Risk Assessment Monitoring System
2014.
Major findings
The prevalence of marijuana use before pregnancy was statistically higher than use during
pregnancy or use by breastfeeding mothers after delivery. There was no statistical difference
between use during pregnancy and use by breastfeeding mothers after delivery.
c
c
2014 marijuana use: before pregnancy 11.2% (95% CI 9.0-13.3%), during pregnancy 5.7% (95% CI 4.2-7.2%), by breastfeeding
mothers after delivery 4.5% (95% CI 3.1-5.9%)
For an explanation
of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix E. For data, see
Appendix E, Table E.3.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
67
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0086.png
Section 1: Pregnancy Risk Assessment Monitoring System (PRAMS)
Figure 4. Colorado women who reported using marijuana during pregnancy by
intention to become pregnant, 2014.
Produced by: EEOHT, CDPHE 2016
*95% confidence intervals do not overlap.
†Black bars indicate margins of error (95% Confidence Intervals).
‡Data Source: Colorado Pregnancy Risk Assessment Monitoring System 2014.
Major findings
The prevalence of marijuana use during pregnancy was statistically higher among women with an
unintended pregnancy than among women who intended to become pregnant.
d
d
2014 marijuana use during pregnancy, by intention to become pregnant: intended pregnancy 4.0% (95% CI 2.3-5.7%), unintended
pregnancy 9.1% (95% CI 6.0-12.3%)
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix E. For data, see
Appendix E, Table E.4.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
68
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0087.png
Section 1: Pregnancy Risk Assessment Monitoring System (PRAMS)
Figure 5. Colorado women who reported using marijuana during pregnancy by maternal
education (a), age (b), and race (c), 2014.
(a) Maternal Education
(b) Maternal Age
(c) Maternal Race
Produced by: EEOHT, CDPHE 2016
†Black bars indicate margins of error (95% Confidence Intervals).
‡Data Source: Colorado Pregnancy Risk Assessment Monitoring System 2014.
Major Findings
The prevalence of marijuana use during pregnancy was statistically higher among women with less
than a 12
th
grade education than among women with some college.
e
The prevalence of marijuana use during pregnancy was statistically higher among women 20-24
years old than among women 25-34 years old or women 35 years old or older.
f
There were no statistical differences in marijuana use during pregnancy by race/ethnicity.
g
e
2014 marijuana use during pregnancy, by education: <12 years 15.7% (95% CI 6.9-24.5%), 12 years 6.3% (95% CI 3.2-9.5%), >12
years 4.1% (95% CI 2.6-5.5%)
f
2014 marijuana use during pregnancy, by maternal age: 15-19 years old 14.0% (95% CI 3.9-24.1%), 20-24 years old 12.6% (95% CI
7.2-18.0%), 25-34 years old 4.3% (95% CI 2.5-6.1%), 35 years or older 2.7% (95% CI 0.6-4.9%)
g
2014 marijuana use during pregnancy, by race/ethnicity: White/non-Hispanic 6.4% (95% CI 4.4-8.4%), Black 8.7% (95% CI 0.0-
22.5%), Hispanic 3.4% (95% CI 0.7-6.2%), Other 5.9% (95% CI 1.1-10.8%)
For an explanation of terms, see “How
to interpret survey results” above. For statistical methods, see Appendix E. For data, see
Appendix E, Table E.5.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
69
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0088.png
Section 1: Pregnancy Risk Assessment Monitoring System (PRAMS)
References
1. Centers for Disease Control and Prevention. PRAMS. 2016; https://www.cdc.gov/prams/,
https://www.cdc.gov/prams/.
2. Colorado Department of Public Health and Environment. Pregnancy Risk Assessment Monitoring
System. https://www.colorado.gov/pacific/cdphe/pregnancysurvey.
3. Volkow ND, Compton WM, Wargo EM. The Risks of Marijuana Use During Pregnancy.
JAMA.
2017;317(2):129-130.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
70
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0089.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0090.png
Section 2: Scientific Literature Review on Potential Health Effects of Marijuana Use
Background
The Colorado Department of Public Health and Environment (CDPHE) was given statutory (25-1.5-110,
C.R.S.) responsibility to:
• “…monitor changes in drug use patterns, broken down by county and race and ethnicity, and the
emerging science and medical information relevant to the health effects associated with marijuana
use.”
• “…appoint a panel of health care professionals with expertise
in cannabinoid physiology to monitor
the relevant information.”
Based on this charge, CDPHE appointed a 14-member committee, the Retail Marijuana Public Health
Advisory Committee, to review scientific literature on the health effects of marijuana. Members of this
committee (see Appendix, Retail Marijuana Public Health Advisory Committee Membership Roster) are
individuals in the fields of public health, medicine, epidemiology, and medical toxicology who
demonstrate expertise related to marijuana through their work, training or research. This committee
was charged with the duties as outlined in 25-1.5-110 C.R.S.
to “...establish
criteria for studies to be
reviewed, review studies and other data, and make recommendations, as appropriate, for policies
intended to protect consumers of marijuana or marijuana products and the general public.”
The committee has met since May 2014 to complete these duties. The overall goal was to implement an
unbiased and transparent process for evaluating scientific literature and data on marijuana use and
health outcomes. The committee was particularly interested in ensuring quality information is shared
about the known physical and mental health effects associated with marijuana use
and also about
what is unknown at present. The official bylaws of this committee are included in Appendix A, Retail
Marijuana Public Health Advisory Committee By-laws.
The committee used a standardized systematic literature review process to search and grade the
existing scientific literature on health effects of marijuana. Findings were synthesized into evidence
statements that summarize the quantity and quality of scientific evidence supporting an association
between marijuana use and a health outcome. These evidence statements were classified as follows:
Substantial evidence
-
indicates robust scientific findings that support an association between
marijuana use and the outcome.
Moderate evidence
-
indicates scientific findings support an association between marijuana use
and the outcome, but these findings have some limitations.
Limited evidence
-
indicates modest scientific findings that support an association between
marijuana use and the outcome, but these findings have significant limitations.
Mixed evidence
-
indicates both supporting and non-supporting scientific findings for an
association between marijuana use and the outcome, with neither direction dominating.
Body of research failing to show an association
-
indicates the topic has been researched without
evidence of an association; is further classified as a
limited, moderate
or
substantial
body of
research.
Insufficient evidence
-
indicates the outcome has not been sufficiently studied to conclude
whether or not there is an association between marijuana use and the outcome.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
72
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0091.png
Section 2: Scientific Literature Review on Potential Health Effects of Marijuana Use
The committee also translated these evidence statements into plain language so they are
understandable to the general public for future use in public health messaging. In addition, the
committee was asked to develop public health recommendations based on potential concerns identified
through the review process and to articulate research gaps based on common limitations of existing
research. All these were presented to the full committee during open public meetings with
opportunities for stakeholder input. Final statements, recommendations and research gaps were
formally approved by a majority vote of the committee.
The topics for review were originally chosen in 2014 based on recently published peer-reviewed
publications outlining the potential health effects of marijuana use, and public health priorities
identified from key informant interviews of local public health officials across Colorado, including in
urban, rural, and resort communities. Additional topics added in 2015 and 2016 were based on
committee and stakeholder suggestions. Key findings for each topic are presented below. More detailed
findings including literature citations are included in each of the individual chapters.
An important note for all key findings is the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove the marijuana
use alone
caused
the effect. Despite the best efforts of researchers to account for confounding
factors, there may be other important factors related to
causality
that were not identified. In
addition, marijuana use was illegal everywhere in the United States prior to 1996. Research funding,
when appropriated, was commonly sought to identify adverse effects from marijuana use. This legal
fact introduces both funding bias and publication bias into the body of literature related to marijuana
use. Another limitation of the available research data is that most studies did not or could not measure
the THC level (potency) of marijuana used by subjects, nor which other cannabinoids were present.
There are diverse products now available in Colorado, many of which are likely higher in potency than
the marijuana used by study subjects for much of the literature reviewed.
The Retail Marijuana Public Health Advisory Committee recognizes the limitations and biases inherent
in the published literature and made efforts to ensure the information reviewed and synthesized is
reflective of the current state of medical knowledge. Where information was lacking
for whatever
reason
the committee identified this knowledge gap and recommended further research. This
information will be updated as new research becomes available.
Summary of key findings
Marijuana use among adolescents and young adults
The committee reviewed the relationships between adolescent and young adult marijuana use and
cognitive abilities, academic performance, mental health and future substance use. Weekly marijuana
use by adolescents is associated with impaired learning, memory, math and reading, even 28 days after
last use. Weekly use is also associated with failure to graduate from high school. Adolescents and young
adults who use marijuana are more likely to experience psychotic symptoms as adults, such as
hallucinations, paranoia, delusional beliefs and feeling emotionally unresponsive. Evidence shows
marijuana users can become addicted to marijuana and treatment for marijuana addiction can
decrease use and dependence. Additionally, marijuana users who quit have lower risks of cognitive and
mental health outcomes than those who continue to use.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
73
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0092.png
Section 2: Scientific Literature Review on Potential Health Effects of Marijuana Use
Marijuana use and cancer
The committee reviewed different forms of cancer relative to marijuana use, as well as the chemicals
released in marijuana smoke and vapor. Strong evidence shows marijuana smoke contains many of the
same cancer-causing chemicals found in tobacco smoke. However, there is conflicting research for
whether or not a higher cumulative level of marijuana smoking is associated with lung cancer. Limited
evidence suggests an association between marijuana use and both testicular and prostate cancers. On
the other hand, the limited evidence available concerning cancers of the bladder, head and neck
suggests that they might not have any association with marijuana use.
Marijuana use and cardiovascular effects
The committee reviewed myocardial infarction, stroke and death from cardiovascular causes, relative
to marijuana use. There is a moderate level of scientific evidence that marijuana use increases risk for
some forms of stroke in individuals younger than 55, and more limited evidence that marijuana use
may increase risk for heart attack. Research is lacking concerning other cardiovascular events and
conditions, including death.
Marijuana dose and drug interactions
The committee reviewed THC (tetrahydrocannabinol, the main psychoactive component of marijuana)
levels relative to marijuana dose and method of use, the effects of secondhand marijuana smoke, drug-
drug interactions involving marijuana, and relationships between marijuana and opioid use. One
important finding is that it can take up to four hours after consuming an edible marijuana product to
reach the peak THC blood concentration and feel the full effects. There is credible evidence of
clinically important drug-drug interactions between marijuana and multiple medications, including
some anti-seizure medications and a common blood-thinner. Data about potential interactions are
lacking for many drugs at this time and likely to evolve substantially over coming years. Finally, there
is some evidence that opioid pain medication overdose deaths are lower in states with legal medical
marijuana than would be expected based on trends in states without legal medical marijuana. There is
conflicting evidence for whether or not marijuana use is associated with a decrease in opioid use
among chronic pain patients or individuals with a history of problem drug use.
Marijuana use and driving
The committee reviewed driving impairment and motor vehicle crash risk relative to marijuana use, as
well as evidence indicating how long it takes for impairment to resolve after marijuana use. It found
the risk of a motor vehicle crash increases among drivers with recent marijuana use. Furthermore, the
higher the blood THC level, the higher the motor vehicle crash risk. In addition, using alcohol and
marijuana together increases impairment and the risk of a motor vehicle crash more than using either
substance alone. For less-than-weekly marijuana users, using marijuana containing 10 milligrams or
more of THC is likely to impair the ability to safely drive, bike or perform other safety-sensitive
activities. Less-than-weekly users should wait at least six hours after smoking or eight hours after
eating or drinking marijuana to allow time for impairment to resolve.
Marijuana use and gastrointestinal or reproductive effects
The committee reviewed gastrointestinal diseases, particularly cyclic vomiting, and infertility or
abnormal reproductive function. Evidence shows that long-time, daily or near daily marijuana use is
associated with cyclic vomiting. This condition has been called cannabinoid hyperemesis syndrome. In
such cases, stopping marijuana use may relieve the vomiting. There is conflicting research for whether
or not marijuana use is associated with male infertility or abnormal reproductive function, and
research is lacking on female reproductive function related to marijuana use.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
74
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0093.png
Section 2: Scientific Literature Review on Potential Health Effects of Marijuana Use
Marijuana use and injury
The committee reviewed workplace, recreational and other non-driving injuries, burns from hash-oil
extraction or failed electronic smoking devices, and physical dating violence. Evidence shows
marijuana use may increase the risk of workplace injury while impaired, but is unclear for other types
of non-driving related injury. There have been many reports of severe burns resulting from home-
extraction of butane hash oil leading to explosions, and cases of electronic smoking devices exploding,
leading to trauma and burns. Concerning dating violence, adolescent girls who use marijuana may be
more likely to commit physical violence against their dating partners, and adolescent boys who use
marijuana may be more likely to be victims of physical dating violence.
Marijuana use and neurological, cognitive and mental health effects
The committee reviewed the potential relationships between marijuana use and cognitive impairment,
mental health disorders and substance abuse. Strong evidence shows that daily or near daily marijuana
users are more likely to have impaired memory lasting a week or more after quitting. An important
acute effect of THC is psychotic symptoms, such as hallucinations, paranoia and delusional beliefs
during intoxication. These symptoms are worse with higher doses. Daily or near daily marijuana use is
associated with developing a psychotic disorder such as schizophrenia. Finally, evidence shows
marijuana users can become addicted to marijuana and treatment for marijuana addiction can
decrease use and dependence.
Marijuana use during pregnancy and breastfeeding
The committee reviewed adverse birth outcomes, effects of prenatal marijuana use on exposed
offspring later in childhood or adolescence and effects of marijuana use by a breastfeeding mother.
Biological evidence shows THC passes through the placenta to the fetus, so the unborn child is exposed
to THC if the mother uses marijuana, and THC passes through breast milk to a breastfeeding child.
Marijuana use during pregnancy may be associated with an increased risk of heart defects or stillbirth.
Stronger evidence
was found for effects that are seen months or years after birth if a child’s mother
used marijuana while pregnant with the child. These include decreased growth and impaired cognitive
function and attention. Decreased academic ability or increased depression symptoms may also occur.
Marijuana use and respiratory effects
The committee reviewed respiratory diseases such as chronic obstructive pulmonary disorder (COPD),
chronic bronchitis and asthma, respiratory infections and lung function relative to smoked marijuana.
It also reviewed potential health effects of vaporized marijuana. Strong evidence shows an association
between daily or near-daily marijuana use and chronic bronchitis. Additionally, daily or near daily
marijuana use may be associated with bullous lung disease and pneumothorax in individuals younger
than 40 years of age. Research is lacking concerning any possible association between marijuana use
and COPD, emphysema or respiratory infections. Smokers who switch from marijuana smoking to
marijuana vaporizing may have fewer respiratory symptoms and improved pulmonary function. Finally,
a notable effect of acute use is a short-term improvement in lung airflow.
Unintentional marijuana exposures in children
The committee reviewed unintentional marijuana exposure relative to marijuana legalization and
child-resistant packaging. They found strong evidence that more unintentional marijuana exposures of
children occur in states with increased legal access to marijuana, and that the exposures can lead to
significant clinical effects requiring hospitalization. Additionally, evidence shows child resistant
packaging prevents exposure to children from potentially harmful substances, such as THC.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
75
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0094.png
Section 2: Scientific Literature Review on Potential Health Effects of Marijuana Use
The following table includes the committee’s most prominent findings from reviews of scientific
literature on marijuana use and potential health effects.
Table 1. Substantial and moderate findings from systematic literature review
Marijuana use among adolescents and young adults (p.97)
Substantial
Cognitive and
academic
Mental health
Moderate
Impaired cognitive abilities and
academic performance after 28
days abstinence
Psychotic disorder in adulthood
(daily or near-daily users)
Increased marijuana use and
addiction
after adolescence
Alcohol or tobacco use and
addiction
after adolescence
Quitting marijuana lowers risk of
cognitive and mental health
effects
Less high school graduation
Psychotic symptoms in adulthood
Substance use,
abuse and
addiction
Can develop marijuana addiction
Other illicit drug use and addiction
after
adolescence
Benefits of
quitting
Treatment for marijuana addiction
can reduce
use and dependence
Marijuana use and cancer (p.113)
Substantial
Chemicals in MJ
smoke or vapor
Marijuana smoke contains same cancer-causing
chemicals as tobacco smoke
Moderate
Cancer and pre-
cancerous
lesions
Pre-cancerous lesions with daily or near-daily
use
Failure to show association with
lung cancer for less than 10
joint-years cumulative use
Marijuana use and cardiovascular effects (p.123)
Substantial
Moderate
Increased risk of ischemic stroke
in individuals younger than 55
In this document, the term marijuana addiction is considered equivalent to cannabis use disorder (and addiction to another
substance is considered equivalent to use disorder for that substance).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
76
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0095.png
Section 2: Scientific Literature Review on Potential Health Effects of Marijuana Use
Table 1. (continued) Substantial and moderate findings from systematic literature
review
Marijuana dose and drug interaction (p.131)
= results in/produces.
Substantial
THC levels
Smoking >10 mg THC produces blood THC level
near or > 5 ng/mL within 10 minutes
Time to peak blood THC level is up to four hours
post ingestion
Secondhand
exposure
Typical secondhand exposure
NO positive drug
screen by urine or blood
Moderate
Ingesting >15 mg THC may
blood THC level > 5 ng/mL
Inhaling vaporized THC blood
THC level similar to smoking the
same dose
Marijuana use and driving (p.149)
* = applies only to less-than-weekly users.
= results in/produces.
Substantial
Impairment and
crash risk
Increased motor vehicle crash risk with recent
use
Increased risk of driving impairment at blood
THC of 2-5 ng/mL*
Smoking >10 mg THC leads to driving
impairment*
Orally ingesting >10 mg THC leads to driving
impairment*
Combined use with alcohol increases crash risk
Time to wait
before driving
Waiting > 6 hrs after smoking < 18 mg
driving
impairment resolves/nearly resolves*
Waiting > 8 hrs after orally ingesting < 18 mg
driving impairment resolves/nearly resolves*
* = applies only to less-than-weekly users.
= results in/produces.
There were no substantial or moderate findings for Marijuana Use and Injury
Moderate
THC blood level and motor
vehicle crash risk
Higher blood THC in impaired
drivers now than in the past
Waiting > 6 hrs after smoking
about 35 mg
driving
impairment resolves/nearly
resolves*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
77
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0096.png
Section 2: Scientific Literature Review on Potential Health Effects of Marijuana Use
Table 1. (continued) Substantial and moderate findings from systematic literature
review
Marijuana use and gastrointestinal and reproductive effects (p.161)
Substantial
Moderate
Cyclic vomiting with long-time,
daily or near-daily use
(cannabinoid hyperemesis
syndrome)
Marijuana use and neurological, cognitive, mental health effects (p.183)
Substantial
Cognitive
effects
Mental health
effects
Substance use
and addiction
Impaired memory for at least 7 days (daily or
near-daily users)
Acute psychotic symptoms during intoxication
Can develop marijuana addiction
Daily or near-daily users may experience
withdrawal symptoms
Treatment of marijuana addiction
can reduce
use and dependence
Psychotic disorder in adulthood
(daily or near-daily users)
Moderate
Marijuana use during pregnancy and breastfeeding (p.197)
Substantial
Effects on
exposed
offspring
Moderate
Attention problems
Decreased IQ scores in young
children
Decreased cognitive function
Decreased growth
There were no substantial or moderate findings for Marijuana Use and Injury
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
78
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0097.png
Section 2: Scientific Literature Review on Potential Health Effects of Marijuana Use
Table 1. (continued) Substantial and moderate findings from systematic literature
review
Marijuana use and respiratory effects (p.213)
Substantial
Smoked
marijuana
Chronic bronchitis with cough/wheeze/ sputum
Acute use improves airflow
Moderate
Unintentional marijuana exposures in children (p.225)
Substantial
Legal marijuana access increases unintentional
marijuana exposures in children
Moderate
Child-resistant packaging
reduces unintentional pediatric
poisonings
Public Health Recommendations
It is important to continue improving data quality by systematically collecting information on the
frequency, amount, potency and method of marijuana use in both public health surveillance and
medical care settings. During hospitalizations and emergency department visits, marijuana use should
be a standard question, and follow-up questions should clarify timing and amount of last use. Improved
testing methods and documentation are needed in relation to motor vehicle crashes and driving under
the influence of drugs (DUID).
Questions regarding marijuana use should be continued on population-based surveys such as the
Behavioral Risk Factors Surveillance System (BRFSS), the Healthy Kids Colorado Survey (HKCS) and
Pregnancy Risk Assessment Monitoring System (PRAMS). Surveillance methods should continue to be
expanded to collect more detailed information, such as quantity and methods of use, perceptions of
risk, reasons for using and adverse effects experienced. To better assess potential health impacts, data
on hospitalizations and emergency department visits related to marijuana should be further explored.
Public education on potential health effects of marijuana is important, particularly related to the
effects of use during pregnancy, adolescent use, driving after using and unsafe storage around
children. Dispensaries and industry should continue to partner with public health in disseminating
education about these topics of highest concern. Education for health care providers on the known
health effects of marijuana use may encourage more open dialog between providers and patients.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
79
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0098.png
Section 2: Scientific Literature Review on Potential Health Effects of Marijuana Use
Research Gaps
Important research gaps related to the population-based health effects of marijuana use were
identified during the literature and data review process. These research gaps were based on common
limitations of existing research, exposures or outcomes not sufficiently studied, or issues important to
public education or policymaking. These research gaps provide an important framework for continuing
to prioritize research related to marijuana use and public health. The committee strongly recommends
Colorado support research to fill these important gaps in public health knowledge. While outside the
scope of this committee’s duties, the committee also recognizes more research is needed on the
potential therapeutic benefits of marijuana.
A common theme among the research gaps was the need for studies with better defined marijuana-use
histories and practices. This should include frequency, amount, potency, and method of marijuana use;
length of abstinence; and a standardized method for documenting cumulative lifetime marijuana
exposure. A particularly important need is the evaluation of effects separately for less frequent users
versus daily or near-daily users. Researchers should consider evaluating separately by age group,
gender or other characteristics when the health effect being studied could differ among groups - for
example, by age for cardiovascular effects or by gender for mental health effects.
Research gaps particularly important to public health and safety include the need for: 1) additional
research using marijuana with THC levels consistent with currently available products; 2) research on
impairment in marijuana users who use more than weekly and may have developed tolerance; 3)
research to identify improved testing methods for impairment either through alternate biological
testing methods or physical tests of impairment; and 4) research to better characterize the
pharmacokinetics/pharmacodynamics, potential drug interactions, health effects, and impairment
related to newer methods of marijuana use such as edibles and vaporizing as well as other
cannabinoids such as cannabidiol (CBD).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
80
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0099.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Chapter 1
Systematic Literature Review
Process
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0100.png
Section 2: Systematic Literature Review Process
Authors
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Mike Van Dyke, PhD, CIH
Chief
Environmental Epidemiology, Occupational Health, and Toxicology Branch, Colorado Department of
Public Health and Environment
Lisa Barker, MPH
Retail Marijuana Health Monitoring, Colorado Department of Public Health and Environment
Reviewer
Andrew Monte, MD
Emergency Medicine Physician and Medical Toxicologist
University of Colorado and Rocky Mountain Poison and Drug Center
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
82
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0101.png
Section 2: Systematic Literature Review Process
Committee objectives
The RMPHAC was appointed in April 2014, had its first organizational meeting in May 2014, and began
the scientific review process in June 2014. The committee established these objectives:
Develop well-designed, systematic, unbiased criteria for selecting and evaluating studies
Systematically review the scientific literature currently available on health effects of marijuana
use
Judge and openly discuss the science using expert scientific and medical opinion.
Establish committee consensus on population health effects of marijuana use based on current
science
Establish committee consensus on translation of the science into public health messages
Recommend public health-related policies based on the current science and expert medical
discussion
Recommend public health surveillance activities to address any gaps in knowledge discovered
Identify and prioritize gaps in science important to public health
Create a framework to add emerging evidence and update committee findings
The committee also selected and prioritized review topics based on recently published peer-reviewed
publications outlining the potential health effects of marijuana use, and public health priorities
identified from key informant interviews of Colorado public health officials. These topics included:
Marijuana Use During Pregnancy and Breastfeeding
Neurological and Mental Health Effects
Effects on Youth and Unintentional Poisonings
Marijuana Dose and Drug Interactions
Extrapulmonary Effects and Injuries
Respiratory Effects and Lung Cancer
Within each of these topics, Colorado Department of Public Health and Environment (CDPHE) staff
established specific research questions to ensure that the relevant public health issues were covered in
the literature review process.
The overall goal of the committee was to implement an unbiased and transparent process for
evaluating scientific literature. The official committee bylaws included procedures for disclosing
potential conflicts of interest, including financial relationships with companies in the marijuana
industry; financial relationships with companies engaged in the treatment of patients for marijuana-
related health effects; funding support from the National Institute on Drug Abuse; and personal or
political beliefs that may prevent an unbiased recommendation.
Outside technical experts were recruited from CDPHE staff, the University of Colorado School of
Medicine, and the Colorado School of Public Health to search the scientific literature and summarize
and present findings to the full committee. All committee members were provided access to the
summary findings and the full-text literature for review before each committee meeting.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
83
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0102.png
Section 2: Systematic Literature Review Process
Overview of systematic review process
The committee utilized a PRISMA framework to ensure an unbiased and complete systematic literature
review.
1
The following are the general steps that were followed for each review topic:
1. Search: Conduct a broad search of peer-reviewed publications (Medline).
2. Review: Download articles from search and relevant cited articles.
3. Rate the findings: Each finding in the articles is rated as a high, medium, or low quality finding
based on the strengths and limitations of the methods. Evaluation of the strengths and limitations
was based on criteria in the GRADE system, which is a well-accepted method for evaluating the
quality of scientific evidence.
4. Group related findings: Each finding is categorized based on population, exposure, and outcome
(health effect).
5. Weigh the evidence: Draft evidence statements that summarize the quantity and quality of
evidence.
6. Translate the evidence: Draft public health statements that translate the evidence statements into
lay language understandable by the general public.
7. Synthesize the evidence: Draft public health recommendations based on potential concerns
identified through the review process.
8. Identify research gaps: Draft statements to articulate the research gaps identified during the
review process.
9. Present to committee: Findings, evidence statements, public health statements, public health
recommendations, and research gaps are formally presented to committee for review and revision
during open public meetings.
10. Public comment: During the open public meetings, interested stakeholders and members of the
general public are invited to provide comments relevant to the topic presented.
11. Reach consensus: Committee members come to consensus on findings, evidence statements, public
health statements, public health recommendations, and research gaps.
12. Officially adopt summary statements: Committee votes to officially accept findings, evidence
statements, public health statements, public health recommendations, and research gaps.
Searching the literature
Literature review methods were approved by the full committee. Medline was the priority research
database used to obtain articles for the review, though the Embase biomedical database and gray
literature were secondarily reviewed when references in included articles were not included in the
initial Medline search. Relevant articles cited in reviews or other primary studies also were included.
Studies of marijuana use in humans were the primary focus of the review. Review of animal studies was
reserved for specific topics with limited human research. In general, highly specialized research, such
as brain imaging studies not directly associated with measurable clinical outcomes, was not evaluated
in-depth unless an appropriately experienced reviewer was available. Research databases other than
Medline were searched primarily when time allowed though very little additional data was found via
these additional searches. All available peer-reviewed literature on a given topic identified through
these methods was reviewed, regardless of positive or negative findings.
For Medline searches, the appropriate Medical Subject Heading (MeSH) terms were chosen for each
topic and used for the search. To find newer articles relevant to the topic (those without MeSH yet
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
84
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0103.png
Section 2: Systematic Literature Review Process
applied), a list of specific terms was established for each topic area. For example, the general search
string used for marijuana was: “Cannabis
[mesh] OR Cannabis OR Marijuana OR Marihuana OR Ganja OR
Hashish OR Hemp OR Bhang OR Tetrahydrocannabinol.”
Rating the findings
Findings were rated as a high, medium, or low quality based on the strengths and limitations of the
methods.
Evaluation of the strengths and limitations was based on criteria in the “GRADE approach to
evaluating the quality of evidence.”
2
The GRADE system is a well-established method for systematic
literature review and has been used by the Cochrane Collaboration, British Medical Journal, American
College of Physicians, World Health Organization, and many others.
2
High quality
The
official definition is: “We
are very confident that the true effect lies close to that of the estimate
of the effect
outlined in the study.” High quality findings
originate from well-designed and well-
controlled studies with few limitations. In the context of observational epidemiology studies, which
was the most common study type in this systematic review, high quality does not necessarily imply
causation. High quality implies that an observed association persists between an exposure and effect in
an appropriately-sized study population after adjusting for the appropriate confounders.
Medium quality
The official definition is: “We
are moderately confident in the effect estimate outlined in the study.
The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.”
Moderate quality findings originate from
studies that may be well designed,
but have limitations that affect the interpretation of the results. In the context of observational
epidemiology studies, moderate quality implies the finding of an observed association with an
interpretation that may be limited by a small study population or insufficient adjustment for important
confounders.
Low quality
The official definition is: “Our
confidence in the effect estimate outlined in the study is limited. The
true effect may be substantially different from the estimate of the effect.”
Low quality findings
originate from studies with significant methodological limitations that affect the interpretation of the
results. In the context of observational epidemiology studies, low quality implies the finding of an
observed association with an interpretation that is significantly restricted by major study limitations.
When critically reviewing the literature, all findings were initially considered medium quality and
subsequently adjusted up or down in quality based on the strengths and limitations of the
methodology. Quality ratings were applied to individual outcomes; therefore, it was possible for a
single study to have multiple findings of differing quality. Criteria for evaluating strengths and
limitations for this literature review included:
Methods of selecting exposed and comparison groups
Relevance of study population to the population of interest
Method for describing extent of exposure or marijuana use (e.g., ever vs. never, frequency
measured by days used, measured by number of times used, etc.)
Method for measuring exposure (self-report or other methods)
Adequacy of exposure and outcome group sizes
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
85
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0104.png
Section 2: Systematic Literature Review Process
Methods for measurement of outcome (validated tools, blinded if subjective, etc.)
Adequacy of adjustment for confounders (e.g., tobacco smoking, other drug use, education level,
etc.) for both positive effects and lack of positive effect
Full vs. selective outcome reporting
Effect size and width of confidence intervals
Temporal relationship between exposure and effect
Completeness of follow-up
Adequacy of sample size for assessing lack of positive effect
Grouping the findings and weighing the evidence
Findings from individual studies were grouped together to facilitate weighing the overall scientific
evidence. Findings were usually grouped based on outcome (health effect). However, in specific
situations, findings could be further subdivided based on factors such as: age group of the exposed
population, special subject circumstances such as pregnancy or breastfeeding, level or method of
marijuana use, and time period since last use of marijuana. Standardized definitions of level of use and
age groups were established to help facilitate the grouping of findings:
Levels of marijuana use
Daily or near daily use: 5-7 days/week.
Weekly use: 1-4 days/week.
Less-than-weekly use: less than 1 day/week.
Acute use: Used within the last few hours, such that the short-term effects or symptoms are still
being experienced.
Age groups
Child: up to 9 years of age.
Adolescent: 9 through 17 years of age.
Young Adult: 18 through 24 years of age.
Adult: 25 through 64 years of age.
Older Adult: 65 years of age and older.
Once findings were appropriately grouped, evidence statements (e.g., “We found moderate evidence
that adolescents who regularly use marijuana are less likely than non-users to graduate high school.”)
were drafted based on the following criteria which were approved by the committee:
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
86
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0105.png
Section 2: Systematic Literature Review Process
Substantial evidence refers to:
1. Robust scientific findings that support the outcome with no credible opposing scientific evidence.
This was defined as any of the following:
At least one high quality positive finding, plus supporting findings at least one of which is
medium quality, with no opposing findings (must include studies of at least two cohorts)
At least three medium quality positive findings from studies of at least two cohorts, with no
opposing findings
Many high and medium quality positive findings from studies of at least two cohorts that
heavily outweigh opposing findings
At least two high quality positive findings from systematic reviews or meta-analyses published
within the past 10 years
2. A robust body of scientific literature that has examined the outcome and failed to demonstrate a
positive finding. This was defined as any of the following:
At least one high quality study lacking a positive finding, plus at least one medium quality
supporting study, and no opposing findings (must include studies of at least two cohorts)
At least three medium quality studies lacking a positive finding from studies of at least two
cohorts, and no opposing findings
Many high and medium quality studies lacking a positive finding that heavily outweigh opposing
findings
At least two high quality systematic reviews or meta-analyses published within the past 10
years lacking positive findings
Moderate evidence refers to
:
1. Strong scientific findings that support the outcome, but these findings have some limitations. This
was defined as any of the following:
A single high quality positive finding , with no opposing findings
At least one medium quality positive finding, plus supporting findings with no opposing
findings; supporting findings can include animal studies
Many medium and low quality positive findings from studies of at least two cohorts that heavily
outweigh opposing findings
A single high quality positive finding from a systematic review or meta-analysis published
within the past 10 years
2. A strong body of scientific literature that has examined the outcome and failed to demonstrate a
positive finding. This was defined as any of the following:
A single high quality study lacking a positive finding, and no opposing findings
At least one medium quality study lacking a positive finding, plus supporting findings, and no
opposing findings
Many medium and low quality studies lacking positive findings from studies of at least two
cohorts that heavily outweigh opposing findings
A single high quality systematic review or meta-analysis published within the past 10 years
lacking positive findings
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
87
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0106.png
Section 2: Systematic Literature Review Process
Limited evidence refers to:
1. Modest scientific findings that support the outcome, but these findings have significant limitations.
This was defined as any of the following:
A single medium quality positive finding
Two or more low quality positive findings from studies of at least two cohorts
One low quality positive finding supported by animal studies
Many low quality positive findings from studies of at least two cohorts that outweigh opposing
findings
2. Modest scientific finding that have examined the outcome and failed to demonstrate a positive
finding. This was defined as any of the following:
A single medium quality study lacking a positive finding
Two or more low quality studies lacking positive findings from studies of at least two cohorts
One low quality study lacking a positive finding supported by animal studies
Many low quality studies lacking positive findings from studies of at least two cohorts that
outweigh opposing findings
Mixed evidence refers to:
Both supporting and non-supporting scientific findings for the outcome with neither direction
dominating. This was defined as the following:
Mixed findings, with neither direction dominating
Insufficient evidence refers to:
The outcome has not been sufficiently studied. This was defined as any of the following:
A single low quality positive finding with no supporting findings
There are no studies examining the outcome or relevant parameters
These criteria were translated into evidence statements using the following
guidelines:
Substantial positive evidence becomes:
“We found substantial evidence…”
Substantial lack of positive evidence becomes: “We
found a substantial body of research that failed
to show an association…”
Moderate positive evidence becomes: “We found moderate evidence…”
Moderate lack of positive evidence becomes: “We found a moderate
body of research that failed to
show an association…”
Limited evidence becomes: “We found limited evidence…”
Limited lack of positive evidence becomes: “We found a limited body of research that failed to
show an association…”
Mixed evidence becomes: “We found mixed evidence for whether or not…”
Insufficient evidence becomes: “There is insufficient evidence to determine…”
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
88
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0107.png
Section 2: Systematic Literature Review Process
Evidence statements were drafted by CDPHE technical staff, revised based on committee review and
feedback from technical advisors and public stakeholders, and finally approved by a vote of the
committee.
Translating the evidence statements into public health statements
Evidence Statements were translated into Public Health Statements using a standardized convention to
ensure traceability back to the scientific literature. Public Health Statements were designed to
accurately reflect the evidence statements using language that could be understood by the general
public. The goals of the committee were to ensure that the Public Health Statements: 1) conveyed the
volume and quality of research related to the outcome; 2) provided a generalized framework to allow
consistent language for all findings regardless of topic; and 3) allowed the statement to stand on its
own without context. These statements were drafted by CDPHE technical staff, revised based on
comments from the committee, technical advisors and public stakeholders, and finally approved by a
vote of the committee. The standardized convention used for the translation is shown below:
Standardized convention: <level of> marijuana use <by specific group> <strength of relationship>
associated with <outcome>, <specific circumstances>.
A specific example:
“Regular
marijuana use by adolescents and young adults is strongly associated with
impaired learning, memory, math and reading achievement, even after 28 days or more since last use.”
Standard language was chosen for the
“strength
of relationship,”
corresponding to the level of
evidence from the Evidence Statements:
Substantial positive
evidence becomes “is strongly associated”
Substantial research lacking positive evidence becomes “an association is unlikely”
Moderate positive evidence
becomes “is associated”
Moderate research lacking positive evidence becomes “an association appears unlikely”
Limited evidence becomes “may be associated”
Limited research lacking
positive evidence becomes “might
not be associated"
Mixed evidence becomes “There is conflicting
evidence for whether or not ___
is associated”
The wording “associated with” was
specifically chosen to represent epidemiologic (i.e., statistical)
associations, and NOT to imply causality.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
89
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0108.png
Section 2: Systematic Literature Review Process
Synthesizing the evidence: public health recommendations and
research gaps
Based on the literature review, public health recommendations were drafted. The committee
recommendations were separated into data quality issues, surveillance, and education
recommendations. Data quality issues were defined as recommendations to improve current data
collection deficiencies at the clinical or governmental level that prevent full analysis of public health
outcomes related to marijuana use. Public health surveillance recommendations were based on
improving capacity to detect an acute public health danger (e.g., real-time emergency department
surveillance for detection of poisonings from contaminated products); the ability to characterize
chronic public health dangers to support policy and other intervention decisions (e.g., surveillance of
marijuana-related traffic fatalities or skiing injuries); or the ability to generate epidemiologic data
(e.g. BRFSS survey questions), to contribute to planning and evaluating population level interventions.
Education recommendations were included to ensure health-based information on marijuana use is
provided to the appropriate target audiences.
In addition to public health recommendations, important research gaps related to the population-based
health effects of marijuana use were identified during the literature review process. These research
gaps were based on common limitations of existing research (e.g., not enough focus on occasional
marijuana use, distinct from regular or heavy use); exposures not sufficiently studied (e.g., dabbing or
edibles); outcomes not sufficiently studied; or issues important to public education or policymaking
(e.g., impairment in frequent users). These research gaps provide an important framework for
prioritizing research related to marijuana use and public health. Statements articulating the public
health recommendations and research gaps were initially drafted by CDPHE technical staff, revised
based on comments from the committee, technical advisors and public stakeholders, and finally
approved by a vote of the committee.
Consensus and approval by the committee
CDPHE technical staff formally presented findings, evidence statements, public health statements,
public health recommendations and research gaps to the committee for review and revision during
open public meetings. During these open public meetings, interested stakeholders and members of the
general public were invited to provide comments relevant to the topic presented. The committee chair
facilitated a consensus process to ensure all committee members could agree on the scientific
evaluation and wording. Once consensus was achieved, the committee voted to officially accept these
statements and recommendations.
Procedures for reviewing and updating documents
The Retail Marijuana Public Health Advisory Committee will continue to meet quarterly throughout
2017 and 2018. All approved evidence statements, public health statements, public health
recommendations, and research gaps will be reviewed and updated if needed on a two-year cycle. The
committee also will expand the reviewed literature to include new topics as new research becomes
available or new public health concerns arise.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
90
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0109.png
Section 2: Systematic Literature Review Process
References
1. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA statement.
J Clin Epidemiol.
2009;62(10):1006-1012.
2. GRADE guidelines - best practices using the GRADE framework.
GRADE working group
http://training.cochrane.org/path/grade-approach-evaluating-quality-evidence-pathway, 2014.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
91
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0110.png
Section 2: Systematic Literature Review Process
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
92
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0111.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Chapter 2
Marijuana Use Among
Adolescents and Young Adults
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0112.png
Section 2: Marijuana Use Among Adolescents and Young Adults
Authors
Lisa Barker, MPH
Retail Marijuana Health Monitoring, Colorado Department of Public Health and Environment
(2016)
Kristina Phillips, PhD
Clinical Psychologist, Professor
School of Psychological Sciences, University of Northern Colorado
(2016)
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2014, 2016)
Reviewer
George Sam Wang, MD
Assistant Professor, University of Colorado Anschutz Medical Campus
Emergency Medicine Physician and Medical Toxicologist,
Children’s Hospital Colorado
Volunteer Faculty, Rocky Mountain Poison and Drug Center
(2014, 2016)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
94
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0113.png
Section 2: Marijuana Use Among Adolescents and Young Adults
Introduction
The Retail Marijuana Public Health Advisory Committee identified many important public health topics
related to marijuana and has reviewed the scientific evidence currently available regarding those
topics. This chapter includes reviews of potential health effects among adolescents and young adults
who use marijuana. In particular, the relationships between marijuana use and cognitive abilities,
academic performance, mental health and future substance use were reviewed.
Adolescence through young adulthood is a critical window for social and emotional development and
for neurocognitive functioning. It also is a time that has an increased risk of developing mental health
disorders, including depression and anxiety. In Colorado, almost 23 percent of students who started
high school in 2011 did not graduate by 2015.
1
Almost 30 percent of Colorado high school students in
2015 felt sad or hopeless almost every day for two weeks or more, an indicator for depression, and 6
percent attempted suicide.
2
A growing body of literature suggests parts of the brain continue to develop well into a person’s
twenties.
3
Alcohol use is known to affect this development and have negative cognitive, mental health
and social consequences.
4,5
This raises concern that marijuana use may do the same. The impact of
marijuana use on brain development, and on future cognitive abilities and mental health, has been the
subject of much public debate. A recent example is the claim that marijuana use lowers IQ
6
and the
counterclaim that it does not.
7
While most health effects of interest are long-term, there is also
concern that marijuana’s acute
health effects, which include fragmented thinking and anxiety,
8
might
lead to rash decisions or abnormal behavior. One prominent case in Colorado was a 19-year-old college
student who behaved strangely and fell to his death after using marijuana.
9
Analyses of 2015 Behavioral Risk Factor Surveillance System data, completed for this report, estimated
that 26 percent of young adults in Colorado ages 18-25 have used marijuana within the last month.
About half of them use daily or near-daily. 2015 Healthy Kids Colorado Survey data, also analyzed for
this report, estimate that 21 percent of Colorado high school students used marijuana within the last
month. With that many adolescents and young adults using marijuana at least monthly, the potential
adverse health effects are a significant public health concern. It is of critical importance to evaluate
what the scientific literature says about the health effects of marijuana use among adolescents and
young adults.
Definitions
Age groups
Adolescents: 9 to 17 years of age.
Young adults: 18 to 24 years of age.
Levels of marijuana use
Daily or near-daily use: 5-7 days/week.
Weekly use: 1-4 days/week.
Less-than-weekly use: less than 1 day/week.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
95
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0114.png
Section 2: Marijuana Use Among Adolescents and Young Adults
Cannabis use disorder
a formal diagnosis indicating two or more of these factors: hazardous use,
social/interpersonal problems related to use, neglects major roles in order to use, legal problems,
withdrawal, tolerance, uses more or longer than planned, repeated attempts to quit or reduce use,
much time is spent using, physical or psychological problems related to use, and/or gives up activities
in order to use;
10
commonly called addiction.
Cognitive abilities
- brain-based skills we need to carry out any task from the simplest to the most
complex, which include retrieving information from memory, using logic to solve problems,
communicating through language, mentally visualizing a concept, and focusing attention when
distractions are present.
Illicit drugs
fall into two categories: 1) Those drugs that are illegal to process, sell, and consume;
includes cocaine, methamphetamine, ecstasy and heroin. 2) Those drugs that are legal to process, sell,
and consume when prescribed by a physician, but are then misused or used without a prescription;
includes prescription pain medication and prescription sedatives.
Intelligence quotient (IQ)
- a number used to express the apparent relative intelligence of a person,
determined by one's performance on a standardized intelligence test relative to the average
performance of others of the same age.
Marijuana addiction
- an informal term which is more commonly used than cannabis use disorder, but
the two are considered equivalent by the committee and many mental health professionals.
Psychotic disorders
these include schizophrenia, schizoaffective, schizophreniform, schizotypal, and
delusional disorders. These formal diagnoses are made when a combination of psychotic symptoms are
present (possibly combined with other mental health symptoms), the symptoms cause significant
problems with work, relationships or self-care and they have been present for six months or longer.
10
Psychotic symptoms
- these include auditory or visual hallucinations, difficulty separating real from
imagined, perception that self or others can read minds, perceived ability to predict the future, feeling
that an outside force is controlling thoughts or actions, fear that someone intends to harm them, belief
they have supernatural gifts, apathy, social withdrawal, absent or blunted emotions, occurrences of
unclear speech or inability to speak or difficulty organizing thoughts to complete activities.
10
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
96
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0115.png
Section 2: Marijuana Use Among Adolescents and Young Adults
Key findings
The committee’s strongest findings
are related to reduced cognitive abilities and academic
achievement, problem use or addiction
to marijuana or other substances after adolescence and
experiencing psychotic symptoms or diagnoses. Weekly marijuana use by adolescents is associated with
impaired learning, memory, math and reading, even 28 days after last use. Weekly use is also
associated with failure to graduate from high school and may be associated with failure to attain a
college degree. Adolescents and young adults who use marijuana are more likely to experience
psychotic symptoms as adults, such as hallucinations, paranoia, delusional beliefs and feeling
emotionally unresponsive. Daily or near-daily use is associated with developing a psychotic disorder
such as schizophrenia in adulthood.
Concerning future substance use, marijuana use among adolescents and young adults is associated with
future tobacco and illicit drug use and high-risk use of alcohol. In addition, marijuana users can
develop addiction
to marijuana. Strong evidence shows that treatment for marijuana addiction
can
decrease use and dependence. Additionally, marijuana users who quit have lower risks of cognitive and
mental health outcomes than those who continue to use. Finally, the committee found conflicting
evidence regarding the potential effect of adolescent marijuana use on future IQ.
An important note for all key findings is that the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove that the
marijuana use alone
caused
the effect. Despite the best efforts of researchers to account for
confounding factors, there may be other important factors related to
causality
that were not
identified. In addition, marijuana use was illegal everywhere in the United States prior to 1996.
Research funding, when appropriated, was commonly sought to identify adverse effects from marijuana
use. This legal fact introduces both funding bias and publication bias into the body of literature related
to marijuana use. The Retail Marijuana Public Health Advisory Committee recognizes the limitations
and biases inherent in the published literature and made efforts to ensure the information reviewed
and synthesized is reflective of the current state of medical knowledge. Where information was lacking
for whatever reason
the committee identified this knowledge gap and recommended further
research. This information will be updated as new research becomes available.
In this document, the term marijuana addiction is considered equivalent to cannabis use disorder (and addiction to another
substance is considered equivalent to use disorder for that substance).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
97
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0116.png
Section 2: Marijuana Use Among Adolescents and Young Adults
Recommendations
A number of important public health recommendations were identified. There were significant
limitations in the reviewed literature regarding the characterization of marijuana use. To facilitate
future study of the effects of marijuana, it is important to improve data quality by systematically
collecting information on the frequency, amount, potency, and method of marijuana use in both public
health surveillance and clinical settings.
It also is important to better characterize the prevalence of marijuana use among Colorado adolescents
and young adults. Questions regarding marijuana use should be added (or continued) on population-
based surveys such as the Behavioral Risk Factors Surveillance System (BRFSS), the Healthy Kids
Colorado Survey (HKCS) and the National College Health Assessment (NCHS). In order to better assess
potential adverse outcomes, adolescent and young adult hospitalizations and emergency department
visits related to marijuana should be monitored using de-identified data available from the Colorado
Hospital Association. Addiction
treatment admissions should be monitored using data from the
Colorado Office of Behavioral Health, and the prevalence of addiction
among different groups should
be obtained.
Public education on the potential effects of marijuana use also is important and should be designed for
adolescents and young adults themselves as well as parents and caregivers. Educational materials for
schools and colleges should be accurate and could be combined with other behavioral education.
Education should include information on what addiction looks like. Finally, availability and access to
treatment should be promoted.
The committee also identified a number of important research gaps. A common theme among the
research gaps was the need for studies with better defined marijuana-use histories, including
frequency, amount, potency, and method of marijuana use and length of abstinence. A particular need
was identified for evaluation of effects separately for less-than-weekly users versus daily or near-daily
users. Studies of psychological outcomes suggest a possible difference between males and females, and
future studies should evaluate them separately. Finally, more studies are needed that examine
marijuana use as a predictor of risk behaviors, especially among adolescents, college attending young
adults and non-college attending young adults.
In this document, the term marijuana addiction is considered equivalent to cannabis use disorder (and addiction to another
substance is considered equivalent to use disorder for that substance).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
98
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0117.png
Section 2: Marijuana Use Among Adolescents and Young Adults
Table 1 Findings summary: Marijuana use among adolescents and young adults
For information on the classifications “Substantial,” “Moderate,” etc., see Chapter 7. Systematic
literature review process.
Substantial
Cognitive and
academic
Less high school
graduation
Moderate
Impaired cognitive
abilities and
academic
performance after 28
days abstinence
Limited
Less likely
to earn
college
degree
Insufficient
Lower IQ
after brief
abstinence
Mixed
Lower future
IQ scores
Mental health
Psychotic
symptoms in
adulthood
Psychotic disorder in
adulthood (daily or
near-daily users)
Depression or
anxiety after
adolescence
Suicidal
thoughts or
attempts
Substance use, abuse and
addiction
Can develop
marijuana
addiction
Increased marijuana
use and addiction
after adolescence
Alcohol or tobacco
use and addiction
after adolescence
Other illicit drug
use and
addiction
after
adolescence
Treatment for
marijuana
addiction
can
reduce use and
dependence
Quitting marijuana
lowers risk of
cognitive and mental
health effects
In this document, the term marijuana addiction is considered equivalent to cannabis use disorder (and addiction to another
substance is considered equivalent to use disorder for that substance).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
Benefits of
quitting
99
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0118.png
Section 2: Marijuana Use Among Adolescents and Young Adults
Evidence statements
Evidence statements are based on systematic scientific literature reviews performed by Colorado
Department of Public Health and Environment staff with oversight and approval by the Retail Marijuana
Public Health Advisory Committee.
For an explanation of the classifications “Substantial,” “Moderate,”
etc., see Chapter 7. Systematic literature review process. For details about the studies reviewed, see
Appendix F.
Cognitive and academic
1. We found
MODERATE
evidence that adolescents and young adults who use marijuana weekly or
more frequently are more likely than non-users to have ongoing impairment of cognitive and
academic abilities for at least 28 days after last use.
11-14
2. We found
INSUFFICIENT
evidence to determine whether or not adolescents who use marijuana are
more likely than non-users to score lower on IQ tests after brief abstinence.
15,16
(Revised*)
3. We found
MIXED
evidence for whether or not adolescent marijuana use affects future IQ scores.
17-19
(Added*)
4. We found
SUBSTANTIAL
evidence that adolescents who use marijuana weekly or more frequently
are less likely than non-users to graduate from high school.
20-24
(Revised
*
)
5. We found
LIMITED
evidence that adolescents and young adults who use marijuana weekly or more
frequently are less likely than non-users to attain a college degree.
23,25-27
Mental health
6. We found
SUBSTANTIAL
evidence that adolescents and young adults who use marijuana are more
likely than non-users to develop psychotic symptoms in adulthood, and this likelihood increases
with more frequent use.
28-32
(Revised*)
7. We found
MODERATE
evidence that adolescents and young adults who use marijuana daily or near-
daily are more likely than non-users to develop psychotic disorders like schizophrenia in
adulthood.
28,33-35
(Revised*)
8. We found
MIXED
evidence for whether or not adolescent and young adult marijuana users are more
likely than non-users to have symptoms or a diagnosis of anxiety in adulthood.
33,36-39
9. We found
MIXED
evidence for whether or not adolescent and young adult marijuana users are more
likely than non-users to have symptoms or a diagnosis of depression in adulthood.
32,33,36-42
10. We found
MIXED
evidence for whether or not adolescent and young adult marijuana users are more
likely than non-users to have suicidal thoughts or attempt suicide.
42-46
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix F for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
100
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0119.png
Section 2: Marijuana Use Among Adolescents and Young Adults
Substance use, abuse and addiction
11. We found
SUBSTANTIAL
evidence that marijuana users can develop cannabis use disorder, including
adolescent and young adult users.
47,48
(Added*)
12. We found
MODERATE
evidence that adolescent and young adult marijuana users are more likely
than non-users to increase their use and to develop cannabis use disorder in adulthood.
21,22,49
13. We found
MODERATE
evidence that adolescent and young adult marijuana users are more likely
than non-users to use and be addicted
to alcohol or tobacco in adulthood.
21,22,50,51
14. We found
SUBSTANTIAL
evidence that adolescent and young adult marijuana users are more likely
than non-users to use and be addicted
to illicit drugs in adulthood.
21,26,38,50,52-56
Benefits of quitting
15. We found
MODERATE
evidence that adolescent and young adult marijuana users who quit have
lower risks of cognitive and mental health outcomes than those who continue to use.
15,16,41,50
16. We found
SUBSTANTIAL
evidence that some adolescent and young adult marijuana users who
receive treatment for cannabis use disorder (including cognitive behavioral therapy, motivational
enhancement/interviewing, multidimensional family therapy and/or abstinence-based contingency
management) can decrease their marijuana use and dependence.
57-61
(Added
*
)
In this document, the term marijuana addiction is considered equivalent to cannabis use disorder (and addiction to another
substance is considered equivalent to use disorder for that substance).
*
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix F for dates of most recent literature review.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
101
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0120.png
Section 2: Marijuana Use Among Adolescents and Young Adults
Public health statements
Public health statements are plain language translations of the major findings (Evidence Statements)
from the systematic literature reviews. These statements have been officially approved by the Retail
Marijuana Public Health Advisory Committee.
Cognitive and academic
1. Weekly or more frequent marijuana use by adolescents and young adults is associated with
impaired learning, memory, math and reading achievement, even 28 days after last use.
a. These impairments increase with more frequent marijuana use.
2. There is conflicting evidence on whether or not adolescent marijuana use is associated with
changes in future IQ scores. (Added*)
3. Weekly or more frequent marijuana use by adolescents is strongly associated with failure to
graduate from high school. (Revised*)
4. Weekly or more frequent marijuana use by adolescents and young adults may be associated with
not attaining a college degree.
Mental health
5. Marijuana use by adolescents and young adults is strongly associated with developing psychotic
symptoms in adulthood, such as hallucinations, paranoia and delusional beliefs. (Revised*)
a. This risk is higher with more frequent marijuana use.
b. This risk may be higher among those who start using marijuana at a younger age.
6. Daily or near-daily marijuana use by adolescents and young adults is associated with developing a
psychotic disorder such as schizophrenia in adulthood. (Revised*)
Substance use, abuse and addiction
7. Some marijuana users become addicted
to marijuana. Starting marijuana use during adolescence
or young adulthood is associated with future marijuana addiction
. (Revised*)
8. Marijuana use by adolescents and young adults - even less-than-weekly use - is associated with
future high-risk use of alcohol, tobacco, and other drugs like cocaine, ecstasy, opioids and
methamphetamine.
Benefits of quitting
9. Adolescents and young adults who quit marijuana use have a lower risk of developing cognitive
impairment or mental health disorders than those who continue to use.
10. There are treatments for marijuana addiction
that can reduce use and dependence. (Added
*
)
In this document, the term marijuana addiction is considered equivalent to cannabis use disorder (and addiction to another
substance is considered equivalent to use disorder for that substance).
*
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix F for dates of most recent literature review.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
102
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0121.png
Section 2: Marijuana Use Among Adolescents and Young Adults
Public health recommendations
Public health recommendations have been suggested and approved by the Retail Marijuana Public
Health Advisory Committee with the goals of: 1) Improving knowledge regarding population-based
health effects of retail marijuana use and 2) Developing and targeting public health education and
prevention strategies for high-risk sub-populations.
Data quality
Standardization of data collection on frequency, amount, potency, and method of marijuana use in
medical records and other surveillance data sources.
Specify marijuana use as separate from other drug use in medical records and other surveillance
data sources.
Surveillance
Monitor adolescent use and the factors associated with adolescents initiating use, through surveys
such as the Healthy Kids Colorado Survey (HKCS).
Monitor young adult use and the factors associated with initiation of use, through surveys such as
the Behavioral Risk Factor Surveillance Survey (BRFSS).
Monitor National College Health Assessment data, Colorado and national, for comparisons related
to college students.
Monitor adolescent and young adult marijuana-related hospitalizations (both psychiatric and non-
psychiatric) and emergency department visits.
Monitor adolescent and young adult cannabis use disorder treatment rates.
Evaluate prevalence of cannabis use disorder among adolescents and young adults and monitor
trends.
Education
Public education for adolescents, young adults, parents and caregivers, using optimal methods
including social media.
Develop accurate educational materials for schools and colleges, either stand-alone or integrated
with other behavioral education.
Promote accurate information about cannabis use disorder.
Promote availability and access to treatment for cannabis use disorder.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
103
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0122.png
Section 2: Marijuana Use Among Adolescents and Young Adults
Research gaps
The Retail Marijuana Public Health Advisory Committee identifies important gaps in the scientific
literature that may impact public health policies and prevention strategies. Colorado should support
unbiased research to help fill the following research gaps identified by the committee.
Research studies on all outcomes should evaluate different levels of use separately, such as daily or
near-daily, weekly and less-than-weekly use.
Research studies on all outcomes should include former users and continuing users with comparable
prior use frequency and age of onset to help separate long-term effects from the effects of current
use.
Additional studies with more varied time periods of abstinence are needed to assess the duration of
cognitive impact of marijuana use.
Studies evaluating the potential psychological outcomes of marijuana use should have separate
evaluations of males and females.
Increase the number of studies that examine marijuana use as a predictor of risk behaviors,
especially among adolescents, college attending young adults and non-college attending young
adults.
More studies are needed to assess the risk of increasing use or developing cannabis use disorder
among groups with different levels of use, especially for less-than-weekly use. These should also
assess this risk based on different ages of initiating use.
Studies are needed to compare the factors associated with adolescents initiating use between
states with different legal status. These studies should include specific factors such as parental
influences, marijuana marketing and marijuana merchandising.
Better studies are needed to assess causality rather than only association, which may be
confounded by other factors.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
104
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0123.png
Section 2: Marijuana Use Among Adolescents and Young Adults
References
1. Colorado Department of Education. Graduation Statistics. 2016;
https://www.cde.state.co.us/cdereval/gradcurrent,.
2. Colorado Department of Public Health and Environment. Adolescent Health Data, Healthy Kids
Colorado Survey.
Colorado Health and Environmental Data
2015;
http://www.chd.dphe.state.co.us/topics.aspx?q=Adolescent_Health_Data, 2016.
3. Johnson SB, Blum RW, Giedd JN. Adolescent maturity and the brain: the promise and pitfalls of
neuroscience research in adolescent health policy.
J Adolesc Health.
2009;45(3):216-221.
4. Skala K, Walter H. Adolescence and Alcohol: a review of the literature.
Neuropsychiatr.
2013;27(4):202-211.
5. White A, Hingson R. The burden of alcohol use: excessive alcohol consumption and related
consequences among college students.
Alcohol Res.
2013;35(2):201-218.
6. Bradberry T. Study Shows Heavy Adolescent Pot Use Permanently Lowers IQ.
Forbes,
http://www.forbes.com/sites/travisbradberry/2015/02/10/new-study-shows-smoking-pot-
permanently-lowers-iq/#7d2d0562185c2015.
7. Ingraham C. No, marijuana use doesn't lower your IQ.
The Washington Post.
October 22, 2014,
2014.
8. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids.
Clin Pharmacokinet.
2003;42(4):327-360.
9. Nicholson K. Man who plunged from Denver balcony ate 6x recommended amount of pot cookie.
The Denver Post.
April 17, 2014, 2014.
10. American Psychiatric Association.
Diagnostic and Statistical Manual of Mental Disorders.
5th ed.
Washington , DC2013.
11. Pope HG, Jr., Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis
use and cognitive deficits: what is the nature of the association?
Drug Alcohol Depend.
2003;69(3):303-310.
12. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana
use.
Neurology.
2002;59(9):1337-1343.
13. Medina KL, Hanson KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF. Neuropsychological
functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence.
J
Int Neuropsychol Soc.
2007;13(5):807-820.
14. Hooper SR, Woolley D, De Bellis MD. Intellectual, neurocognitive, and academic achievement in
abstinent adolescents with cannabis use disorder.
Psychopharmacology (Berl).
2014;231(8):1467-
1477.
15. Fried PA, Watkinson B, Gray R. Neurocognitive consequences of marihuana--a comparison with pre-
drug performance.
Neurotoxicol Teratol.
2005;27(2):231-239.
16. Fried P, Watkinson B, James D, Gray R. Current and former marijuana use: preliminary findings of a
longitudinal study of effects on IQ in young adults.
CMAJ.
2002;166(7):887-891.
17. Jackson NJ, Isen JD, Khoddam R, et al. Impact of adolescent marijuana use on intelligence: Results
from two longitudinal twin studies.
Proc Natl Acad Sci U S A.
2016;113(5):E500-508.
18. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from
childhood to midlife.
Proc Natl Acad Sci U S A.
2012;109(40):E2657-2664.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
105
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0124.png
Section 2: Marijuana Use Among Adolescents and Young Adults
19. Mokrysz C, Landy R, Gage SH, Munafo MR, Roiser JP, Curran HV. Are IQ and educational outcomes
in teenagers related to their cannabis use? A prospective cohort study.
J Psychopharmacol.
2016;30(2):159-168.
20. Fergusson DM, Horwood LJ, Beautrais AL. Cannabis and educational achievement.
Addiction.
2003;98(12):1681-1692.
21. Lynne-Landsman SD, Bradshaw CP, Ialongo NS. Testing a developmental cascade model of
adolescent substance use trajectories and young adult adjustment.
Dev Psychopathol.
2010;22(4):933-948.
22. Brook JS, Balka EB, Whiteman M. The risks for late adolescence of early adolescent marijuana use.
Am J Public Health.
1999;89(10):1549-1554.
23. Horwood LJ, Fergusson DM, Hayatbakhsh MR, et al. Cannabis use and educational achievement:
findings from three Australasian cohort studies.
Drug Alcohol Depend.
2010;110(3):247-253.
24. Stiby AI, Hickman M, Munafo MR, Heron J, Yip VL, Macleod J. Adolescent cannabis and tobacco use
and educational outcomes at age 16: birth cohort study.
Addiction.
2015;110(4):658-668.
25. Fergusson DM, Boden JM. Cannabis use and later life outcomes.
Addiction.
2008;103(6):969-976;
discussion 977-968.
26. Fergusson DM, Horwood LJ. Does cannabis use encourage other forms of illicit drug use?
Addiction.
2000;95(4):505-520.
27. Baggio S, Iglesias K, Deline S, et al. Not in Education, Employment, or Training status among young
Swiss men. Longitudinal associations with mental health and substance use.
J Adolesc Health.
2015;56(2):238-243.
28. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a
longitudinal population-based study.
Am J Epidemiol.
2002;156(4):319-327.
29. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and risk of
incidence and persistence of psychotic symptoms: 10 year follow-up cohort study.
Bmj.
2011;342:d738.
30. Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use,
predisposition for psychosis, and psychotic symptoms in young people.
Bmj.
2005;330(7481):11.
31. Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic
symptoms.
Addiction.
2005;100(3):354-366.
32. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis:
examination of the evidence.
Br J Psychiatry.
2004;184:110-117.
33. Bechtold J, Simpson T, White HR, Pardini D. Chronic Adolescent Marijuana Use as a Risk Factor for
Physical and Mental Health Problems in Young Adult Men.
Psychol Addict Behav.
2015;10.1037/adb0000103.
34. Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode
psychosis attributable to use of high potency cannabis: a case-control study.
Lancet Psychiatry.
2015;2(3):233-238.
35. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk
factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.
Bmj.
2002;325(7374):1199.
36. Miettunen J, Murray GK, Jones PB, et al. Longitudinal associations between childhood and
adulthood externalizing and internalizing psychopathology and adolescent substance use.
Psychol
Med.
2013;10.1017/S0033291713002328:1-12.
37. Degenhardt L, Coffey C, Romaniuk H, et al. The persistence of the association between adolescent
cannabis use and common mental disorders into young adulthood.
Addiction.
2013;108(1):124-133.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
106
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0125.png
Section 2: Marijuana Use Among Adolescents and Young Adults
38. Zaman T, Malowney M, Knight J, Boyd JW. Co-Occurrence of Substance-Related and Other Mental
Health Disorders Among Adolescent Cannabis Users.
J Addict Med.
2015;10.1097/adm.0000000000000138.
39. Gage SH, Hickman M, Heron J, et al. Associations of cannabis and cigarette use with depression and
anxiety at age 18: findings from the Avon Longitudinal Study of Parents and Children.
PLoS One.
2015;10(4):e0122896.
40. Horwood LJ, Fergusson DM, Coffey C, et al. Cannabis and depression: an integrative data analysis
of four Australasian cohorts.
Drug Alcohol Depend.
2012;126(3):369-378.
41. Pahl K, Brook JS, Koppel J. Trajectories of marijuana use and psychological adjustment among
urban African American and Puerto Rican women.
Psychol Med.
2011;41(8):1775-1783.
42. Rasic D, Weerasinghe S, Asbridge M, Langille DB. Longitudinal associations of cannabis and illicit
drug use with depression, suicidal ideation and suicidal attempts among Nova Scotia high school
students.
Drug Alcohol Depend.
2013;129(1-2):49-53.
43. Kokkevi A, Richardson C, Olszewski D, Matias J, Monshouwer K, Bjarnason T. Multiple substance use
and self-reported suicide attempts by adolescents in 16 European countries.
Eur Child Adolesc
Psychiatry.
2012;21(8):443-450.
44. Consoli A, Peyre H, Speranza M, et al. Suicidal behaviors in depressed adolescents: role of
perceived relationships in the family.
Child Adolesc Psychiatry Ment Health.
2013;7(1):8.
45. Spears M, Montgomery AA, Gunnell D, Araya R. Factors associated with the development of self-
harm amongst a socio-economically deprived cohort of adolescents in Santiago, Chile.
Soc
Psychiatry Psychiatr Epidemiol.
2014;49(4):629-637.
46. Zhang X, Wu LT. Suicidal ideation and substance use among adolescents and young adults: a
bidirectional relation?
Drug Alcohol Depend.
2014;142:63-73.
47. Schuermeyer J, Salomonsen-Sautel S, Price RK, et al. Temporal trends in marijuana attitudes,
availability and use in Colorado compared to non-medical marijuana states: 2003-11.
Drug Alcohol
Depend.
2014;140:145-155.
48. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States
Between 2001-2002 and 2012-2013.
JAMA Psychiatry.
2015;72(12):1235-1242.
49. Swift W, Coffey C, Carlin JB, Degenhardt L, Patton GC. Adolescent cannabis users at 24 years:
trajectories to regular weekly use and dependence in young adulthood.
Addiction.
2008;103(8):1361-1370.
50. Swift W, Coffey C, Degenhardt L, Carlin JB, Romaniuk H, Patton GC. Cannabis and progression to
other substance use in young adults: findings from a 13-year prospective population-based study.
J
Epidemiol Community Health.
2012;66(7):e26.
51. Rubinstein ML, Rait MA, Prochaska JJ. Frequent marijuana use is associated with greater nicotine
addiction in adolescent smokers.
Drug Alcohol Depend.
2014;141:159-162.
52. Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: testing the cannabis
gateway hypothesis.
Addiction.
2006;101(4):556-569.
53. Schepis TS, Krishnan-Sarin S. Characterizing adolescent prescription misusers: a population-based
study.
J Am Acad Child Adolesc Psychiatry.
2008;47(7):745-754.
54. Fiellin LE, Tetrault JM, Becker WC, Fiellin DA, Hoff RA. Previous use of alcohol, cigarettes, and
marijuana and subsequent abuse of prescription opioids in young adults.
J Adolesc Health.
2013;52(2):158-163.
55. Nakawaki B, Crano WD. Predicting adolescents' persistence, non-persistence, and recent onset of
nonmedical use of opioids and stimulants.
Addict Behav.
2012;37(6):716-721.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
107
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0126.png
Section 2: Marijuana Use Among Adolescents and Young Adults
56. Moss HB, Chen CM, Yi HY. Early adolescent patterns of alcohol, cigarettes, and marijuana
polysubstance use and young adult substance use outcomes in a nationally representative sample.
Drug Alcohol Depend.
2014;136:51-62.
57. Stanger C, Ryan SR, Scherer EA, Norton GE, Budney AJ. Clinic- and home-based contingency
management plus parent training for adolescent cannabis use disorders.
J Am Acad Child Adolesc
Psychiatry.
2015;54(6):445-453 e442.
58. Stanger C, Budney AJ, Kamon JL, Thostensen J. A randomized trial of contingency management for
adolescent marijuana abuse and dependence.
Drug Alcohol Depend.
2009;105(3):240-247.
59. Rigter H, Henderson CE, Pelc I, et al. Multidimensional family therapy lowers the rate of cannabis
dependence in adolescents: a randomised controlled trial in Western European outpatient settings.
Drug Alcohol Depend.
2013;130(1-3):85-93.
60. Hendriks V, van der Schee E, Blanken P. Treatment of adolescents with a cannabis use disorder:
main findings of a randomized controlled trial comparing multidimensional family therapy and
cognitive behavioral therapy in The Netherlands.
Drug Alcohol Depend.
2011;119(1-2):64-71.
61. Dennis M, Godley SH, Diamond G, et al. The Cannabis Youth Treatment (CYT) Study: main findings
from two randomized trials.
J Subst Abuse Treat.
2004;27(3):197-213.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
108
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0127.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Chapter 3
Marijuana Use and Cancer
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0128.png
Section 2: Marijuana Use and Cancer
Authors
Ken Gershman, MD, MPH
Manager
Medical Marijuana Research Grants Program, Colorado Department of Public Health and Environment
(2016)
Elyse Contreras, MPH
Coordinator
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2016)
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2016)
Lisa Barker, MPH
Retail Marijuana Health Monitoring, Colorado Department of Public Health and Environment
(2014)
Madeline Morris, BS
Graduate Student, Colorado School of Public Health
(2014)
Todd Carlson, MD
Internal Medicine Resident, University of Colorado
(2014)
Mike Van Dyke, PhD, CIH
Chief
Environmental Epidemiology, Occupational Health, and Toxicology, Colorado Department of Public
Health and Environment
(2014)
David Goff Jr., MD, PhD, FACP, FAHA
Dean and Professor, Colorado School of Public Health
(2014)
Reviewers
Russell Bowler, MD, PhD
Professor of Medicine, National Jewish Health and University of Colorado
(2016)
Ken Gershman, MD, MPH
Manager
Medical Marijuana Research Grants Program, Colorado Department of Public Health and Environment
(2014)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
110
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0129.png
Section 2: Marijuana Use and Cancer
Introduction
The Retail Marijuana Public Health Advisory Committee identified many important public health topics
related to marijuana use and has reviewed the scientific evidence currently available regarding those
topics. This chapter includes reviews of different forms of cancer relative to marijuana use, as well as
the chemicals released in marijuana smoke and vapor.
Cancer is a disease that affects all ages and demographics. More than 20,000 Coloradoans are
diagnosed with cancer each year,
1
with nearly one-third eventually dying from it.
2
Many behavioral
factors are known to increase cancer risk, including tobacco smoking,
3
alcohol use,
4
and poor diet.
5
This raises concern that marijuana use may also increase cancer risk. It is important to identify any
cancer-causing chemicals that marijuana users are exposed to and to investigate possible connections
between marijuana use and various forms of cancer.
Definitions
Cancer-causing chemicals
chemicals known to cause cancer in humans, including polycyclic aromatic
hydrocarbons
Combustion by-products
chemicals produced when a material is burned. These chemicals including
carbon monoxide and polycyclic aromatic hydrocarbons.
Marijuana combustion
- the heating of marijuana flower or concentrate by applying a direct heat
source of 230 degrees Celsius or above in order to produce smoke for inhalation. Combustion methods
include burning a joint, blunt, pipe, or bong bowl.
Mainstream smoke
also known as firsthand smoke, it is
the smoke
that a smoker inhales from a lit
cigarette, pipe, or joint and then exhales.
Polycyclic aromatic hydrocarbons
- a group of more than 100 different chemicals released from
burning coal, oil, gasoline, trash, tobacco, wood, or other organic substances.
Sidestream smoke
the smoke that wafts off the end of a lit cigarette, pipe or joint into the
surrounding air.
Secondhand smoke
the smoke that is inhaled by non-smokers when near to a person smoking, also
known as passive exposure.
Vaporization of marijuana (vaping)
a method of marijuana use in which marijuana vapor, rather
than smoke, is inhaled. Marijuana flower or concentrate is heated in a vaporizing device (vaporizer) to
a temperature below the point of combustion, to produce vapor.
Water pipe
- a pipe for smoking tobacco, marijuana, etc., that draws the smoke through water to cool
it. Examples are a hookah and a bong.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
111
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0130.png
Section 2: Marijuana Use and Cancer
Key findings
Strong evidence shows that marijuana smoke contains many of the same cancer-causing chemicals
found in tobacco smoke. Marijuana smoke from water pipes or bongs may contain more cancer-causing
chemicals than smoke from a marijuana joint. On the other hand, marijuana vapor may contain fewer
cancer-causing chemicals than smoke from a marijuana joint.
Most lung cancer studies have used the concept of
“joint-years”
as a measure of total cumulative
marijuana smoking.
A “joint-year”
is the equivalent of smoking one joint per day for a year. Levels of
cumulative use in these studies tended to divide into people who have smoked more than 10 joint-
years and people who have smoked fewer than 10 joint years. There is conflicting research for whether
or not smoking
more
than 10 joint-years is associated with lung cancer. For those who have smoked
fewer
than 10 joint-years, an association appears unlikely.
Limited evidence suggests an association between marijuana use and both testicular (nonseminoma)
and prostate cancers. On the other hand, the limited evidence available concerning cancers of the
bladder, head and neck suggests that they might not have any association with marijuana use.
An important note for all key findings is that the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove that the
marijuana use alone
caused
the effect. Despite the best efforts of researchers to account for
confounding factors, there may be other important factors related to
causality
that were not
identified. In addition, marijuana use was illegal everywhere in the United States prior to 1996.
Research funding, when appropriated, was commonly sought to identify adverse effects from marijuana
use. This legal fact introduces both funding bias and publication bias into the body of literature related
to marijuana use. The Retail Marijuana Public Health Advisory Committee recognizes the limitations
and biases inherent in the published literature and made efforts to ensure the information reviewed
and synthesized is reflective of the current state of medical knowledge. Where information was lacking
for whatever reason
the committee identified this knowledge gap and recommended further
research. This information will be updated as new research becomes available.
Recommendations
The committee recommends improved documentation of cumulative lifetime marijuana use history for
individuals diagnosed with cancer, including methods of use. Public health should monitor the
prevalence of relevant cancers through the Colorado Central Cancer Registry, and educate the public
on the potential for additive risks to lung health related to smoking both tobacco and marijuana.
Additional study is needed about the possible associations between marijuana use and various types of
cancer. These should include improved methods to assess cumulative marijuana exposure to facilitate
comparisons between studies and relevance to the clinical setting. They should include older age
groups separately, due to the increased risk of cancer. Finally, they should include adequate numbers
of non-tobacco smokers, to eliminate the confounding introduced by tobacco smoking.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
112
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0131.png
Section 2: Marijuana Use and Cancer
Table 1 Findings summary: Marijuana use and cancer
For an explanation of the classifications “Substantial,” “Moderate,” etc., see Chapter 7. Systematic
literature review process.
Substantial
Marijuana smoke
contains same
cancer-causing
chemicals as
tobacco smoke
Moderate
Limited
Water-pipe
smoke has more
cancer-causing
chemicals than
smoke from
joints
Vaporized
marijuana has
fewer cancer-
causing
chemicals than
smoke from
joints
Insufficient
Mixed
Chemicals in MJ smoke or vapor
Cancer and pre-cancerous lesions
Pre-cancerous
lesions with
daily or near-
daily use
Failure to show
association with
lung cancer for
less than 10
joint-years
cumulative use
Increased risk of
nonseminoma
testicular cancer
Association with
lung cancer for
more than 10
joint-years
cumulative use
Increased risk of
prostate cancer
Failure to show
association with
bladder cancer
Failure to show
association with
head and neck
cancer
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
113
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0132.png
Section 2: Marijuana Use and Cancer
Evidence statements
Evidence statements are based on systematic scientific literature reviews performed by Colorado
Department of Public Health and Environment staff with oversight and approval by the Retail Marijuana
Public Health Advisory Committee. For an explanation of the
classifications “Substantial,” “Moderate,”
etc., see Chapter 7. Systematic literature review process. For details about the studies reviewed, see
Appendix G.
Chemical content of marijuana smoke or vapor
1. We found
SUBSTANTIAL
evidence that marijuana smoke, both mainstream and sidestream,
contains many of the same cancer-causing chemicals as tobacco smoke.
6-10
2. We found
LIMITED
evidence from simulated smoking studies that smoke from water pipes or bongs
contains more cancer-causing chemicals per milligram of THC compared to smoke from unfiltered
joints.
6,11
3. We found
LIMITED
evidence that marijuana vaporizers produce fewer combustion by-products,
including carbon monoxide and polycyclic aromatic hydrocarbons, compared with smoking
marijuana.
10,12,13
(Added*)
Cancer and pre-cancerous lesions
4. We found
SUBSTANTIAL
evidence that daily or near-daily marijuana smoking is associated with pre-
malignant lesions in the airway.
14-16
5. We found
MIXED
evidence for whether or not cumulative levels of marijuana smoking greater than
the equivalent of one joint per day for 10 years are associated with lung cancer.
17-21
(Revised*)
6. We found a
MODERATE
body of research that failed to show an association between cumulative
levels of marijuana smoking less than the equivalent of one joint per day for 10 years and lung
cancer.
17-22
(Revised*)
7. We found
LIMITED
evidence that marijuana use among adult males increases risk of nonseminoma
testicular cancer.
23-25
8. We found
LIMITED
evidence
1
that marijuana use among adult males increases risk of prostate
cancer.
22
9. We found a
LIMITED
body of research that failed to show an association between marijuana use by
adults and transitional cell carcinoma of the bladder.
22,26,27
(Revised*)
10. We found a
LIMITED
body of research that failed to show an association between marijuana use by
adults and head and neck cancer.
28
(Added*)
*
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix G for dates of most recent literature review.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
114
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0133.png
Section 2: Marijuana Use and Cancer
Public health statements
Public health statements are plain language translations of the major findings (Evidence Statements)
from the systematic literature reviews. These statements have been officially approved by the Retail
Marijuana Public Health Advisory Committee.
1. Marijuana smoke, both firsthand and secondhand, contains many of the same cancer-causing
chemicals as tobacco smoke.
2. Marijuana smoke from water pipes or bongs may contain more cancer-causing chemicals than
smoke from a joint.
3. Vaporized marijuana may contain fewer cancer-causing chemicals than smoke from a joint.
(Added*)
4. Daily or near-daily marijuana smoking is strongly associated with pre-malignant lesions that may
lead to cancer in the airways of your lungs.
5. There is conflicting research on whether or not smoking marijuana more than a joint per day for 10
years is associated with lung cancer. (Revised*)
6. An association appears unlikely between marijuana smoking and lung cancer when used less than a
joint per day for 10 years. (Revised*)
7. Marijuana use may be associated with prostate cancer or nonseminoma testicular cancer.
Public health recommendations
Public health recommendations have been suggested and approved by the Retail Marijuana Public
Health Advisory Committee with the goals of: 1) Improving knowledge regarding population-based
health effects of retail marijuana use and 2) Developing and targeting public health education and
prevention strategies for high-risk sub populations.
Data quality
Improved documentation of cumulative lifetime marijuana use history for individuals diagnosed
with cancer, including methods of use.
Surveillance
Monitor the prevalence of relevant cancers through the Colorado Central Cancer Registry.
Education
Educate the public on the
2
potential for additive risks to lung health related to smoking both
tobacco and marijuana.
*
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix G for dates of most recent literature review.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
115
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0134.png
Section 2: Marijuana Use and Cancer
Research gaps
The Retail Marijuana Public Health Advisory Committee identifies important gaps in the scientific
literature that may impact public health policies and prevention strategies. Colorado should support
unbiased research to help fill the following research gaps identified by the committee.
Improved studies assessing the risk of lung and oropharyngeal cancers related to marijuana use,
especially including adequate numbers of non-tobacco smokers, assessment of cumulative
marijuana exposure, and older age groups.
Additional, high quality studies assessing the risk of relevant non-respiratory-tract cancers related
to marijuana use, using good methods to assess cumulative marijuana exposure.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
116
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0135.png
Section 2: Marijuana Use and Cancer
References
1.
Colorado Department of Public Health and Environment.
Cancer in Colorado 2003-2012,
Statistical Tables and Highlights All Cancers Combined Number of Diagnosed Cancers and
Average Annual Age-Adjusted Incidence Rates per 100,000 by Sex, County/Region, Time
Period, Colorado 2003-2009 and 2010-2012.
2015.
Colorado Department of Public Health and Environment.
Cancer in Colorado 2003-2012,
Statistical Tables and Highlights All Cancers Combined Number of Cancers Deaths and Average
Annual Age-Adjusted Mortality Rates per 100,000 by Sex, County/Region, Time Period,
Colorado 2003-2009 and 2010-2012.
2015.
American Cancer Society. Health Risks of Smoking Tobacco. 2015;
http://www.cancer.org/cancer/cancercauses/tobaccocancer/health-risks-of-smoking-tobacco.
Accessed December 28, 2016,
http://www.cancer.org/cancer/cancercauses/tobaccocancer/health-risks-of-smoking-tobacco.
National Cancer Institute. Alcohol and Cancer Risk. 2013; https://www.cancer.gov/about-
cancer/causes-prevention/risk/alcohol/alcohol-fact-sheet#q2. Accessed December 28, 2016.
Cancer Research UK. Diet Facts and Evidence. 2016; http://www.cancerresearchuk.org/about-
cancer/causes-of-cancer/diet-and-cancer/diet-facts-and-evidence. Accessed December 28,
2016.
Gieringer D. Waterpipe Study.
Multidisciplinary Assocation for Psycheldelic Studies (MAPS).
1996;6(3).
Lee ML, Novotny M, Bartle KD. Gas chromatography/mass spectrometric and nuclear magnetic
resonance spectrometric studies of carcinogenic polynuclear aromatic hydrocarbons in tobacco
and marijuana smoke condensates.
Anal Chem.
1976;48(2):405-416.
Moir D, Rickert WS, Levasseur G, et al. A comparison of mainstream and sidestream marijuana
and tobacco cigarette smoke produced under two machine smoking conditions.
Chem Res
Toxicol.
2008;21(2):494-502.
Sparacino CM, Hyldburg PA, Hughes TJ. Chemical and Biological Analysis of Marijuana Smoke
Condensate. In: Services USDoHaH, ed, 1990.
Gieringer D, St. Laurent J, Goodrich S. Cannabis Vaporizer Combines Efficient Delivery of THC
with Effective Suppression of Pyrolytic Compounds.
Journal of Cannabis Therapeutics.
2004;4(1).
Gowing LR, Ali RL, White JM. Respiratory harms of smoked cannabis. In: Australia DaASCS, ed.
DASC Monograph No. 8, Research Series,
2000.
Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless
cannabis delivery system: a pilot study.
Clin Pharmacol Ther.
2007;82(5):572-578.
Pomahacova B, Van der Kooy F, Verpoorte R. Cannabis smoke condensate III: the cannabinoid
content of vaporised Cannabis sativa.
Inhal Toxicol.
2009;21(13):1108-1112.
Barsky SH, Roth MD, Kleerup EC, Simmons M, Tashkin DP. Histopathologic and molecular
alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco.
J Natl Cancer Inst.
1998;90(16):1198-1205.
Fligiel SE, Roth MD, Kleerup EC, Barsky SH, Simmons MS, Tashkin DP. Tracheobronchial
histopathology in habitual smokers of cocaine, marijuana, and/or tobacco.
Chest.
1997;112(2):319-326.
Gong H, Jr., Fligiel S, Tashkin DP, Barbers RG. Tracheobronchial changes in habitual, heavy
smokers of marijuana with and without tobacco.
Am Rev Respir Dis.
1987;136(1):142-149.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
117
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0136.png
Section 2: Marijuana Use and Cancer
17.
18.
19.
Aldington S, Harwood M, Cox B, et al. Cannabis use and risk of lung cancer: a case-control
study.
Eur Respir J.
2008;31(2):280-286.
Callaghan RC, Allecbeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort
study.
Cancer Causes Control.
2013;24:1811-1820.
Han B, Gfroerer JC, Colliver JD. Associations between duration of illicit drug use and health
conditions: results from the 2005-2007 national surveys on drug use and health.
Ann Epidemiol.
2010;20(4):289-297.
Hashibe M, Morgenstern H, Cui Y, et al. Marijuana use and the risk of lung and upper
aerodigestive tract cancers: results of a population-based case-control study.
Cancer Epidemiol
Biomarkers Prev.
2006;15(10):1829-1834.
Zhang LR, Morgenstern H, Greenland S, et al. Cannabis smoking and lung cancer risk: Pooled
analysis in the International Lung Cancer Consortium.
Int J Cancer.
2014;10.1002/ijc.29036.
Sidney S, Jr CPQ, Friedman GD, Tekawa IS. Marijuana use and cancer incidence (California,
United States).
Cancer Causes & Control.
1997;8(5):722-728.
Trabert B, Sigurdson AJ, Sweeney AM, Strom SS, McGlynn KA. Marijuana use and testicular germ
cell tumors.
Cancer.
2011;117(4):848-853.
Daling JR, Doody DR, Sun X, et al. Association of marijuana use and the incidence of testicular
germ cell tumors.
Cancer.
2009;115(6):1215-1223.
Lacson JCA, Carroll JD, Tuazon E, Castelao EJ, Bernstein L, Cortessis VK. Population-based
case-control study of recreational drug use and testis cancer risk confirms an association
between marijuana use and nonseminoma risk.
Cancer.
2012;118(21):5374-5383.
Chacko Ja, Heiner JG, Siu W, Macy M, Terris MK. Association between marijuana use and
transitional cell carcinoma.
Urology.
2006;67(1):100-104.
Thomas AA, Wallner LP, Quinn VP, et al. Association between cannabis use and the risk of
bladder cancer: results from the California Men's Health Study.
Urology.
2015;85(2):388-392.
de Carvalho MF, Dourado MR, Fernandes IB, Araujo CT, Mesquita AT, Ramos-Jorge ML. Head and
neck cancer among marijuana users: a meta-analysis of matched case-control studies.
Arch
Oral Biol.
2015;60(12):1750-1755.
20.
21.
22.
23.
24.
25.
26.
27.
28.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
118
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0137.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Chapter 4
Marijuana Use and
Cardiovascular Effects
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0138.png
Section 2: Marijuana Use and Cardiovascular Effects
Authors
Elyse Contreras, MPH
Coordinator
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2016)
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2016)
Lisa Barker, MPH
Retail Marijuana Health Monitoring, Colorado Department of Public Health and Environment
(2014)
Katelyn E. Hall, MPH
Retail Marijuana Health Monitoring Program, Colorado Department of Public Health and Environment
(2014)
David Goff Jr., MD, PhD, FACP, FAHA
Dean and Professor, Colorado School of Public Health
(2014)
Reviewers
Andrew Monte, MD
Emergency Medicine Physician, University of Colorado
Medical Toxicologist, Rocky Mountain Poison and Drug Center
(2016)
Ken Gershman, MD, MPH
Manager
Medical Marijuana Research Grants Program, Colorado Department of Public Health and Environment
(2016)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
120
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0139.png
Section 2: Marijuana Use and Cardiovascular Effects
Introduction
The Retail Marijuana Public Health Advisory Committee identified many important public health topics
related to marijuana use and has reviewed the scientific evidence currently available regarding those
topics. This chapter includes reviews of myocardial infarction, stroke and death from cardiovascular
causes, relative to marijuana use.
Cardiovascular disease is the leading cause of death for both men and women in the United States and
is responsible for one in four deaths.
1
The financial cost in the United States is over $200 billion each
year.
1
Tobacco smoking is a major risk factor and causes one of every three deaths from heart disease.
2
There is concern that marijuana smoking may contribute to heart disease in ways similar to tobacco
smoking. Marijuana use often causes a faster heart rate, elevated blood pressure, and an increased
need for oxygen
3
in the hours immediately after use, all of which are effects that can contribute to
cardiovascular disease or be dangerous in a person who already has cardiovascular disease. With
approximately 13 percent of Colorado adults using marijuana, it is important to identify any potential
connections between marijuana use and the development or worsening of cardiovascular disease.
Definitions
Acute marijuana use
marijuana used within the past few hours, such that the short-term effects or
symptoms are still being experienced.
Cardiovascular disease
a disease of the heart and/or blood vessels, including both heart disease and
stroke.
Heart disease
encompasses several conditions that affect the heart, including coronary heart disease,
myocardial infarction (heart attack), heart failure, arrhythmias and heart valve problems.
Myocardial infarction
the medical term for a
“heart attack,”
which occurs when blood flow to the
heart is blocked, causing injury to part of the heart muscle. This can cause a life-threatening change in
heart rhythm (arrhythmia).
Stroke
an event that blocks blood flow to part of the brain or causes bleeding into the brain, causing
permanent damage.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
121
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0140.png
Section 2: Marijuana Use and Cardiovascular Effects
Key findings
There is a moderate level of scientific evidence that marijuana use increases risk for some forms of
stroke in individuals younger than age 55 years, and more limited evidence that marijuana use may
increase risk for heart attack. Research is lacking for other cardiovascular events and conditions,
including death.
An important note for all key findings is that the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove that the
marijuana use alone
caused
the effect. Despite the best efforts of researchers to account for
confounding factors, there may be other important factors related to
causality
that were not
identified. In addition, marijuana use was illegal everywhere in the United States prior to 1996.
Research funding, when appropriated, was commonly sought to identify adverse effects from marijuana
use. This legal fact introduces both funding bias and publication bias into the body of literature related
to marijuana use. The Retail Marijuana Public Health Advisory Committee recognizes the limitations
and biases inherent in the published literature and made efforts to ensure the information reviewed
and synthesized is reflective of the current state of medical knowledge. Where information was lacking
for whatever reason
the committee identified this knowledge gap and recommended further
research. This information will be updated as new research becomes available.
Recommendations
The committee recommends that health care systems and providers improve the documentation of
marijuana use history during hospitalizations and emergency department visits, including timing,
potency and amount of last marijuana use and measures of cumulative lifetime use. Public health
should monitor and analyze this data for possible associations between marijuana use and
cardiovascular events. Educational programs for adult users, their families, and health care providers
who care for them should be developed to ensure more information is shared about the known health
effects of marijuana use, as well as what is unknown at present.
Additional research on critical cardiovascular events is needed. This research should seek good data on
timing, potency and amount of last marijuana use, in order to evaluate potential acute associations.
Similarly, better data on cumulative lifetime use is important when evaluating potential long-term
associations. Prospective studies enlisting groups of marijuana users and non-users should be done, and
observed outcomes should include both the development of chronic cardiovascular disease and the
occurrence of acute cardiovascular events.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
122
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0141.png
Section 2: Marijuana Use and Cardiovascular Effects
Table 1 Findings summary: Marijuana use and cardiovascular effects
For an explanation of the classifications “Substantial,” “Moderate,” etc., see Chapter 7. Systematic
literature review process.
Substantial
Moderate
Increased risk of
ischemic stroke in
individuals younger
than 55
Limited
Increased risk of
myocardial infarction
(heart attack) with
acute use
Insufficient
Death due to
cardiovascular
cause with acute
or long-term use
Mixed
Evidence statements
Evidence statements are based on systematic scientific literature reviews performed by Colorado
Department of Public Health and Environment staff with oversight and approval by the Retail Marijuana
Public Health Advisory Committee. For an explanation of the
classifications “Substantial,” “Moderate,”
etc., see Chapter 7. Systematic literature review process. For details about the studies reviewed, see
Appendix H.
1. We found
MODERATE
evidence that marijuana use increases risk of ischemic stroke in individuals
younger than 55 years of age.
4-9
(Revised*)
2. We found
LIMITED
evidence that acute marijuana use increases risk of myocardial infarction.
10,11
3. We found
INSUFFICIENT
evidence to determine whether or not marijuana use changes the risk of
death related to a cardiovascular event, either acutely or over time.
12-14
Public health statements
Public health statements are plain language translations of the major findings (Evidence Statements)
from the systematic literature reviews. These statements have been officially approved by the Retail
Marijuana Public Health Advisory Committee.
1. Marijuana use is associated with increased risk of stroke in individuals younger than 55 years of
age. (Revised*)
2. Acute marijuana use may be associated with increased risk of heart attack among adults.
1
*
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix H for dates of most recent literature review.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
123
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0142.png
Section 2: Marijuana Use and Cardiovascular Effects
Public health recommendations
Public health recommendations have been suggested and approved by the Retail Marijuana Public
Health Advisory Committee with the goals of: 1) Improving knowledge regarding population-based
health effects of retail marijuana use and 2) Developing and targeting public health education and
prevention strategies for high-risk sub populations.
Data quality
Improved documentation of marijuana use history during hospitalizations and emergency
department visits, including timing, potency and amount of last marijuana use and measures of
cumulative lifetime use.
Surveillance
Monitor and analyze emergency department and hospitalization data for possible associations
between marijuana use and cardiovascular events.
Education
Public education about the potential cardiovascular risks of cannabis use.
Research gaps
The Retail Marijuana Public Health Advisory Committee identifies important gaps in the scientific
literature that may impact public health policies and prevention strategies. Colorado should support
unbiased research to help fill the following research gaps identified by the committee.
Additional studies of critical cardiovascular events, with improved data on timing, potency and
amount of last marijuana use (for potential acute associations) and cumulative lifetime use (for
potential long-term associations).
Prospective studies of cohorts of marijuana users and non-users for possible associations with the
development of chronic cardiovascular disease or with acute cardiovascular events.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
124
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0143.png
Section 2: Marijuana Use and Cardiovascular Effects
References
1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2016 Update: A
Report From the American Heart Association.
Circulation.
2016;133(4):e38-360.
2. U.S. Department of Health & Human Services.
The Health Consequences of Smoking - 50 Years of
Progress, A Report of the Surgeon General.
2014.
3. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids.
Clin Pharmacokinet.
2003;42(4):327-360.
4. Geller T, Loftis L, Brink DS. Cerebellar infarction in adolescent males associated with acute
marijuana use.
Pediatrics.
2004;113(4):e365-370.
5. Barber PA, Pridmore HM, Krishnamurthy V, et al. Cannabis, ischemic stroke, and transient ischemic
attack: a case-control study.
Stroke.
2013;44(8):2327-2329.
6. Wolff V, Armspach J-P, Lauer V, et al. Cannabis-related stroke: myth or reality?
Stroke.
2013;44(2):558-563.
7. Hackam DG. Cannabis and stroke: systematic appraisal of case reports.
Stroke.
2015;46(3):852-856.
8. Rumalla K, Reddy AY, Mittal MK. Recreational marijuana use and acute ischemic stroke: A
population-based analysis of hospitalized patients in the United States.
J Neurol Sci.
2016;364:191-
196.
9. Thanvi BR, Treadwell SD. Cannabis and stroke: is there a link?
Postgrad Med J.
2009;85(1000):80-
83.
10. Mittleman Ma, Lewis Ra, Maclure M, Sherwood JB, Muller JE. Triggering Myocardial Infarction by
Marijuana.
Circulation.
2001;103(23):2805-2809.
11. Jouanjus E, Lapeyre-Mestre M, Micallef J, French Association of the Regional A, Dependence
Monitoring Centres Working Group on Cannabis C. Cannabis use: signal of increasing risk of serious
cardiovascular disorders.
J Am Heart Assoc.
2014;3(2):e000638.
12. Mukamal KJ, Maclure M, Muller JE, Mittleman Ma. An exploratory prospective study of marijuana
use and mortality following acute myocardial infarction.
American Heart Journal.
2008;155(3):465-
470.
13. Frost L, Mostofsky E, Rosenbloom JI, Mukamal KJ, Mittleman Ma. Marijuana use and long-term
mortality among survivors of acute myocardial infarction.
American Heart Journal.
2013;165(2):170-175.
14. Sidney S, Beck JE, Tekawa IS, Quesenberry CP, Friedman GD. Marijuana use and mortality.
Am J
Public Health.
1997;87(4):585-590.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
125
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0144.png
Section 2: Marijuana Use and Cardiovascular Effects
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
126
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0145.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Chapter 5
Marijuana Dose and Drug
Interactions
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0146.png
Section 2: Marijuana Dose and Drug Interactions
Authors
Michael F. Wempe, PhD
Associate Research Professor
Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus
(2016)
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2016)
Lisa Barker, MPH
Retail Marijuana Health Monitoring, Colorado Department of Public Health and Environment
(2014, 2016)
Kim Siegel, MD, MPH
Occupational Medicine Resident, University of Colorado Denver
(2014)
Mike Kosnett, MD, MPH
Associate Clinical Professor, Division of Clinical Pharmacology and Toxicology, Department of Medicine,
University of Colorado School of Medicine, Department of Environmental and Occupational Health,
Colorado School of Public Health
(2014)
Reviewer
Laura Borgelt, PharmD
Associate Dean and Professor
Departments of Clinical Pharmacy and Family Medicine, University of Colorado Anschutz Medical
Campus
(2014, 2016)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
128
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0147.png
Section 2: Marijuana Dose and Drug Interactions
Introduction
The Retail Marijuana Public Health Advisory Committee identified many important public health topics
related to marijuana and has reviewed the scientific evidence currently available regarding those
topics. This chapter includes reviews of THC levels relative to marijuana dose and method of use, the
effects of secondhand marijuana smoke, drug-drug interactions involving marijuana, and relationships
between marijuana and opioid use.
In an era of legalized marijuana, it is possible that more individuals will drive or work while under the
influence of marijuana. Many employers are creating new marijuana policies and need accurate and
easily interpretable marijuana testing. The Colorado State Patrol also is working to improve its
marijuana testing.
1
As a result, it is important to have good information about marijuana testing
methods and THC levels that can be expected relative to different types and amounts of use.
Another prominent public health question about marijuana is the health effects secondhand marijuana
smoke may have, especially on children. Secondhand tobacco smoke is known to be associated with
many diseases and health problems for both children and adults.
2
Many argue that marijuana smoke
may be just as harmful. Analysis of 2014 and 2015 Colorado Child Health Survey data, completed for
this report, estimated that approximately 16,000 homes in Colorado had children 1-14 years old with
possible exposure to secondhand marijuana smoke or vapor in the home. While current public health
education already advises against using marijuana around children, it is important to investigate the
potential health effects of secondhand marijuana smoke.
About 1 percent of hospital admissions are due to drug-drug interactions, which occur when the effects
of one medication are changed by the use of another medication or drug.
3
With an aging population,
many of whom use multiple medications, these interactions are a growing concern.
4
Many medications
have been found to have such interactions with alcohol or tobacco, raising reasonable concern for
interactions with marijuana.
5,6
In 2014, about 3 percent of adults 65 years and older used marijuana.
7
Drug-drug interactions can be minimized if prescribers are aware of which medications and drugs affect
each other, so
they can adjust or change patients’ medications appropriately.
Therefore, it is
important to identify any drug-drug interactions involving marijuana and inform the medical
community.
Opioid abuse has increased dramatically in the United States over the past 15 years and has been
declared an epidemic by the U.S. Department of Health & Human Services, causing more than 28,000
deaths in 2014.
8
In Colorado, 5 percent of people 12 years and older misused prescription pain relievers
(primarily opioids) in 2013 and 2014.
9
The possibility that marijuana use can reduce opioid use and
abuse is a prominent claim.
10
Others argue that marijuana use makes using opioids and other drugs
more likely. It is important to clarify the relationships between marijuana use and opioid use.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
129
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0148.png
Section 2: Marijuana Dose and Drug Interactions
Definitions
Levels of marijuana use
Daily or near-daily use: 5-7 days/week
Weekly use: 1-4 days/week
Less-than-weekly use: less than 1 day/week
Analgesic
a medication used to relieve pain.
Dabbing
a method of marijuana use where a "dab" (small amount) of marijuana concentrate is placed
on a pre-heated surface, creating concentrated marijuana vapor to be inhaled.
Drug-drug interaction
a potentially dangerous interaction that occurs when the effects of one
medication are changed by the use of another medication or drug. An example is when a person taking
a blood thinner starts a new medication or drug that causes an increase in the blood thinner, leading to
bleeding. Similar interactions can occur with many medications.
Opioid
- one of many medications or street drugs including heroin, opium and prescription pain
medications such as morphine, hydrocodone (Vicodin, Norco, Lortab), oxycodone (Percocet,
OxyContin), hydromorphone (Dilaudid), fentanyl and methadone.
Pharmacokinetic / pharmacodynamic
- the absorption, distribution, metabolism and excretion of a
drug and the effect the drug has on the body.
Secondhand marijuana smoke exposure
- the smoke that is inhaled by non-smokers when near to a
person smoking marijuana, also known as passive exposure.
Typical conditions: exposure at or below the level of smoke present in a small ventilated room
(such as with open windows or an exhaust fan) with multiple people smoking marijuana.
Extreme conditions: exposure at or above the level of smoke present in a small room (or a vehicle)
without ventilation and with multiple people smoking marijuana.
Tetrahydrocannabinol (THC)
- the main psychoactive component of marijuana.
Thirdhand marijuana smoke exposure
residual contamination left in rooms and on clothes after
marijuana smoking.
Vaporization of marijuana (vaping)
a method of marijuana use in which marijuana vapor, rather than
smoke, is inhaled. Marijuana flower or concentrate is heated in a vaporizing device (vaporizer) to a
temperature below the point of combustion, to produce vapor.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
130
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0149.png
Section 2: Marijuana Dose and Drug Interactions
Key findings
Multiple studies have measured blood THC levels following marijuana use. One important finding is that
it can take up to four hours after consuming an edible marijuana product to reach the peak THC blood
concentration and feel the full effects. This has important implications for the time to wait between
doses or prior to safety-sensitive activities like driving. Smoking or vaporizing more than 10mg THC, or
consuming an edible marijuana product with more than 15mg THC can lead to a blood THC level above
5ng/mL, which can be used to support a conviction for driving under the influence.
Regarding secondhand marijuana exposure, evidence shows that individuals passively exposed under
usual conditions would not test above standard cutoffs for marijuana on a workplace urine test or
driving impairment blood test. There is some evidence that secondhand exposure under extreme
conditions can cause psychomotor impairment and increased heart rate.
Much has been said about the relationship between marijuana use and opioid use, but research remains
limited. There is some evidence that opioid analgesic overdose deaths are lower in states with legal
medical marijuana than would be expected based on trends in states without legal medical marijuana.
There is conflicting evidence for whether or not marijuana use is associated with a decrease in opioid
use among chronic pain patients or individuals with a history of problem drug use.
Clinical and pharmacokinetic data about potential drug-drug interactions with marijuana are currently
lacking for many drugs and are likely to evolve substantially over coming years. There is credible
evidence of clinically important drug-drug interactions with marijuana including the following:
chlorpromazine, clobazam, clozapine, CNS depressants (e.g. barbiturates, benzodiazepines),
disulfiram, hexobarbital, hydrocortisone, ketoconazole, MAO inhibitors, phenytoin, protease inhibitors
(indinavir, nelfinavir), theophylline, tricyclic antidepressants and warfarin (see Table 2 for additional
details). The lack of a cited interaction with other medications does not preclude the possibility that
drug interactions exist; it simply means no studies have yet reported an interaction with that particular
drug.
An important note for all key findings is that the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove that the
marijuana use alone
caused
the effect. Despite the best efforts of researchers to account for
confounding factors, there may be other important factors related to
causality
that were not
identified. In addition, marijuana use was illegal everywhere in the United States prior to 1996.
Research funding, when appropriated, was commonly sought to identify adverse effects from marijuana
use. This legal fact introduces both funding bias and publication bias into the body of literature related
to marijuana use. The Retail Marijuana Public Health Advisory Committee recognizes the limitations
and biases inherent in the published literature and made efforts to ensure the information reviewed
and synthesized is reflective of the current state of medical knowledge. Where information was lacking
for whatever reason
the committee identified this knowledge gap and recommended further
research. This information will be updated as new research becomes available.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
131
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0150.png
Section 2: Marijuana Dose and Drug Interactions
Recommendations
The committee recommends continued data collection efforts to assess marijuana use patterns among
Colorado users, including better characterization of method, amount, potency and frequency. Data on
the THC content of Colorado products is also needed. Data collected in relation to impairment should
include type, amount, potency and timing of marijuana used. The public should be educated on
possible unwanted interactions between marijuana and medications and the potential effects of
secondhand marijuana smoke.
Further research is needed to identify potential interactions between marijuana and medications.
Secondhand and thirdhand marijuana smoke should be further studied, including identification of
biomarkers of exposure and evaluation of health effects, especially in children. The relationship
between marijuana use and opioid use remains unclear, and further research is needed, especially at
the individual level. Research is also needed to better characterize the
pharmacokinetics/pharmacodynamics of cannabinoids.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
132
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0151.png
Section 2: Marijuana Dose and Drug Interactions
Table 1 Findings summary: Marijuana dose and drug interaction
All statements apply only to less-than-weekly users.
= results in/produces. For an explanation of the
classifications “Substantial,” “Moderate,” etc., see Chapter 7. Systematic literature review process.
Substantial
Smoking >10
mg THC
produces blood
THC level near
or > 5 ng/mL
within 10
minutes
Time to peak
blood THC level
is up to four
hours post
ingestion
Moderate
Ingesting >15
mg THC may
blood THC level
> 5 ng/mL
Limited
Insufficient
Mixed
THC levels
Inhaling
vaporized
THC blood
THC level
similar to
smoking the
same dose
Extreme
secondhand
exposure
psychomotor
impairment and
increased heart
rate
Secondhand
exposure
positive drug
screen by oral
fluid
Secondhand exposure
Typical
secondhand
exposure
NO
positive drug
screen by urine
or blood
Health effects
of secondhand
exposure on
children
Health effects
of third-hand
exposure
Health effects
of secondhand
vapor
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
133
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0152.png
Section 2: Marijuana Dose and Drug Interactions
Table 1 (continued) Findings summary: marijuana dose and drug interaction
All statements apply only to less-than-weekly users.
= results in/produces. For an explanation of the
classifications “Substantial,” “Moderate,” etc., see Chapter 7. Systematic literature review process.
Substantial
Moderate
Limited
Less opioid
overdose
deaths than
expected in
states with
legal medical
marijuana
Insufficient
Association
between legal
medical
marijuana and
opioid use
Mixed
Marijuana use
and reduction
in opioid use by
chronic pain
patients
Marijuana and opioids
Marijuana use
and reduction
in opioid use by
individuals with
a history of
problem drug
use
Dabbing and
tolerance or
withdrawal
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
Alternate
methods
134
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0153.png
Section 2: Marijuana Dose and Drug Interactions
Evidence statements
Evidence statements are based on systematic scientific literature reviews performed by Colorado
Department of Public Health and Environment staff with oversight and approval by the Retail Marijuana
Public Health Advisory Committee. For an explanation of the
classifications “Substantial,” “Moderate,”
etc., see Chapter 7. Systematic literature review process. For details about the studies reviewed, see
Appendix J.
THC levels resulting from different exposures
1. We found
SUBSTANTIAL
evidence that smoking more than about 10 mg THC (or part of a currently
available marijuana cigarette) is likely to yield whole blood THC concentrations near or above 5
ng/mL within 10 minutes.
11-14
2. We found
MODERATE
evidence that ingesting more than about 15 mg THC is capable of yielding a
whole blood THC concentration above 5 ng/mL.
15-20
3. We found
MODERATE
evidence that inhaling vaporized marijuana yields blood THC levels that are
similar to those produced by smoking the same dose.
21,22
4. We found
SUBSTANTIAL
evidence that it takes up to 4 hours after ingesting marijuana to reach
peak blood THC concentrations.
15,16,18,19
Secondhand (passive) exposure
5. We found
SUBSTANTIAL
evidence that an individual passively exposed to marijuana smoke (up to
approximately 10% THC) under typical passive exposure conditions would NOT test above standard
cutoffs for marijuana on a urine screening test or a blood test (given the current federal screening
cutoff of 50 ng/mL for urine cannabinoid metabolites and the current Colorado limit for driving of 5
ng/mL whole blood THC).
23-35
6. We found
INSUFFICIENT
evidence to determine whether individuals passively exposed to marijuana
smoke would test above standard cutoffs by oral fluid testing because it has not yet been
established which analyte or analytes to measure and which cutoff(s) to use.
23,24,36-39
7. We found
LIMITED
evidence that individuals passively exposed to marijuana smoke under extreme
passive exposure conditions (such as spending one hour in an unventilated space with individuals
smoking marijuana of 11% potency) experience psychomotor impairment and increased heart rate
in the hour immediately following exposure.
34,35
(Added*)
8. We found
INSUFFICIENT
evidence to determine the health effects of secondhand marijuana smoke
in children. (Added*)
9. We found
INSUFFICIENT
evidence to determine the health effects of thirdhand marijuana smoke
(the residual smoke that lingers in a room or on clothes). (Added*)
10. We found
INSUFFICIENT
evidence to determine whether or not secondhand marijuana vapor
exposure is associated with adverse health effects. (Added*)
*
*
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix J for dates of most recent literature review.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
135
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0154.png
Section 2: Marijuana Dose and Drug Interactions
Drug-drug interactions
11. There is credible evidence of clinically important drug-drug interactions between marijuana and
the following medications: chlorpromazine, clobazam, clozapine, CNS depressants (e.g.
barbiturates, benzodiazepines), disulfiram, hexobarbital, hydrocortisone, ketoconazole, MAO
inhibitors, phenytoin, protease inhibitors (indinavir, nelfinavir), theophylline, tricyclic
antidepressants and warfarin. The lack of a cited interaction does not preclude the possibility that
drug interactions exist; it simply means no studies have yet reported an interaction with that
particular drug.
22,40-56
(Revised*)
Marijuana and opioids
12. We found
INSUFFICIENT
evidence to determine whether or not there is an association between the
availability of legal medical marijuana and the prevalence of opioid use.
57,58
(Added*)
13. We found
LIMITED
evidence that states with legal medical marijuana had a lower rate of opioid
analgesic overdose deaths than would be expected based on trends in states without legal medical
marijuana.
59
(Added*)
14. We found
MIXED
evidence for whether or not marijuana use is associated with a reduction in the
number of patients using opioids or the amount of opioid use among chronic pain patients.
60,61
(Added*)
15. We found
MIXED
evidence for whether or not marijuana use is associated with a reduction in opioid
use among individuals with a history of opioid addiction treatment or injection drug use.
62,63
(Added*)
Alternate methods of use
16. We found
INSUFFICIENT
evidence to determine whether dabbing concentrated marijuana is
associated with an increase in marijuana tolerance or more severe withdrawal upon cessation of
use compared to smoking marijuana.
64
(Added*)
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix J for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
136
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0155.png
Section 2: Marijuana Dose and Drug Interactions
Public health statements
Public health statements are plain language translations of the major findings (Evidence Statements)
from the systematic literature reviews. These statements have been officially approved by the Retail
Marijuana Public Health Advisory Committee.
THC levels resulting from different exposures
1.
It takes up to 4 hours after consuming an edible marijuana product to reach maximum blood
levels of THC and feel the full effects. It is important to delay consuming another THC-
containing product or engaging in safety-sensitive activities like driving until the effects from
the first edible serving are known, especially for new or less-than-weekly users.
Smoking or vaporizing more than 10mg THC, or consuming an edible marijuana product with
more than 15mg THC can lead to a blood THC level above 5ng/mL, which can be used to
support a conviction for driving under the influence.
2.
Secondhand (passive) exposure
3.
4.
Typical secondhand exposure to marijuana smoke is unlikely to result in a failed workplace
urine test or a failed driving impairment blood test.
Extreme secondhand exposure to marijuana smoke (such as one hour of exposure in an
unventilated space), may be associated with psychomotor impairment and an increase in heart
rate. (Added*)
Drug-drug interactions
5.
Use caution when taking medications and marijuana at the same time. Some medications have
known interactions with marijuana, and others may have interactions that have not yet been
identified.
Marijuana and opioids
6.
Rates of overdose death from opioid pain relievers may be reduced in states with legal medical
marijuana compared to states without. (Added*)
There is conflicting research on whether or not marijuana use is associated with a decrease in
opioid use by chronic pain patients. (Added*)
There is conflicting research on whether or not marijuana use is associated with a decrease in
opioid use by individuals with a history of opioid addiction treatment or injection drug
use.(Added*)
7.
8.
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix J for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
137
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0156.png
Section 2: Marijuana Dose and Drug Interactions
Public health recommendations
Public health recommendations have been suggested and approved by the Retail Marijuana Public
Health Advisory Committee with the goals of: 1) Improving knowledge regarding population-based
health effects of retail marijuana use and 2) Developing and targeting public health education and
prevention strategies for high-risk sub populations.
Data quality issues
Monitor data on THC content of marijuana products in Colorado.
Monitor airborne THC/cannabinoid/by-products in future test chamber studies.
Increase sample size in future pharmacologic studies.
Surveillance
Monitor type, amount, potency and timing of marijuana consumed in correlation with impairment.
Monitor health effects of secondhand marijuana smoke exposure.
Add method of use questions (including vaporization and dabbing) to existing population-based
surveys.
Conduct targeted surveys of marijuana users (non-population-based surveys), including detailed
questions on method, amount, potency and frequency of use.
Education
Educate the public on potential interactions when using marijuana with medications.
Educate the public about the potential effects of secondhand marijuana smoke and encourage safe
and responsible use.
Ensure marijuana smoking is prohibited in all venues where tobacco smoking is not permitted.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
138
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0157.png
Section 2: Marijuana Dose and Drug Interactions
Research gaps
The Retail Marijuana Public Health Advisory Committee identifies important gaps in the scientific
literature that may impact public health policies and prevention strategies. Colorado should support
unbiased research to help fill the following research gaps identified by the committee.
More research to identify interactions between marijuana and prescription drugs.
Research to better characterize the pharmacokinetics/pharmacodynamics of cannabinoids, via
various methods of marijuana use.
Study possible differences in health effects of different methods of marijuana use.
Analysis of chemicals released or produced by different methods of marijuana use.
Identify biomarkers to assess secondhand marijuana smoke exposures.
Further research on potential short-term and long-term health effects of secondhand marijuana
smoke exposure, particularly in children.
Impacts of secondhand marijuana vapor.
Research on the relationship between marijuana use and opioid use at the individual level, both in
the general population and in relevant subpopulations.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
139
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0158.png
Section 2: Marijuana Dose and Drug Interactions
Table 2
Specific drug/drug classes with published clinical evidence of interactions with marijuana. Some drugs
with published clinical evidence of a lack of interaction with marijuana are also included. These are
marked with *. (Y=Yes, N= No, P=Possible)
Increased
Concomitant Drug Effect
P
P
P
P
P
P
P
P
P
140
Decreased
Concomitant Drug Effect
P
P
P
P
P
Increased THC Effect
Concomitant
Drug/Drug Class
Description of Interaction
Chlorpromazine
Marijuana smoking increased clearance of chlorpromazine, as did tobacco
smoking.
41
N
Clobazam
In subjects taking cannabidiol (CBD), mean clobazam levels were about 60-80%
higher, and nCLB levels 300-500% higher.
A decrease in the clobazam dose was required in subjects taking CBD.
55
N
Clozapine
Possible increased clozapine metabolism by marijuana induction of CYP1A2
(similar to tobacco). Therefore cessation may lead to increased clozapine
levels and toxicity. Single case report of clozapine toxicity after tobacco and
marijuana cessation.
43
Additive drowsiness and CNS depression
Includes: alcohol, opioids, sedative-hypnotics, barbiturates, benzodiazepine,
buspirone, antihistamines, muscles relaxants, and many more.
22,40,42
Possible hypomanic/psychotic reaction.
40,42
No change in fluoxetine efficacy and no serious adverse reactions in a 12 week
clinical study of fluoxetine vs. placebo for marijuana-related depression.
45
May enhance CNS depressant effect. CBD decreased metabolism of
hexabarbital but did not change its clinical effects.
44
THC increased serum cortisol, but effect is blunted in frequent users.
Theoretical possibility of cushingoid syndrome.
46
Peak THC concentration was increased by 27%.
53
Possible enhancement of orthostatic hypotension.
40
N
CNS depressants
N
Disulfiram
N
P
Fluoxetine*
N
Hexobarbital
Hydrocortisone
Ketoconazole
MAO Inhibitors
N
N
N
N
Phenytoin
May enhance CNS depressant effect. In vitro, decreased phenytoin levels due
to induction of metabolism by THC. Therefore, phenytoin levels may rise
rapidly after THC cessation, causing toxicity. Intermittent THC use may cause
transient subtherapeutic phenytoin levels. Case report of phenytoin toxicity
after recreational use of phenytoin concomitantly with EtOH and
marijuana.
40,48,51
Statistically significant decrease in peak concentration of indinavir and
nelfinavir with THC use.
47
Smoked marijuana lowers theophylline concentrations, similar to tobacco.
Unclear if only a smoking-related effect. No studies of oral marijuana/THC.
49,52
May cause transient cognitive changes, delirium, or tachycardia.
56
Possible enhanced anticoagulant effect.
40,50,54
N
Protease inhibitors
N
Theophylline
Tricyclic
antidepressants
Warfarin
N
N
N
P
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
Increased CNS
Depressant Effect
Y
Y
Y
Y
Contra-indicated
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0159.png
Section 2: Marijuana Dose and Drug Interactions
References
1. Hernandez E. Pilot program eyes pot-DUI devices.
The Denver Post.
January 9, 2016, 2016.
2. Cao S, Yang C, Gan Y, Lu Z. The Health Effects of Passive Smoking: An Overview of Systematic
Reviews Based on Observational Epidemiological Evidence.
PLoS One.
2015;10(10):e0139907.
3. Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug-
drug interactions: a systematic review and meta-analysis.
Pharmacoepidemiol Drug Saf.
2014;23(5):489-497.
4. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in Prescription Drug Use Among
Adults in the United States From 1999-2012.
JAMA.
2015;314(17):1818-1831.
5. Chan LN, Anderson GD. Pharmacokinetic and pharmacodynamic drug interactions with ethanol
(alcohol).
Clin Pharmacokinet.
2014;53(12):1115-1136.
6. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update.
Clin Pharmacokinet.
1999;36(6):425-438.
7. Colorado Department of Public Health and Environment. Adult Health Data, Behavioral Risk Factor
Surveillance System.
Colorado Health and Environmental Data
2015;
http://www.chd.dphe.state.co.us/topics.aspx?q=Adult_Health_Data.
8. U.S. Department of Health & Human Services. Opioids: The Prescription Drug & Heroin Overdose
Epidemic. 2016; https://www.hhs.gov/opioids/. Accessed December 21, 2016.
9. Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and
Health: Comparison of 2012-2013 and 2013-2014 Population Percentages (50 States and the District
of Columbia).
https://www.samhsa.gov/data/sites/default/files/NSDUHsaeShortTermCHG2014/NSDUHsaeShortTe
rmCHG2014.htm2015.
10. Sifferlin A. Can Medical Marijuana Help End the Opioid Epidemic?
Time,
http://time.com/4419003/can-medical-marijuana-help-end-the-opioid-epidemic/ 2016.
11. Berghaus G, Sticht G, Grellner W.
Meta-analysis of empirical studies concerning the effects of
medicines and illegal drugs including pharmacokinetics on safe driving.
Center for Traffic Sciences
at the University of Wurzburg;2011.
12. Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ. Characterization of the absorption
phase of marijuana smoking.
Clin Pharmacol Ther.
1992;52(1):31-41.
13. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognition and
motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of
impairment.
Drug Alcohol Depend.
2006;85(2):114-122.
14. Reeve VC, Grant JD, Robertson W, Gillespie HK, Hollister LE. Plasma concentrations of delta-9-
tetrahydrocannabinol and impaired motor function.
Drug Alcohol Depend.
1983;11(2):167-175.
15. Bosker WM, Kuypers KP, Theunissen EL, et al. Medicinal Delta(9) -tetrahydrocannabinol
(dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is
not detected in Standard Field Sobriety Tests.
Addiction.
2012;107(10):1837-1844.
16. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective dose-response
effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.
Psychopharmacology (Berl).
2002;164(1):61-70.
17. Huestis MA. Human cannabinoid pharmacokinetics.
Chem Biodivers.
2007;4(8):1770-1804.
18. Lile JA, Kelly TH, Charnigo RJ, Stinchcomb AL, Hays LR. Pharmacokinetic and pharmacodynamic
profile of supratherapeutic oral doses of Delta(9) -THC in cannabis users.
J Clin Pharmacol.
2013;53(7):680-690.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
141
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0160.png
Section 2: Marijuana Dose and Drug Interactions
19. Menetrey A, Augsburger M, Favrat B, et al. Assessment of driving capability through the use of
clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration
of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
J Anal Toxicol.
2005;29(5):327-338.
20. Perez-Reyes M, Lipton MA, Timmons MC, Wall ME, Brine DR, Davis KH. Pharmacology of orally
administered 9 -tetrahydrocannabinol.
Clin Pharmacol Ther.
1973;14(1):48-55.
21. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless
cannabis delivery system: a pilot study.
Clin Pharmacol Ther.
2007;82(5):572-578.
22. Abramovici H. Information for Health Care Professionals. In: Canada H, ed, 2013.
23. Niedbala RS, Kardos KW, Fritch DF, et al. Passive cannabis smoke exposure and oral fluid testing. II.
Two studies of extreme cannabis smoke exposure in a motor vehicle.
J Anal Toxicol.
2005;29(7):607-615.
24. Niedbala S, Kardos K, Salamone S, Fritch D, Bronsgeest M, Cone EJ. Passive cannabis smoke
exposure and oral fluid testing.
J Anal Toxicol.
2004;28(7):546-552.
25. Rohrich J, Schimmel I, Zorntlein S, et al. Concentrations of delta9-tetrahydrocannabinol and 11-
nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis smoke in
a coffee shop.
J Anal Toxicol.
2010;34(4):196-203.
26. Cone EJ, Johnson RE. Contact highs and urinary cannabinoid excretion after passive exposure to
marijuana smoke.
Clin Pharmacol Ther.
1986;40(3):247-256.
27. Cone EJ, Johnson RE, Darwin WD, et al. Passive inhalation of marijuana smoke: urinalysis and room
air levels of delta-9-tetrahydrocannabinol.
J Anal Toxicol.
1987;11(3):89-96.
28. Morland J, Bugge A, Skuterud B, Steen A, Wethe GH, Kjeldsen T. Cannabinoids in blood and urine
after passive inhalation of Cannabis smoke.
J Forensic Sci.
1985;30(4):997-1002.
29. Law B, Mason PA, Moffat AC, King LJ, Marks V. Passive inhalation of cannabis smoke.
J Pharm
Pharmacol.
1984;36(9):578-581.
30. Mason AP, Perez-Reyes M, McBay AJ, Foltz RL. Cannabinoids in plasma after passive inhalation of
marijuana smoke.
JAMA.
1983;249(4):475-476.
31. Mule SJ, Lomax P, Gross SJ. Active and realistic passive marijuana exposure tested by three
immunoassays and GC/MS in urine.
J Anal Toxicol.
1988;12(3):113-116.
32. Perez-Reyes M, di Guiseppi S, Davis KH. Passive inhalation of marijuana smoke and urinary
excretion cannabinoids.
JAMA.
1983;249(4):475.
33. Norchem Lab. Urine Drug Test Information Sheet: Marijuana. http://www.norchemlab.com/wp-
content/uploads/2011/10/marijuana.pdf. Accessed 8/8/2014.
34. Herrmann ES, Cone EJ, Mitchell JM, et al. Non-smoker exposure to secondhand cannabis smoke II:
Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects.
Drug
Alcohol Depend.
2015;151:194-202.
35. Cone EJ, Bigelow GE, Herrmann ES, et al. Non-smoker exposure to secondhand cannabis smoke. I.
Urine screening and confirmation results.
J Anal Toxicol.
2015;39(1):1-12.
36. Moore C. Response to "Is THCCOOH a useful determinant for passive inhalation in oral fluid THC
testing?".
J Anal Toxicol.
Vol 36. United States2012:358.
37. Moore C, Coulter C, Uges D, et al. Cannabinoids in oral fluid following passive exposure to
marijuana smoke.
Forensic Sci Int.
2011;212(1-3):227-230.
38. Walsh JM, Cone EJ, Crouch DJ, Caplan YH. Is THC-COOH a useful determinant for passive inhalation
in oral fluid THC testing?
J Anal Toxicol.
Vol 36. United States2012:291.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
142
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0161.png
Section 2: Marijuana Dose and Drug Interactions
39. Cone EJ, Bigelow GE, Herrmann ES, et al. Nonsmoker Exposure to Secondhand Cannabis Smoke. III.
Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects.
J Anal Toxicol.
2015;39(7):497-509.
40. Lexi-Comp Online.
Interaction Lookup,
http://www.uptodate.com.hsl-ezproxy.ucdenver.edu/.
41. Chetty M, Miller R, Moodley SV. Smoking and body weight influence the clearance of
chlorpromazine.
Eur J Clin Pharmacol.
1994;46(6):523-526.
42. Unimed Pharmaceuticals. Marinol (Dronabinol) package insert. 2004.
43. Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P. Tobacco and cannabis smoking cessation can
lead to intoxication with clozapine or olanzapine.
Int Clin Psychopharmacol.
2002;17(3):141-143.
44. Benowitz NL, Nguyen TL, Jones RT, Herning RI, Bachman J. Metabolic and psychophysiologic studies
of cannabidiol-hexobarbital interaction.
Clin Pharmacol Ther.
1980;28(1):115-120.
45. Cornelius JR, Bukstein OG, Douaihy AB, et al. Double-blind fluoxetine trial in comorbid MDD-CUD
youth and young adults.
Drug Alcohol Depend.
2010;112(1-2):39-45.
46. D'Souza DC, Ranganathan M, Braley G, et al. Blunted psychotomimetic and amnestic effects of
delta-9-tetrahydrocannabinol in frequent users of cannabis.
Neuropsychopharmacology.
2008;33(10):2505-2516.
47. Kosel BW, Aweeka FT, Benowitz NL, et al. The effects of cannabinoids on the pharmacokinetics of
indinavir and nelfinavir.
Aids.
2002;16(4):543-550.
48. Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta9-tetrahydrocannabinol
metabolism: kinetics, pharmacogenetics and interaction with phenytoin.
Biochem Pharmacol.
2005;70(7):1096-1103.
49. Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R. Effects of tobacco smoking and oral
contraceptive use on theophylline disposition.
Br J Clin Pharmacol.
1983;16(3):271-280.
50. Ge B, Zhang Z, Zuo Z. Updates on the clinical evidenced herb-warfarin interactions.
Evid Based
Complement Alternat Med.
2014;2014:957362.
51. Jessen K. Recreational use of phenytoin, marijuana, and alcohol: a case report.
Neurology.
2004;62(12):2330.
52. Jusko WJ, Gardner MJ, Mangione A, Schentag JJ, Koup JR, Vance JW. Factors affecting
theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral
contraceptives, benzodiazepines, barbiturates, and ethanol.
J Pharm Sci.
1979;68(11):1358-1366.
53. Stott C, White L, Wright S, Wilbraham D, Guy G. A Phase I, open-label, randomized, crossover
study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole
on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers.
Springerplus.
2013;2(1):236.
54. Yamreudeewong W, Wong HK, Brausch LM, Pulley KR. Probable interaction between warfarin and
marijuana smoking.
Ann Pharmacother.
2009;43(7):1347-1353.
55. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and
cannabidiol in children with refractory epilepsy.
Epilepsia.
2015;56(8):1246-1251.
56. Wilens TE, Biederman J, Spencer TJ. Case study: adverse effects of smoking marijuana while
receiving tricyclic antidepressants.
J Am Acad Child Adolesc Psychiatry.
1997;36(1):45-48.
57. Kim JH, Santaella-Tenorio J, Mauro C, et al. State Medical Marijuana Laws and the Prevalence of
Opioids Detected Among Fatally Injured Drivers.
Am J Public Health.
2016;106(11):2032-2037.
58. Bradford AC, Bradford WD. Medical Marijuana Laws Reduce Prescription Medication Use In Medicare
Part D.
Health Aff (Millwood).
2016;35(7):1230-1236.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
143
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0162.png
Section 2: Marijuana Dose and Drug Interactions
59. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic
overdose mortality in the United States, 1999-2010.
JAMA Intern Med.
2014;174(10):1668-1673.
60. Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate
Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain.
J Pain.
2016;17(6):739-744.
61. Haroutounian S, Ratz Y, Ginosar Y, et al. The Effect of Medicinal Cannabis on Pain and Quality-of-
Life Outcomes in Chronic Pain: A Prospective Open-label Study.
Clin J Pain.
2016;32(12):1036-1043.
62. Kral AH, Wenger L, Novak SP, et al. Is cannabis use associated with less opioid use among people
who inject drugs?
Drug and Alcohol Dependence.
2015;153:236-241.
63. Scavone JL, Sterling RC, Weinstein SP, Van Bockstaele EJ. Impact of cannabis use during
stabilization on methadone maintenance treatment.
Am J Addict.
2013;22(4):344-351.
64. Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs?
Addict Behav.
2014;39(10):1430-1433.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
144
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0163.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Chapter 6
Marijuana Use and Driving
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0164.png
Section 2: Marijuana Use and Driving
Authors
Ashley Brooks-Russell, PhD, MPH
Assistant Professor
Injury Prevention, Education and Research Program, Colorado School of Public Health
(2014, 2016)
Michael F. Wempe, PhD
Associate Research Professor, Department of Pharmaceutical Sciences, University of Colorado Anschutz
Medical Campus
(2016)
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2016)
Lisa Barker, MPH
Retail Marijuana Health Monitoring, Colorado Department of Public Health and Environment
(2016)
Kim Siegel, MD, MPH
Occupational Medicine Resident, University of Colorado Denver
(2014)
Mike Kosnett, MD, MPH
Associate Clinical Professor, Division of Clinical Pharmacology and Toxicology, Department of Medicine,
University of Colorado School of Medicine, Department of Environmental and Occupational Health,
Colorado School of Public Health
(2014)
Reviewers
Kristina T. Phillips, PhD
Clinical Psychologist and Professor, School of Psychological Sciences, University of Northern Colorado
(2016)
Laura Borgelt, PharmD
Associate Dean and Professor
Departments of Clinical Pharmacy and Family Medicine, University of Colorado Anschutz Medical
Campus
(2014, 2016)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
146
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0165.png
Section 2: Marijuana Use and Driving
Introduction
The Retail Marijuana Public Health Advisory Committee identified many important public health topics
related to marijuana and has reviewed the scientific evidence currently available regarding those
topics. This chapter includes reviews of driving impairment and motor vehicle crash risk relative to
amounts of marijuana used and to blood THC levels. It also includes reviews of evidence indicating how
long it takes after marijuana use for impairment to resolve.
There are more than 80 crashes in Colorado each day, on average, and 12 percent of them cause
injuries or fatalities.
1
Motor vehicle crashes are the leading cause of death among 10-24 year olds.
2
About 30 percent of all driving fatalities in Colorado are alcohol related.
3
Marijuana legalization has
raised concern about the impact it may have on motor vehicle crashes. Marijuana is known to cause
slowed reaction time and poorer motor coordination and attention.
4
In 2014, more than 18 percent of
current marijuana users reported driving after using marijuana.
5
A Denver initiative passed in
November 2016, allowing businesses to obtain marijuana use permits, has further raised concern for
marijuana-impaired driving.
6
The different methods of marijuana use, such as edibles and vaporizing,
complicate matters further because they may lead to different levels of impairment and require
different wait times to allow the impairment to resolve. It is extremely important to investigate these
topics to determine the impact marijuana use has on driving impairment and motor vehicle crashes and
how it is affected by different methods of use, amounts used, and time since using.
Definitions
Levels of marijuana use
Daily or near-daily use: 5-7 days/week.
Weekly use: 1-4 days/week.
Less-than-weekly use: less than 1 day/week.
Tetrahydrocannabinol (THC)
- the main psychoactive component of marijuana.
Vaporization of marijuana (vaping) -
a method of marijuana use in which marijuana vapor, rather than
smoke, is inhaled. Marijuana flower or concentrate is heated in a vaporizing device (vaporizer) to a
temperature below the point of combustion, to produce vapor.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
147
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0166.png
Section 2: Marijuana Use and Driving
Key findings
The committee found that the risk of a motor vehicle crash increases among drivers with recent
marijuana use. Furthermore, the higher the blood THC level, the higher the motor vehicle crash risk. In
addition, using alcohol and marijuana together increases impairment and the risk of a motor vehicle
crash even more than using either substance alone. For less-than-weekly marijuana users, using
marijuana containing 10 milligrams or more of THC is likely to impair the ability to safely drive, bike,
or perform other safety-sensitive activities. This applies to smoking, eating, or drinking the marijuana
or marijuana product. Waiting at least six hours after smoking marijuana containing less than 35
milligrams of THC likely will allow sufficient time for the impairment to resolve among less-than-
weekly users. The waiting time is longer for eating or drinking marijuana products. It is necessary for
marijuana users who use it less-than-weekly to wait at least eight hours for impairment to resolve after
eating or drinking less than 18 milligrams of THC. Data on doses that cause impairment and time for
impairment to resolve is lacking for frequent marijuana users.
An important note for all key findings is that the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove that the
marijuana use alone
caused
the effect. Despite the best efforts of researchers to account for
confounding factors, there may be other important factors related to
causality
that were not
identified. In addition, marijuana use was illegal everywhere in the United States prior to 1996.
Research funding, when appropriated, was commonly sought to identify adverse effects from marijuana
use. This legal fact introduces both funding bias and publication bias into the body of literature related
to marijuana use. The Retail Marijuana Public Health Advisory Committee recognizes the limitations
and biases inherent in the published literature and made efforts to ensure the information reviewed
and synthesized is reflective of the current state of medical knowledge. Where information was lacking
for whatever reason
the committee identified this knowledge gap and recommended further
research. This information will be updated as new research becomes available.
Recommendations
The committee recommended improved testing and documentation of marijuana involvement in motor
vehicle crashes and impaired driving encounters. This includes testing for THC and its metabolites in
drivers, and accurately recording the timing of blood testing relative to the time impairment was
suspected. If such data becomes more consistent, research should use blood THC levels rather than
self-reported use, when possible. Centralized reporting of these levels would help both with
surveillance and research. There are significant intervention opportunities for public education on
marijuana-related impairment, including the dangers of driving after using marijuana, especially when
combined with alcohol, and the amount of time a person should wait after using various types and
doses of marijuana products before driving. However, in order to measure the impact of these
educational interventions over time, additional questions are needed on population-based surveys such
as the Behavioral Risk Factor Surveillance System (BRFSS) to measure self-reported impaired driving
behaviors and perceptions of risk associated with impaired driving.
The committee identified several research gaps including the need for more research on the
relationship of THC levels in saliva, blood and urine, and how these biomarkers relate to measures of
functional impairment. Research focusing on impairment in daily or near-daily marijuana users is
needed, as the relationship between timing of use, THC levels and impairment may differ from these
effects in less-than-weekly users. Improved testing methods for impairment should be researched
further, in order to develop best methods, either using alternate biological testing or physical and
cognitive tests of impairment.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
148
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0167.png
Section 2: Marijuana Use and Driving
Table 1 Findings summary: Marijuana use and driving
* = applies only to less-than-weekly users.
= results in/produces. For an explanation of the
classifications “Substantial,” “Moderate,” etc., see Chapter
7. Systematic literature review process.
Substantial
Increased motor
vehicle crash risk with
recent use
Moderate
THC blood level and
motor vehicle crash
risk
Limited
Insufficient
Risk of motor
vehicle crash
differs based on
frequency of use
Mixed
Impairment and crash risk
Increased risk of
driving impairment at
blood THC of 2-5
ng/mL*
Smoking >10 mg THC
leads to driving
impairment*
Orally ingesting >10
mg THC leads to
driving impairment*
Combined use with
alcohol increases crash
risk
Higher blood THC in
impaired drivers
now than in the
past
Time to wait before driving
Waiting > 6 hrs
after smoking about
35 mg
driving
impairment
resolves/nearly
resolves*
Waiting > 6 hrs after
smoking < 18 mg
driving impairment
resolves/nearly
resolves*
Waiting > 8 hrs after
orally ingesting < 18
mg
driving
impairment
resolves/nearly
resolves*
How long to wait
after smoking > 35
mg for impairment
to resolve
How long daily or
near-daily users
should wait before
driving
How long to wait
after vaporizing,
dermal
application, or
other methods of
use
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
149
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0168.png
Section 2: Marijuana Use and Driving
Evidence statements
Evidence statements are based on systematic scientific literature reviews performed by Colorado
Department of Public Health and Environment staff with oversight and approval by the Retail Marijuana
Public Health Advisory Committee. For an explanation of the
classifications “Substantial,” “Moderate,”
etc., see Chapter 7. Systematic literature review process. For details about the studies reviewed, see
Appendix K.
Impairment and crash risk
1. We found
SUBSTANTIAL
evidence that recent marijuana use by a driver increases their risk of
motor vehicle crash.
7-11
(Revised
*)
2. We found
MODERATE
evidence for a positive relationship between THC blood level and motor
vehicle crash risk.
12-15
(Revised*)
3. We found
SUBSTANTIAL
evidence that for marijuana users who use less-than-weekly, there is
meaningful driving impairment with a whole blood THC of 2-5 ng/mL.
8,16-18
4. We found
SUBSTANTIAL
evidence that for marijuana users who use less-than-weekly, smoking more
than about 10 mg THC (or part of a currently available marijuana cigarette) is likely to
meaningfully impair driving ability.
16,17,19-30
5. We found
SUBSTANTIAL
evidence that for marijuana users who use less-than-weekly, orally
ingesting 10 mg or more of THC is likely to meaningfully impair driving ability.
17,20,31,32
6. We found
MODERATE
evidence that blood THC levels of marijuana-impaired drivers are higher now
than in the past.
33
7. We found
INSUFFICIENT
evidence to determine whether or not motor vehicle crash risk differs for
users who use less-than-weekly compared to daily or near-daily users.
34-37
Combined marijuana and alcohol use
8. We found
SUBSTANTIAL
evidence that the combined use of marijuana and alcohol increases
impairment and motor vehicle crash risk more than use of either substance alone.
12,14,15,38-42
Time to wait before driving
9. We found
SUBSTANTIAL
evidence that delaying driving for at least 6 hours after smoking less than
18 mg THC allows THC-induced impairment to resolve or nearly resolve for users who use less-than-
weekly.
8,16,17,19,26,43
10. We found
MODERATE
evidence that delaying driving at least 6 hours after smoking about 35 mg
THC allows THC-induced impairment to resolve or nearly resolve for users who use less-than-
weekly.
22,25,26
11. We found
SUBSTANTIAL
evidence that delaying driving at least 8 hours after oral ingestion of less
than 18 mg THC allows THC-induced impairment to resolve or nearly resolve for users who use less-
than-weekly.
17,20,32,44
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix K for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
150
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0169.png
Section 2: Marijuana Use and Driving
12. We found
INSUFFICIENT
evidence to determine the amount of time necessary to wait after smoking
more than 35 mg THC to allow THC-induced impairment to resolve for users who use less-than-
weekly.
17,22,45
13. We found
INSUFFICIENT
evidence to determine the amount of time necessary to delay driving to
allow THC-induced impairment to resolve or nearly resolve for daily or near-daily users after using
marijuana.
8,21,25,29,46,47
14. We found
INSUFFICIENT
evidence to determine the amount of time to delay driving after other
methods of marijuana use (such as vaporizing or application of dermal or mucosal preparations).
Public health statements
Public health statements are plain language translations of the major findings (Evidence Statements)
from the systematic literature reviews. These statements have been officially approved by the Retail
Marijuana Public Health Advisory Committee.
1. Driving soon after using marijuana increases the risk of a motor vehicle crash. (Revised
*
)
2. Using alcohol and marijuana together increases impairment and the risk of a motor vehicle crash
more than using either substance alone.
3. The typical marijuana cigarette or joint in Colorado contains approximately 0.5 grams of
marijuana, and the THC content in marijuana ranges from 12-23% THC; therefore, a typical joint
contains between 60-115 mg THC. The standard serving size for a marijuana edible is 10 mg.
a) For less-than-weekly marijuana users, smoking, eating, or drinking marijuana containing 10
mg or more of THC is likely to cause impairment that affects your ability to drive, bike, or
perform other safety-sensitive activities.
b) Wait at least 6 hours after smoking marijuana containing less than 35 mg THC before
driving, biking, or performing other safety-sensitive activities. If you have smoked more
than 35 mg, wait longer.
c) Wait at least 8 hours after eating or drinking marijuana containing less than 18 mg THC
before driving, biking, or performing other safety-sensitive activities. If you have consumed
more than 18 mg, wait longer.
4. Use caution when driving, biking, or performing other safety-sensitive activities after using any
form of marijuana or marijuana product.
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix K for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
151
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0170.png
Section 2: Marijuana Use and Driving
Public health recommendations
Public health recommendations have been suggested and approved by the Retail Marijuana Public
Health Advisory Committee with the goals of: 1) Improving knowledge regarding population-based
health effects of retail marijuana use and 2) Developing and targeting public health education and
prevention strategies for high-risk sub populations.
Data quality
Use better quality measures of marijuana use exposure, for example, blood THC levels instead of
self-reported cannabis use, for studies of impairment and accidents.
Increase testing for THC and its metabolites in drivers, especially fatally injured drivers and at-
fault drivers.
Accurately record timing of THC blood testing relevant to motor vehicle crashes and driving under
the influence of drugs (DUID).
Surveillance
Monitor perceptions of the risk associated with driving after using marijuana and self-report of
personally doing so.
Centralize reporting of blood THC levels (not just presence/absence of THC) for driving under the
influence of drugs (DUID).
Monitor method of use and dose of marijuana consumed in correlation with impairment.
Education
Educate the public on marijuana-related impairment (driving, biking, and safety sensitive
activities), including riding with impaired drivers.
Educate the public on minimum time to wait before driving, biking, or participating in safety
sensitive activities after using various types and doses of marijuana products.
Educate the public on the combined effects and increased risk when using marijuana with alcohol
or other substances.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
152
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0171.png
Section 2: Marijuana Use and Driving
Research gaps
The Retail Marijuana Public Health Advisory Committee identifies important gaps in the scientific
literature that may impact public health policies and prevention strategies. Colorado should support
unbiased research to help fill the following research gaps identified by the committee.
Research to further clarify the relationship of saliva and urine levels to blood levels and
relationship of all biomarkers to measures of functional impairment.
Study the difference in impairment based on frequency of use/tolerance.
Pharmacokinetic/pharmacodynamic and impairment research using doses consistent with the THC
content of currently available marijuana products.
Research on duration of driving impairment after oral marijuana and after high-dose smoked
marijuana.
Research to improve road-side marijuana testing.
Research to identify reliable methods of assessing tolerance to marijuana in frequent users and to
determine the extent to which tolerance affects impairment.
Identification of better methods for measuring meaningful impairment.
Research to determine whether THC metabolite ratios may be helpful in defining a better
biomarker for impairment.
Research to determine impairment after other methods of marijuana use (vaporizing, mucosal and
dermal preparations).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
153
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0172.png
Section 2: Marijuana Use and Driving
References
1. Colorado State Patrol. Traffic Safety Statistics. 2016;
https://www.colorado.gov/pacific/csp/traffic-safety-statistics. Accessed December 28, 2016.
2. CDC WONDER. Multiple Causes of Death Files, 1999-2014. http://wonder.cdc.gov/ucd-icd10.html:
Centers for Disease Control and Prevention; 2016.
3. Colorado Task Force on Drunk & Impaired Driving.
Colorado Task Force on Drunk & Impaired Driving
2015 Annual Report.
2016.
4. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use.
Lancet.
2009;374(9698):1383-1391.
5. New data show 13.6 percent of Colorado adults use marijuana [press release]. June 15, 2015.
6. Baca R. Initiative 300: Everything you need to know about Denver's social cannabis use measure.
The Denver Post2016.
7. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk:
Systematic review of observational studies and meta-analysis.
Bmj.
2012;344:e536.
8. Hartman RL, Huestis MA. Cannabis effects on driving skills.
Clin Chem.
2013;59(3):478-492.
9. Lowenstein SR, Koziol-McLain J. Drugs and traffic crash responsibility: A study of injured motorists
in Colorado.
The Journal of Trauma: Injury, Infection, and Critical Care.
2001;50(2):313-320.
10. Gjerde H, Strand MC, Morland J. Driving under the influence of non-alcohol drugs--An update Part I:
Epidemiological Studies.
Forensic Sci Rev.
2015;27(2):89-113.
11. Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and
revised.
Addiction.
2016;111(8):1348-1359.
12. Drummer OH, Gerostamoulos J, Batziris H, et al. The involvement of drugs in drivers of motor
vehicles killed in Australian road traffic crashes.
Accident Analysis & Prevention.
2004;36(2):239-
248.
13. Kuypers KP, Legrand SA, Ramaekers JG, Verstraete AG. A case-control study estimating accident
risk for alcohol, medicines and illegal drugs.
PLoS One.
2012;7(8):e43496.
14. Laumon B, Gadegbeku B, Martin JL, Biecheler MB, Group SAM. Cannabis intoxication and fatal road
crashes in France: population based case-control study.
Bmj.
2005;331(7529):1371.
15. Poulsen H, Moar R, Pirie R. The culpability of drivers killed in New Zealand road crashes and their
use of alcohol and other drugs.
Accid Anal Prev.
2014;67:119-128.
16. Berghaus G, Scheer N, Schmidt P. Effects of cannabis on psychomotor skills and driving
performance - a metaanalysis of experimental studies. 1995;
http://casr.adelaide.edu.au/T95/paper/s16p2.html. Accessed 8/31/2014.
17. Berghaus G, Sticht G, Grellner W.
Meta-analysis of empirical studies concerning the effects of
medicines and illegal drugs including pharmacokinetics on safe driving.
Center for Traffic Sciences
at the University of Wurzburg;2011.
18. Grotenhermen F, Leson G, Berghaus G, et al. Developing limits for driving under cannabis.
Addiction.
2007;102(12):1910-1917.
19. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognition and
motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of
impairment.
Drug Alcohol Depend.
2006;85(2):114-122.
20. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective dose-response
effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.
Psychopharmacology (Berl).
2002;164(1):61-70.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
154
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0173.png
Section 2: Marijuana Use and Driving
21. Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW. Effects of acute smoked marijuana on
complex cognitive performance.
Neuropsychopharmacology.
2001;25(5):757-765.
22. Hunault CC, Mensinga TT, Bocker KB, et al. Cognitive and psychomotor effects in males after
smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-
tetrahydrocannabinol (THC).
Psychopharmacology (Berl).
2009;204(1):85-94.
23. Kelly TH, Foltin RW, Emurian CS, Fischman MW. Performance-based testing for drugs of abuse: dose
and time profiles of marijuana, amphetamine, alcohol, and diazepam.
J Anal Toxicol.
1993;17(5):264-272.
24. Lenne MG, Dietze PM, Triggs TJ, Walmsley S, Murphy B, Redman JR. The effects of cannabis and
alcohol on simulated arterial driving: Influences of driving experience and task demand.
Accid Anal
Prev.
2010;42(3):859-866.
25. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. Neurocognitive performance
during acute THC intoxication in heavy and occasional cannabis users.
J Psychopharmacol.
2009;23(3):266-277.
26. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR. High-potency
marijuana impairs executive function and inhibitory motor control.
Neuropsychopharmacology.
2006;31(10):2296-2303.
27. Ronen A, Chassidim HS, Gershon P, et al. The effect of alcohol, THC and their combination on
perceived effects, willingness to drive and performance of driving and non-driving tasks.
Accid Anal
Prev.
2010;42(6):1855-1865.
28. Ronen A, Gershon P, Drobiner H, et al. Effects of THC on driving performance, physiological state
and subjective feelings relative to alcohol.
Accid Anal Prev.
2008;40(3):926-934.
29. Schwope DM, Bosker WM, Ramaekers JG, Gorelick DA, Huestis MA. Psychomotor performance,
subjective and physiological effects and whole blood Delta(9)-tetrahydrocannabinol concentrations
in heavy, chronic cannabis smokers following acute smoked cannabis.
J Anal Toxicol.
2012;36(6):405-412.
30. Weinstein A, Brickner O, Lerman H, et al. A study investigating the acute dose-response effects of
13 mg and 17 mg Delta 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic
measures in regular users of marijuana.
J Psychopharmacol.
2008;22(4):441-451.
31. Bosker WM, Kuypers KP, Theunissen EL, et al. Medicinal Delta(9) -tetrahydrocannabinol
(dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is
not detected in Standard Field Sobriety Tests.
Addiction.
2012;107(10):1837-1844.
32. Menetrey A, Augsburger M, Favrat B, et al. Assessment of driving capability through the use of
clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration
of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
J Anal Toxicol.
2005;29(5):327-338.
33. Vindenes V, Strand DH, Kristoffersen L, Boix F, Morland J. Has the intake of THC by cannabis users
changed over the last decade? Evidence of increased exposure by analysis of blood THC
concentrations in impaired drivers.
Forensic Sci Int.
2013;226(1-3):197-201.
34. Blows S, Ivers RQ, Connor J, Ameratunga S, Woodward M, Norton R. Marijuana use and car crash
injury.
Addiction (Abingdon, England).
2005;100(5):605-611.
35. Chipman ML, Macdonald S, Mann RE. Being "at fault" in traffic crashes: does alcohol, cannabis,
cocaine, or polydrug abuse make a difference?
Inj Prev.
2003;9(4):343-348.
36. Mann RE, Adlaf E, Zhao J, et al. Cannabis use and self-reported collisions in a representative
sample of adult drivers.
J Safety Res.
2007;38(6):669-674.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
155
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0174.png
Section 2: Marijuana Use and Driving
37. Pulido J, Barrio G, Lardelli P, Bravo MJ, Regidor E, de la Fuente L. Association between cannabis
and cocaine use, traffic injuries and use of protective devices.
Eur J Public Health.
2011;21(6):753-
755.
38. Mura P, Kintz P, Ludes B, et al. Comparison of the prevalence of alcohol, cannabis and other drugs
between 900 injured drivers and 900 control subjects: results of a French collaborative study.
Forensic Sci Int.
2003;133(1-2):79-85.
39. Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared with alcohol on driving.
Am J
Addict.
2009;18(3):185-193.
40. Dubois S, Mullen N, Weaver B, Bedard M. The combined effects of alcohol and cannabis on driving:
Impact on crash risk.
Forensic Sci Int.
2015;248:94-100.
41. Fierro I, González-Luque JC, Álvarez FJ. The relationship between observed signs of impairment
and THC concentration in oral fluid.
Drug and Alcohol Dependence.
2014;144:231-238.
42. Hartman RL, Brown TL, Milavetz G, et al. Controlled vaporized cannabis, with and without alcohol:
Subjective effects and oral fluid-blood cannabinoid relationships.
Drug Test Anal.
2015;10.1002/dta.1839.
43. Cone EJ, Johnson RE. Contact highs and urinary cannabinoid excretion after passive exposure to
marijuana smoke.
Clin Pharmacol Ther.
1986;40(3):247-256.
44. Huestis MA. Human cannabinoid pharmacokinetics.
Chem Biodivers.
2007;4(8):1770-1804.
45. Hunault CC, Bocker KB, Stellato RK, Kenemans JL, de Vries I, Meulenbelt J. Acute subjective
effects after smoking joints containing up to 69 mg Delta9-tetrahydrocannabinol in recreational
users: a randomized, crossover clinical trial.
Psychopharmacology (Berl).
2014;231(24):4723-4733.
46. Bosker WM, Karschner EL, Lee D, et al. Psychomotor function in chronic daily Cannabis smokers
during sustained abstinence.
PLoS One.
2013;8(1):e53127.
47. Wolff K, Johnston A. Cannabis use: a perspective in relation to the proposed UK drug-driving
legislation.
Drug Test Anal.
2014;6(1-2):143-154.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
156
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0175.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Chapter 7
Marijuana Use and
Gastrointestinal and
Reproductive Effects
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0176.png
Section 2: Marijuana Use and Gastrointestinal and Reproductive Effects
Authors
Andrew Monte, MD
Emergency Medicine Physician, University of Colorado
Medical Toxicologist, Rocky Mountain Poison and Drug Center
(2016)
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2016)
Lisa Barker, MPH
Retail Marijuana Health Monitoring, Colorado Department of Public Health and Environment
(2016)
Madeline Morris, BS
Graduate Student, Colorado School of Public Health
(2014)
David Goff Jr., MD, PhD
Dean and Professor, Colorado School of Public Health
(2014)
Reviewer
Ken Gershman, MD, MPH
Manager
Marijuana Research Grants Program, Colorado Department of Public Health and Environment
(2014, 2016)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
158
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0177.png
Section 2: Marijuana Use and Gastrointestinal and Reproductive Effects
Introduction
The Retail Marijuana Public Health Advisory Committee identified many important public health topics
related to marijuana use and has reviewed the scientific evidence currently available regarding those
topics. This chapter includes reviews of gastrointestinal diseases, particularly cyclic vomiting, and
infertility or abnormal reproductive function.
Gastrointestinal diseases affect 60 to 70 million people in the United States,
1
and caused more than 20
million hospitalizations in 2010.
2
Both tobacco and alcohol contribute to some of these diseases, and it
is possible marijuana could as well. One condition of concern, reported by emergency department
providers, is cyclic vomiting among long-time, frequent marijuana users. Analysis of 2015 data from the
Behavioral Risk Factor Surveillance System (BRFSS), completed for this report, estimated that 6
percent of adults in Colorado use marijuana daily or near-daily. Potential connections between
marijuana use and cyclic vomiting or other gastrointestinal diseases are important to clarify.
Many women who want to become pregnant are unable. Eleven percent of women 15-44 years of age in
the United States have used infertility services,
3
often at great expense. Many men also have conditions
that can prevent a desired pregnancy, such as low sperm count. Because normal reproductive function
is dependent on so many factors, any substance that has effects throughout the body could potentially
contribute to infertility. Marijuana use in Colorado is highest among individuals of reproductive age.
Analysis of 2015 data from the BRFSS, completed for this report, estimated that 26 percent of 18-25
year olds and 18 percent of 26-34 year olds in Colorado were current marijuana users. It is important to
evaluate possible associations between infertility and marijuana use.
Definitions
Cannabinoid hyperemesis syndrome
- a term currently used by some medical professionals to describe
cyclic vomiting occurring in long-time marijuana users. A formal medical definition, including clinical
diagnostic criteria, has not yet been established.
Cyclic vomiting
- episodes of severe, repeated vomiting.
Abnormal male reproductive function
- abnormal sperm count, concentration, motility or structure,
or abnormal reproductive hormone levels.
Abnormal female reproductive function
- abnormal ovulation, implantation, placenta formation, or
reproductive hormone levels.
Levels of marijuana use
Daily or near-daily use: 5-7 days/week.
Weekly use: 1-4 days/week.
Less-than-weekly use: less than 1 day/week.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
159
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0178.png
Section 2: Marijuana Use and Gastrointestinal and Reproductive Effects
Key findings
Evidence shows that long-time, daily or near-daily marijuana use is associated with cyclic vomiting.
This condition has been called cannabinoid hyperemesis syndrome. In such cases, stopping marijuana
use may relieve the vomiting. There is conflicting research on whether or not marijuana use is
associated with male infertility or abnormal reproductive function, and research is lacking on female
reproductive function related to marijuana use.
An important note for all key findings is that the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove that the
marijuana use alone
caused
the effect. Despite the best efforts of researchers to account for
confounding factors, there may be other important factors related to
causality
that were not
identified. In addition, marijuana use was illegal everywhere in the United States prior to 1996.
Research funding, when appropriated, was commonly sought to identify adverse effects from marijuana
use. This legal fact introduces both funding bias and publication bias into the body of literature related
to marijuana use. The Retail Marijuana Public Health Advisory Committee recognizes the limitations
and biases inherent in the published literature and made efforts to ensure the information reviewed
and synthesized is reflective of the current state of medical knowledge. Where information was lacking
for whatever reason
the committee identified this knowledge gap and recommended further
research. This information will be updated as new research becomes available.
Recommendations
The committee recommends that health care systems and providers improve the documentation of
marijuana use history during hospitalizations and emergency department visits, including timing,
potency and amount of last marijuana use and measures of cumulative lifetime use. Because
cannabinoid hyperemesis syndrome is an emerging medical concern, public health should assess and
monitor its prevalence among marijuana users, and educate the public about the potential for cyclic
vomiting with long-time, daily or near-daily marijuana use.
It is also important to reach a consensus on diagnostic criteria for cannabinoid hyperemesis syndrome.
Treatment of the condition should be studied using randomized, controlled trials, including an
assessment of the effectiveness of marijuana cessation. High-quality observational research is needed
to further assess the effects of marijuana use on reproductive function.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
160
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0179.png
Section 2: Marijuana Use and Gastrointestinal and Reproductive Effects
Table 1 Findings summary: Marijuana use and gastrointestinal and reproductive
effects
For an explanation of the classifications “Substantial,” “Moderate,” etc., see Chapter 7. Systematic
literature review process.
Substantial
Moderate
Cyclic vomiting
with long-time,
daily or near-daily
use (cannabinoid
hyperemesis
syndrome)
Limited
Relief from cyclic
vomiting by
stopping
marijuana use
Insufficient
Female infertility
or altered
reproductive
function
Mixed
Male infertility or
altered
reproductive
function
Evidence statements
Evidence statements are based on systematic scientific literature reviews performed by Colorado
Department of Public Health and Environment staff with oversight and approval by the Retail Marijuana
Public Health Advisory Committee. For an explanation
of the classifications “Substantial,” “Moderate,”
etc., see Chapter 7. Systematic literature review process. For details about the studies reviewed, see
Appendix L.
1. We found
MODERATE
evidence that long-time, daily or near-daily marijuana use is associated with
cases of cyclic vomiting (some medical experts have called this cannabinoid hyperemesis
syndrome).
4-8
(Added
*
)
2. We found
LIMITED
evidence that marijuana users who experience cyclic vomiting have found relief
by stopping marijuana use.
6,8,9
(Added*)
3. We found
MIXED
evidence for whether or not marijuana use is associated with male infertility or
abnormal reproductive function (such as abnormal sperm count, concentration, motility or
structure, or abnormal reproductive hormone levels).
10-13
(Revised*)
4. We found
INSUFFICIENT
evidence to determine whether or not marijuana use is associated with
female infertility or abnormal reproductive function (such as abnormal ovulation, implantation,
placenta formation, or reproductive hormone levels).
14
(Added*)
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix L for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
161
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0180.png
Section 2: Marijuana Use and Gastrointestinal and Reproductive Effects
Public health statements
Public health statements are plain language translations of the major findings (Evidence Statements)
from the systematic literature reviews. These statements have been officially approved by the Retail
Marijuana Public Health Advisory Committee.
1. Long-time, daily or near-daily marijuana use is associated with cyclic vomiting, which some
medical experts have called cannabinoid hyperemesis syndrome. (Added*)
2. Marijuana users who experience cyclic vomiting may find relief by stopping marijuana use. (Added
*
)
3. There is conflicting research on whether or not marijuana use is associated with male infertility or
reproductive function.
Public health recommendations
Public health recommendations have been suggested and approved by the Retail Marijuana Public
Health Advisory Committee with the goals of: 1) Improving knowledge regarding population-based
health effects of retail marijuana use and 2) Developing and targeting public health education and
prevention strategies for high-risk sub populations.
Data quality
Improved documentation of marijuana use history during hospitalizations and emergency
department visits, including timing, potency and amount of last marijuana use and measures of
cumulative lifetime use.
Surveillance
Population based analyses to evaluate the prevalence of cannabinoid hyperemesis syndrome or
cyclic vomiting among marijuana users, including separate rates for medical versus recreational
users.
Education
Public education about the potential for cyclic vomiting with long-time, daily or near-daily
marijuana use.
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix L for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
162
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0181.png
Section 2: Marijuana Use and Gastrointestinal and Reproductive Effects
Research gaps
The Retail Marijuana Public Health Advisory Committee identifies important gaps in the scientific
literature that may impact public health policies and prevention strategies. Colorado should support
unbiased research to help fill the following research gaps identified by the committee.
High quality studies assessing reproductive function related to marijuana use.
Consensus diagnostic criteria for cannabinoid hyperemesis syndrome (CHS) to be used in subsequent
research.
Determination of the molecular etiology of CHS.
Clinical studies of CHS treatment, including the effectiveness of marijuana cessation.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
163
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0182.png
Section 2: Marijuana Use and Gastrointestinal and Reproductive Effects
References
1. National Institute of Diabetes and Digestive and Kidney Diseases.
Opportunities & Challenges in
Digestive Diseases Research: Recommendations of the National Commission on Digestive Diseases.
National Institutes of Health;2009.
2. National Center for Health Statistics. National Hosptial Discharge Survey, United States 2010
https://www.cdc.gov/nchs/fastats/hospital.htm: Centers for Disease Control and Prevention.
3. National Center for Health Statistics. Key Statistics from the National Survey of Family Growth.
https://www.cdc.gov/nchs/nsfg/key_statistics.htm. Accessed December 27, 2016.
4. Wallace EA, Andrews SE, Garmany CL, Jelley MJ. Cannabinoid hyperemesis syndrome: literature
review and proposed diagnosis and treatment algorithm.
South Med J.
2011;104(9):659-664.
5. Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by
persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic
marijuana use: a report of eight cases in the United States.
Dig Dis Sci.
2010;55(11):3113-3119.
6. Simonetto Da, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98
patients.
Mayo Clinic Proceedings.
2012;87(2):114-119.
7. Kim HS, Anderson JD, Saghafi O, Heard KJ, Monte AA. Cyclic vomiting presentations following
marijuana liberalization in Colorado.
Acad Emerg Med.
2015;22(6):694-699.
8. Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in
association with chronic cannabis abuse.
Gut.
2004;53(11):1566-1570.
9. Namin F, Patel J, Lin Z, et al. Clinical, psychiatric and manometric profile of cyclic vomiting
syndrome in adults and response to tricyclic therapy.
Neurogastroenterol Motil.
2007;19(3):196-
202.
10. Pacey AA, Povey AC, Clyma JA, et al. Modifiable and non-modifiable risk factors for poor sperm
morphology.
Hum Reprod.
2014;29(8):1629-1636.
11. Povey AC, Clyma JA, McNamee R, et al. Modifiable and non-modifiable risk factors for poor semen
quality: a case-referent study.
Hum Reprod.
2012;27(9):2799-2806.
12. Block RI, Farinpour R, Schlechte JA. Effects of chronic marijuana use on testosterone, luteinizing
hormone, follicle stimulating hormone, prolactin and cortisol in men and women.
Drug Alcohol
Depend.
1991;28(2):121-128.
13. Gundersen TD, Jorgensen N, Andersson AM, et al. Association Between Use of Marijuana and Male
Reproductive Hormones and Semen Quality: A Study Among 1,215 Healthy Young Men.
Am J
Epidemiol.
2015;182(6):473-481.
14. Mueller BA, Daling JR, Weiss NS, Moore DE. Recreational drug use and the risk of primary infertility.
Epidemiology.
1990;1(3):195-200.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
164
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0183.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Chapter 8
Marijuana Use and Injury
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0184.png
Section 2: Marijuana Use and Injury
Authors
Ashley Brooks-Russell, PhD, MPH
Assistant Professor
Injury Prevention, Education and Research Program, Colorado School of Public Health
(2014, 2016)
Elyse Contreras, MPH
Coordinator
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2016)
Renee M. Johnson, PhD, MPH
Associate Professor
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health
(2016)
Lisa Barker, MPH
Retail Marijuana Health Monitoring, Colorado Department of Public Health and Environment
(2014, 2016)
Katelyn E. Hall, MPH
Statistical Analyst
Retail Marijuana Health Monitoring Program, Colorado Department of Public Health and Environment
(2014)
Madeline Morris, BS
Graduate Student, Colorado School of Public Health
(2014)
Dr. David Goff Jr., MD, PhD
Dean and Professor, Colorado School of Public Health
(2014)
Reviewers
Heath Harmon, MPH
Director of Health Divisions, Boulder County Public Health
(2016)
Ashley Brooks-Russell, PhD, MPH
Assistant Professor, Colorado School of Public Health
(2014)
Ken Gershman, MD, MPH
Manager
Medical Marijuana Research Grants Program, Colorado Department of Public Health and Environment
(2014)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
166
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0185.png
Section 2: Marijuana Use and Injury
Introduction
The Retail Marijuana Public Health Advisory Committee identified many important public health topics
related to marijuana and has reviewed the scientific evidence currently available regarding those
topics. This chapter includes reviews of workplace, recreational and other non-driving injuries (driving-
related injuries are described in Chapter 12. Marijuana use and driving), burns from hash oil extraction
or failed electronic smoking devices, and physical dating violence.
In Colorado, thousands of people are injured on the job each year, and a work-related death occurs
every three to four days.
1
Outdoor recreational activities are extremely popular in Colorado, drawing
participation from about two-thirds of residents annually,
2
and recreational injuries are common.
Additionally, many of the tourists visiting Colorado - 64 million in 2013
3
come to enjoy outdoor
recreation. Unintentional injuries, excluding motor vehicle crashes, are responsible for 17 percent of
all deaths among persons 10-24 years of age in the United States.
4
Marijuana use can cause unsteady
gait, slower reaction time, impaired motor coordination, and impaired attention,
5,6
which are all
factors that contribute to accidental injuries.
Analyses of 2015 Behavioral Risk Factor Surveillance System data, completed for this report, estimated
that 26 percent of 18-25 year olds and 18 percent of 26-34 year olds in Colorado have used marijuana
within the last month. These age groups make up a large portion of the workforce. Recreational
activities are common among these 18-34 year olds, as well as adolescents. 2015 Healthy Kids Colorado
Survey data, also analyzed for this report, estimate that 21 percent of Colorado high school students
used marijuana within the last month. It is important to investigate possible associations between
marijuana use and workplace, recreational and other non-driving injuries.
Recently, there have been increased reports of explosions related to hash oil extraction. In 2014, there
were 32 hash oil extraction explosions in Colorado, which injured 30 people (most often burns).
7
Another emerging topic of concern has been the explosion of electronic smoking devices
8,9
, which are
used for both marijuana and nicotine. The devices have grown in popularity, and injuries resulting from
explosions are increasing.
10
These topics should be evaluated.
Approximately 10 percent of U.S. high school students report having experienced physical dating
violence,
11
and the prevalence is similar among college students.
12
The consequences of this violence
are serious. Those who are victimized are at increased risk for a range of negative outcomes including
poor health outcomes, depressive symptoms, unhealthy eating behavior, academic difficulties, and
physical injury.
13-15
Alcohol use has been clearly linked with intimate partner violence,
16,17
and some
have argued that marijuana use is also a contributing factor. It is important to identify factors that
may contribute to dating violence, including examination of possible associations with marijuana use.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
167
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0186.png
Section 2: Marijuana Use and Injury
Definitions
Age groups
Adolescent: 12 to 17 years of age.
Young adult: 18 to 24 years of age.
Adult: 25 years or older.
Older adult: 65 years of age and older.
Electronic smoking device (vaporizer or e-cigarette)
-
a vaporizing device with a rechargeable
battery that heats material such as marijuana flower (bud) or liquids containing THC or nicotine to
produce vapor for inhalation. Used as an alternative to smoking marijuana or tobacco.
Hash oil extraction -
a technique that removes THC (the psychoactive component of marijuana) from
the plant material in a concentrated form. This concentrate can then be smoked, vaporized, mixed
into food or drink, or used on the skin. A very common method of extraction uses butane, which is
highly flammable.
Physical dating violence
- physically aggressive behavior among current or former romantic,
sexual/intimate, or dating partners, including hitting, kicking, choking, slapping, etc. Psychological,
emotional, verbal or sexual violence were not included, nor were threats of violence.
Physical dating violence victimization (PDVV) -
to be harmed by physical violence committed by a
partner.
Physical dating violence perpetration (PDVP) -
to commit physical violence against a partner.
Tetrahydrocannabinol (THC) -
the main psychoactive component of marijuana.
Key findings
There is some evidence that marijuana use increases the risk of workplace injury. Evidence is
conflicting for other types of non-driving injury, including marijuana use alone or in combination with
alcohol. There have been many cases of severe burns resulting from explosions that occurred during
home-extraction of hash oil through the use of butane. There also have been cases of electronic
smoking devices exploding, leading to trauma and burns. Concerning dating violence, marijuana use by
adolescent girls may be associated with their committing physical violence against their dating
partners, and marijuana use by adolescent boys may be associated with their being victims of physical
violence from their dating partners.
An important note for all key findings is that the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove that the
marijuana use alone
caused
the effect. Despite the best efforts of researchers to account for
confounding factors, there may be other important factors related to
causality
that were not
identified. In addition, marijuana use was illegal everywhere in the United States prior to 1996.
Research funding, when appropriated, was commonly sought to identify adverse effects from marijuana
use. This legal fact introduces both funding bias and publication bias into the body of literature related
to marijuana use. The Retail Marijuana Public Health Advisory Committee recognizes the limitations
and biases inherent in the published literature and made efforts to ensure the information reviewed
and synthesized is reflective of the current state of medical knowledge. Where information was lacking
for whatever reason
the committee identified this knowledge gap and recommended further
research. This information will be updated as new research becomes available.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
168
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0187.png
Section 2: Marijuana Use and Injury
Recommendations
The committee recommended more consistent collection of blood samples following recreational,
workplace or any other injury requiring medical attention, including accurately recording the timing of
testing, and specifying marijuana use as distinct from other substances. Improved collection of
information on individual marijuana use history by amount, potency, frequency, and method is also
important. The link between exposure to marijuana and adverse health outcomes, in both injury and
chronic disease medical settings, cannot be adequately assessed until consistent, standardized data on
individual marijuana use is collected during encounters with medical care settings, mental health
settings and, when necessary, law enforcement. Collecting accurate exposure (or dose) information
and injury outcome data will permit analysis of the data to determine the severity of injury and its
possible relationship with marijuana use.
Surveillance or monitoring systems currently in place (e.g., hospitalization and emergency department
data from the Colorado Hospital Association) can be interrogated to assess injuries potentially related
to marijuana use. The committee recommended additional small-scale pilot projects to determine the
relationship between marijuana use and injury in focused settings including recreational, workplaces,
and where services are provided for the elderly. Monitoring the incidence of injuries caused by
electronic device explosions and hash oil extraction explosions is also recommended.
Educational programs for adult users, their families, and health care providers are needed to ensure
more information is shared about the potential risks of marijuana use and injury. Such information also
should be available and distributed to customers at marijuana dispensaries. Education about the
potential explosion of electronic smoking devices and at-home hash oil extractions is important.
The committee identified several research gaps including the need for more research on the
relationship of THC levels in saliva, blood and urine, and how these biomarkers relate to measures of
functional impairment. Research is also needed on differences in impairment levels based on marijuana
use frequency and tolerance in daily or near-daily users versus other levels of use. More publicly
accessible product safety research is needed for electronic smoking devices. Finally, more studies are
needed that examine marijuana use as a predictor of risk behaviors, especially among adolescents,
college attending young adults and non-college attending young adults.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
169
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0188.png
Section 2: Marijuana Use and Injury
Table 1 Findings summary: Marijuana use and injury
For an
explanation of the classifications “Substantial,” “Moderate,” etc., see Chapter 7. Systematic
literature review process.
Substantial
Moderate
Limited
Increased risk of
workplace
injury
Insufficient
Mixed
Marijuana use and
risk of non-driving
injury
Combined marijuana
and alcohol use and
non-driving injury
Marijuana use and
risk of recreational
injury
Non-driving injury
Burns
Severe burns
and
hospitalization
from hash oil
extraction
Serious injury
from exploding
electronic
smoking devices
Physical dating
violence
perpetration by
adolescent girls
Physical dating
violence
victimization in
adolescent boys
Failure to show
physical dating
violence
perpetration by
young adult
women or men
Marijuana use and
burns
Physical Dating Violence
Physical dating
violence
victimization in
young adults
Physical dating
violence
perpetration by
adolescent boys
Physical dating
violence
victimization in
adolescent girls
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
170
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0189.png
Section 2: Marijuana Use and Injury
Evidence statements
Evidence statements are based on systematic scientific literature reviews performed by Colorado
Department of Public Health and Environment staff with oversight and approval by the Retail Marijuana
Public Health Advisory Committee. For an explanation of the
classifications “Substantial,” “Moderate,”
etc., see Chapter 7. Systematic literature review process. For details about the studies reviewed, see
Appendix M.
Workplace, recreational, other non-driving
1. We found
LIMITED
evidence that marijuana use increases workplace injury risk (non-driving
injury).
18-20
2. We found
MIXED
evidence for whether or not adults who use marijuana are at a higher risk of non-
driving related injuries.
20-27
3. We found
MIXED
evidence for whether or not adults who use marijuana and alcohol combined are
at a higher risk of non-driving related injury than those who use either substance alone.
23,24,27-29
4. We found
MIXED
evidence for whether or not adults who use marijuana are at a higher risk of
injury due to recreational activity.
28,30,31
Burns
5. We found
LIMITED
evidence that home extraction of hash oil has resulted in cases of severe burns
requiring hospitalization.
32-36
(Added
*
)
6. We found
LIMITED
evidence that electronic smoking devices have failed (exploded), resulting in
cases of trauma and burn injury.
37-39
(Added*)
7. We found
INSUFFICIENT
evidence to determine whether or not there is an association between
marijuana-use in the past 30-days and burn injury.
40
(Added*)
Physical dating violence
8. We found
LIMITED
evidence that marijuana use is associated with physical dating violence
perpetration (PDVP) by adolescent girls.
41-44
(Added*)
9. We found
LIMITED
evidence that marijuana use is associated with physical dating violence
victimization (PDVV) among adolescent boys.
45-47
(Added*)
10. We found
MIXED
evidence for whether or not marijuana use is associated with physical dating
violence perpetration (PDVP) by adolescent boys.
43,44
(Added*)
11. We found
MIXED
evidence for whether or not marijuana use is associated with physical dating
violence victimization (PDVV) among adolescent girls .
41,45,46
(Added*)
12. We found a
LIMITED
body of research that failed to show an association between marijuana use
and physical dating violence perpetration (PDVP) by young adult men.
48,49
(Added*)
13. We found a
LIMITED
body of research that failed to show an association between marijuana use
and physical dating violence perpetration (PDVP) by young adult women.
41,48,50,51
(Added*)
14. We found
INSUFFICIENT
evidence to determine whether or not marijuana use is associated with
physical dating violence victimization (PDVV) among young adults.
52
(Added*)
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix M for dates of most recent literature review
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
171
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0190.png
Section 2: Marijuana Use and Injury
Public health statements
Public health recommendations have been suggested and approved by the Retail Marijuana Public
Health Advisory Committee with the goals of: 1) Improving knowledge regarding population-based
health effects of retail marijuana use and 2) Developing and targeting public health education and
prevention strategies for high-risk sub populations.
1. Marijuana use may be associated with increased risk of non-driving related workplace injuries.
2. There is conflicting research on whether or not marijuana use alone or combined with alcohol
increases the risk of other non-driving related injury among adults.
3. Use caution when driving, biking, or performing other safety-sensitive activities after using any
form of marijuana or marijuana product.
4.
Electronic smoking or vaporizing devices can explode, causing serious injury. (Added*)
5. Extracting hash oil yourself with flammable substances can cause severe burns requiring
hospitalization. (Added
*
)
6. Marijuana use by adolescent girls may be associated with a higher risk of committing physical
violence against their dating partners. Marijuana use by adolescent boys may be associated with a
higher risk of being the victim of physical violence from their dating partners.
*Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement
is new since the 2014 edition of the report. See Appendix M for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
172
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0191.png
Section 2: Marijuana Use and Injury
Public health recommendations
Public health recommendations have been suggested and approved by the Retail Marijuana Public
Health Advisory Committee with the goals of: 1) improving knowledge regarding population-based
health effects of retail marijuana use, 2) developing and targeting public health education and
prevention strategies for high-risk subpopulations.
Data quality
Accurately record timing of THC blood testing, relevant to recreational, workplace or any other
injury requiring medical attention, and specify marijuana use as distinct from other substances.
Use better quality measure of marijuana use exposure, for example, blood THC levels instead of
self-reported marijuana use, for studies of impairment and accidents.
Ensure quality description of burns related to marijuana use or production.
Improve the measures of marijuana exposure used in population-based studies.
Report measures of association separately by age group (e.g. adolescent, young adult), sex, and
other characteristics that may lead to differing findings.
Surveillance
Improve and centralize reporting of blood THC levels (not just presence/absence of THC) for
trauma and workplace injury surveillance.
Develop small-scale surveillance projects to assess the use of marijuana among those injured in
recreational activities.
Monitor incidence of recreational injuries related to marijuana use.
Monitor incidence of workplace injuries related to marijuana production or use.
Monitor the prevalence of marijuana use and incidence of fall-related injuries among older adults.
Monitor incidence of injuries caused by electronic device explosions and hash oil extraction
explosions.
Education
Educate the public on marijuana-related impairment, including related risks of recreational
injuries, workplace injuries and falls in older adults.
Educate the public about the potential hazards of exploding electronic smoking devices.
Educate the public on the hazards and laws pertaining to at-home hash oil extraction.
Expand public education about the link between marijuana use and risk behaviors among
adolescents and young adults.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
173
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0192.png
Section 2: Marijuana Use and Injury
Research gaps
The Retail Marijuana Public Health Advisory Committee identifies important gaps in the scientific
literature that may impact public health policies and prevention strategies. Colorado should support
unbiased research to help fill the following research gaps identified by the committee.
Research to further clarify the relationship of saliva and urine levels to blood levels and
relationship of all biomarkers to measures of functional impairment.
Study differences in impairment based on frequency of use/tolerance.
Develop studies to evaluate risk of burn injuries among marijuana users.
Study consumer product safety of electronic smoking devices.
Increase the number of studies that examine marijuana use as a predictor of risk behaviors,
especially among adolescents, college attending young adults and non-college attending young
adults.
Identify the independent effect of marijuana use on adolescent risk behaviors, adjusting for alcohol
use and other potential confounders.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
174
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0193.png
Section 2: Marijuana Use and Injury
References
1. Colorado Department of Public Health and Environment. Workplace safety data and reports. 2016;
https://www.colorado.gov/pacific/cdphe/workplace-safety-data-and-reports. Accessed December
27, 2016.
2. Outdoor Industry Association.
The Outdoor Recreation Economy: Colorado.
2012.
3. Development Research Partners Inc. and Progress Colorado. Tourism continues as state's economic
cornerstone. 2015; http://progressco.org/recreation-tourism-overview/. Accessed December 28,
2016.
4. CDC WONDER. About Underlying Cause of Death, 1999-2015. http://wonder.cdc.gov/ucd-
icd10.html: Centers for Disease Control and Prevention.
5. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids.
Clin Pharmacokinet.
2003;42(4):327-360.
6. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use.
Lancet.
2009;374(9698):1383-1391.
7. Rocky Mountain High Intensity Drug Trafficing Area.
The Legalization of Marijuana in Colorado: The
Impact.
September 2015 2015.
8. Whaley M. Some Colorado smokers burned by exploding e-cigarettes.
The Denver Post.
February 7,
2016, 2016.
9. Glaser A. Vape Pens and E-Cigs Are Blowing Up. Like, Literally.
Wired,
https://www.wired.com/2016/02/exploding-e-cigs-and-vape-pens/2016.
10. Eltman F. E-cigarette fires and injuries are on the rise, with faulty batteries suspected.
The Denver
Post.
December 14, 2016, 2016.
11. Rothman EF, Xuan Z. Trends in Physical Dating Violence Victimization Among U.S. High School
Students, 1999-2011.
J Sch Violence.
2014;13(3):277-290.
12. Black MC, Basile, K.C., Breiding, M.J., Smith, S.G., Walters, M.L., Merrick, M.T., Chen, J., &
Stevens, M.R.
The National Intimate Partner and Sexual Violence Survey (NISVS): 2010 Summary
Report.
Atlanta, GA: National Center for Injury Prevention and Control, Centers for Disease Control
and Prevention;2011.
13. Fletcher J. The effects of intimate partner violence on health in young adulthood in the United
States.
Soc Sci Med.
2010;70(1):130-135.
14. Bonomi AE, Anderson ML, Nemeth J, Rivara FP, Buettner C. History of dating violence and the
association with late adolescent health.
BMC Public Health.
2013;13:821.
15. Ackard DM, Eisenberg ME, Neumark-Sztainer D. Long-term impact of adolescent dating violence on
the behavioral and psychological health of male and female youth.
J Pediatr.
2007;151(5):476-481.
16. Foran HM, O'Leary KD. Alcohol and intimate partner violence: a meta-analytic review.
Clin Psychol
Rev.
2008;28(7):1222-1234.
17. Leonard KE. Alcohol and intimate partner violence: when can we say that heavy drinking is a
contributing cause of violence?
Addiction.
2005;100(4):422-425.
18. Shipp EM, Tortolero SR, Cooper SP, Baumler EG, Weller NF. Substance use and occupational injuries
among high school students in South Texas.
Am J Drug Alcohol Abuse.
2005;31(2):253-265.
19. Price JW. Marijuana and workplace safety: an examination of urine drug tests.
J Addict Dis.
2014;33(1):24-27.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
175
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0194.png
Section 2: Marijuana Use and Injury
20. Wadsworth EJK, Moss SC, Simpson Sa, Smith aP. A community based investigation of the association
between cannabis use, injuries and accidents.
Journal of psychopharmacology (Oxford, England).
2006;20(1):5-13.
21. Polen MR, Sidney S, Tekawa IS, Sadler M, Friedman GD. Health care use by frequent marijuana
smokers who do not smoke tobacco.
West J Med.
1993;158(6):596-601.
22. Barrio G, Jiménez-Mejías E, Pulido J, Lardelli-Claret P, Bravo MJ, de la Fuente L. Association
between cannabis use and non-traffic injuries.
Accid Anal Prev.
2012;47:172-176.
23. Gerberich S. Marijuana Use and Injury Events Resulting in Hospitalization.
Annals of Epidemiology.
2003;13(4):230-237.
24. Gmel G, Kuendig H, Rehm J, Schreyer N, Daeppen J-B. Alcohol and cannabis use as risk factors for
injury--a case-crossover analysis in a Swiss hospital emergency department.
BMC Public Health.
2009;9(1):40-40.
25. Tait RJ, Anstey KJ, Butterworth P. Incidence of self-reported brain injury and the relationship with
substance abuse: findings from a longitudinal community survey.
BMC Public Health.
2010;10(1):171-171.
26. Braun BL, Tekawa IS, Gerberich SG, Sidney S. Marijuana Use and Medically Attended Injury Events.
Ann Emerg Med.
1998;32(3):353-360.
27. Vinson DC. Marijuana and other illicit drug use and the risk of injury: A case-control study.
Mo Med.
2006;103(2):152-156.
28. Asbridge M, Mann R, Cusimano MD, Tallon JM, Pauley C, Rehm J. Cycling-related crash risk and the
role of cannabis and alcohol: a case-crossover study.
Preventive Medicine.
2014;66:80-86.
29. Woolard R, Nirenberg TD, Becker B, et al. Marijuana Use and Prior Injury among Injured Problem
Drinkers.
Academic Emergency Medicine.
2003;10(1):43-51.
30. Siwani R, Tombers NM, Rieck KL, Cofer SA. Comparative analysis of fracture characteristics of the
developing mandible: the Mayo Clinic experience.
International journal of pediatric
otorhinolaryngology.
2014;78(7):1066-1070.
31. Chiolero A, Schmid H. Repeated self-reported injuries and substance use among young adolescents:
the case of Switzerland.
Sozial- und Präventivmedizin.
2002;47(5):289-297.
32. Bell C, Slim J, Flaten HK, Lindberg G, Arek W, Monte AA. Butane Hash Oil Burns Associated with
Marijuana Liberalization in Colorado.
J Med Toxicol.
2015;11(4):422-425.
33. Jensen G, Bertelotti R, Greenhalgh D, Palmieri T, Maguina P. Honey oil burns: a growing problem.
J
Burn Care Res.
2015;36(2):e34-37.
34. Porter CJ, Armstrong JR. Burns from illegal drug manufacture: case series and management.
J Burn
Care Rehabil.
2004;25(3):314-318.
35. Schneberk T, Valenzuela RG, Sterling G, Mallon WK. Hot Wax.
JEMS.
2015;40(9):44-47, 52.
36. Williams GD. Hash-oil manufacture: an important factor in the occurrence of adult burns in
Jamaica.
West Indian Med J.
1988;37(4):210-214.
37. Colaianni CA, Tapias LF, Cauley R, Sheridan R, Schulz JT, Goverman J. Injuries Caused by Explosion
of Electronic Cigarette Devices.
Eplasty.
2016;16:ic9.
38. Roger JM, Abayon M, Elad S, Kolokythas A. Oral Trauma and Tooth Avulsion Following Explosion of
E-Cigarette.
J Oral Maxillofac Surg.
2016;10.1016/j.joms.2015.12.017.
39. United States Fire Administration. Electronic Cigarette Fires and Explosions. October 2014.
40. Jehle CC, Jr., Nazir N, Bhavsar D. The rapidly increasing trend of cannabis use in burn injury.
J
Burn Care Res.
2015;36(1):e12-17.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
176
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0195.png
Section 2: Marijuana Use and Injury
41. Epstein-Ngo QM, Cunningham RM, Whiteside LK, et al. A daily calendar analysis of substance use
and dating violence among high risk urban youth.
Drug Alcohol Depend.
2013;130(1-3):194-200.
42. Foshee VA, Reyes HL, Ennett ST. Examination of Sex and Race Differences in Longitudinal
Predictors of the Initiation of Adolescent Dating Violence Perpetration.
J Aggress Maltreat Trauma.
2010;19(5):492-516.
43. McNaughton Reyes HL, Foshee VA, Bauer DJ, Ennett ST. Proximal and time-varying effects of
cigarette, alcohol, marijuana and other hard drug use on adolescent dating aggression.
J Adolesc.
2014;37(3):281-289.
44. Rothman EF, Johnson RM, Azrael D, Hall DM, Weinberg J. Perpetration of physical assault against
dating partners, peers, and siblings among a locally representative sample of high school students
in Boston, Massachusetts.
Arch Pediatr Adolesc Med.
2010;164(12):1118-1124.
45. Eaton DK, Davis KS, Barrios L, Brener ND, Noonan RK. Associations of dating violence victimization
with lifetime participation, co-occurrence, and early initiation of risk behaviors among U.S. high
school students.
J Interpers Violence.
2007;22(5):585-602.
46. Shorey RC, Fite PJ, Choi H, Cohen JR, Stuart GL, Temple JR. Dating Violence and Substance Use as
Longitudinal Predictors of Adolescents' Risky Sexual Behavior.
Prev Sci.
2015;16(6):853-861.
47. Yan FA, Howard DE, Beck KH, Shattuck T, Hallmark-Kerr M. Psychosocial correlates of physical
dating violence victimization among Latino early adolescents.
J Interpers Violence.
2010;25(5):808-
831.
48. Nabors EL. Drug use and intimate partner violence among college students: an in-depth
exploration.
J Interpers Violence.
2010;25(6):1043-1063.
49. Shorey RC, Stuart GL, McNulty JK, Moore TM. Acute alcohol use temporally increases the odds of
male perpetrated dating violence: a 90-day diary analysis.
Addict Behav.
2014;39(1):365-368.
50. Shorey RC, Stuart GL, Moore TM, McNulty JK. The temporal relationship between alcohol,
marijuana, angry affect, and dating violence perpetration: A daily diary study with female college
students.
Psychol Addict Behav.
2014;28(2):516-523.
51. Testa M, Hoffman JH, Leonard KE. Female intimate partner violence perpetration: stability and
predictors of mutual and nonmutual aggression across the first year of college.
Aggress Behav.
2011;37(4):362-373.
52. Melander LA, Noel H, Tyler KA. Bidirectional, unidirectional, and nonviolence: a comparison of the
predictors among partnered young adults.
Violence Vict.
2010;25(5):617-630.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
177
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0196.png
Section 2: Marijuana Use and Injury
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
178
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0197.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Chapter 9
Marijuana Use and
Neurological, Cognitive and
Mental Health Effects
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0198.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
Authors
*Allison
Rosenthal, MPH
Applied Epidemiology Fellow, Substance Abuse Mental Health Services Administration and Council of
State and Territorial Epidemiologists
(2016)
Christian Thurstone, MD
Psychiatrist and Medical Director of Addiction Services, University of Colorado
Associate Professor of Psychiatry, Denver Health
(2016)
Christopher H. Domen, PhD, ABPP-CN
Assistant Professor, Department of Neurosurgery, University of Colorado School of Medicine
(2016)
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2016)
Reviewers
Rebecca Helfand, PhD
Director of Data and Evaluation
Office of Behavioral Health, Colorado Department of Human Services
(2016)
Ken Gershman, MD, MPH
Manager
Marijuana Research Grants Program, Colorado Department of Public Health and Environment
(2014)
*This work was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council
of State and Territorial Epidemiologists (CSTE) and funded through the Centers for Disease Control and Prevention (CDC)
Cooperative Agreement Number 1U38OT000143-04 by the Substance Abuse and Mental Health Services Administration
.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
180
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0199.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
Introduction
The Retail Marijuana Public Health Advisory Committee identified many important public health topics
related to marijuana and has reviewed the scientific evidence currently available regarding those
topics. This chapter includes reviews of the potential relationships between marijuana use and
cognitive impairment, mental health disorders and substance abuse.
Many adults in the United States suffer from some form of mental illness. In 2015, approximately 18
percent of the adult U.S. population (43 million people), had a diagnosable mental, behavioral, or
emotional disorder, according to the National Survey on Drug Use and Health.
1
While the effects of
these disorders can range from mild impairment to severe disability, all have a detrimental individual
impact. In addition, these disorders place a considerable financial burden on our health care system.
The extent and impact of cognitive impairment is difficult to measure among the general adult
population. Many adults may not realize if they have a cognitive impairment. Those who do may
downplay and attempt to compensate for it, but cognitive impairments can greatly affect
a person’s
quality of life.
Some researchers have suggested that marijuana use can cause lasting cognitive impairment or mental
health disorders such as anxiety, depression, and psychosis. Known acute effects of marijuana use
include fragmented thinking, disturbed memory, reduced motor coordination, anxiety and distorted
awareness.
2,3
It is conceivable that ongoing marijuana use might cause some of these effects to be
long-lasting. Many adults in Colorado use marijuana. Analysis of 2015 survey data, completed for this
report, estimated that 13 percent of Colorado adults 18 years and older have used marijuana within
the last month. About 6 percent use marijuana daily or near-daily. With at least one in 10 adults using
marijuana, nearly one in five having a mental health disorder, and an uncertain number with cognitive
impairment; it is extremely important to investigate the relationships between marijuana use,
cognitive functioning and mental health.
Definitions
Levels of marijuana use
Daily or near-daily use: 5-7 days/week.
Weekly use: 1-4 days/week.
Less-than-weekly use: less than 1 day/week.
Acute use: used within the past few hours, such that the short-term effects or symptoms are still
being experienced.
Cannabis use disorder
- a formal diagnosis indicating two or more of these factors: hazardous use,
social/interpersonal problems related to use, neglects major roles in order to use, legal problems,
withdrawal, tolerance, uses more or longer than planned, repeated attempts to quit or reduce use,
much time is spent using, physical or psychological problems related to use, and/or gives up activities
in order to use;
4
commonly called addiction.
Dabbing
a method of marijuana use where a "dab" (small amount) of marijuana concentrate is placed
on a pre-heated surface, creating concentrated marijuana vapor to be inhaled.
Marijuana addiction
- an informal term which is more commonly used than cannabis use disorder, but
the two are considered equivalent by the committee and many mental health professionals.
Psychotic disorders
these include schizophrenia, schizoaffective, schizophreniform, schizotypal, and
delusional disorders. These formal diagnoses are made when a combination of psychotic symptoms are
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
181
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0200.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
present (possibly combined with other mental health symptoms), the symptoms cause significant
problems with work, relationships or self-care, and they have been present for six months or longer.
4
Psychotic symptoms
- these include auditory or visual hallucinations, difficulty separating real from
imagined, perception that self or others can read minds, perceived ability to predict the future, feeling
that an outside force is controlling thoughts or actions, fear that someone intends to harm them, belief
they have supernatural gifts, apathy, social withdrawal, absent or blunted emotions, occurrences of
unclear speech or inability to speak, or difficulty organizing thoughts to complete activities.
4
Tetrahydrocannabinol (THC) -
the main psychoactive component of marijuana.
Key findings
Strong evidence shows that daily or near-daily marijuana users are more likely to have impaired
memory lasting a week or more after quitting. Evidence regarding other cognitive effects is either
lacking or the results are mixed. An important acute effect of THC, the primary psychoactive
component of marijuana, is psychotic symptoms, such as hallucinations, paranoia, delusional beliefs
and feeling emotionally unresponsive during intoxication. These symptoms are worse with higher doses.
Furthermore, daily or near-daily marijuana use is associated with developing a psychotic disorder such
as schizophrenia. There is limited evidence that use of more potent marijuana is also associated with
developing a psychotic disorder. Finally, marijuana users can develop cannabis use disorder (addiction
)
and daily or near-daily marijuana users can experience withdrawal symptoms when abstaining from
marijuana. Evidence also shows there are treatments for marijuana addiction
that can reduce use and
dependence.
An important note for all key findings is that the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove that the
marijuana use alone
caused
the effect. Despite the best efforts of researchers to account for
confounding factors, there may be other important factors related to
causality
that were not
identified. In addition, marijuana use was illegal everywhere in the United States prior to 1996.
Research funding, when appropriated, was commonly sought to identify adverse effects from marijuana
use. This legal fact introduces both funding bias and publication bias into the body of literature related
to marijuana use. The Retail Marijuana Public Health Advisory Committee recognizes the limitations
and biases inherent in the published literature and made efforts to ensure the information reviewed
and synthesized is reflective of the current state of medical knowledge. Where information was lacking
for whatever reason
the committee identified this knowledge gap and recommended further
research. This information will be updated as new research becomes available.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
182
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0201.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
Recommendations
Several important public health recommendations were identified. To facilitate future study on the
effects of marijuana, it is important to improve data quality by systematically collecting information
on the frequency, amount, potency, and method of marijuana use in both public health surveillance
and clinical settings. To that end, improved measures of marijuana use and cumulative marijuana
exposure should be developed and standardized. It also is important to better characterize the
prevalence and patterns of marijuana use among Colorado adults, including breakdowns by age and
other demographics. To better assess potential adverse outcomes, adult hospitalizations and
emergency department visits related to marijuana use should be monitored using de-identified data
available from the Colorado Hospital Association. Addiction
treatment admissions should be monitored
using data from the Colorado Office of Behavioral Health.
High-quality educational materials on the potential cognitive and mental health effects of marijuana
use should be developed and distributed, including the risk specific to daily or near-daily marijuana use
and use of high potency marijuana. The public should also be educated on the signs of marijuana abuse
and addiction
and treatment should be made available and accessible.
The committee also identified a number of important research gaps. Long-term studies on mental
health and cognitive effects of marijuana use would help assess temporality and clarify associations.
These should have well defined marijuana-use histories and evaluation of study groups with different
levels or methods of marijuana use. Research should thoroughly identify potential confounding
variables and measure and adjust for them. Studies using longer periods of abstinence are needed to
evaluate the potential long-term effects in former users. Of special importance in Colorado, research
studies are needed to determine the potential effects of higher potency marijuana and the effects of
different methods of use (e.g., dabbing, edibles). Finally, there is no literature examining the potential
adverse effects of other important cannabinoids such as cannabidiol (CBD).
In this document, the term marijuana addiction is considered equivalent to cannabis use disorder (and addiction to another
substance is considered equivalent to use disorder for that substance).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
183
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0202.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
Table 1 Findings summary: Marijuana use and neurological, cognitive, and mental
health effects
For an explanation of the
classifications “Substantial,” “Moderate,” etc., see Chapter 7. Systematic
literature review process.
Substantial
Impaired
memory for at
least 7 days
(daily or near-
daily users)
Moderate
Limited
Impaired
decision-making
up to 2 days
after last use
(weekly users)
Insufficient
Mixed
Impaired
executive
functioning
after short
abstinence
Cognitive
impairment for
at least 28 days
(daily or near-
daily users)
Cognitive effects
Mental health effects
Acute psychotic
symptoms
during
intoxication
Psychotic
disorder (daily
or near-daily
users)
Diagnosis of
psychotic
disorder with
use of potent
marijuana
Failure to show
psychotic
symptoms or
disorder with
less-than-
weekly use
Bipolar Disorder
diagnosis
Depression or
Anxiety
symptoms or
diagnosis
Substance use and addiction
Can develop
marijuana
addiction
Daily or near-
daily users may
experience
withdrawal
symptoms
Treatment of
marijuana
addiction
can
reduce use and
dependence
‡In
this document, the term marijuana addiction is considered equivalent to cannabis use disorder (and addiction
to another substance is considered equivalent to use disorder for that substance).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
184
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0203.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
Evidence statements
Evidence statements are based on systematic scientific literature reviews performed by Colorado
Department of Public Health and Environment staff with oversight and approval by the Retail Marijuana
Public Health Advisory Committee. For an explanation of the
classifications “Substantial,” “Moderate,”
etc., see Chapter 7. Systematic literature review process. For details about the studies reviewed, see
Appendix N.
Cognitive effects
1. We found
SUBSTANTIAL
evidence that adults who use marijuana daily or near-daily are more likely
than non-users to have memory impairments for at least seven days after last use.
5-13
2. We found
LIMITED
evidence that adults who use marijuana weekly are more likely than non-users
to have impaired decision-making lasting up to two days after last use.
11,14
3. We found
MIXED
evidence for whether or not adults who use marijuana are more likely than non-
users to have impaired executive functioning, after not using for a short time.
5,6,8,9
4. We found
MIXED
evidence for whether or not adults who use marijuana daily or near-daily are more
likely than non-users to have impairment of memory or other cognitive functions for at least 28
days after last use.
6,8,15-17
Mental health effects
5. We found
MIXED
evidence for whether or not adults who use marijuana are more likely than non-
users to have symptoms or diagnosis of depression or anxiety.
18-25
(Revised
*
)
6. We found
INSUFFICIENT
evidence to determine whether or not adults who use marijuana are more
likely than non-users to have symptoms or diagnosis of bipolar disorder.
21,22
(Added*)
7. We found
SUBSTANTIAL
evidence that THC intoxication can cause acute psychotic symptoms,
which are worse with higher doses.
26-31
8. We found
MODERATE
evidence that adults who use marijuana daily or near-daily are more likely
than non-users to be diagnosed with a psychotic disorder, such as schizophrenia.
32-34
(Revised*)
9. We found
LIMITED
evidence that individuals who use more potent marijuana (>10% THC) are more
likely than non-users to be diagnosed with a psychotic disorder, such as schizophrenia.
32,33
(Added*)
10. We found a
LIMITED
body of research that failed to show an association between less-than-weekly
marijuana use and psychotic symptoms or disorders.
30,31,35
(Added*)
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix N for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
185
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0204.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
Substance use, abuse and addiction
11. We found
SUBSTANTIAL
evidence that marijuana users can develop cannabis use disorder.
36-38
(Added*)
12. We found
SUBSTANTIAL
evidence that individuals who use marijuana daily or near-daily can
experience withdrawal symptoms when abstaining from marijuana.
39-46
(Added*)
13. We found
SUBSTANTIAL
evidence that some marijuana users who receive treatment for cannabis
use disorder (including cognitive behavioral therapy, motivational enhancement/interviewing,
multidimensional family therapy, and/or abstinence-based contingency management) can decrease
their marijuana use and dependence.
47-54
(Added
*
)
Public health statements
Public health statements are plain language translations of the major findings (Evidence Statements)
from systematic literature reviews. These statements have been officially approved by the Retail
Marijuana Public Health Advisory Committee.
1. Daily or near-daily use of marijuana is strongly associated with impaired memory, persisting a week
or more after quitting.
2. THC, a component of marijuana, can cause acute psychotic symptoms such as hallucinations,
paranoia, delusional beliefs, and feeling emotionally unresponsive during intoxication. These
symptoms are worse with higher doses.
3. Daily or near-daily use of marijuana is associated with development of psychotic disorders such as
schizophrenia. (Added*)
4. Marijuana users can become addicted
to marijuana. (Added*)
5. Daily or near-daily marijuana users can experience withdrawal symptoms when abstaining.
(Added*)
6. There are treatments for marijuana addiction
that can reduce use and dependence. (Added*)
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix N for dates of most recent literature review.
In this document, the term marijuana addiction is considered equivalent to cannabis use disorder (and addiction to another
substance is considered equivalent to use disorder for that substance).
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
186
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0205.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
Public health recommendations
Public health recommendations have been suggested and approved by the Retail Marijuana Public
Health Advisory Committee with the goals of: 1) Improving knowledge regarding population-based
health effects of retail marijuana use and 2) Developing and targeting public health education and
prevention strategies for high-risk sub populations.
Data quality issues
Standardize and improve data collection on potency, amount, frequency and method of marijuana
use in medical records and other surveillance data sources.
Specify marijuana use as separate from other drug use in medical records and other surveillance
data sources.
Improved measures to determine levels of marijuana use and cumulative marijuana exposure.
Provide power calculations for smaller studies.
Surveillance
Monitor adult patterns of use through surveys such as the Behavioral Risk Factor Surveillance Survey
(BRFSS), including breakdowns by age and other demographics.
Population-based monitoring of mental health conditions through surveys such as the Behavioral
Risk Factor Surveillance System (BRFSS)
Monitor marijuana-related hospitalizations and emergency department visits.
Evaluate prevalence of cannabis use disorder and monitor trends and treatment rates, including
breakdowns by age and other demographics.
Evaluate prevalence of schizophrenia and monitor trends, including breakdowns by age and other
demographics.
Education
Public education concerning the potential cognitive and mental health effects of marijuana use.
Communicate potential risks associated with daily or near-daily use and use of potent marijuana.
Promote accurate information about cannabis use disorder.
Promote availability and access to treatment for cannabis use disorder.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
187
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0206.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
Research gaps
The Retail Marijuana Public Health Advisory Committee identifies important gaps in the scientific
literature that may impact public health policies and prevention strategies. Colorado should support
unbiased research to help fill the following research gaps identified by the committee.
Longitudinal studies on mental health and cognitive effects to assess temporality.
Expand evaluation of covariates and make proper statistical adjustments to account for their
effects.
Evaluate and provide information on the potency of marijuana in future studies and if different
potencies are involved, categorize them and conduct separate analyses.
Effects of higher potency marijuana, especially dabbing (high-dose rate).
Effects of different methods of marijuana use.
Effects of other cannabinoids, especially cannabidiol (CBD).
More on duration of impact (after various lengths of abstinence).
More studies are needed to assess the risk of increasing use or developing cannabis use disorder
among groups with different levels of use, especially among users who use less-than-weekly.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
188
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0207.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
References
1. United States Department of Health and Human Services; Substance Abuse and Mental Health
Services Administration.
Key Substance Use and Mental Health Indicators in the United States:
Results from the 2015 National Survey on Drug Use and Health.
September 2016.
2. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids.
Clin Pharmacokinet.
2003;42(4):327-360.
3. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use.
Lancet.
2009;374(9698):1383-1391.
4. American Psychiatric Association.
Diagnostic and Statistical Manual of Mental Disorders.
5th ed.
Washington , DC2013.
5. Solowij N. Cognitive Functioning of Long-term Heavy Cannabis Users Seeking Treatment.
JAMA.
2002;287(9):1123-1123.
6. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana
use.
Neurology.
2002;59(9):1337-1343.
7. Roebke PV, Vadhan NP, Brooks DJ, Levin FR. Verbal learning in marijuana users seeking treatment:
a comparison between depressed and non-depressed samples.
Am J Drug Alcohol Abuse.
2014;10.3109/00952990.2013.875551:1-6.
8. Thames AD, Arbid N, Sayegh P. Cannabis use and neurocognitive functioning in a non-clinical
sample of users.
Addict Behav.
2014;39(5):994-999.
9. Sanchez-Torres AM, Basterra V, Rosa A, et al. Lifetime cannabis use and cognition in patients with
schizophrenia spectrum disorders and their unaffected siblings.
European Archives of Psychiatry
and Clinical Neuroscience.
2013;263(8):643-653.
10. Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott A. Differential effects of Ecstasy
and cannabis on self-reports of memory ability: a web-based study.
Hum Psychopharmacol.
2001;16(8):619-625.
11. Tamm L, Epstein JN, Lisdahl KM, et al. Impact of ADHD and cannabis use on executive functioning
in young adults.
Drug Alcohol Depend.
2013;133(2):607-614.
12. Pope HG, Jr., Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance
in long-term cannabis users.
Arch Gen Psychiatry.
2001;58(10):909-915.
13. Schoeler T, Kambeitz J, Behlke I, Murray R, Bhattacharyya S. The effects of cannabis on memory
function in users with and without a psychotic disorder: findings from a combined meta-analysis.
Psychol Med.
2016;46(1):177-188.
14. Fridberg DJ, Queller S, Ahn WY, et al. Cognitive Mechanisms Underlying Risky Decision-Making in
Chronic Cannabis Users.
J Math Psychol.
2010;54(1):28-38.
15. Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological Performance in
Long-term Cannabis Users.
Arch Gen Psychiatry.
2001;58(10):909-909.
16. Smith MJ, Cobia DJ, Wang L, et al. Cannabis-related working memory deficits and associated
subcortical morphological differences in healthy individuals and schizophrenia subjects.
Schizophr
Bull.
2014;40(2):287-299.
17. Bayrakci A, Sert E, Zorlu N, Erol A, Saricicek A, Mete L. Facial emotion recognition deficits in
abstinent cannabis dependent patients.
Compr Psychiatry.
2015;58:160-164.
18. Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between
cannabis use and depression: a systematic review and meta-analysis of longitudinal studies.
Psychol
Med.
2014;44(4):797-810.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
189
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0208.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
19. Pacek LR, Martins SS, Crum RM. The bidirectional relationships between alcohol, cannabis, co-
occurring alcohol and cannabis use disorders with major depressive disorder: results from a
national sample.
J Affect Disord.
2013;148(2-3):188-195.
20. Choi NG, DiNitto DM, Marti CN. Risk Factors for Self-reported Driving Under the Influence of Alcohol
and/or Illicit Drugs Among Older Adults.
Gerontologist.
2014;10.1093/geront/gnu070.
21. Cougle JR, Hakes JK, Macatee RJ, Chavarria J, Zvolensky MJ. Quality of life and risk of psychiatric
disorders among regular users of alcohol, nicotine, and cannabis: An analysis of the National
Epidemiological Survey on Alcohol and Related Conditions (NESARC).
J Psychiatr Res.
2015;66-
67:135-141.
22. Feingold D, Weiser M, Rehm J, Lev-Ran S. The association between cannabis use and mood
disorders: A longitudinal study.
J Affect Disord.
2015;172:211-218.
23. Huijbregts SC, Griffith-Lendering MF, Vollebergh WA, Swaab H. Neurocognitive moderation of
associations between cannabis use and psychoneuroticism.
J Clin Exp Neuropsychol.
2014;36(8):794-805.
24. Schuler MS, Vasilenko SA, Lanza ST. Age-varying associations between substance use behaviors and
depressive symptoms during adolescence and young adulthood.
Drug Alcohol Depend.
2015;157:75-
82.
25. Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or
cannabis use disorders in the general population- a meta-analysis of 31 studies.
BMC Psychiatry.
2014;14(1):136.
26. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-
tetrahydrocannabinol in healthy individuals: implications for psychosis.
Neuropsychopharmacology.
2004;29(8):1558-1572.
27. Morrison PD, Zois V, McKeown DA, et al. The acute effects of synthetic intravenous Delta9-
tetrahydrocannabinol on psychosis, mood and cognitive functioning.
Psychol Med.
2009;39(10):1607-1616.
28. Morrison PD, Stone JM. Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative
symptoms which are distinct from sedation.
Hum Psychopharmacol.
2011;26(1):77-80.
29. Englund A, Atakan Z, Kralj A, Tunstall N, Murray R, Morrison P. The effect of five day dosing with
THCV on THC-induced cognitive, psychological and physiological effects in healthy male human
volunteers: A placebo-controlled, double-blind, crossover pilot trial.
J Psychopharmacol.
2016;30(2):140-151.
30. Mason O, Morgan CJ, Dhiman SK, et al. Acute cannabis use causes increased psychotomimetic
experiences in individuals prone to psychosis.
Psychol Med.
2009;39(6):951-956.
31. Morgan CJ, Rothwell E, Atkinson H, Mason O, Curran HV. Hyper-priming in cannabis users: a
naturalistic study of the effects of cannabis on semantic memory function.
Psychiatry Res.
2010;176(2-3):213-218.
32. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a
longitudinal population-based study.
Am J Epidemiol.
2002;156(4):319-327.
33. Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode
psychosis attributable to use of high potency cannabis: a case-control study.
Lancet Psychiatry.
2015;2(3):233-238.
34. Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler KS. The association between cannabis
abuse and subsequent schizophrenia: a Swedish national co-relative control study.
Psychol Med.
2015;45(2):407-414.
35. Van Dam NT, Earleywine M, DiGiacomo G. Polydrug use, cannabis, and psychosis-like symptoms.
Hum Psychopharmacol.
2008;23(6):475-485.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
190
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0209.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
36. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States
Between 2001-2002 and 2012-2013.
JAMA Psychiatry.
2015;72(12):1235-1242.
37. Lopez-Quintero C, Perez de los Cobos J, Hasin DS, et al. Probability and predictors of transition
from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National
Epidemiologic Survey on Alcohol and Related Conditions (NESARC).
Drug Alcohol Depend.
2011;115(1-2):120-130.
38. Schuermeyer J, Salomonsen-Sautel S, Price RK, et al. Temporal trends in marijuana attitudes,
availability and use in Colorado compared to non-medical marijuana states: 2003-11.
Drug Alcohol
Depend.
2014;140:145-155.
39. Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis
withdrawal.
J Abnorm Psychol.
2003;112(3):393-402.
40. Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for
marijuana dependence.
Addiction.
1999;94(9):1311-1322.
41. Budney AJ, Radonovich KJ, Higgins ST, Wong CJ. Adults seeking treatment for marijuana
dependence: a comparison with cocaine-dependent treatment seekers.
Exp Clin Psychopharmacol.
1998;6(4):419-426.
42. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol
suppresses cannabis withdrawal symptoms.
Drug Alcohol Depend.
2007;86(1):22-29.
43. Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z. Comparison of cannabis and tobacco
withdrawal: severity and contribution to relapse.
J Subst Abuse Treat.
2008;35(4):362-368.
44. Vandrey R, Budney AJ, Kamon JL, Stanger C. Cannabis withdrawal in adolescent treatment seekers.
Drug Alcohol Depend.
2005;78(2):205-210.
45. Vandrey RG, Budney AJ, Hughes JR, Liguori A. A within-subject comparison of withdrawal
symptoms during abstinence from cannabis, tobacco, and both substances.
Drug Alcohol Depend.
2008;92(1-3):48-54.
46. Vandrey RG, Budney AJ, Moore BA, Hughes JR. A cross-study comparison of cannabis and tobacco
withdrawal.
Am J Addict.
2005;14(1):54-63.
47. Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills
and motivational enhancement improves outcomes during treatment for marijuana dependence.
J
Consult Clin Psychol.
2000;68(6):1051-1061.
48. Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive-
behavioral interventions for cannabis use disorder.
J Subst Abuse Treat.
2001;21(2):55-64;
discussion 65-56.
49. Dennis M, Godley SH, Diamond G, et al. The Cannabis Youth Treatment (CYT) Study: main findings
from two randomized trials.
J Subst Abuse Treat.
2004;27(3):197-213.
50. Hendriks V, van der Schee E, Blanken P. Treatment of adolescents with a cannabis use disorder:
main findings of a randomized controlled trial comparing multidimensional family therapy and
cognitive behavioral therapy in The Netherlands.
Drug Alcohol Depend.
2011;119(1-2):64-71.
51. Rigter H, Henderson CE, Pelc I, et al. Multidimensional family therapy lowers the rate of cannabis
dependence in adolescents: a randomised controlled trial in Western European outpatient settings.
Drug Alcohol Depend.
2013;130(1-3):85-93.
52. Rooke S, Copeland J, Norberg M, Hine D, McCambridge J. Effectiveness of a self-guided web-based
cannabis treatment program: randomized controlled trial.
J Med Internet Res.
2013;15(2):e26.
53. Stanger C, Budney AJ, Kamon JL, Thostensen J. A randomized trial of contingency management for
adolescent marijuana abuse and dependence.
Drug Alcohol Depend.
2009;105(3):240-247.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
191
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0210.png
Section 2: Marijuana Use and Neurological, Cognitive and Mental Health Effects
54. Stanger C, Ryan SR, Scherer EA, Norton GE, Budney AJ. Clinic- and home-based contingency
management plus parent training for adolescent cannabis use disorders.
J Am Acad Child Adolesc
Psychiatry.
2015;54(6):445-453 e442.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
192
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0211.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Chapter 10
Marijuana Use During
Pregnancy and Breastfeeding
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0212.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
Authors
Lisa Barker, MPH
Retail Marijuana Health Monitoring, Colorado Department of Public Health and Environment
(2016)
*Teresa Foo, MD, MPH
Marijuana Clinical Guidelines Coordinator, Colorado Department of Public Health and Environment
Clinical Instructor, University of Colorado
(2014)
Reviewers
Sharon Langendoerfer, MD
Retired Pediatrician and Neonatologist, Denver Health Medical Center
(2014, 2016)
Judith Shlay, MD, MSPH
Interim Director, Denver Public Health
Professor of Family Medicine, University of Colorado School of Medicine
(2014)
*
Dr. Foo's work as a preventive medicine resident was supported by Grant Number D33HP25768 from the Health Resources and
Services Administration (HRSA). Its contents are solely the responsibility of the authors and do not necessarily represent the
official views of the HRSA
.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
194
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0213.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
Introduction
The Retail Marijuana Public Health Advisory Committee identified many important public health topics
related to marijuana and has reviewed the scientific evidence currently available regarding those
topics. This chapter includes reviews of adverse birth outcomes, effects of prenatal marijuana use on
exposed offspring later in childhood or adolescence and effects of marijuana use by breastfeeding
mothers.
Fetal development is a complex process that is dependent on conditions in the
mother’s
body. It is
sensitive to disruptions in her circulation, oxygen level, stress, hormones and other conditions and to
chemicals passed from her blood to the fetus through the placenta. Three percent of all babies born in
the United States have a birth defect.
1
Eight percent of Colorado babies are born at a low birth
weight,
2
which puts them at risk for immediate health problems as well as inhibited growth, impaired
cognitive development and chronic diseases later in life.
3
Adverse effects of alcohol and tobacco consumption during pregnancy are well-documented. Women
who smoke during pregnancy are more likely to have miscarriage and their babies are more likely to be
premature, have low birth weight, have birth defects, or die from sudden infant death syndrome.
4
Babies of mothers who use alcohol during pregnancy are more likely to have birth defects, poor
growth, and problems later in childhood with learning, memory, language, attention and coordination.
5
These known adverse effects of alcohol and tobacco use raise significant concern about the possible
effects of marijuana use during pregnancy or breastfeeding.
Analysis of 2014 Pregnancy Risk Assessment Monitoring System (PRAMS) survey data, completed for this
report, estimated that 5.7 percent of Colorado women who gave birth used marijuana during
pregnancy and 4.5 percent used marijuana after delivery despite also breastfeeding. Marijuana’s anti-
nausea properties are a prominent reason women report using it during pregnancy.
6
It is critically
important to investigate the effects of marijuana use during pregnancy on maternal and fetal health
and the effects of use during pregnancy or breastfeeding on growth and development of children
months or years after birth.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
195
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0214.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
Definitions
Anencephaly
a neural tube defect that results in underdevelopment or the absence of portions of the
brain, skull, and scalp.
Cannabidiol (CBD)
a non-psychoactive cannabinoid that is a component of marijuana.
Gastroschisis
a birth defect where the abdominal (belly) wall has failed to close properly. The
resulting hole allows the intestines to protrude outside the fetus.
Low birth weight
a baby who weighs less than birth 5.5 pounds at birth, regardless of the gestational
age.
Miscarriage
a baby born before reaching 20 weeks of pregnancy and therefore unable to survive.
Neural tube defects (NTD)
birth defects of the brain, spinal cord or spine. The defects occur in the
embryo during the first few weeks of pregnancy.
Newborn behavior issues
may include fussiness and sleep difficulties occurring during the first 28
days after birth.
Preterm delivery
- a birth that occurs more than three weeks before the baby is due
in other words,
after less than 37 weeks of pregnancy.
Psychotic symptoms
- these include auditory or visual hallucinations, difficulty separating real from
imagined, perception that self or others can read minds, perceived ability to predict the future, feeling
that an outside force is controlling thoughts or actions, fear that someone intends to harm them, belief
they have supernatural gifts, feeling emotionally unresponsive, occurrences of unclear speech or
inability to speak, or difficulty organizing thoughts to complete activities.
Ventricular septal defects
a congenital heart defect also known as a "hole in the heart." The defect
occurs when the wall (septum) that separates the right and left ventricles of the heart does not form
properly.
Small for gestational age (SGA)
a baby that is born smaller than 90 percent of babies of the same
gestational age (number of weeks of pregnancy).
Stillbirth
- the birth of a baby that has died in the womb after having reached at least 20 weeks of
pregnancy (earlier instances being regarded as abortion or miscarriage).
Sudden infant death syndrome (SIDS)
- The sudden and unexplained death of a seemingly healthy
baby less than a year old.
Tetrahydrocannabinol (THC)
- the main psychoactive component of marijuana.
Vaporization of marijuana (vaping) -
a method of marijuana use in which marijuana vapor, rather than
smoke, is inhaled. Marijuana flower or concentrate is heated in a vaporizing device (vaporizer) to a
temperature below the point of combustion, to produce vapor.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
196
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0215.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
Key findings
The
committee’s
findings about the effects of marijuana use during pregnancy fell primarily into two
broad areas - effects seen at birth and effects seen months or years after birth. Biological evidence
shows that THC, the main psychoactive component of marijuana, passes through the placenta to the
fetus, so that the unborn child is exposed to THC if the mother uses marijuana. Marijuana use during
pregnancy may be associated with an increased risk of heart defects or stillbirth. Stronger evidence
was found for negative effects that are seen months or years after birth if a
child’s
mother used
marijuana while pregnant with the child. These include decreased growth and impaired cognitive
function and attention. Decreased academic ability or increased depression symptoms may also occur.
Finally, biological evidence shows that THC passes through breast milk to a breastfeeding child.
An important note for all key findings is that the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove that the
marijuana use alone
caused
the effect. Despite the best efforts of researchers to account for
confounding factors, there may be other important factors related to
causality
that were not
identified. In addition, marijuana use was illegal everywhere in the United States prior to 1996.
Research funding, when appropriated, was commonly sought to identify adverse effects from marijuana
use. This legal fact introduces both funding bias and publication bias into the body of literature related
to marijuana use. The Retail Marijuana Public Health Advisory Committee recognizes the limitations
and biases inherent in the published literature and made efforts to ensure the information reviewed
and synthesized is reflective of the current state of medical knowledge. Where information was lacking
for whatever reason
the committee identified this knowledge gap and recommended further
research. This information will be updated as new research becomes available.
Recommendations
Health care
providers’
current collection of information on marijuana use by frequency, amount,
potency and method is limited. Adequate assessment of the link between marijuana use during
pregnancy and adverse health outcomes must begin with consistent, standardized data collection about
marijuana use from pregnant women at each pregnancy-related medical appointment and followed by
collection of accurate birth outcome data. The committee recommended public health monitoring to
help clarify the possible contribution of marijuana use to key birth outcomes.
Educational programs for pregnant women, their families, and health care providers who care for
pregnant women are needed to ensure that more information is shared about the known health effects,
and also about what is unknown at present. Routinely asking about marijuana use during pregnancy
would improve the ability of health care providers to identify and assist women who would benefit
from education about the risks to exposed offspring and therapeutic alternatives to marijuana to treat
symptoms during pregnancy. Educational materials about the potential risks of marijuana use during
pregnancy and breastfeeding should be available and distributed at marijuana dispensaries.
The committee identified several research gaps. Most topics reviewed in this chapter need further
research. Additionally, two important topics without identified research are miscarriage and placental
health. Further research is needed on the presence of THC in breast milk, its absorption and
metabolism by infants, and any resulting health effects. Additional research should be conducted
regarding the effects of different forms of marijuana (e.g., smoked, edible, tinctures), increased
marijuana potency, and cannabinoids such as cannabidiol (CBD) on the health of exposed offspring.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
197
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0216.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
For an explanation of the classifications
“Substantial,” “Moderate,”
etc., see Chapter 7. Systematic
literature review process.
Table 1 Findings summary: Marijuana use during pregnancy and breastfeeding -
effects on exposed offspring
Substantial
Moderate
Limited
Stillbirth
Insufficient
Mixed
Birth defects
including NTD,
gastroschisis
Preterm delivery
Effects on birth outcome
Isolated simple
ventricular septal
defects
Decreased birth
weight
Low birth weight
Small for
gestational age
Attention
problems
Decreased
academic ability
Psychosis
Symptoms at
adolescence
Frequency of
marijuana use
during
adolescence
Newborn
behavior issues
Effects on exposed offspring
Decreased IQ
scores in young
children
Decreased
cognitive
function
Decreased
growth
Increased
depression
symptoms
Delinquent
behavior
Future initiation
of marijuana use
Failure to show
association with
SIDS (with use
during pregnancy)
Breastfeeding and
SIDS
Breastfeeding
and infant motor
development
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
Breastfeeding
198
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0217.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
Evidence statements
Evidence statements are based on systematic scientific literature reviews performed by Colorado
Department of Public Health and Environment staff with oversight and approval by the Retail Marijuana
Public Health Advisory Committee. For an explanation of the classifications
“Substantial,” “Moderate,”
etc., see Chapter 7. Systematic literature review process. For details about the studies reviewed, see
Appendix O.
Passage of THC through the placenta
1. Biological evidence shows that THC is passed through the placentas of women who use marijuana
during pregnancy and that the fetus absorbs and metabolizes the THC and passes THC metabolites
in the meconium.
7-10
(Added
*
)
Effects of marijuana use during pregnancy on outcomes seen at birth
Stillbirth
2. We found
LIMITED
evidence that maternal use of marijuana during pregnancy is associated with an
increased risk of stillbirth.
11
Birth defects
3. We found
MIXED
evidence for whether or not maternal use of marijuana during pregnancy is
associated with birth defects.
12-14
4. We found
MIXED
evidence for whether or not maternal use of marijuana during pregnancy is
associated with neural tube defects such as anencephaly.
15-18
5. We found
MIXED
evidence for whether or not maternal use of marijuana during pregnancy is
associated with gastroschisis.
15,18,19
6. We found
LIMITED
evidence that maternal use of marijuana during pregnancy is associated with
isolated, simple ventricular septal defects (heart defects).
20
Preterm delivery or abnormal birthweight
7. We found
MIXED
evidence for whether or not maternal use of marijuana during pregnancy is
associated with preterm delivery.
12,21-27
8. We found
MIXED
evidence for whether or not maternal use of marijuana during pregnancy is
associated with decreased birth weight.
12,14,23,28-33
9. We found
MIXED
evidence for whether or not maternal use of marijuana during pregnancy is
associated with low-birth weight infants (birth weight <2,500g regardless of gestational
age).
21,24,25,27,34,35
10. We found
MIXED
evidence for whether or not maternal use of marijuana during pregnancy is
associated with infants being born small for gestational age (birth weight less than 10
th
percentile
for gestational age).
12,24,26
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix O for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
199
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0218.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
Effects of prenatal marijuana use on exposed offspring
Cognitive and academic
11. We found
MODERATE
evidence that maternal use of marijuana during pregnancy is associated with
attention problems in exposed offspring.
36-39
12. We found
MODERATE
evidence that maternal use of marijuana during pregnancy is associated with
decreased IQ scores in exposed offspring.
40,41
13. We found
MODERATE
evidence that maternal use of marijuana during pregnancy is associated with
reduced cognitive function in exposed offspring.
42-44
14. We found
LIMITED
evidence that maternal marijuana use during pregnancy is associated with
decreased academic ability of exposed offspring.
45-47
(Revised
*
)
Mental health and substance use
15. We found
LIMITED
evidence that maternal use of marijuana during pregnancy is associated with
increased depression symptoms in exposed offspring.
48
16. We found
INSUFFICIENT
evidence to determine whether or not maternal marijuana use during
pregnancy is associated with psychosis symptoms in exposed adolescent offspring.
49
17. We found
INSUFFICIENT
evidence to determine whether or not maternal marijuana use during
pregnancy is associated with initiation of marijuana use by the exposed offspring during
adolescence.
50
18. We found
MIXED
evidence for whether or not maternal marijuana use during pregnancy is
associated with frequency of marijuana use by the exposed offspring during adolescence.
50,51
Other
19. We found
MODERATE
evidence that maternal use of marijuana during pregnancy is associated with
decreased growth in exposed offspring.
52,53
20. We found
LIMITED
evidence that maternal marijuana use during pregnancy is associated with
delinquent behaviors in exposed offspring.
54
21. We found
MIXED
evidence for whether or not maternal use of marijuana during pregnancy is
associated with newborn behavior issues.
55-59
22. We found a
LIMITED
body of research that failed to show association between maternal use of
cannabis during pregnancy and SIDS.
60,61
Presence of THC in breast milk
23. Biological evidence shows that THC is present in the breast milk of women who use marijuana.
62
24. Biological evidence shows that infants who drink breast milk containing THC absorb and metabolize
the THC.
62
Effects of marijuana use while breastfeeding
25. We found
MIXED
evidence for whether or not an association exists between maternal use of
marijuana while breastfeeding and motor development in exposed infants.
63,64
26. We found
INSUFFICIENT
evidence to determine whether or not infant exposure to marijuana
(either from maternal marijuana use during breastfeeding or infant exposure to marijuana smoke)
is associated with SIDS.
60
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix O for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
200
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0219.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
Public health statements
Public health statements are plain language translations of the major findings (Evidence Statements)
from the systematic literature reviews. These statements have been officially approved by the Retail
Marijuana Public Health Advisory Committee.
1. There is no known safe amount of marijuana use during pregnancy.
2. THC can pass from mother to the unborn child through the placenta.
3. The unborn child is exposed to THC used by the mother during pregnancy.
4. Marijuana use during pregnancy may be associated with an increased risk of stillbirth.
5. Marijuana use during pregnancy may be associated with an increased risk of heart defects (isolated
simple ventricular septal defects) in exposed offspring.
6. Maternal use of marijuana during pregnancy is associated with negative effects on exposed
offspring, including decreased cognitive function and attention. These effects may not appear until
adolescence. (Revised
*
)
7. Maternal use of marijuana during pregnancy may be associated with decreased academic ability in
exposed offspring. This effect may not appear until adolescence.(Revised*)
8. Maternal use of marijuana during pregnancy is associated with negative effects on exposed
offspring, including decreased growth.
9. Marijuana use during pregnancy may be associated with increased depression symptoms and
delinquent behaviors in exposed offspring.
10. There are negative effects of marijuana use during pregnancy regardless of when it is used during
pregnancy.
11. THC can be passed from the
mother’s
breast milk, potentially affecting the baby.
Public health recommendations
Public health recommendations have been suggested and approved by the Retail Marijuana Public
Health Advisory Committee with the goals of: 1) Improving knowledge regarding population-based
health effects of retail marijuana use and 2) Developing and targeting public health education and
prevention strategies for high-risk sub populations.
Data quality issues
Standardization of data collection on frequency, amount, potency, and method of marijuana use in
medical records and other surveillance data sources.
Specify marijuana use as separate from other drug use in medical records and other surveillance
data sources.
Add blood or urine testing in addition to self-report of marijuana use among pregnant women in
Colorado.
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix O for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
201
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0220.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
Surveillance
Monitor prevalence of marijuana use by pregnant and breastfeeding women, reasons for use and
perception of risks, including breakdowns by age and other demographics.
Enhanced surveillance for birth outcomes of concern.
Collection of reported marijuana use in electronic health records, including details of use.
Education
Education for pregnant women on known risks of marijuana use during pregnancy and
breastfeeding.
Education for health care providers on known risks, prevalence of use among different patient
populations, reported reasons for use, etc.
Consider age of pregnant mother in risk reduction/educational programming.
Public education via different media platforms, including those specific for pregnant women.
Engage dispensaries as partners to post or make available educational materials about marijuana
use during pregnancy or breastfeeding.
Informational resources
Marijuana Pregnancy and Breastfeeding Guidance for Colorado Health Care Providers (CDPHE)
65
Marijuana and Your Baby (CDPHE)
66
Guidelines and recommendations
The links provided below are for additional information purposes only. The RMPHAC has not formally
reviewed these guidelines and recommendations.
American College of Obstetrics and Gynecology (ACOG)
67
The Academy of Breastfeeding Medicine (ABM)
68
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
202
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0221.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
Research gaps
The Retail Marijuana Public Health Advisory Committee identifies important gaps in the scientific
literature that may impact public health policies and prevention strategies. Colorado should support
unbiased research to help fill the following research gaps identified by the committee.
Additional study on key birth outcomes and developmental outcomes months or years after birth,
in relation to marijuana use during pregnancy.
Study the effects of marijuana use during pregnancy on placental health
Study possible association between marijuana use during pregnancy and miscarriage
Additional research on the passage of THC into breast milk and metabolism by breastfeeding
infants, including the length of time THC remains in breast milk.
Study the effects of marijuana use while breastfeeding on growth and weight gain in infants.
Study the effects of consuming marijuana edibles or vaping marijuana during pregnancy or
breastfeeding.
Impact of marijuana potency (THC content) on health effects of exposed offspring.
Effect of cannabidiol (CBD) and other cannabinoid use during pregnancy and breastfeeding
Include the reasons subjects use marijuana during pregnancy or breastfeeding in research.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
203
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0222.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
References
1. Centers for Disease Control and Prevention. Birth Defects, Data & Statistics. 2016;
https://www.cdc.gov/ncbddd/birthdefects/data.html. Accessed December 28, 2016,.
2. Colorado Department of Public Health and Environment. Low birth weight. 2016.
https://www.colorado.gov/cdphe/low-birth-weight. Accessed December 28, 2016.
3. World Health Organization and UNICEF.
Low Birthweight: Country, Regional and Global Estimates.
2004.
4. Centers for Disease Control and Prevention. Reproductive Health: Tobacco Use and Pregnancy.
2016; https://www.cdc.gov/reproductivehealth/maternalinfanthealth/tobaccousepregnancy/.
Accessed December 28, 2016.
5. Centers for Disease Control and Prevention. Fetal Alcohol Spectrum Disorders (FASDs). 2016;
https://www.cdc.gov/ncbddd/fasd/alcohol-use.html. Accessed December 28, 2016,
6. Roberson EK, Patrick WK, Hurwitz EL. Marijuana use and maternal experiences of severe nausea
during pregnancy in Hawai'i.
Hawaii J Med Public Health.
2014;73(9):283-287.
7. Joya X, Pujadas M, Falcon M, et al. Gas chromatography-mass spectrometry assay for the
simultaneous quantification of drugs of abuse in human placenta at 12th week of gestation.
Forensic Sci Int.
2010;196(1-3):38-42.
8. Marchei E, Pellegrini M, Pacifici R, et al. Quantification of Delta9-tetrahydrocannabinol and its
major metabolites in meconium by gas chromatographic-mass spectrometric assay: assay validation
and preliminary results of the "meconium project".
Ther Drug Monit.
2006;28(5):700-706.
9. ElSohly MA, Stanford DF, Murphy TP, et al. Immunoassay and GC-MS procedures for the analysis of
drugs of abuse in meconium.
J Anal Toxicol.
1999;23(6):436-445.
10. ElSohly MA, Feng S. delta 9-THC metabolites in meconium: identification of 11-OH-delta 9-THC, 8
beta,11-diOH-delta 9-THC, and 11-nor-delta 9-THC-9-COOH as major metabolites of delta 9-THC.
J
Anal Toxicol.
1998;22(4):329-335.
11. Varner MW, Silver RM, Rowland Hogue CJ, et al. Association between stillbirth and illicit drug use
and smoking during pregnancy.
Obstet Gynecol.
2014;123(1):113-125.
12. Day N, Sambamoorthi U, Taylor P, et al. Prenatal marijuana use and neonatal outcome.
Neurotoxicol Teratol.
1991;13(3):329-334.
13. Forrester MB, Merz RD. Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986-
2002.
J Toxicol Environ Health A.
2007;70(1):7-18.
14. Linn S, Schoenbaum SC, Monson RR, Rosner R, Stubblefield PC, Ryan KJ. The association of
marijuana use with outcome of pregnancy.
Am J Public Health.
1983;73(10):1161-1164.
15. David AL, Holloway A, Thomasson L, et al. A case-control study of maternal periconceptual and
pregnancy recreational drug use and fetal malformation using hair analysis.
PLoS One.
2014;9(10):e111038.
16. Shaw GM, Velie EM, Morland KB. Parental recreational drug use and risk for neural tube defects.
Am J Epidemiol.
1996;144(12):1155-1160.
17. Suarez L, Brender JD, Langlois PH, Zhan FB, Moody K. Maternal exposures to hazardous waste sites
and industrial facilities and risk of neural tube defects in offspring.
Ann Epidemiol.
2007;17(10):772-777.
18. van Gelder MM, Reefhuis J, Caton AR, et al. Maternal periconceptional illicit drug use and the risk
of congenital malformations.
Epidemiology.
2009;20(1):60-66.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
204
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0223.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
19. Forrester MB, Merz RD. Comparison of trends in gastroschisis and prenatal illicit drug use rates.
J
Toxicol Environ Health A.
2006;69(13):1253-1259.
20. Williams LJ, Correa A, Rasmussen S. Maternal lifestyle factors and risk for ventricular septal
defects.
Birth Defects Res A Clin Mol Teratol.
2004;70(2):59-64.
21. Bada HS, Das A, Bauer CR, et al. Low birth weight and preterm births: etiologic fraction
attributable to prenatal drug exposure.
J Perinatol.
2005;25(10):631-637.
22. Dekker GA, Lee SY, North RA, McCowan LM, Simpson NA, Roberts CT. Risk factors for preterm birth
in an international prospective cohort of nulliparous women.
PLoS One.
2012;7(7):e39154.
23. Fergusson DM, Horwood LJ, Northstone K, Childhood ASTALSoPa. Maternal use of cannabis and
pregnancy outcome.
BJOG.
2002;109(1):21-27.
24. Hayatbakhsh MR, Flenady VJ, Gibbons KS, et al. Birth outcomes associated with cannabis use
before and during pregnancy.
Pediatr Res.
2012;71(2):215-219.
25. Mark K, Desai A, Terplan M. Marijuana use and pregnancy: prevalence, associated characteristics,
and birth outcomes.
Arch Womens Ment Health.
2015;10.1007/s00737-015-0529-9.
26. Saurel-Cubizolles MJ, Prunet C, Blondel B. Cannabis use during pregnancy in France in 2010.
BJOG.
2014;10.1111/1471-0528.12626.
27. Shiono PH, Klebanoff MA, Nugent RP, et al. The impact of cocaine and marijuana use on low birth
weight and preterm birth: a multicenter study.
Am J Obstet Gynecol.
1995;172(1 Pt 1):19-27.
28. El Marroun H, Tiemeier H, Steegers EA, et al. Intrauterine cannabis exposure affects fetal growth
trajectories: the Generation R Study.
J Am Acad Child Adolesc Psychiatry.
2009;48(12):1173-1181.
29. English DR, Hulse GK, Milne E, Holman CD, Bower CI. Maternal cannabis use and birth weight: a
meta-analysis.
Addiction.
1997;92(11):1553-1560.
30. Fried PA, O'Connell CM. A comparison of the effects of prenatal exposure to tobacco, alcohol,
cannabis and caffeine on birth size and subsequent growth.
Neurotoxicol Teratol.
1987;9(2):79-85.
31. Gray TR, Eiden RD, Leonard KE, Connors GJ, Shisler S, Huestis MA. Identifying prenatal cannabis
exposure and effects of concurrent tobacco exposure on neonatal growth.
Clin Chem.
2010;56(9):1442-1450.
32. Hingson R, Alpert JJ, Day N, et al. Effects of maternal drinking and marijuana use on fetal growth
and development.
Pediatrics.
1982;70(4):539-546.
33. Janisse JJ, Bailey BA, Ager J, Sokol RJ. Alcohol, tobacco, cocaine, and marijuana use: relative
contributions to preterm delivery and fetal growth restriction.
Subst Abus.
2014;35(1):60-67.
34. Conner SN, Carter EB, Tuuli MG, Macones GA, Cahill AG. Maternal marijuana use and neonatal
morbidity.
Am J Obstet Gynecol.
2015;10.1016/j.ajog.2015.05.050.
35. Schempf AH, Strobino DM. Illicit drug use and adverse birth outcomes: is it drugs or context?
J
Urban Health.
2008;85(6):858-873.
36. El Marroun H, Hudziak JJ, Tiemeier H, et al. Intrauterine cannabis exposure leads to more
aggressive behavior and attention problems in 18-month-old girls.
Drug Alcohol Depend.
2011;118(2-3):470-474.
37. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior
problems at age 10.
Neurotoxicol Teratol.
2000;22(3):325-336.
38. Noland JS, Singer LT, Short EJ, et al. Prenatal drug exposure and selective attention in
preschoolers.
Neurotoxicol Teratol.
2005;27(3):429-438.
39. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An
emerging theme of a deficiency in aspects of executive function.
Neurotoxicol Teratol.
2001;23(1):1-11.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
205
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0224.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
40. Day NL, Richardson GA, Goldschmidt L, et al. Effect of prenatal marijuana exposure on the
cognitive development of offspring at age three.
Neurotoxicol Teratol.
1994;16(2):169-175.
41. Goldschmidt L, Richardson GA, Willford J, Day NL. Prenatal marijuana exposure and intelligence
test performance at age 6.
J Am Acad Child Adolesc Psychiatry.
2008;47(3):254-263.
42. Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13- to 16-year-olds
prenatally exposed to cigarettes and marihuana.
Neurotoxicol Teratol.
2003;25(4):427-436.
43. Smith AM, Fried PA, Hogan MJ, Cameron I. Effects of prenatal marijuana on response inhibition: an
fMRI study of young adults.
Neurotoxicol Teratol.
2004;26(4):533-542.
44. Willford JA, Chandler LS, Goldschmidt L, Day NL. Effects of prenatal tobacco, alcohol and
marijuana exposure on processing speed, visual-motor coordination, and interhemispheric transfer.
Neurotoxicol Teratol.
2010;32(6):580-588.
45. Fried PA, Watkinson B, Siegel LS. Reading and language in 9- to 12-year olds prenatally exposed to
cigarettes and marijuana.
Neurotoxicol Teratol.
1997;19(3):171-183.
46. Goldschmidt L, Richardson GA, Cornelius MD, Day NL. Prenatal marijuana and alcohol exposure and
academic achievement at age 10.
Neurotoxicol Teratol.
2004;26(4):521-532.
47. Goldschmidt L, Richardson GA, Willford JA, Severtson SG, Day NL. School achievement in 14-year-
old youths prenatally exposed to marijuana.
Neurotoxicol Teratol.
2012;34(1):161-167.
48. Gray KA, Day NL, Leech S, Richardson GA. Prenatal marijuana exposure: effect on child depressive
symptoms at ten years of age.
Neurotoxicol Teratol.
2005;27(3):439-448.
49. Zammit S, Thomas K, Thompson A, et al. Maternal tobacco, cannabis and alcohol use during
pregnancy and risk of adolescent psychotic symptoms in offspring.
Br J Psychiatry.
2009;195(4):294-300.
50. Porath AJ, Fried PA. Effects of prenatal cigarette and marijuana exposure on drug use among
offspring.
Neurotoxicol Teratol.
2005;27(2):267-277.
51. Day NL, Goldschmidt L, Thomas CA. Prenatal marijuana exposure contributes to the prediction of
marijuana use at age 14.
Addiction.
2006;101(9):1313-1322.
52. Cornelius MD, Goldschmidt L, Day NL, Larkby C. Alcohol, tobacco and marijuana use among
pregnant teenagers: 6-year follow-up of offspring growth effects.
Neurotoxicol Teratol.
2002;24(6):703-710.
53. Fried PA, Watkinson B, Gray R. Growth from birth to early adolescence in offspring prenatally
exposed to cigarettes and marijuana.
Neurotoxicol Teratol.
1999;21(5):513-525.
54. Day NL, Leech SL, Goldschmidt L. The effects of prenatal marijuana exposure on delinquent
behaviors are mediated by measures of neurocognitive functioning.
Neurotoxicol Teratol.
2011;33(1):129-136.
55. de Moraes Barros MC, Guinsburg R, de Araújo Peres C, Mitsuhiro S, Chalem E, Laranjeira RR.
Exposure to marijuana during pregnancy alters neurobehavior in the early neonatal period.
J
Pediatr.
2006;149(6):781-787.
56. Dreher MC, Nugent K, Hudgins R. Prenatal marijuana exposure and neonatal outcomes in Jamaica:
an ethnographic study.
Pediatrics.
1994;93(2):254-260.
57. Hayes JS, Lampart R, Dreher MC, Morgan L. Five-year follow-up of rural Jamaican children whose
mothers used marijuana during pregnancy.
West Indian Med J.
1991;40(3):120-123.
58. Lester BM, Dreher M. Effects of marijuana use during pregnancy on newborn cry.
Child Dev.
1989;60(4):765-771.
59. Richardson GA, Day N, Taylor PM. The Effect of Prenatal Alcohol, Marijuana, and Tobacco Exposure
on Neonatal Behavior.
Infant Behavior and Development.
1989;12:199-209.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
206
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0225.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
60. Klonoff-Cohen H, Lam-Kruglick P. Maternal and paternal recreational drug use and sudden infant
death syndrome.
Arch Pediatr Adolesc Med.
2001;155(7):765-770.
61. Scragg RK, Mitchell EA, Ford RP, Thompson JM, Taylor BJ, Stewart AW. Maternal cannabis use in
the sudden death syndrome.
Acta Paediatr.
2001;90(1):57-60.
62. Perez-Reyes M, Wall ME. Presence of delta9-tetrahydrocannabinol in human milk.
N Engl J Med.
1982;307(13):819-820.
63. Astley SJ, Little RE. Maternal marijuana use during lactation and infant development at one year.
Neurotoxicol Teratol.
1990;12(2):161-168.
64. Tennes K, Avitable N, Blackard C, et al. Marijuana: prenatal and postnatal exposure in the human.
NIDA Res Monogr.
1985;59:48-60.
65. Colorado Department of Public Health and Environment. Marijuana Pregnancy and Breastfeeding
Guidance For Colorado Health Care Providers.
https://www.colorado.gov/pacific/sites/default/files/MJ_RMEP_Pregnancy-Breastfeeding-Clinical-
Guidelines.pdf.
66. Colorado Department of Public Health and Environment. Marijuana and Your Baby.
https://www.colorado.gov/pacific/sites/default/files/MJ_RMEP_Factsheet-Pregnancy-
Breastfeeding.pdf.
67. The American College of Obstetricians and Gynecologists Committee Opinion. Marijuana Use During
Pregnancy and Lactation. 2015, http://www.acog.org/Resources-And-Publications/Committee-
Opinions/Committee-on-Obstetric-Practice/Marijuana-Use-During-Pregnancy-and-Lactation(637).
68. Reece-Stremtan S, Marinelli KA. ABM clinical protocol #21: guidelines for breastfeeding and
substance use or substance use disorder, revised 2015.
Breastfeed Med.
2015;10(3):135-141.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
207
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0226.png
Section 2: Marijuana Use During Pregnancy and Breastfeeding
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
208
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0227.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Chapter 11
Marijuana Use and Respiratory
Effects
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0228.png
Section 2: Marijuana Use and Respiratory Effects
Authors
Ken Gershman, MD, MPH
Manager
Marijuana Research Grants Program, Colorado Department of Public Health and Environment
(2016)
Elyse Contreras, MPH
Coordinator
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2016)
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2016)
Todd Carlson, MD
Internal Medicine Resident, University of Colorado
(2014)
Mike Van Dyke, PhD, CIH
Chief
Environmental Epidemiology, Occupational Health and Toxicology Branch, Colorado Department of
Public Health and Environment
(2014)
Reviewers
Judith Shlay, MD, MSPH
Interim Director, Denver Public Health
Professor of Family Medicine, University of Colorado School of Medicine
(2016)
Russell Bowler, MD, PhD
Professor of Medicine, National Jewish Health and University of Colorado Anschutz Medical Campus
(2014)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
210
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0229.png
Section 2: Marijuana Use and Respiratory Effects
Introduction
The Retail Marijuana Public Health Advisory Committee identified many important public health topics
related to marijuana and has reviewed the scientific evidence currently available regarding those
topics. This chapter includes reviews of respiratory diseases like chronic obstructive pulmonary disease
(COPD), chronic bronchitis and asthma, respiratory infections and lung function relative to smoked
marijuana, as well as potential health effects of vaporized marijuana.
Respiratory diseases and illnesses are a major burden in both health impact and financial cost in the
United States. COPD, a progressive lung disease, is the third leading cause of death in the United
States.
1
In Colorado, it is estimated that in 2010 there were more than 120,000 adults being treated for
COPD with a total medical treatment cost over $735 million.
2
Asthma affects even more Colorado
residents, estimated at more than 450,000 in 2012.
3
The financial cost of asthma in the United States
in 2007 was estimated at $56 billion.
4
Inhalation of combustion products, from tobacco smoking to wood-burning stoves, has consistently
been associated with respiratory diseases.
5,6
For example, tobacco smoking is known to be the most
common cause of COPD.
7
The U.S. National Health and Nutrition Examination Survey (NHANES) recently
found that daily marijuana users have higher levels of toxic combustion by-products than non-users.
8
Furthermore, exposure to harmful products from smoking marijuana may be exacerbated by the way a
marijuana joint is typically smoked, with deep and prolonged inhalation and no filter. Investigating the
long-term respiratory effects of smoking marijuana is very important.
Marijuana vaporizing (vaping) is increasing in popularity as an alternative to smoking marijuana.
9
Marijuana users in two separate surveys believed vaporizing marijuana to be less harmful or “healthier”
than smoking marijuana.
9,10
It is important to identify the potential harms from vaporized marijuana
relative to not using marijuana and also to compare them with the potential harms from smoked
marijuana.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
211
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0230.png
Section 2: Marijuana Use and Respiratory Effects
Definitions
Levels of marijuana use
Daily or near-daily use: 5-7 days/week.
Weekly use: 1-4 days/week.
Less-than-weekly use: less than 1 day/week.
Acute use: marijuana used within the past few hours, such that the short-term effects or symptoms
are still being experienced.
Bullous lung disease
- destruction of lung tissue causing pockets of air to replace lung tissue,
diagnosed by imaging.
Chronic bronchitis
- a long term cough with sputum production that is diagnosed by symptoms.
Chronic obstructive pulmonary disease (COPD) -
a severe form of small airway obstruction
characterized by long-term poor airflow from the lungs, with common symptoms including of shortness
of breath and cough with sputum production, diagnosed by pulmonary function tests.
Combustion by-products
chemicals produced when a material is burned. These chemicals including
carbon monoxide and polycyclic aromatic hydrocarbons.
Dabbing
a method of marijuana use where a "dab" (small amount) of marijuana concentrate is placed
on a pre-heated surface, creating concentrated marijuana vapor to be inhaled.
Emphysema
- the breakdown of lung tissue, typically causing air trapping, poor airflow and shortness
of breath, diagnosed by imaging.
Pneumothorax
- the collapse of a lung caused by air or fluid filling up the space around the lung, an
emergency condition diagnosed by physical exam and/or imaging.
Polycyclic aromatic hydrocarbons -
a group of more than 100 different chemicals released from
burning coal, oil, gasoline, trash, tobacco, wood, or other organic substances.
Pulmonary function (tests)
- measurements that show how well the lungs move air in and out and how
well they exchange oxygen and carbon dioxide with the blood.
Small airway obstruction
- a condition causing air to be trapped in the lungs, making it difficult to
breathe the air out to make room for the next breath, diagnosed by pulmonary function tests.
Tetrahydrocannabinol (THC) -
the main psychoactive component of marijuana.
Vaporization of marijuana (vaping) -
a method of marijuana use in which marijuana vapor, rather than
smoke, is inhaled. Marijuana flower or concentrate is heated in a vaporizing device (vaporizer) to a
temperature below the point of combustion, to produce vapor.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
212
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0231.png
Section 2: Marijuana Use and Respiratory Effects
Key findings
The committee found strong evidence for an association between daily or near-daily marijuana use and
chronic bronchitis with cough, wheezing and sputum production. Additionally, daily or near-daily
marijuana use may be associated with bullous lung disease and pneumothorax in individuals younger
than 40 years of age. Research is lacking on other aspects of lung health related to marijuana use.
There is conflicting research regarding small airway obstruction and research is lacking concerning any
possible association between marijuana use and COPD, emphysema or respiratory infections. A notable
effect of acute use is a short-term improvement in lung airflow; however, evidence for long term
benefits is lacking. Finally, smoked marijuana may deposit more particulate matter in the lungs per
puff than tobacco smoking, and smokers who switch from marijuana smoking to marijuana vaporizing
may have fewer respiratory symptoms and improved pulmonary function.
An important note for all key findings is that the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove that the
marijuana use alone
caused
the effect. Despite the best efforts of researchers to account for
confounding factors, there may be other important factors related to
causality
that were not
identified. In addition, marijuana use was illegal everywhere in the United States prior to 1996.
Research funding, when appropriated, was commonly sought to identify adverse effects from marijuana
use. This legal fact introduces both funding bias and publication bias into the body of literature related
to marijuana use. The Retail Marijuana Public Health Advisory Committee recognizes the limitations
and biases inherent in the published literature and made efforts to ensure the information reviewed
and synthesized is reflective of the current state of medical knowledge. Where information was lacking
for whatever reason
the committee identified this knowledge gap and recommended further
research. This information will be updated as new research becomes available.
Recommendations
Recommendations from the committee reflect the need for improvement and standardization of data
collection. Information on frequency, amount, potency and method of marijuana use should be
collected consistently in both clinical settings and public health surveillance tools. Determinations of
cumulative marijuana exposure also need improvement. Better quality measures of recent marijuana
use should be used, such as blood THC levels or urinary metabolites instead of self-reported marijuana
use. Public health should use data available in the Colorado Central Cancer Registry to monitor new
cases of lung cancer. Additionally, monitoring for the prevalence of more chronic conditions such as
COPD and asthma should be conducted in collaboration with the Colorado Hospital Association (CHA)
and the All-Payer Claims Database available through the Center for Improving Value in Health Care
(CIVHC). Educational opportunities exist with both primary and specialized health care providers
regarding the potential adverse health effects related to marijuana use and respiratory disease,
including the importance of understanding the possible additive risks to lung health related to smoking
both tobacco and marijuana.
Research gaps identified include the need for studies of COPD and lung function, including improved
methods to assess cumulative marijuana exposure, older age groups, and adequate numbers of non-
tobacco smokers to eliminate the confounding introduced by tobacco smoking. Prospective studies of
groups of marijuana users, monitoring lung function and symptoms over long time periods, are needed
to clarify relationships between long-term marijuana use and respiratory diseases. Additional research
on the potential respiratory effects of different methods of marijuana use (including vaporizing and
dabbing) is needed to assess the long-term safety of these methods.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
213
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0232.png
Section 2: Marijuana Use and Respiratory Effects
Table 1 Findings summary: Marijuana use and respiratory effects
For an explanation of the classifications “Substantial,” “Moderate,” etc., see Chapter 7. Systematic
literature review process.
Substantial
Chronic
bronchitis with
cough/wheeze/
sputum
Moderate
Limited
More
particulate
matter deposits
compared to
tobacco
Insufficient
COPD
Mixed
Long-term daily
or near-daily
marijuana use
associated with
airway
obstruction
Smoked marijuana
Acute use
improves airflow
Failure to show
association
between less-
than-weekly
marijuana use
and airway
obstruction
Bullous lung
disease and
pneumothorax
under 40 years
of age
Fewer
symptoms and
improved lung
function after
switching to
vaporizing
Emphysema
Respiratory
infections
Health effects
of vaporized
marijuana
Vaporized marijuana
Effects of
vaporized
marijuana on
asthma
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
214
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0233.png
Section 2: Marijuana Use and Respiratory Effects
Evidence statements
Evidence statements are based on systematic scientific literature reviews performed by Colorado
Department of Public Health and Environment staff with oversight and approval by the Retail Marijuana
Public Health Advisory Committee. For an explanation of the
classifications “Substantial,” “Moderate,”
etc., see Chapter 7. Systematic literature review process. For details about the studies reviewed, see
Appendix P.
Smoked marijuana
1. We found
LIMITED
evidence that smoking marijuana deposits more particulate matter per puff in
the lungs compared to tobacco smoke.
11
2. We found
SUBSTANTIAL
evidence that daily or near-daily marijuana smoking is associated with
chronic bronchitis, including chronic cough, sputum production, and wheezing.
12-20
3. We found
INSUFFICIENT
evidence to determine whether or not smoking marijuana is associated
with chronic obstructive pulmonary disease (COPD).
20,23
(Revised
*
)
4. We found
INSUFFICIENT
evidence to determine whether or not smoking marijuana is associated
with emphysema.
16
5. We found a
LIMITED
body of research that failed to show an association between less-than-weekly
marijuana smoking and small airway obstruction.
19,22-25
(Added*)
6. We found
MIXED
evidence for whether or not long-term, daily or near-daily marijuana smoking is
associated with small airway obstruction.
12,14-16,18-20,26
(Revised*)
7. We found
LIMITED
evidence that daily or near-daily marijuana smoking is associated with bullous
lung disease leading to pneumothorax in individuals younger than 40 years of age.
27-30
(Revised*)
8. We found
INSUFFICIENT
evidence to determine whether or not smoking marijuana is associated
with increased risk of respiratory infections.
17,31
9. We found
SUBSTANTIAL
evidence that marijuana use (inhaled or oral) results in an immediate
short-term improvement of lung airflow.
32-34
Vaporized marijuana
10. We found
INSUFFICIENT
evidence to determine whether or not vaporizing marijuana is associated
with long-term respiratory health effects
35
.
11. We found
LIMITED
evidence that after one month, weekly or daily marijuana smokers who switched
to vaporizing had fewer respiratory symptoms and improved pulmonary function.
36,37
(Added*)
12. We found
INSUFFICIENT
evidence to determine whether or not marijuana vaporization affects
asthma symptoms. (Added*)
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix P for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
215
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0234.png
Section 2: Marijuana Use and Respiratory Effects
Public health statements
Public health statements are plain language translations of the major findings (Evidence Statements)
from the systematic literature reviews. These statements have been officially approved by the Retail
Marijuana Public Health Advisory Committee.
1. Marijuana smoke may deposit more particulate matter in the lungs per puff compared to tobacco
smoke.
2. Daily or near-daily marijuana smoking is strongly associated with chronic bronchitis, including
chronic cough, sputum production and wheezing.
3. There is conflicting research on whether or not long-term daily or near-daily marijuana smoking is
associated with decreased airflow from the lungs. (Revised
*
)
4. Daily or near-daily marijuana smoking may be associated with a specific type of lung damage called
bullous lung disease, resulting in a collapsed lung, in individuals younger than 40 years of age.
5. One-time marijuana use (edible or smoked) is strongly associated with immediate, short-term (1 to
6 hours) improved airflow in the lungs.
6. Compared with weekly or daily marijuana smoking, short-term marijuana vaporizing (vaping) may
be associated with fewer respiratory symptoms and improved pulmonary function. (Added*)
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix P for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
216
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0235.png
Section 2: Marijuana Use and Respiratory Effects
Public health recommendations
Public health recommendations have been suggested and approved by the Retail Marijuana Public
Health Advisory Committee with the goals of: 1) Improving knowledge regarding population-based
health effects of retail marijuana use and 2) Developing and targeting public health education and
prevention strategies for high-risk sub populations.
Data quality issues
Include marijuana use on questionnaires completed during spirometry and pulmonary function
testing, including method of use, frequency, amount and potency.
Improved measures to determine cumulative marijuana exposure.
Better quality measures of recent marijuana use, such as blood THC levels or urinary metabolites
instead of self-reported cannabis use.
Surveillance
Monitor statewide prevalence of COPD, asthma and other respiratory diseases through existing
population-based surveys.
Monitor health care utilization related to respiratory disorders using Colorado Hospital Association
and/or All-Payer Claims databases.
Education
Public education on marijuana use and chronic respiratory diseases.
Public education on the potential for additive risks to lung health related to smoking both tobacco
and marijuana.
Public education that smoking marijuana is not a long-term treatment for asthma.
Research gaps
The Retail Marijuana Public Health Advisory Committee identifies important gaps in the scientific
literature that may impact public health policies and prevention strategies. Colorado should support
unbiased research to help fill the following research gaps identified by the committee.
Improved studies of COPD and lung function related to marijuana use, especially including
adequate numbers of non-tobacco smokers, assessment of cumulative marijuana exposure, and
older age groups.
Prospective studies of groups of marijuana users’ lung function and symptoms over time.
Improved studies of bullous lung disease to better define its relationship to marijuana use.
Research on the potential respiratory effects of different methods of marijuana use, including
vaporizing and dabbing.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
217
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0236.png
Section 2: Marijuana Use and Respiratory Effects
References
1. American Lung Association. Lung Health & Diseases, COPD. 2016; http://www.lung.org/lung-
health-and-diseases/lung-disease-lookup/copd/?referrer=https://www.google.com/. Accessed
December 19, 2016,.
2. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and
absenteeism costs of COPD among adults aged >/= 18 years in the United States for 2010 and
projections through 2020.
Chest.
2015;147(1):31-45.
3. American Lung Association EaSU.
Estimated Prevalence and Incidence of Lung Disease.
May 2014
2014.
4. Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007.
J Allergy Clin
Immunol.
2011;127(1):145-152.
5. Centers for Disease Control and Prevention. Smoking & Tobacco Use, Health Effects of Cigarette
Smoking. 2016;
https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/effects_cig_smoking/.
Accessed December 21, 2016, 2016.
6. Naeher LP, Brauer M, Lipsett M, et al. Woodsmoke health effects: a review.
Inhal Toxicol.
2007;19(1):67-106.
7. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease.
Lancet.
2012;379(9823):1341-1351.
8. Wei B, Alwis KU, Li Z, et al. Urinary concentrations of PAH and VOC metabolites in marijuana users.
Environ Int.
2016;88:1-8.
9. Lee DC, Crosier BS, Borodovsky JT, Sargent JD, Budney AJ. Online survey characterizing vaporizer
use among cannabis users.
Drug Alcohol Depend.
2016;159:227-233.
10. Malouff JM, Rooke SE, Copeland J. Experiences of marijuana-vaporizer users.
Subst Abus.
2014;35(2):127-128.
11. Wu TC, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared with
tobacco.
N Engl J Med.
1988;318(6):347-351.
12. Bloom JW, Kaltenborn WT, Paoletti P, Camilli A, Lebowitz MD. Respiratory effects of non-tobacco
cigarettes.
Br Med J (Clin Res Ed).
1987;295(6612):1516-1518.
13. Roth MD, Arora A, Barsky SH, Kleerup EC, Simmons M, Tashkin DP. Airway inflammation in young
marijuana and tobacco smokers.
Am J Respir Crit Care Med.
1998;157(3 Pt 1):928-937.
14. Sherrill DL, Krzyzanowski M, Bloom JW, Lebowitz MD. Respiratory effects of non-tobacco
cigarettes: a longitudinal study in general population.
Int J Epidemiol.
1991;20(1):132-137.
15. Tashkin DP, Coulson AH, Clark VA, et al. Respiratory symptoms and lung function in habitual heavy
smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and
nonsmokers.
Am Rev Respir Dis.
1987;135(1):209-216.
16. Aldington S, Williams M, Nowitz M, et al. Effects of cannabis on pulmonary structure, function and
symptoms.
Thorax.
2007;62(12):1058-1063.
17. Moore BA, Augustson EM, Moser RP, Budney AJ. Respiratory effects of marijuana and tobacco use in
a U.S. sample.
J Gen Intern Med.
2005;20(1):33-37.
18. Taylor DR, Poulton R, Moffitt TE, Ramankutty P, Sears MR. The respiratory effects of cannabis
dependence in young adults.
Addiction.
2000;95(11):1669-1677.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
218
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0237.png
Section 2: Marijuana Use and Respiratory Effects
19. Kempker JA, Honig EG, Martin GS. The effects of marijuana exposure on expiratory airflow. A study
of adults who participated in the U.S. National Health and Nutrition Examination Study.
Ann Am
Thorac Soc.
2015;12(2):135-141.
20. Macleod J, Robertson R, Copeland L, McKenzie J, Elton R, Reid P. Cannabis, tobacco smoking, and
lung function: a cross-sectional observational study in a general practice population.
Br J Gen
Pract.
2015;65(631):e89-95.
21. Tashkin DP, Shapiro BJ, Lee YE, Harper CE. Subacute effects of heavy marihuana smoking on
pulmonary function in healthy men.
N Engl J Med.
1976;294(3):125-129.
22. Hancox RJ, Poulton R, Ely M, et al. Effects of cannabis on lung function: a population-based cohort
study.
Eur Respir J.
2010;35(1):42-47.
23. Tan WC, Lo C, Jong A, et al. Marijuana and chronic obstructive lung disease: a population-based
study.
CMAJ.
2009;180(8):814-820.
24. Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary
function over 20 years.
JAMA.
2012;307(2):173-181.
25. Taylor DR, Fergusson DM, Milne BJ, et al. A longitudinal study of the effects of tobacco and
cannabis exposure on lung function in young adults.
Addiction.
2002;97(8):1055-1061.
26. Tashkin DP, Simmons MS, Sherrill DL, Coulson AH. Heavy habitual marijuana smoking does not cause
an accelerated decline in FEV1 with age.
Am J Respir Crit Care Med.
1997;155(1):141-148.
27. Beshay M, Kaiser H, Niedhart D, Reymond MA, Schmid RA. Emphysema and secondary
pneumothorax in young adults smoking cannabis.
Eur J Cardiothorac Surg.
2007;32(6):834-838.
28. Hii SW, Tam JD, Thompson BR, Naughton MT. Bullous lung disease due to marijuana.
Respirology.
2008;13(1):122-127.
29. Johnson MK, Smith RP, Morrison D, Laszlo G, White RJ. Large lung bullae in marijuana smokers.
Thorax.
2000;55(4):340-342.
30. Fiorelli A, Accardo M, Vicidomini G, Messina G, Laperuta P, Santini M. Does cannabis smoking
predispose to lung bulla formation?
Asian Cardiovasc Thorac Ann.
2014;22(1):65-71.
31. Polen MR, Sidney S, Tekawa IS, Sadler M, Friedman GD. Health care use by frequent marijuana
smokers who do not smoke tobacco.
West J Med.
1993;158(6):596-601.
32. Tashkin DP, Shapiro BJ, Frank IM. Acute pulmonary physiologic effects of smoked marijuana and
oral 9 -tetrahydrocannabinol in healthy young men.
N Engl J Med.
1973;289(7):336-341.
33. Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and oral delta9-
tetrahydrocannabinol on specific airway conductance in asthmatic subjects.
Am Rev Respir Dis.
1974;109(4):420-428.
34. Tashkin DP, Shapiro BJ, Lee YE, Harper CE. Effects of smoked marijuana in experimentally induced
asthma.
Am Rev Respir Dis.
1975;112(3):377-386.
35. Gieringer D. Waterpipe Study.
Multidisciplinary Assocation for Psycheldelic Studies (MAPS).
1996;6(3).
36. Earleywine M, Barnwell SS. Decreased respiratory symptoms in cannabis users who vaporize.
Harm
Reduct J.
2007;4:11.
37. Van Dam NT, Earleywine M. Pulmonary function in cannabis users: Support for a clinical trial of the
vaporizer.
Int J Drug Policy.
2010;21(6):511-513.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
219
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0238.png
Section 2: Marijuana Use and Respiratory Effects
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
220
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0239.png
Section 2
Scientific Literature
Review on Potential
Health Effects of
Marijuana Use
Chapter 12
Unintentional Marijuana
Exposures in Children
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0240.png
Section 2: Unintentional Marijuana Exposures in Children
Authors
Lisa Barker, MPH
Retail Marijuana Health Monitoring, Colorado Department of Public Health and Environment
(2016)
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
(2016)
George Sam Wang, MD
Assistant Professor, University of Colorado Anschutz Medical Campus
Emergency Medicine Physician and Medical Toxicologist, Children’s Hospital Colorado
Volunteer Faculty, Rocky Mountain Poison and Drug Center
(2016)
Reviewers
Judith Shlay, MD, MSPH
Interim Director, Denver Public Health
Professor of Family Medicine, University of Colorado School of Medicine
(2016)
George Sam Wang, MD
Assistant Professor, University of Colorado Anschutz Medical Campus
Emergency Medicine Physician and Medical Toxicologist, Children’s Hospital Colorado
Volunteer Faculty, Rocky Mountain Poison and Drug Center
(2014)
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
222
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0241.png
Section 2: Unintentional Marijuana Exposures in Children
Introduction
The Retail Marijuana Public Health Advisory Committee identified many important public health topics
related to marijuana use and has reviewed the scientific evidence currently available regarding those
topics. This chapter includes reviews of unintentional marijuana exposure relative to marijuana
legalization and child-resistant packaging.
In 2014, the Rocky Mountain Poison and Drug Center
*
(RMPDC) received nearly 25,000 calls about
children under age five who had accidentally eaten or been exposed to medications or chemicals.
1
About one-third of RMPDC calls are referred to receive medical care. Parents and caregivers know that
very young children naturally put things in their mouths, and, as they get older, eat things they mistake
for candy or food they like. Many edible marijuana products are made by adding concentrated THC to
existing foods that look exactly like foods or candies a child might normally eat. Medical providers
report that children who ingest marijuana can experience loss of coordination, trouble breathing,
difficulty waking up, or even coma.
2
Analysis of 2014 and 2015 Colorado Child Health Survey data,
completed for this report, estimated that approximately 14,000 homes in Colorado had children 1-14
years old and marijuana in the home with potentially unsafe storage. It is important to investigate the
extent and impact of unintentional marijuana exposures, especially in children.
Definitions
Tetrahydrocannabinol (THC)
the main psychoactive component of marijuana.
Unintentional marijuana exposures
ingesting a substance without knowing that it contains THC or
other cannabinoids, more commonly observed with edible marijuana products.
Key findings
Findings from this review have important implications. The committee found strong evidence that more
unintentional marijuana exposures of children occur in states with increased legal access to marijuana,
and that the exposures can lead to significant clinical effects requiring hospitalization. Additionally,
evidence shows that child resistant packaging prevents exposure to children from potentially harmful
substances.
An important note for all key findings is that the available research evaluated the
association
between
marijuana use and potential adverse health outcomes. This
association
does not prove that the
marijuana use alone
caused
the effect. Despite the best efforts of researchers to account for
confounding factors, there may be other important factors related to
causality
that were not
identified. In addition, marijuana use was illegal everywhere in the United States prior to 1996.
Research funding, when appropriated, was commonly sought to identify adverse effects from marijuana
use. This legal fact introduces both funding bias and publication bias into the body of literature related
to marijuana use. The Retail Marijuana Public Health Advisory Committee recognizes the limitations
and biases inherent in the published literature and made efforts to ensure the information reviewed
and synthesized is reflective of the current state of medical knowledge. Where information was lacking
for whatever reason
the committee identified this knowledge gap and recommended further
research. This information will be updated as new research becomes available.
*
See Section 3, Chapter 1 Rocky Mountain Poison and Drug Center data for analyses of calls related to marijuana.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
223
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0242.png
Section 2: Unintentional Marijuana Exposures in Children
Recommendations
As in many other medical specialties, there is a critical need to collect complete data on amount, type
and potency of marijuana product ingested. For pediatric exposures, this data is critical for clinical
management if emergency medical services or hospitalization is needed. It is also valuable for future
research. Continued monitoring of data on poison center calls, emergency room visits and
hospitalizations will provide prevalence data on unintentional exposures in the pediatric population.
The committee identified multiple opportunities to educate parents and caregivers about safe adult
use and safe storage. Further research is needed on unintentional marijuana exposures in children,
including the impact of various environmental factors, beliefs, laws and regulations. Examples of
possible research topics include the effects of child-resistant packaging requirements, point-of-sale
education, marijuana marketing and perception of harm.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
224
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0243.png
Section 2: Unintentional Marijuana Exposures in Children
Table 1 Findings summary: Unintentional marijuana exposures in children
For an explanation of the classifications
“Substantial,” “Moderate,” etc., see Chapter 7. Systematic
literature review process.
Substantial
Legal marijuana
access increases
unintentional
marijuana
exposures in
children
Moderate
Child-resistant
packaging
reduces
unintentional
pediatric
poisonings
Limited
Insufficient
Mixed
Evidence statements
Evidence statements are based on systematic scientific literature reviews performed by Colorado
Department of Public Health and Environment staff with oversight and approval by the Retail Marijuana
Public Health Advisory Committee.
For an explanation of the classifications “Substantial,” “Moderate,”
etc., see Chapter 7. Systematic literature review process. For details about the studies reviewed, see
Appendix Q.
1. We found
SUBSTANTIAL
evidence that more unintentional marijuana exposures among children
occur in states with increased legal access to marijuana; and that the exposures can lead to
significant clinical effects requiring medical attention.
3-5
(Revised*)
2. We found
MODERATE
evidence that the use of child-resistant packaging reduces unintentional
pediatric poisonings from a wide range of hazardous household products including pharmaceutical
products.
6-8
Public health statements
Public health statements are plain language translations of the major findings (Evidence Statements)
from the systematic literature reviews. These statements have been officially approved by the Retail
Marijuana Public Health Advisory Committee.
1. Legal marijuana access is strongly associated with increased numbers of unintentional exposures in
children which can lead to hospitalizations. (Revised
*
)
2. While little data are available for marijuana, evidence indicates that child resistant packaging
prevents exposure to children from potentially harmful substances.
Revised = the statement has been adjusted since the 2014 edition of the report, due to new evidence. Added = the statement is
new since the 2014 edition of the report. See Appendix Q for dates of most recent literature review.
*
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
225
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0244.png
Section 2: Unintentional Marijuana Exposures in Children
Public health recommendations
Public health recommendations have been suggested and approved by the Retail Marijuana Public
Health Advisory Committee with the goals of: 1) Improving knowledge regarding population-based
health effects of retail marijuana use and 2) Developing and targeting public health education and
prevention strategies for high-risk sub populations.
Data quality issues
Data collection in cases of unintentional marijuana exposure should include amount, type and
potency of the marijuana when possible.
Surveillance
Monitor pediatric emergency department visits, hospitalizations and poison center calls resulting
from unintentional marijuana exposure.
Education
Educate parents and caregivers about keeping marijuana and marijuana products away from
children and using child resistant packaging.
Research gaps
The Retail Marijuana Public Health Advisory Committee identifies important gaps in the scientific
literature that may impact public health policies and prevention strategies. Colorado should support
unbiased research to help fill the following research gaps identified by the committee.
Studies are needed to evaluate the impact of various environmental factors, beliefs, laws and
regulations on unintentional marijuana exposure. These studies should include specific factors such
as perception of harm, marijuana marketing, point-of-sale education and marijuana packaging
requirements.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
226
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0245.png
Section 2: Unintentional Marijuana Exposures in Children
References
1. Rocky Mountain Poison & Drug Center (RMPDC).
Colorado 2014 Annual Report.
2015.
2. Children's Hospital Colorado. Acute Marijuana Intoxication. 2016;
https://www.childrenscolorado.org/conditions-and-advice/conditions-and-
symptoms/conditions/acute-marijuana-intoxication/. Accessed December 23, 2016,
3. Wang GS, Roosevelt G, Le Lait MC, et al. Association of unintentional pediatric exposures with
decriminalization of marijuana in the United States.
Ann Emerg Med.
2014;63(6):684-689.
4. Onders B, Casavant MJ, Spiller HA, Chounthirath T, Smith GA. Marijuana Exposure Among Children
Younger Than Six Years in the United States.
Clin Pediatr (Phila).
2015;10.1177/0009922815589912.
5. Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state.
JAMA
Pediatr.
2013;167(7):630-633.
6. Breault HJ. Five years with 5 million child-resistant containers.
Clin Toxicol.
1974;7(1):91-95.
7. Clarke A, Walton WW. Effect of safety packaging on aspirin ingestion by children.
Pediatrics.
1979;63(5):687-693.
8. Rodgers GB. The effectiveness of child-resistant packaging for aspirin.
Arch Pediatr Adolesc Med.
2002;156(9):929-933.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
227
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0246.png
Section 2: Unintentional Marijuana Exposures in Children
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
228
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0247.png
Section 3
Monitoring Possible
Marijuana-Related
Health Effects in
Colorado
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0248.png
Section 3: Monitoring Possible Marijuana-Related Health Effects in Colorado
Background
This chapter presents efforts of the Colorado Department of Public Health and Environment (CDPHE) to
monitor the potential population-based health effects of legalized marijuana. Through 25-1.5-110,
C.R.S., CDPHE was given statutory authority to:
“...collect
Colorado-specific data that reports adverse health events involving marijuana use from
the all-payer
claims database, hospital discharge data, and behavioral risk factors.”
The purpose of this data collection and analysis was stated in 25-1.5-110 C.R.S.
to “...monitor
the
emerging science and medical information relevant to the health effects associated with marijuana
use.” The data analyses reported in this chapter were reviewed by the Retail
Marijuana Public Health
Advisory Committee as outlined in 25-1.5-110 C.R.S.
to help “...make
recommendations as appropriate,
for policies intended to protect consumers of marijuana or
marijuana products and the general public.”
This chapter focuses on the analysis of the two primary public health datasets used to monitor: 1)
exposures to drugs and other toxic substances and 2) hospital and emergency department use.
We analyzed the data in this chapter using the following four time periods that reflect the status of
marijuana legalization in Colorado:
2000
prior to legalized medical marijuana
2001-2009
medical marijuana legalized
2010-2013
medical marijuana commercialized
2014-2016
retail (recreational) marijuana legalized
Data sources
Rocky Mountain Poison and Drug Center data
The Rocky Mountain Poison and Drug Center (RMPDC) provides medical information to health care
providers and the public to reduce toxicity, injury, and disease related to exposures of all kinds.
RMPDC has been providing information and assistance to Colorado and the surrounding region for more
than 50 years. RMPDC participates in the American Association of Poison Control Centers’ National
Poison Data System (NPDS). RMPDC and NPDS information is used by public health, pharmaceutical and
medical institutions for research, education and prevention initiatives in Colorado and throughout the
nation. Poison center call volume data are typically used as a surrogate data source to determine the
potential for adverse health effects from exposure to chemicals, environmental agents, biotoxins and
drugs. RMPDC data is one of the few near “real-time” data sources available to public health
professionals. In this report marijuana exposure calls to RMPDC were examined from 2000 to 2016 to
examine potential trends in relation to marijuana legalization periods.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
230
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0249.png
Section 3: Monitoring Possible Marijuana-Related Health Effects in Colorado
Colorado Hospital Association data
The Colorado Hospital Association (CHA) collects data on hospitalizations and emergency department
(ED) visits from participating hospitals in Colorado. The data include patient demographics, admit and
discharge dates, and discharge diagnoses/billing codes and procedure codes. CHA has about 100
member hospitals, the vast majority of hospitals in Colorado. However, the database does not include
inpatient mental health facilities, ambulatory surgical centers, long-term care facilities, military
hospitals, and other outpatient treatment settings. The CHA dataset was used to investigate rates of
hospitalizations and ED visits with marijuana-related billing codes.
Summary of key findings
The most prominent findings from Rocky Mountain Poison and Drug Center and Colorado Hospital
Association data are described below. For additional results and details, see the individual chapters for
RMPDC (page 239) and CHA (page 251).
RMPDC data
From 2000 to 2009, RMPDC marijuana exposure call volume remained fairly constant. In 2010, total
annual marijuana exposure calls doubled, from 44 to 93. From 2010 to 2013, there was a slight
additional increase in counts of marijuana exposure calls. Another large increase was seen in 2014,
from 127 to 222. There were 229 marijuana exposure calls in 2015 and 201 in 2016. Most of these
changes were due to calls involving marijuana only, with only a small increase in calls involving
marijuana and other substances together.
For children ages 0-8 years, marijuana exposure calls averaged 5 per year from 2000 to 2009. They
peaked in 2015 at 48 calls and dropped to 40 in 2016. Ages 9-17 years averaged 17 calls per year from
2000-2009, peaked at 63 in 2015 and dropped to 42 in 2016. Ages 18-24 years averaged 17 calls per
year from 2000-2009, and increased to 35 in 2016. Adults age 25 years and older had the largest
increase in the number of marijuana exposure calls, averaging 15 calls per year from 2000 to 2009 and
peaking at 90 calls in 2014. Calls in this age group decreased to 78 in 2015 and 73 in 2016.
Nearly all calls for children ages 0-8 years were unintentional exposure in all time periods. From 2014
to 2016, unintentional exposures comprised 17 percent of calls for ages 9-17 years, 9 percent of calls
for ages 18-24 years, and 23 percent of calls for ages 25 years and older. Data on type of marijuana
product was only available for July 2014 to December 2016. For children ages 0-8 years, twice as many
exposure calls were about edible marijuana products compared to smokeable products. In all other age
groups, smokeable products were most common.
CHA data
The rates of hospitalizations and emergency department (ED) visits with poisonings possibly due to
marijuana in children under 9 years old have increased over time since medical marijuana legalization
in 2000, with the largest increase following medical marijuana commercialization in 2010. For 2014 and
2015, this rate was 14 per 100,000 hospitalizations and 9 per 100,000 ED visits. The number of
hospitalizations and ED visits with poisonings possibly due to marijuana among children under 9 years
old was higher in urban areas compared to rural areas.
When examining the rates of hospitalizations and ED visits with marijuana-related billing codes for all
ages, there was an increasing trend in hospitalizations from 2001 to 2015, reaching 3,025 per 100,000.
There was an increasing trend in ED visits from 2012 to 2014, reaching 1,039 per 100,000. ED visits
declined in 2015 to 754 per 100,000. Rates of hospitalizations with marijuana-related billing codes
were highest among males, adolescents and young adults, and blacks. Rates of ED visits were highest
among males, young adults, and black and unknown races.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
231
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0250.png
Section 3: Monitoring Possible Marijuana-Related Health Effects in Colorado
Rates of hospitalizations and ED visits with marijuana-related billing codes have increased throughout
most counties in Colorado. In 2014, hospitalization rates tended to be highest in urban, mountain and
southern counties and ED visit rates tended to be highest in mountain and southern counties.
Examination of primary diagnosis categories revealed that hospitalizations with marijuana-related
billing codes were nine times more likely to have a primary diagnosis of a mental illness than those
without marijuana-related billing codes. ED visits with marijuana-related billing codes were five times
more likely to have a primary diagnosis of a mental illness than those without. Other primary diagnosis
categories that were more likely among hospitalizations with marijuana-related billing codes were
injuries and poisonings, diseases of the skin and subcutaneous tissue, diseases of the nervous system
and sense organs, endocrine, nutritional, and metabolic diseases and immunity, and infectious and
parasitic diseases. Among ED visits, unclassified codes and E codes were also more likely when a
marijuana-related billing code was present.
Discussion
The data presented here provide important insights into 1) the yearly volume, trends over time and
nature of marijuana exposure calls to the poison center among different age groups and 2) the rates of
hospitalizations and emergency department visits for which a marijuana-related billing code was used,
including patterns by age and other demographics. These data do have limitations. Changes in poison
center calls, hospitalizations and emergency department visits might occur as a result of changes in the
amount or type of marijuana use or an increased honesty in reporting marijuana use to health care
providers. Changes in physician screening or reporting related to marijuana or changes in coding
practices could affect the rates of hospitalizations and emergency department visits with marijuana-
related billing codes. Some hospitalizations and ED visits with marijuana-related billing codes may not
have been caused or contributed to by marijuana use. Finally, the poison center is not called in all
cases of someone experiencing a marijuana-related adverse health symptoms or requiring medical
attention following marijuana exposure. Nonetheless, these data reveal important trends.
Encouraging trends
Marijuana exposure calls to the poison center appear to be decreasing since 2015, including
unintentional exposures in children ages 0-8 years.
The overall rate of emergency department visits with marijuana-related billing codes dropped 27
percent from 2014 to 2015 (2016 data is not available yet).
Trends to continue monitoring
Marijuana exposure calls to the poison center continue to be higher in years after medical
marijuana commercialization (2010-2016) than in previous years (2000-2009), including calls about
children 0-8 years old with unintentional marijuana exposure.
Edible marijuana products were involved in about 40 percent of marijuana exposure calls to the
poison center. For children 0-8 years old, calls about edible marijuana were twice as common as
calls about smokeable marijuana.
The overall rate of hospitalizations with marijuana-related billing codes has increased each year
since 2008.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
232
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0251.png
Section 3: Monitoring Possible Marijuana-Related Health Effects in Colorado
Among young adults (ages 18-25 years) in 2014 and 2015, about 8 percent of all hospitalizations and
2 percent of all emergency department visits had a marijuana-related billing code. This was higher
than the rate among other age groups, and likely reflects the higher rate of marijuana use in this
age group.
Disparities in hospitalizations and emergency department visits also existed by sex and race, with
higher rates among males and blacks across all time periods.
Hospitalizations with marijuana-related billing codes are nine times more likely to have a primary
mental health diagnosis compared to those without marijuana-related billing codes.
Recommendations and future directions
1. Continue using RMPDC and CHA data to monitor trends in potential marijuana health effects and
assess the impact over time, especially among groups with higher rates of marijuana use.
2. Continue to monitor marijuana exposure calls, including intentionality and type of marijuana.
CDPHE and RMPDC are working together to develop a surveillance protocol including additional
information such as product name, source and potency.
3. Perform more detailed analyses on unintentional exposures to marijuana in children under age 9.
This includes collecting additional primary data from medical records to assess the severity of the
outcome, the source of the exposure and possible public health intervention strategies.
4. CDPHE is in the process of analyzing hospitalization and emergency department visit data to assess
primary diagnoses in relation to marijuana-related billing codes, in particular for further
clarification concerning mental health diagnoses.
5. Use the recent changes in hospitalization and emergency department visit coding (ICD-9 to ICD-10)
to explore relationships between different marijuana-related billing codes and primary diagnoses.
6. CDPHE is evaluating death
certificate and coroner’s report data to determine how it can best be
used in monitoring for potential-marijuana-related deaths.
7. CDPHE is working with a hospital in a Colorado ski town to collect new data regarding marijuana
use associated with ski-related injuries.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
233
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0252.png
Section 3: Monitoring Possible Marijuana-Related Health Effects in Colorado
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
234
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0253.png
Section 3
Monitoring Possible
Marijuana-Related
Health Effects in
Colorado
Chapter 1
Rocky Mountain Poison and
Drug Center (RMPDC) Data,
2000-2016
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0254.png
Section 3: Rocky Mountain Poison and Drug Center (RMPDC) Data
Authors
Katelyn E. Hall, MPH
Statistical Analyst
Retail Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Shireen Banerji, PharmD, DABAT
Clinical Manager, Rocky Mountain Poison Center
Elyse Contreras, MPH
Coordinator
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Lisa Barker, MPH
Retail Marijuana Health Monitoring, Colorado Department of Public Health and Environment
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Mike Van Dyke, PhD, CIH
Chief
Environmental Epidemiology, Occupational Health, and Toxicology Branch, Colorado Department of
Public Health and Environment
Reviewer
Ken Gershman, MD, MPH
Manager
Medical Marijuana Research Grants Program, Colorado Department of Public Health and Environment
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
236
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0255.png
Section 3: Rocky Mountain Poison and Drug Center (RMPDC) Data
Introduction
The Rocky Mountain Poison and Drug Center (RMPDC) provides medical information to health care
providers and the public to reduce toxicity, injury, and disease related to exposures of all kinds.
RMPDC has been providing information and assistance to Colorado and the surrounding region for more
than 50 years. RMPDC participates in the American Association of Poison Control Centers’ National
Poison Data System (NPDS). RMPDC and NPDS information is used by public health, pharmaceutical and
medical institutions for research, education and prevention initiatives in Colorado and throughout the
nation. Poison Center call volume data are typically used as a surrogate data source to determine the
potential for adverse health effects from exposure to chemicals, environmental agents, biotoxins, and
drugs. RMPDC data are
one of the few near “real-time” data sources available to public health
professionals. These data have become an integral component of monitoring marijuana-related adverse
health events
1-3
. In this report marijuana exposure calls to RMPDC were examined from 2000-2016 to
examine potential trends in relation to marijuana legalization periods.
Methods
Human marijuana exposure calls to RMPDC were queried from NPDS using the marijuana generic
category “cannabinoids and analogs” to assess counts of calls received regarding marijuana exposures
(Appendix R). Calls with missing exposure information, exposures unrelated to marijuana, or exposures
indicating
Medical Review Officer
were validated through a review of the call case notes by a
pharmacist and physician. Exposures indicating synthetic marijuana analogs and THC medications like
marinol, dronabinol, and cannabidiol were excluded from this analysis.
Counts of marijuana exposure calls were quantified by calendar year (2000-2016) for calls with
marijuana exposures only and calls with marijuana in combination with other drug exposures. Counts of
marijuana exposure calls were stratified into four age categories, intentionality (unintentional &
intentional exposures), intentionality and age categories, and marijuana type (edibles, smokeables, &
other) (Appendix R).
Results
There were 1,688 human marijuana exposure calls to RMPDC from 2000 to 2016 (See details about
analytic population in Appendix Figure R.1). From 2000 to 2009, RMPDC marijuana exposure call volume
remained fairly constant. However, in 2010 marijuana exposure calls significantly increased twofold
compared to 2009 from 44 to 93. From 2010 to 2013 counts of marijuana exposure calls increased from
93 to 127 but the change was not significant. In 2014 marijuana exposure calls significantly increased
compared to 2013 by 74.8% from 127 to 222. The number of marijuana exposures calls remained
constant from 2014 (n=222) to 2015 (n=229).In 2016 the number of marijuana exposure calls decreased
(n=201) but the change was not significant.
Beginning in 2012 larger proportions of the marijuana exposures calls were of marijuana only exposures
(Figure 1). Ages 0-17 years and 25 years and older showed increased numbers of marijuana exposure
calls in the
Medical Marijuana Commercialized
era (2010-2013) compared to the
Medical Marijuana
Legalized
era (2001-2009), while ages 18-24 years remain fairly constant since the
Prior to Legalization
of Medical Marijuana
era( 2000) (Figure 2). In 2014 with the beginning of the
Retail Marijuana
Legalized
era, all ages showed increased numbers of marijuana exposure calls compared to the
Medical
Marijuana Commercialized
era (2010-2013) (Figure 2). This increase continued for ages 0-17 years in
2015. In 2016, only ages 18-24 years showed an increase in marijuana exposure calls (25 to 35 calls)
after decreasing from 2014 to 2015 (31 to 25 calls)(Figure 2). All other ages showed a decrease in
marijuana exposure calls in 2016 (Figure 2).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
237
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0256.png
Section 3: Rocky Mountain Poison and Drug Center (RMPDC) Data
The numbers of intentional and unintentional marijuana exposure calls remained constant when
examined from the
Prior to Legalization of Medical Marijuana
era (2000) through the
Medical
Marijuana Legalized
era (2001-2009). However, both types of exposures began to increase in 2010 with
the commercialization of medical marijuana and continued to increase through the legalization of
retail marijuana and in 2015 (Figure 3). In 2016, both intentional and unintentional marijuana exposure
calls decreased, from 139 to 113 and 80 to 73, respectively (Figure 3). Stratifying the calls into age
groups by intentionality showed similar results where the number of marijuana exposure calls remained
constant from 2000 to 2009 for both intentional and unintentional exposures (Figure 4). In 2010,
numbers of intentional and unintentional marijuana exposure calls in all age groups began to increase;
however, the highest numbers of unintentional marijuana exposures were among children 0-8 years
old. The highest numbers of intentional marijuana exposures were in adults 25 years or older (Figure
4).
RMPDC began collecting information regarding the type of marijuana involved in the exposure call on
July 1, 2014. Therefore the data were limited to July 1, 2014 to December 31, 2016 to examine the
type of marijuana involved in the marijuana exposure calls. There were 529 marijuana exposure calls
during this time period. Among these 38.3% (n=203) were edibles, 37.6% (n=199) were smokeables, and
24.0% (n=127) were other marijuana products (Figure 5). Among calls for children ages 0-8, edible
marijuana products constitute 54.5% (n=60) of marijuana exposures, followed by smokeables (25.4%,
n=28, typically eaten in this age group) and other marijuana products (22.7%, n=22) (Figure 6). Among
ages 25 years and older, the proportion of edible (35.6%, n=69) and smokeable (37.6%, n=73) marijuana
products were similar (Figure 6). Smokeable marijuana products represented the most prevalent type
of exposures among those 9 to 24 years, followed by edibles and other marijuana products (Figure 6).
Limitations
Limitations of poison center data include self-selection bias: calls are self-reported; neither all
individuals with symptoms, nor all health care providers managing patients with marijuana exposures
call the poison center. Therefore, the number of cases reported is likely an underestimation and not
necessarily a full representation of the population that needs the services of either RMPDC or
urgent/emergency medical services for a toxic exposure.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
238
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0257.png
Section 3: Rocky Mountain Poison and Drug Center (RMPDC) Data
Figure 1. Number of marijuana exposure calls to poison center by marijuana only
and marijuana with other substances in Colorado
Produced by: EEOHT, CDPHE 2016.
*Counts significantly increased from previous year with a p value <0.003.
†Prior
to legalized medical marijuana.
‡Data
Source: National Poison Data System (NPDS) closed, human, marijuana exposure calls in Colorado from 2000 to 2016,
n=1,688.
Major Findings
Counts of calls remain fairly constant from 2000 to 2009.
In 2010, marijuana exposure calls significantly increased from 44 to 93
a
and in 2014 calls related to
marijuana significantly increased by 74.8% from 127 to 222.
b
In 2016, marijuana exposure calls decreased from 229 calls in 2015 to 201 calls.
c
a
b
c
p
value<0.0001
p
value<0.0001
For an explanation of terms and statistical comparisons used see Appendix R Table R.1.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
239
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0258.png
Section 3: Rocky Mountain Poison and Drug Center (RMPDC) Data
Figure 2. Number of marijuana exposure calls to poison center by age group in
Colorado
Produced by: EEOHT, CDPHE 2016.
†Data
Source: National Poison Data System (NPDS) closed, human, marijuana exposure calls in Colorado from 2000 to 2016,
n=1,542.
Major Findings
Ages 0-17 years and 25 years and older showed increased numbers of marijuana exposure calls in
the
Medical Marijuana Commercialized
era (2010-2013) compared to the
Medical Marijuana
Legalized
era (2001-2009), while ages 18-24 years remain fairly constant since the
Prior to
Legalization of Medical Marijuana
era (2000).
In 2014, with the beginning of the
Retail Marijuana Legalized
era (2014-2016), all ages showed
increased numbers of marijuana exposures calls compared to the
Medical Marijuana
Commercialized
era (2010-2013).
Marijuana exposure calls for 25 years and older increased from 34 in 2013 to peak at 90 in 2014,
and then decreased in both 2015 (78) and 2016 (73).
Marijuana exposure calls decreased from 2015 to 2016 in ages 0-8 years (48 to 40) and 9-17 years
(63 to 42), and increased in ages 18-25 years (25 to 35).
d
d
For an explanation of terms and statistical comparisons used see Appendix R Table R.2.
240
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0259.png
Section 3: Rocky Mountain Poison and Drug Center (RMPDC) Data
Figure 3. Number of intentional and unintentional marijuana exposure calls to
poison center in Colorado
Produced by: EEOHT, CDPHE 2016.
†Prior
to legalized medical marijuana.
‡Data
Source: National Poison Data System (NPDS) closed, human, marijuana exposure calls in Colorado from 2000 to 2016,
n=1,578.
Major Findings
Numbers of both intentional and unintentional marijuana exposure calls remained constant from
the
Prior to Legalization of Medical Marijuana
era (2000) through the
Medical Marijuana Legalized
era (2001-2009); however, they begin to increase in 2010 with the
Medical Marijuana
Commercialized
era (2010-2013) and continued to increase through the
Retail Marijuana Legalized
era (2014-2016) until 2015.
In 2016, both intentional and unintentional marijuana exposure calls decreased, from 139 and 80
in 2015 to 113 and 73, respectively; however, this trend was not significant.
e
e
For an explanation of terms and statistical comparisons used see Appendix R Table R.3.
241
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0260.png
Section 3: Rocky Mountain Poison and Drug Center (RMPDC) Data
Figure 4. Number of marijuana exposure calls to poison center by intention and
age groups in Colorado
Produced by: EEOHT, CDPHE 2016.
†Data
Source: National Poison Data System (NPDS) closed, human, marijuana exposure calls in Colorado from 2000 to 2016,
n=1,437.
Major Findings
Among all age groups, numbers of both intentional and unintentional marijuana exposures
remained constant through the Medical Marijuana Legalized era (2000-2009).
Numbers of intentional marijuana exposures began to increase among those aged 9 years and older
in 2010 with those 25 years and older showing the largest increases.
Numbers of unintentional marijuana exposures increased among all age groups beginning in 2010;
however, those aged 0-8 years showed the largest increases.
In 2016, intentional marijuana exposure among those 18-24 years increased (24 to 32) as well as
unintentional marijuana exposure among those 25 years or older (18 to 21). Marijuana exposure
calls, intentional and unintentional, among other age groups decreased or remained constant in
2016.
f
f
For an explanation of terms and statistical comparisons used see Appendix R Table R.4.
242
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0261.png
Section 3: Rocky Mountain Poison and Drug Center (RMPDC) Data
Figure 5. Number of marijuana exposure calls to poison center by marijuana type
in Colorado, July 2014 to December 2016
Produced by: EEOHT, CDPHE 2016.
*Data Source: National Poison Data System (NPDS) closed, human, marijuana exposure calls in Colorado from July 1, 2014 to
December 31, 2016, n=529.
Major Findings
There were 529 marijuana exposure calls from July 1, 2014 to December 31, 2016.
Among marijuana exposure calls during this time period, 38.3% were edibles, 37.6% were
smokeables, and 24.0% were other marijuana products.
g
g
For an explanation of terms and statistical comparisons used see Appendix R Table R.5.
243
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0262.png
Section 3: Rocky Mountain Poison and Drug Center (RMPDC) Data
Figure 6. Number of marijuana exposure calls to poison center by marijuana type
and age groups in Colorado, July 2014 to December 2016
Produced by: EEOHT, CDPHE 2016.
†There
were 29 calls not shown due to unknown age.
‡Data
Source: National Poison Data System (NPDS) closed, human, marijuana exposure calls in Colorado from 2000 to 2016,
n=529.
Major Findings
Among children ages 0-8 years, edible marijuana products accounted for 54.5% (N=60) of marijuana
exposures, followed by smokeables (25.4%, N=28) and other marijuana products (22.7%, N=22).
Among those 9 to 24 years, the most prevalent type of marijuana exposures were smokeable
marijuana products, followed by edibles and other marijuana products.
Among ages 25 years and older, the number of marijuana exposure calls for edible and smokeable
marijuana products were similar.
h
h
For an explanation of terms and statistical comparisons used see Appendix R Table R.5.
244
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0263.png
Section 3: Rocky Mountain Poison and Drug Center (RMPDC) Data
References
1. Davis JM, Mendelson B, Berkes JJ, Suleta K, Corsi KF, Booth RE. Public Health Effects of Medical
Marijuana Legalization in Colorado.
Am J Prev Med.
2015;10.1016/j.amepre.2015.06.034.
2. Onders B, Casavant MJ, Spiller HA, Chounthirath T, Smith GA. Marijuana Exposure Among Children
Younger Than Six Years in the United States.
Clin Pediatr (Phila).
2015;10.1177/0009922815589912.
3. Wang GS, Roosevelt G, Le Lait MC, et al. Association of unintentional pediatric exposures with
decriminalization of marijuana in the United States.
Ann Emerg Med.
2014;63(6):684-689.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
245
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0264.png
Section 3: Rocky Mountain Poison and Drug Center (RMPDC) Data
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
246
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0265.png
Section 3
Monitoring Possible
Marijuana-Related
Health Effects in
Colorado
Chapter 2
Colorado Hospital Association
(CHA) Data, 2000-September
2015
Retail Marijuana Public Health Advisory
Committee
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0266.png
Section 3: Colorado Hospital Association (CHA) Data
Authors
Katelyn E. Hall, MPH
Statistical Analyst
Retail Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Daniel I. Vigil, MD, MPH
Manager
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Elyse Contreras, MPH
Coordinator
Marijuana Health Monitoring and Research Program, Colorado Department of Public Health and
Environment
Lisa Barker, MPH
Retail Marijuana Health Monitoring, Colorado Department of Public Health and Environment
Kevin Berg, MA
GIS Epidemiologist
Environmental Epidemiology, Colorado Department of Public Health and Environment
Kirk Bol, MSPH
Manager
Vital Statistics and Disease Registry Branch, Colorado Department of Public Health and Environment
Mike Van Dyke, PhD, CIH
Chief
Environmental Epidemiology, Occupational Health, and Toxicology Branch, Colorado Department of
Public Health and Environment
Reviewer
Andrew Monte, MD
Emergency Medicine Physician, University of Colorado
Medical Toxicologist, Rocky Mountain Poison and Drug Center
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
248
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0267.png
Section 3: Colorado Hospital Association (CHA) Data
Introduction
The Colorado Hospital Association (CHA) collects data on hospitalizations (HD) and emergency
department (ED) discharges from participating hospitals in the state of Colorado. The data include
patient demographics, admit and discharge dates, and discharge diagnoses/billing codes and procedure
codes. There are roughly 100 member hospitals of CHA which includes the vast majority of hospitals in
Colorado. However, the database does not include inpatient mental health facilities, ambulatory
surgical centers, long term care facilities, military hospitals, and other outpatient treatment settings.
The CHA dataset was used to investigate rates of HD and ED visits associated with possible marijuana
exposures, diagnoses, and billing codes.
Methods
Marijuana-related billing codes
To determine HD and ED visits that were possibly associated with marijuana, four marijuana-related
billing codes were used. The International Classification of Diseases, 9
th
Revision, Clinical Modification
(ICD-9-CM) is a U.S. Centers for Disease Control and Prevention modification of a set of codes
established by the World Health Organization.
1,2
These billing codes are used to assign alphanumeric
codes to patient diagnoses. On October 1, 2015 the nation updated its administrative coding from the
ICD-9-CM system to ICD-10-CM. This analysis spans HD and ED visits from 2000 (2011 for ED visits)
through September 2015. Analysis of the ICD-10-CM coded HD and ED visits will be completed once a
full year of ICD-10-CM data is available. The four marijuana-related billing codes used were 305.20-
305.23, 304.30-304.33, 969.6, and E854.1 and details about these codes can be found in Appendix S.
We examined HD and ED visit data in three different ways:
1.
Poisonings possibly due to marijuana in children under 9 years of age:
These data were chosen
to represent unintentional use of marijuana by children and consisted of HD or ED visits that were
coded with discharge codes related to poisoning by psychodysleptics.
3,4
Though psychodysleptic
drugs include more than just marijuana, other drugs in this class have a low prevalence of use
among children under 9 years of age. In addition, the age cut-off of 9 years was chosen to
represent children who were unlikely to be intentionally using marijuana. This applies to Figure 1
and Map 1.
2.
Marijuana-related billing codes in listed diagnosis codes:
These data were chosen to represent
the HD and ED visits where marijuana could be a causal, contributing, or coexisting factor noted by
the physician during the HD or ED visit. HD and ED visits were included if they had a marijuana-
related billing code in one or more of the up to 30 listed codes provided, but marijuana may not be
a causal reason for the HD or ED visit. This applies to Figures 2-6 and Maps 2-6.
3.
Primary diagnoses:
Primary diagnoses were examined and compared for HD and ED visits with and
without marijuana-related billing codes for all Colorado HD and ED visits from 2000 through
September 2015 (2011 through September 2015 for ED visits). See Appendix S, Table S.7 for details.
This applies to Figures 7 and 8.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
249
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0268.png
Section 3: Colorado Hospital Association (CHA) Data
Marijuana legalization eras
Rates of HD and ED visits were described over time by year. To evaluate the impact of changes in
marijuana laws in Colorado, four marijuana legalization eras were chosen to display and compare these
findings.
2000
Prior to Legalized Medical Marijuana
2001-2009
Medical Marijuana Legalized
5
2010-2013
Medical Marijuana Commercialized
6,7
2014- September 2015
Retail (Recreational) Marijuana Legalized
8
Rates of HD and ED visits were calculated with the number of HD or ED visits with marijuana-related
billing codes for a time period in the numerator and total number of HD or ED visits during that time
period in the denominator. This proportion was multiplied by 100,000 (1,000 for county level data) to
obtain a rate (Appendix S, Figure S.2). Rates of HD and ED visits were compared across years and
marijuana legalization eras, and stratified by gender, age, race/ethnicity, and county (Appendix S).
Prevalence of primary diagnosis categories were calculated for HD and ED visits with marijuana-related
billing codes and for HD and ED visits without marijuana-related billing codes. Prevalence ratios and
95% confidence intervals were calculated comparing the prevalence of primary diagnosis categories by
HD or ED visits with marijuana-related billing codes to HD or ED visits without marijuana-related billing
codes for the top ten primary diagnosis categories (Appendix S, Figure S.3).
Results
The rates of HD and ED visits with poisonings possibly due to marijuana in children under 9 years old
have increased over time since medical marijuana legalization in 2000 (Figure 1). However, this trend
was only significant from medical marijuana legalization (2001-2009) to medical marijuana
commercialization (2010-2013) (Figure 1). The number of HD and ED visits with poisonings possibly due
to marijuana among children under 9 years was higher in urban areas compared to rural areas in
Colorado (Map1).
When examining the rates of HD and ED visits with marijuana-related billing codes across years, there
was an increasing trend in HD from 2001 to January through September 2015 with the highest rate of
1,260 per 100,000 in January through September 2015. There was also an increasing trend in ED visits
from 2012 to 2014 with the highest rate of 1,039 per 100,000 in 2014. However, in January through
September 2015 there was a decline in ED visits to 754 per 100,000 (Figure 2). When viewing the annual
rates collapsed into marijuana legalization eras, the rate of HD with marijuana-related billing codes
increased significantly from the legalization of medical marijuana (2001-2009) to the legalization of
retail marijuana (2014-September 2015) (Figure 3). Furthermore, the decrease in ED visits observed in
January through September of 2015 was no longer apparent when collapsed to marijuana legalization
eras, and a significantly increasing trend was observed from the commercialization of medical
marijuana (2011-2013) of 739 per 100,000 to the legalization of retail marijuana (2014-September
2015) of 913 per 100,000 (Figures 3).
The rates of HD with marijuana-related billing codes was highest in males (Figures 4.b), ages 9-24 years
(Figures 5.b), and blacks (Figures 6.b). The rates of ED visits with marijuana-related billing codes was
highest in males (Figures 4.a), ages 18-24 years (Figures 5.a), and black and unknown races (Figures
6.a).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
250
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0269.png
Section 3: Colorado Hospital Association (CHA) Data
Rates of HD marijuana-related billing codes have increased throughout most counties in Colorado since
2004, with the highest rates in Crowley county in 2014 (Maps 2, 3, & 4). Rates of ED visits marijuana-
related billing codes have increased in throughout Colorado from 2011-2013 to 2014 (Maps 5 & 6). In
2014, the highest rates of ED visits with marijuana-related billing codes were in Summit County, while
the highest numbers of ED visits were in Pueblo County (Map 6).
Examination of the 18 broad primary diagnosis categories for HD and ED visits revealed a nine-fold and
five-fold increased prevalence of
mental illness
among HD and ED visits respectively with marijuana-
related billing codes compared to HD and ED visits without marijuana-related billing codes (Figures 7 &
8). Also, there was a higher prevalence of
injuries and poisonings, diseases of the skin and
subcutaneous tissue, diseases of the nervous system and sense organs, endocrine, nutritional, and
metabolic diseases and immunity,
and
infectious and parasitic diseases
among HD with marijuana-
related billing codes compared to HD without marijuana-related billing codes (Figure 8). The
prevalence of
unclassified codes and E codes
was higher among ED visits with marijuana-related billing
codes (Figure 7).
A summary of the results can be found with the following figures and detailed results can be found in
Appendix S.
Limitations
The use of marijuana-related ICD-9-CM billing codes is not fully standardized and there may be
differences in coding from hospital to hospital. This summary does not account for confounders like
increases or changes in marijuana-related discharge coding by the hospitals. Changes in coding could
have occurred due to an overall increased awareness regarding marijuana, changes in physician care or
reporting related to marijuana, an increased honesty in patients reporting marijuana use to health care
providers, or changes in coding practices by hospitals and emergency departments. Changes in
marijuana coding could result in an over or underestimate HD and ED visit rates depending on the
marijuana legalization era.
A major limitation is the inability to determine whether a discharge code is an exposure or diagnosis or
if it is merely for billing. Furthermore, use of these billing codes does not necessarily indicate
marijuana was the primary (or even secondary) reason for the HD or ED visit, rather the presence of a
marijuana-related code reflects that marijuana use was noted by the treating physician. Therefore,
this summary quantifies HD and ED visits with marijuana-related billing codes and does not quantify HD
and ED visits due to marijuana. We hypothesize that this summary reflects marijuana use despite the
limitations; however, it does not necessarily show the health care burden of marijuana use. Transition
to ICD-10 coding may help clarify this issue.
In examining the 18 broad primary diagnosis categories in HD and ED visits with any mention of
marijuana, causal associations between marijuana use and the diagnosis categories cannot be made.
Furthermore, temporality between the associations found cannot be assessed; meaning it is unclear
whether marijuana use preceded the primary diagnosis or the primary diagnosis preceded marijuana
use. The associations found between HD and ED visits with marijuana coding and primary diagnosis
categories point to specific health outcomes to direct future investigation and resources.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
251
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0270.png
Section 3: Colorado Hospital Association (CHA) Data
Figure 1. Children under 9 years of age; Rates of hospitalizations (HD) and emergency
department (ED) visits with poisoning possibly due to marijuana in Colorado
Produced by: EEOHT, CDPHE 2016
*Rate significantly increased from previous time period with a p-value <0.001.
†ICD-9-CM
codes 969.6 and E854.1, poisoning and accidental poisoning by psychodysleptics, were used to determine HD and ED
visits with poisonings possibly due to marijuana.
‡The Ns are the total
number of HD or ED visits with poisoning possibly due to marijuana in the specified time period.
§Data Source: Colorado Hospital Association 2000-Sept 2015 (2011-Sept 2015 for ED visits).
Major findings:
For children under 9 years old, rates of HD and ED visits had an increasing trend across
legalization eras.
Rates of HD with poisonings possibly due to marijuana in children under 9 years old increased
eight-fold from 2001-2009 to 2010-2013.
a
The highest rates for both HD and ED visits in children under 9 years old were in 2014 through
September 2015, though these rates were not significantly different from the previous time
period.
b
HD rate per 100,000 2001-2009: 1 2010-2013: 8:
Χ
2
= 30.0, p<0.001
2014 to Sept 2015: HD rate per 100,000 (14), ED rate per 100,000 (9)
For an explanation of statistical comparisons used, see Appendix S. For data, see Appendix S Table S.1.
a
b
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
252
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0271.png
Section 3: Colorado Hospital Association (CHA) Data
Map 1. Numbers of hospitalizations (HD) and emergency department (ED) Visits with
poisonings possibly due to marijuana in children Under 9 Years of age in Colorado, 2004-
2014 by county.
Produced by: EEOHT, CDPHE 2016
*Counties shown in white have no reported HD or ED visits with poisonings possibly due to marijuana in children under 9 years.
†ICD-9-CM
codes 969.6 and E854.1 were used to determine HD and ED visits with poisonings possibly due to marijuana.
‡Data source:
Colorado Hospital Association (CHA).
Major findings:
Numbers of HD and ED visits were highest in Denver, El Paso, and Adams counties.
Higher numbers of HD and ED visits were in urban areas compared to rural.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
253
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0272.png
Section 3: Colorado Hospital Association (CHA) Data
Figure 2. Rates of hospitalizations (HD) and emergency department (ED) visits with
marijuana-related billing codes in Colorado.
Produced by: EEOHT, CDPHE 2016
*Rate significantly increased from previous time period with a p-value <0.001.
†The percent change in rates of HD and ED visits compared to the previous year.
‡ICD-9-CM
codes 305.20-305.23, 304.30-304.33, 969.6, and E854.1 were used to determine HD and ED visits with marijuana-
related billing codes.
§Data Source: Colorado Hospital Association 2000-Sept 2015 (2011-Sept 2015 for ED visits).
Major findings:
Rates of ED visits with marijuana-related billing codes showed an increasing trend from 2012 to 2014
and then decreased from 2014 to January through September of 2015 by 27%.
c
Rates of HD with marijuana-related billing codes showed an increasing trend beginning in 2001 with
the highest rate of HD in January through September 2015.
d
The largest increases in rates were from 2013 to 2014 of 37% for HD
e
and 2012 to 2013 of 25% for ED
visits.
f
Rate of ED visits per 100,000 : 2012 (701), 2013 (873), 2014 (1039), Jan- Sept 2015 (754) increase 27%
Rate of HD per 100,000: Jan- Sept 2015 (3025)
e
Rate of HD per 100,000: 2013 (1779), 2014 (2443) Increase 37%
f
Rate of ED per 100,000: 2012 (701), 2013 (873) Increase 25%
For an explanation of statistical comparisons used, see Appendix S. For data, see Appendix S Table S.2.
d
c
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
254
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0273.png
Section 3: Colorado Hospital Association (CHA) Data
Figure 3. Rates of hospitalizations (HD) and emergency department (ED) visits with
marijuana-related billing codes in Colorado.
Produced by: EEOHT, CDPHE 2016
*Rate significantly increased from previous time period with a p-value <0.001.
†The Ns are the total number of HD or ED visits with
marijuana-related billing codes in the specified time period.
‡ICD-9-CM
codes 305.20-305.23, 304.30-304.33, 969.6, and E854.1 were used to determine HD and ED visits with marijuana-
related billing codes.
§Data Source: Colorado Hospital Association 2000-Sept 2015 (2011-Sept 2015 for ED visits).
Major findings:
Rates of HD with marijuana-related billing codes significantly increased by each time period from
2000 to 2014 through September 2015 with the largest increase of 87.2% from 2010-2013 to 2014
through September 2015.
g
Rates of ED visits significantly increased by 23.5% from 2010-2013 to 2014 through September 2015.
h
The highest rates for both HD and ED visits with marijuana-related billing codes were in 2014
through September 2015.
i
Rates of HD per 100,000: 2000 (575) vs 2001-2009 (803)
Χ
2
= 686.5, p<0.001; 2001-2009 (803) vs 2010-2013 (1440)
Χ
2
= 5384.4,
p<0.001; 2010-2013 (1440) vs 2014-Sept 2015 (2696)
Χ
2
= 5084.9, p<0.001
h
Rates of ED per 100,000: 2010-2013 (739) vs 2014-Sept 2015 (913) :
Χ
2
= 686.5, p<0.001
i
Highest rates per 100,000: HD 2014-Sept 2015 (2696), ED: 2014-Sept 2015 (913)
For an explanation of statistical comparisons used, see Appendix S. For data, see Appendix S table S.3.
g
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
255
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0274.png
Section 3: Colorado Hospital Association (CHA) Data
Figure 4.a Rates of emergency department (ED) visits with marijuana-related billing codes
by gender.
Produced by: EEOHT, CDPHE 2016
*Rate significantly increased from previous time period with a p-value <0.001.
†ICD-9-CM
codes 969.6 and E854.1 were used to determine ED visits with marijuana-related billing codes.
‡Data Source: Colorado Hospital
Association 2011-Sept 2015.
Major findings:
Rates of ED visits significantly increased from 2011-2013 to 2014 through September 2015 for both
males and females.
j
Males had consistently higher rates of ED visits with marijuana-related billing codes across time
periods.
Rate ED visits per 100,000: male 2011-2013 (1070) vs 2014-Sept 2015 (1277),
Χ
2
= 303.2, p<0.001;
female 2011-2013 (485) vs 2014-Sept 2015 (624),
Χ
2
= 364.7, p<0.001
For an explanation of statistical comparisons used, see Appendix S. data, see Appendix S table S.4.
j
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
256
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0275.png
Section 3: Colorado Hospital Association (CHA) Data
Figure 4.b Rates of hospitalizations (HD) with marijuana-related billing codes by gender.
Produced by: EEOHT, CDPHE 2016
*Rate significantly increased from previous time period with a p-value <0.001.
†ICD-9-CM
codes 969.6 and E854.1 were used to determine HD with marijuana-related billing codes.
‡Data Source: Colorado Hospital
Association 2000-Sept 2015.
Major findings:
Rates of HD with marijuana-related billing codes significantly increased each time period from year
2000 to 2014 through September 2015 for both males
k
and females.
l
Males had consistently higher rates of HD with possible marijuana exposures, diagnoses, or billing
codes across time periods.
Rate of male HD visits per 100,000: 2000 (887) vs 2001-2009 (1204),
Χ
2
= 138.7, p<0.001; 2001-2009 (1204) vs 2010-2013 (2145),
Χ
= 3252.5, p<0.001; 2010-2013 (2145) vs 2014-Sept 2015 (1277),
Χ
2
= 2926.8, p<0.001
l
Rate of female HD visits per 100,000: 2000 (368) vs 2001-2009 (533),
Χ
2
= 128.0, p<0.001; 2001-2009 (533) vs 2010-2013 (933),
Χ
2
=
1895.8, p<0.001; 2010-2013 (933) vs 2014-Sept 2015 (1788),
Χ
2
= 2065.0, p<0.001
For an explanation of statistical comparisons used, see Appendix S. For data, see Appendix S table S.4.
k
2
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
257
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0276.png
Section 3: Colorado Hospital Association (CHA) Data
Figure 5.a Rates of emergency department (ED) visits with marijuana-related billing codes
by age categories.
Produced by: EEOHT, CDPHE 2016
*Rate significantly increased from previous time period with a p-value <0.001.
†ICD-9-CM
codes 969.6 and E854.1 were used to determine ED visits with marijuana-related billing codes.
‡Data Source: Colorado Hospital
Association 2011-Sept 2015.
Major findings:
Rates of ED visits with marijuana-related billing codes significantly increased for all age groups
except children and adolescents from 2011-2013 to 2014 through September 2015.
m
Rate of ED visits per 100,000: YA 2010-2013 (1576) vs 2014-Sept 2015 (1893),
Χ
2
= 154.3, p<0.001; adult 2010-2013 (1168) vs
2014-Sept 2015 (1427),
Χ
2
= 153.1, p<0.001; middle aged 2010-2013 (705) vs 2014-Sept 2015 (897),
Χ
2
= 289.5, p<0.001; elderly
2010-2013 (70) vs 2014-Sept 2015 (122),
Χ
2
= 64.4, p<0.001
For an explanation of statistical comparisons used, see Appendix S. For data, see Appendix S table S.5.
m
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
258
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0277.png
Section 3: Colorado Hospital Association (CHA) Data
Figure 5.b Rates of hospitalizations (HD) with marijuana-related billing codes by age
categories.
Produced by: EEOHT, CDPHE 2016
*Rate significantly increased from previous time period with a p-value <0.001.
†ICD-9-CM
codes 969.6 and E854.1 were used to determine HD with marijuana-related billing codes.
‡Data Source: Colorado Hospital Association 2000-Sept
2015.
Major findings:
Rates of HD with marijuana-related billing codes significantly increased for all age groups from
2001-2009 to 2010-2013 and for those 9 and older for 2010-2013 to 2014 through September 2015.
n
Rate of HD visits per 100,000: Child 2001-2009 (2) vs 2010-2013 (2),
Χ
2
= 28.2, p<0.001; Adolescent 2001-2009 (4348) vs 2010-
2013 (6411),
Χ
2
= 315.6, p<0.001; 2010-2013 (6411) vs 2014-Sept 2015 (7325),
Χ
2
= 19.6, p<0.001; YA 2000(1624) vs 2001-2009
(2571),
Χ
2
= 131.5, p<0.001; 2001-2009 (2571) vs 2010-2013 (5129),
Χ
2
= 2123.6, p<0.001; 2010-2013 (5129) vs 2014-Sept 2015
(8072),
Χ
2
= 634.9, p<0.001; Adult 2000(997) vs 2001-2009 (1371),
Χ
2
= 48.7, p<0.001; 2001-2009 (1371) vs 2010-2013 (2546),
Χ
2
=
1205.2, p<0.001; 2010-2013 (2546) vs 2014-Sept 2015 (4584),
Χ
2
= 904.0, p<0.001; middle aged 2000(627) vs 2001-2009 (958),
Χ
2
=
143.4, p<0.001; 2001-2009 (958) vs 2010-2013 (1788),
Χ
2
= 2384.5, p<0.001; 2010-2013 (1788) vs 2014-Sept 2015 (4004),
Χ
2
= 3754,
p<0.001; Elderly 2001-2009 (22) vs 2010-2013 (89),
Χ
2
= 406.2, p<0.001; 2010-2013 (89) 2014-Sept 2015 (435),
Χ
2
= 1082.3, p<0.001
For an explanation of statistical comparisons used, see Appendix S. For data, see Appendix S table S.5.
n
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
259
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0278.png
Section 3: Colorado Hospital Association (CHA) Data
Figure 6.a Rates of emergency department (ED) visits with marijuana-related billing codes
by race/ethnicity.
Produced by: EEOHT, CDPHE 2016
*Rate significantly increased from previous time period with a p-value <0.001.
†ICD-9-CM
codes 969.6 and E854.1 were used to determine ED visits with marijuana-related billing codes.
‡Other race included Asian, Native American, and Other races. Unknown race was recorded as “unknown” not including missing
data.
§Data Source: Colorado Hospital Association 2011-Sept 2015.
Major findings:
Rates of ED visits with marijuana-related billing codes significantly increased from 2010-2013 to
2014 through September 2015 for White, Black, Other, and Unknown races.
o
Rate of ED visits per 100,000: White 2010-2013 (729) vs 2014-Sept 2015 (895),
Χ
2
= 409.0, p<0.001; Black 2010-2013 (1111) vs
2014-Sept 2015 (895),
Χ
2
= 50.7, p<0.001; Other 2010-2013 (581) vs 2014-Sept 2015 (562),
Χ
2
= 13.1, p<0.001; Unknown 2010-2013
(676) vs 2014-Sept 2015 (1743),
Χ
2
= 1509.3, p<0.001
For an explanation of statistical comparisons used, see Appendix S. For data, see Appendix S table S.6.
o
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
260
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0279.png
Section 3: Colorado Hospital Association (CHA) Data
Figure 6.b Rates of hospitalizations (HD) with marijuana-related billing codes by
race/ethnicity.
Produced by: EEOHT, CDPHE 2016
*Rate significantly increased from previous time period with a p-value <0.001.
†ICD-9-CM
codes 969.6 and E854.1 were used to determine HD with marijuana-related billing codes.
‡Other race included Asian, Native American, and Other races. Unknown race was recorded as “unknown” not including missing
data.
§Data Source: Colorado Hospital Association 2000-Sept 2015.
Major findings:
Rates of HD with marijuana-related billing codes significantly increased each time period for White,
Black, and Unknown races.
p
Rates of HD with marijuana-related billing codes for all races significantly increased each time
period from 2001-2009 to 2014 through September 2015.
q
Rate of HD visits per 100,000: White 2000 (547) vs 2001-2009 (745),
Χ
2
= 122.0, p<0.001; 2001-2009 (745) vs 2010-2013 (1333),
Χ
= 3127.2, p<0.001; 2010-2013 (1333) vs 2014-Sept 2015 (2599),
Χ
2
= 3903.7, p<0.001; Black 2000 (1710) vs 2001-2009 (2159),
Χ
2
=
12.3, p<0.001; 2001-2009 (2159) vs 2010-2013 (3473),
Χ
2
= 362.5, p<0.001; 2010-2013 (3473) vs 2014-Sept 2015 (5178),
Χ
2
= 198.1,
p<0.001; Unknown 2000 (342) vs 2001-2009 (682),
Χ
2
= 165.4, p<0.001; 2001-2009 (682) vs 2010-2013 (1256),
Χ
2
= 594.7, p<0.001;
2010-2013 (1256) vs 2014-Sept 2015 (2549),
Χ
2
= 431.2, p<0.001
q
Rate of HD visits per 100,000: Hispanic 2001-2009 (894) vs 2010-2013 (1683),
Χ
2
= 793.8, p<0.001; 2010-2013 (1683) vs 2014-Sept
2015 (2641),
Χ
2
= 223.1, p<0.001; Other 2001-2009 (941) vs 2010-2013 (1133),
Χ
2
= 31.6, p<0.001; 2010-2013 (1133) vs 2014-Sept
2015 (2339),
Χ
2
= 455.1, p<0.001
For an explanation of statistical comparisons used, see Appendix S. For data, see Appendix S table S.6.
p
2
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
261
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0280.png
Section 3: Colorado Hospital Association (CHA) Data
Map 2. Rates and numbers of hospitalizations (HD) with marijuana-related billing codes
Per 1,000 HD in all ages in Colorado From 2004-2009.
Produced by: EEOHT, CDPHE 2016
*Counties shown in white have no reported ED visits with marijuana-related billing codes.
†The
number inside the counties was the total number of HD with marijuana-related billing codes in the specified county.
‡ICD-9-CM
codes 305.20-305.23, 304.30-304.33, 969.6, and E854.1 were used to determine HD with marijuana-related billing
codes.
§ Data Source: Colorado Hospital Association 2004-2009.
Major findings
Rates and numbers of HD with marijuana-related billing codes were higher in urban areas
compared to rural areas.
The highest rates were in Pueblo (16 per 1,000 HD), Denver (13 per 1,000 HD), and Custer (12 per
1,000 HD) counties while the highest numbers of HD were in Denver (N=4,976 HD), Arapahoe
(N=2,561 HD), and Adams (N=2,561 HD) counties.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
262
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0281.png
Section 3: Colorado Hospital Association (CHA) Data
Map 3. Rates and numbers of hospitalizations (HD) with marijuana-related billing codes
per 1,000 hospitalizations in all ages in Colorado from 2010-2013.
Produced by: EEOHT, CDPHE 2016
*Counties shown in white have no reported ED visits with marijuana-related billing codes.
†The
number inside the county was the total number of HD with marijuana-related billing codes in the specified county.
‡ICD-9-CM
codes 305.20-305.23, 304.30-304.33, 969.6, and E854.1 were used to determine HD with marijuana-related billing
codes.
§ Data Source: Colorado Hospital Association 2010-2013.
Major findings
Rates and numbers of HD with marijuana-related billing codes were higher in urban areas compared
to rural areas.
The highest rates were in Pueblo County (24 HD per 1,000 HD); however, the highest number of HD
was in Denver County (N=5,204 HD).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
263
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0282.png
Section 3: Colorado Hospital Association (CHA) Data
Map 4. Rates and numbers of hospitalizations (HD) with marijuana-related billing codes
per 1,000 hospitalizations in all ages in Colorado in 2014-September 2015.
Produced by: EEOHT, CDPHE 2016
* Counties shown in white have no reported HD with marijuana-related billing codes.
†The
number inside the county was the total number of HD marijuana-related billing codes in the specified county.
‡ICD-9-CM
codes 305.20-305.23, 304.30-304.33, 969.6, and E854.1 were used to determine HD with marijuana-related billing
codes.
§ Data Source: Colorado Hospital Association 2014-Sept 2015.
Major findings
Numbers of HD with marijuana-related billing codes were higher in urban areas compared to rural
areas.
The highest rates of HD were in Crowley County (56 per 1,000 HD) while the highest numbers of HD
were in Denver County (N=1,749 HD).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
264
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0283.png
Section 3: Colorado Hospital Association (CHA) Data
Map 5. Rates and numbers of emergency department (ED) Visits with marijuana-related
billing codes per 1,000 ED visits in all ages in Colorado from 2011-2013.
Produced by: EEOHT, CDPHE 2016
* Counties shown in white have no reported ED visits with marijuana-related billing codes.
†The
number inside the county was the total number of ED visits with possible marijuana-related billing codes in the specified
county.
‡ICD-9-CM
codes 305.20-305.23, 304.30-304.33, 969.6, and E854.1 were used to determine ED visits with marijuana-related
billing codes.
§ Data Source: Colorado Hospital Association 2011-2013.
Major findings
The rates of ED visits remained fairly constant from urban to rural counties; however, the numbers of
ED visits were higher in urban counties compared to rural counties.
The highest rates of ED visits were in Summit (21 per 1,000), Routt (17 per 1,000), Pueblo (17 per
1,000), Lake (13 per 1,000), Park (13 per 1,000) and Archuleta (13 per 1,000) counties, while the
highest numbers of ED visits were in Denver (N=6,834) and Pueblo (N=3,967) counties.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
265
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0284.png
Section 3: Colorado Hospital Association (CHA) Data
Map 6. Rates and numbers of emergency department (ED) visits with marijuana-related
billing codes
b
per 1,000 hospitalizations in all ages in Colorado in 2014-September 2015.
Produced by: EEOHT, CDPHE 2016
* Counties shown in white have no reported ED visits with marijuana-related billing codes.
†The
number inside the county was the total number of ED visits with marijuana-related billing codes in the specified county.
‡ICD-9-CM
codes 305.20-305.23, 304.30-304.33, 969.6, and E854.1 were used to determine ED visits with marijuana-related billing
codes.
§ Data Source: Colorado Hospital Association 2014-Sept 2015.
Major findings
The rate of ED visits increased in Adams, Alamosa, Arapahoe, Archuleta, Baca, Boulder, Broomfield,
Chaffee, Clear Creek, Costilla, Crowley, Custer, Dolores, Douglas, El Paso, Elbert, Fremont, Garfield,
Gilpin, Grand, Jefferson, Kit Carson, La Plata, Lake, Las Animas, Logan, Mesa, Moffat, Montezuma,
Montrose, Morgan, Otero, Park, Phillips, Pueblo, Routt, Summit, Teller, Washington, Weld, and Yuma
counties from 2011-2013.
The highest rates of ED visits were in Summit County (56 per 1,000), while the highest numbers of ED
visits were in Pueblo County (N=2,529).
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
266
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0285.png
Section 3: Colorado Hospital Association (CHA) Data
Figure 7. Top ten primary diagnosis categories among emergency department (ED) visits
with marijuana-related billing codes compared to those without in Colorado from 2011
through September 2015.
Produced by: EEOHT, CDPHE 2016
*ED visits with marijuana-related billing codes included 304.30-304.33, 305.20-305.23, 969.6, and E854.1 in any of the listed 30
diagnosis codes.
†PR=Prevalence
Ratio, CI=Confidence Interval
‡Data Source: Colorado Hospital
Association 2011-Sept 2015.
Major findings
The prevalence of the primary diagnosis category
mental illness
was five-fold higher and the
category of
unclassified codes and E codes
was two-fold higher among ED visits with marijuana-
related billing codes compared to ED visits without marijuana-related billing codes.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
267
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0286.png
Section 3: Colorado Hospital Association (CHA) Data
Figure 8. Top ten primary diagnosis categories among hospitalizations (HD) with
marijuana-related billing codes compared to those without in Colorado from 2000 through
September 2015.
Produced by: EEOHT, CDPHE 2016
*Hospitalizations with marijuana-related billing codes included 304.30-304.33, 305.20-305.23, 969.6, and E854.1 in any of the
listed 30 diagnosis codes.
†PR=Prevalence
Ratio, CI=Confidence Interval
‡Data Source: Colorado Hospital
Association 2000-Sept 2015
Major findings
The prevalence of the primary diagnosis category
mental illness
among HD with marijuana-related
billing codes was nine-fold higher compared to HD without marijuana-related billing codes.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
268
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0287.png
Section 3: Colorado Hospital Association (CHA) Data
References
1. Centers for Disease Control and Prevention. Scientific Data Documentation: International
Classificaiton of Diseases-9-CM, (1979). 2014;
http://wonder.cdc.gov/wonder/sci_data/codes/icd9/type_txt/icd9cm.asp. Accessed November 3,
2015.
2. Practice Management Information Corporation [PMIC].
International Classification of Diseases 9th
Revision Clinical Modification.
Vol 1, 2, & 3. Sixth ed. Los Angeles, California 2015.
3. Thomas K, Johnson R.
State Injury Indicators Report: Instruction for Preparing 2013 Data.
Atlanta
(GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and
Control;2015.
4. Safe States.
Consensus Recommendations for National and State Poisoning Surveillance: Report
from the Injury Surveillance Work-group (ISW7).
Atlanta: Safe States; 2012 2012.
5. CO Const. amend. 20 art. XVIII §14
http://www.lexisnexis.com/hottopics/colorado/?app=00075&view=full&interface=1&docinfo=off&s
earchtype=lt&search=Colo.+Const.+Art.+XVIII%2C+Section+14.
6. H.B. 10-1284 (CO 2010).
7. Ogden DW. "Memorandum to All United States Attorneys on Investigations and Prosecutions in
States Authorizing the Medical Use of Marijuana" 19, October 2009. In: U.S. Department of Justice,
ed, https://www.justice.gov/opa/blog/memorandum-selected-united-state-attorneys-
investigations-and-prosecutions-states. Washington, DC.
8. CO Const. amend. 64 art. XVIII §16.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
269
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0288.png
Section 3: Colorado Hospital Association (CHA) Data
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
270
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0289.png
Retail Marijuana
Public Health Advisory
Committee
Membership Roster
2015-2016
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0290.png
Membership Roster 2015-2016
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
272
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0291.png
Membership Roster 2015-2016
Mike Van Dyke, PhD, CIH
CDPHE Marijuana Health Monitoring & Research Program
Representative,
Chairman
Dr. Van Dyke is the Chief of the Environmental Epidemiology,
Occupational Health, and Toxicology Branch at the Colorado
Department of Public Health and Environment. Dr. Van Dyke is
trained in the evaluation and control of occupational and
environmental chemical exposures. He has spent the last 20 years
working in public and occupational health focusing on chemical
exposures, environmental and occupational epidemiology, and risk
communication.
Shireen Banerji, PharmD, DABAT
Poison Center Representative
Dr. Banerji is the Clinical Manager of the Rocky Mountain Poison
Center (RMPC). RMPC, a division of Denver Health, serves as the
poison center for 5 states. She holds faculty appointments in four
schools of pharmacy including University of Colorado School of
Pharmacy. She is responsible for managing the clinical operations
of RMPC which includes training, teaching, research, quality
control, and continuing education of the poison center hotline
staff. She has select administrative roles and also serves as clinical
toxicologist and resource to staff. She works in conjunction with
EPA, CDC and local and state health departments when
toxicological emergencies with potential threat to public health
arise, to provide clinical management and real-time and historical
surveillance. Areas of interest include pediatric toxicology,
medication safety, and poison prevention.
Laura Borgelt, PharmD
Pharmacologist/Clinical Pharmacy Specialist
Dr. Laura Borgelt is an Associate Dean and Professor at the
University of Colorado Anschutz Medical Campus in the
Departments of Clinical Pharmacy and Family Medicine. Dr.
Borgelt’s teaching, practice, and research focus on patient safety
and women’s health. Her initial interest in educating providers
and patients about medical marijuana started about seven years
ago when she was asked clinical questions about its use in
pregnant and lactating women. Since that time, she has
investigated the potential effectiveness and risks of marijuana in a
comprehensive manner and has provided evidence-based
presentations to various organizations at the state and national
level. She has served on five different working groups regarding
rulemaking in the state of Colorado involving consumer safety and
social issues. Through her training, research, and experience, Dr.
Borgelt has extensive knowledge of marijuana with regards to its
pharmacology, pharmacokinetics, pharmacodynamics, therapeutic
effectiveness, and potential risks.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
273
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0292.png
Membership Roster 2015-2016
Ashley Brooks-Russell, PhD, MPH
Colorado School of Public Health Representative
Dr. Brooks-Russell is an assistant professor at the Colorado School
of Public Health and a member of the Injury Prevention, Education
and Research Program. She completed her doctoral training in
Health Behavior at the University of North Carolina at Chapel Hill
and completed a postdoctoral fellowship at the Prevention
Research Branch at the Eunice Kennedy Shriver National Institute
of Child Health and Human Development. Her current research
focuses on the areas of adolescent substance use and impaired
driving.
Russell Bowler, MD, PhD
Pulmonologist
Dr. Bowler is Professor of Medicine at National Jewish Health in
Denver and University of Colorado in Aurora, Colorado. He has
multiple NIH and foundation grants to study the effects of tobacco
and marijuana on lung health. There is a strong emphasis on
generation and integration of genetics, genomics, proteomics and
metabolomics data. Complementary animal and laboratory
exposure models are used to demonstrate proof of concept using
discoveries from human Omics work. He runs on of the country’s
largest clinical databases and biobanks of smokers with over 3000
well-characterized subjects.
Ken Gershman, MD, MPH
CDPHE, Medical Marijuana Representative
Dr. Gershman is Manager of the Marijuana Research Grants
Program at the Colorado Department of Public Health and
Environment (CDPHE). He has worked as a public health
practitioner at CDPHE for 24 years in the areas of communicable
disease control and chronic disease prevention, including
managing the Cancer, Cardiovascular Disease and Chronic
Pulmonary Disease (CCPD) Amendment 35 grant program.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
274
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0293.png
Membership Roster 2015-2016
Heath Harmon, MPH
Local Public Health Representative
Heath Harmon is the Director of Health Divisions at Boulder County
Public Health (BCPH). He has more than 20 years of public health
experience spanning communicable disease epidemiology,
environmental health, emergency preparedness and response,
adolescent health, maternal and child health, health
communications, health planning, and health policy. Mr. Harmon
completed his Master of Public Health from the University of South
Florida in 2000 and currently devotes his time at BCPH to health
policy, health equity, and organizational leadership initiatives.
Rebecca Helfand, PhD
Substance Abuse and Mental Health Epidemiologist
Dr. Helfand is the Director of Data and Evaluation at the Colorado
Department of Human Services’ Office of Behavioral Health. She
completed her doctoral training at Baylor University and
completed a postdoctoral fellowship at the Institute for Behavioral
Genetics and the University of Colorado, Boulder. Dr. Helfand's
current work focuses on analysis of mental health and substance
abuse treatment data for the state of Colorado.
Sharon Langendoerfer, MD
Neonatology and Pregnancy
Dr. Langendoerfer is a retired Pediatrician and Neonatologist from
Denver Health
Medical Center. For many years she has cared for high risk infants
and children, including those exposed before birth to alcohol and
other drugs.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
275
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0294.png
Membership Roster 2015-2016
Andrew Monte, MD
Medical Toxicologist
Dr. Monte is an emergency medicine physician and medical
toxicologist at University of Colorado and the Rocky Mountain
Poison and Drug Center. Dr. Monte is an active researcher studying
human exposures to a variety of poisons, toxins, and drugs.
Kristina T. Phillips, PhD
Psychologist
Dr. Phillips is a licensed Clinical Psychologist and Professor in the
School of Psychological Sciences at the University of Northern
Colorado (UNC). She completed her doctoral work at Bowling
Green State University and her post-doctoral training at the
Center for Alcohol and Addiction Studies at Brown University. Her
primary research interests focus on consequences associated with
illicit substance use (e.g., academic problems related to
marijuana use, health consequences of injection drug use),
treatment development and efficacy, and ecological momentary
assessment. Dr. Phillips has been the principal investigator or co-
investigator on several NIH grants, including projects testing the
efficacy of a brief intervention for people who inject drugs and a
new study that examines academic outcomes associated with
heavy marijuana use in college students.
Judith Shlay, MD, MSPH
Surveillance Epidemiologist/Local Public Health Representative
Dr. Shlay is the Interim Director of Denver Public Health (DPH) and
a Professor of Family Medicine at the University of Colorado,
School of Medicine. She has been working on various programs at
DPH for the past 27 years. Dr. Shlay has been the principal
investigator for a number of projects focusing on health promotion
and disease prevention, HIV-related metabolic and neurologic
disorders, immunization delivery, reproductive health, sexually
transmitted infections, substance abuse, teen pregnancy
prevention, and tobacco prevention. In addition to her public
health work, Dr. Shlay is a primary care provider through Denver
Health’s Community Health Services Department.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
276
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0295.png
Membership Roster 2015-2016
Christian Thurstone, MD
Addiction Psychiatrist
Dr. Thurstone is a child psychiatrist, general psychiatrist, and
addiction psychiatrist. He is an Associate Professor of Psychiatry at
the University of Colorado and the Medical Director of Addiction
Services at Denver Health. His research focuses on clinical studies
related to adolescent substance use disorders.
George Sam Wang, MD
Pediatrician
Dr. Wang is board certified in general pediatrics, pediatric
emergency medicine and medical toxicology. He is an Assistant
Professor of Pediatrics, Department of Pediatrics, Section of
Emergency Medicine and Medical Toxicology at University of
Colorado Anschutz Medical Campus and Children’s Hospital
Colorado and a volunteer faculty member with the Rocky Mountain
Poison and Drug Center.
Dr. Wang’s focus or research is ingestions
and exposures in the pediatric population, and a major has been
prevention of unintentional marijuana exposures among
children and also the use of cannabidiol in pediatric epilepsy.
Tista Ghosh, MD, MPH
CDPHE, Alternate Member
Dr. Ghosh is a physician trained in both internal medicine and
preventive medicine, with a master’s degree in public health from
Yale University. She also has had specialized training in applied
epidemiology and public health practice through the Centers for
Disease Control and Prevention’s Epidemic
Intelligence Service
Program. Dr. Ghosh has experience in both communicable and
non-communicable disease epidemiology and public health
research, as well as over a decade of experience in public health
at the local, state, federal and international levels. She serves as
both the deputy chief medical officer of the Colorado Department
of Public Health and Environment and the director of Public Health
Programs.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
277
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0296.png
Membership Roster 2015-2016
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
278
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0297.png
Glossary
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0298.png
Glossary
Abnormal female reproductive function
Abnormal ovulation, implantation, placenta formation, or reproductive hormone levels.
Abnormal male reproductive function
Abnormal sperm count, concentration, motility or structure, or abnormal reproductive hormone levels.
Acute marijuana use
Marijuana used within the past few hours, such that the short-term effects or symptoms are still being
experienced.
Adolescent
Individual 9 to 17 years of age.
Adult
Individual 25 years or older.
Analgesic
A medication used to relieve pain.
Anencephaly
A neural tube defect that results in underdevelopment or the absence of portions of the brain, skull,
and scalp.
Bullous lung disease
Destruction of lung tissue causing pockets of air to replace lung tissue, diagnosed by imaging.
Cancer-causing chemicals
Chemicals known to cause cancer in humans, including polycyclic aromatic hydrocarbons.
Cannabidiol (CBD)
A non-psychoactive cannabinoid that is a component of marijuana.
Cannabinoid hyperemesis syndrome
A term currently used by some medical professionals to describe cyclic vomiting occurring in long-time
marijuana users. A formal medical definition, including clinical diagnostic criteria, has not yet been
established.
Cannabis use disorder
A formal diagnosis indicating two or more of these factors: hazardous use, social/interpersonal
problems related to use, neglects major roles in order to use, legal problems, withdrawal, tolerance,
uses more or longer than planned, repeated attempts to quit or reduce use, much time is spent using,
physical or psychological problems related to use, and/or gives up activities in order to use; commonly
called addiction.
Cardiovascular disease
A disease of the heart and/or blood vessels, including both heart disease and stroke.
Child
Individual up to 9 years of age.
Chronic bronchitis
A long term cough with sputum production that is diagnosed by symptoms.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
280
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0299.png
Glossary
Chronic obstructive pulmonary disease (COPD)
A severe form of small airway obstruction characterized by long-term poor airflow from the lungs, with
common symptoms including of shortness of breath and cough with sputum production, diagnosed by
pulmonary function tests.
Cognitive abilities
Brain-based skills we need to carry out any task from the simplest to the most complex, which include
retrieving information from memory, using logic to solve problems, communicating through language,
mentally visualizing a concept and focusing attention when distractions are present.
Combustion by-products
Chemicals produced when a material is burned. These chemicals including carbon monoxide and
polycyclic aromatic hydrocarbons.
Cyclic vomiting
Eepisodes of severe, repeated vomiting.
Dabbing
A method of marijuana use where a "dab" (small amount) of marijuana concentrate is placed on a pre-
heated surface, creating concentrated marijuana vapor to be inhaled.
Daily or near-daily use
Marijuana use on 5 to 7 days per week.
Driving impairment
A reduced ability to perform the various elements of driving.
Drug-drug interaction
A potentially dangerous interaction that occurs when the effects of one medication are changed by the
use of another medication or drug. An example is when a person taking a blood thinner starts a new
medication or drug that causes an increase in the blood thinner, leading to bleeding. Similar
interactions can occur with many medications.
Electronic smoking device (vaporizer or e-cigarette)
A vaporizing device, with a rechargeable battery, that heats material such as marijuana flower (bud) or
liquids containing THC or nicotine to produce vapor for inhalation. Used as an alternative to smoking
marijuana or tobacco.
mphysema
The breakdown of lung tissue, typically causing air trapping, poor airflow and shortness of breath,
diagnosed by imaging.
Executive function
an umbrella term for the management (regulation, control) of cognitive processes, including working
memory, reasoning, task flexibility, organization, time and space management, and problem solving as
well as planning and execution.
Gastroschisis
A birth defect where the abdominal (belly) wall has failed to close properly. The resulting hole allows
the intestines to protrude outside the fetus.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
281
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0300.png
Glossary
Hash oil extraction
A technique that removes THC (the psychoactive component of marijuana) from the plant material in
a concentrated form. This concentrate can then be smoked, vaporized, mixed into food or drink, or
used on the skin. A very common method of extraction uses butane, which is highly flammable.
Heart disease
Encompasses several conditions that affect the heart, including coronary heart disease, myocardial
infarction (heart attack), heart failure, arrhythmias and heart valve problems.
Injury
Physical damage to the body resulting from acute exposure to thermal, mechanical, electrical, or
chemical energy.
Illicit drugs
Fall into two categories: 1) Those drugs that are illegal to process, sell, and consume; includes cocaine,
methamphetamine, ecstasy and heroin. 2) Those drugs that are legal to process, sell, and consume
when prescribed by a physician, but are then misused or used without a prescription; includes
prescription pain medication and prescription sedatives.
Intelligence quotient (IQ)
a number used to express the apparent relative intelligence of a person, determined by one's
performance on a standardized intelligence test relative to the average performance of others of the
same age.
Ischemic stroke
Occurs as a result of an obstruction within a blood vessel supplying blood to the brain.
Joint
See
Marijuana cigarette
Less-than-weekly use
- marijuana use on less than 1 day/week.
Levels of marijuana use
• Daily or near daily
use - 5-7 days/week.
• Weekly use
- 1-4 days/week.
Less-than-weekly use: less than 1 day/week.
• Acute use: Used within the last few hours, such that the short-term
effects or symptoms are still
being experienced.
Low birth weight
Baby who weighs less than 5.5 pounds at birth, regardless of the gestational age.
Mainstream smoke
Also known as firsthand smoke, it is the smoke that a smoker inhales from a lit cigarette, pipe, or joint
and then exhales.
Marijuana addiction
An informal term which is more commonly used than cannabis use disorder, but the two are considered
equivalent by the committee and many mental health professionals.
Marijuana cigarette
“Currently available” marijuana cigarette contains approximately 0.5 gm total weight and 12-23%%
THC
(potency);
also called a “joint”.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
282
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0301.png
Glossary
Marijuana combustion
The heating of marijuana flower or concentrate by applying a direct heat source of 230 degrees Celsius
or above in order to produce smoke for inhalation. Combustion methods include burning a joint, blunt,
pipe, or bong bowl.
Miscarriage
A baby born before reaching 20 weeks of pregnancy and therefore unable to survive.
Myocardial infarction
The
medical term for a ‘heart attack,’ which occurs when blood flow to the heart is blocked, causing
injury to part of the heart muscle. This can cause a life-threatening change in heart rhythm
(arrhythmia).
Neural tube defects (NTD)
Birth defects of the brain, spinal cord or spine. The defects occur in the embryo during the first few
weeks of pregnancy.
Newborn behavior issues
May include fussiness and sleep difficulties occurring during the first 28 days after birth.
Nonseminoma
The more common type of testicular cancer which tends to grow more quickly than seminomas and are
often made up of more than one type of cell.
Nulliparous
A woman who has never carried a pregnancy beyond 20 weeks.
Opioid
One of many medications or street drugs including heroin, opium and prescription pain medications
such as morphine, hydrocodone (Vicodin, Norco, Lortab), oxycodone (Percocet, OxyContin),
hydromorphone (Dilaudid), fentanyl and methadone.
Older adult
Individual 65 years of age or older
Pharmacokinetic / pharmacodynamic
The absorption, distribution, metabolism and excretion of a drug and the effect the drug has on the
body.
Physical dating violence
Physically aggressive behavior among current or former romantic, sexual/intimate, or dating partners,
including hitting, kicking, choking, slapping, etc. Psychological, emotional, verbal or sexual violence
were not included, nor were threats of violence.
Physical dating violence perpetration (PDVP)
To commit physical violence against a partner.
Physical dating violence victimization (PDVV)
To be harmed by physical violence committed by a partner.
Pneumothorax
The collapse of a lung caused by air or fluid filling up the space around the lung, an emergency
condition diagnosed by physical exam and/or imaging.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
283
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0302.png
Glossary
Polycyclic aromatic hydrocarbons
A group of more than 100 different chemicals released from burning coal, oil, gasoline, trash, tobacco,
wood, or other organic substances.
Preterm delivery
A birth that occurs more than three weeks before the baby is due
in other words, after less than 37
weeks of pregnancy.
PRISMA
Evidence-based minimum set of items for reporting in systematic reviews and meta-analyses to help
authors improve reporting.
Psychotic disorders
These include schizophrenia, schizoaffective, schizophreniform, schizotypal, and delusional disorders.
These formal diagnoses are made when a combination of psychotic symptoms are present (possibly
combined with other mental health symptoms), the symptoms cause significant problems with work,
relationships or self-care, and they have been present for six months or longer.
Psychotic symptoms
These include auditory or visual hallucinations, difficulty separating real from imagined, perception
that self or others can read minds, perceived ability to predict the future, feeling that an outside force
is controlling thoughts or actions, fear that someone intends to harm them, belief they have
supernatural gifts, apathy, social withdrawal, absent or blunted emotions, occurrences of unclear
speech or inability to speak, or difficulty organizing thoughts to complete activities.
Pulmonary function (tests)
Measurements that show how well the lungs move air in and out and how well they exchange oxygen
and carbon dioxide with the blood.
Recreational injury
Any injury outside the workplace and not classified as a motor vehicle (MV) crash.
Route of Exposure
The physical passageway which the marijuana product takes to enter the body; (for example)
oral/ingested, smoked, or topical.
Secondhand marijuana smoke exposure
The smoke that is inhaled by non-smokers when near to a person smoking marijuana, also known as
passive exposure.
• Typical conditions: exposure at or below the level of smoke present in a small ventilated room (such
as with open windows or an exhaust fan) with multiple people smoking marijuana.
• Extreme conditions: exposure at or above the level of
smoke present in an small room (or a vehicle)
without ventilation and with multiple people smoking marijuana.
Sidestream smoke
The smoke that wafts off the end of a lit cigarette, pipe or joint into the surrounding air.
SIDS
See
Sudden infant death syndrome
Small airway obstruction
A condition causing air to be trapped in the lungs, making it difficult to breathe the air out to make
room for the next breath, diagnosed by pulmonary function tests.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
284
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0303.png
Glossary
Small for gestational age (SGA)
A baby that is born smaller than 90 percent of babies of the same gestational age (number of weeks of
pregnancy).
Smoked dose
Dependent on the potency and dry weight of cannabis flower, a.k.a. marijuana bud. It is approximately
equal to the product of potency (%THC) and weight (mg).
Smoking topography
How a person smokes a substance, including measures of the number of puffs and puff volume,
duration, and velocity.
Stillbirth
The birth of an baby that has died in the womb after having reached at least 20 weeks of pregnancy
(earlier instances being regarded as abortion or miscarriage).
Stroke
An event that blocks blood flow to part of the brain or causes bleeding into the brain, causing
permanent damage.
Sudden infant death syndrome (SIDS)
The sudden and unexplained death of a seemingly healthy baby less than a year old.
Tetrahydrocannabinol (THC)
The main psychoactive component of marijuana.
Thirdhand marijuana smoke exposure
Residual contamination left in rooms and on clothes after marijuana smoking.
Unintentional marijuana exposures
Ingesting a substance without knowing that it contains THC or other cannabinoids, more commonly
observed with edible marijuana products.
Vaporization of marijuana (vaping)
A method of marijuana use in which marijuana vapor, rather than smoke, is inhaled. Marijuana flower
or concentrate is heated in a vaporizing device (vaporizer) to a temperature below the point of
combustion, to produce vapor.
Ventricular septal defect
A congenital heart defect also known as a "hole in the heart." The defect occurs when the wall
(septum) that separates the right and left ventricles of the heart does not form properly.
Water pipe
A pipe for smoking tobacco, marijuana, etc., that draws the smoke through water to cool it. Examples
are a hookah and a bong.
Weekly use
Marijuana use on 1 to 4 days/week.
Young adult
Individual 18 to 24 years of age.
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
285
REU, Alm.del - 2017-18 - Endeligt svar på spørgsmål 857: Spm., om staten Colorado har et overblik over udviklingen i antallet af narkorelaterede indlæggelser på hhv. somatiske og psykiatriske behandlingstilbud, til justitsministeren
1945491_0304.png
Glossary
Monitoring Health Concerns Related to Marijuana in Colorado: 2016
286